,id,study.name,effect.key,b,s,n,specialty,outcome.group,outcome.flag,outcome.nr,comparison.nr,RCT,study.year,outcome_name,comparison_name,z,gemini-1.5-flash,human_response,gold_answer_GPT4,llama3-8b-8192,llama_8b_acc,llama3-70b-8192,llama_70b_acc,mixtral-8x7b-32768,mixtral_8x7b_acc,MV,MV_acc,gemini-1.5-pro,gpt4_acc,gemini_1.5flash_acc,gemini_1.5pro_acc,gemini_1.5flash_acc_clean,gemini_1.5pro_acc_clean,gemma_7b_it_acc_clean,gemma_7b_it_acc
0,CD003412,Wang 2001,STD-Wang-2001 1.625 0.457 44 39,0.606135803570315,0.564076074817766,83,Skin & Wounds,efficacy,DICH,1,6,no,2001.0,Recurrence at one year (histological),PDT vs cryotherapy,1.07456392963686,"negative 
",negative,,,,,,,,,,,,,,,,,
1,CD009346,Ayoglu 2007,STD-Ayoglu-2007 0.342 0.282 60 30,-1.83174195061659,0.491670969779808,90,Anaesthesia & Pain,efficacy,DICH,1,2,yes,2007.0,Pain,Rocuronium admixtures,-3.72554424239634,"negative 
",negative,,,,,,,,,,,,,,,,,
2,CD003431,Bielecki 2003,STD-Bielecki-2003 1.056 0.88 21 22,0.054067221270276,0.880257803810674,43,Gastroenterology,efficacy,DICH,1,4,yes,2003.0,NON - Healing,GTN versus Calcium Channel Blocker,0.0614220300418999,"negative 
",negative,,,,,,,,,,,,,,,,,
3,CD002745,Hall 1987,STD-Hall-1987 0.36 0.474 37 32,-1.34547236659964,0.60380736442456,69,Lungs,efficacy,DICH,1,1,no,1987.0,Fever day 3,Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children,-2.22831393896942,"negative 
",negative,,,,,,,,,,,,,,,,,
4,CD007122,Turkey 2014,STD-Turkey-2014 0.514 0.313 377 349,-0.704879331183482,0.33101620006435,726,Pregnancy & Childbirth,efficacy,DICH,1,6,yes,2014.0,Diagnosis of gestational diabetes,Two-step (50 g OGCT and 100 g OGTT) versus one-step (75 g OGTT) approach,-2.12944058643188,"negative 
",negative,,,,,,,,,,,,,,,,,
5,CD003594,Mantan 2008,STD-Mantan-2008 1.126 0.284 26 23,0.241162056816888,0.573588989612187,49,Kidney & Transplant,efficacy,DICH,1,8,yes,2008.0,Treatment response at 6 months,IV versus oral cyclophosphamide (CPA) plus IV dexamethasone (DEXA),0.420444013369123,"neutral 
",neutral,,,,,,,,,,,,,,,,,
6,CD005067,Momeni 2003,STD-Momeni-2003 1.833 0.462 45 45,0.743336925083801,0.559131959310739,90,Skin & Wounds,efficacy,DICH,1,46,yes,2003.0,Participants complete cure,Topical ketoconazole (twice a day) versus vehicle (twice a day) for 30 d,1.32944810738441,"positive 
",positive,,,,,,,,,,,,,,,,,
7,CD000308,Courtney 1992,STD-Courtney-1992 0.304 1.082 23 28,-1.29928298413026,1.1563395747449,51,Neonatal,efficacy,DICH,1,1,no,1992.0,Endotracheal reintubation,Dexamethasone vs Placebo (all infants),-1.1236171558142,"negative 
",negative,,,,,,,,,,,,,,,,,
8,CD005958,Best 1997,STD-Best-1997 0.207 0.755 16 19,-1.57307026826323,0.755403812960274,35,Spine & Muscles,efficacy,DICH,1,9,no,1997.0,Prevalence LBP in the previous year (FU 12 mo),MMH training versus minor advice (cohort studies),-2.08242299188123,"negative 
",negative,,,,,,,,,,,,,,,,,
9,CD008472,Ali 2007,STD-Ali-2007 0.667 0.886 41 41,-0.431440594511425,0.94089858563399,82,Heart & Hypertension,efficacy,DICH,1,1,yes,2007.0,Perioperative mortality,Remote ischaemic preconditioning (RIPC) versus no RIPC,-0.458541017171063,"negative 
",negative,,,,,,,,,,,,,,,,,
10,CD004588,Drenth,STD-Drenth 5.202 1.562 51 51,1.64904705052915,1.56192813404784,102,Heart & Hypertension,efficacy,DICH,1,2,yes,2004.0,Mortality: up to 36 days,Mortality,1.05577652043153,"negative 
",negative,,,,,,,,,,,,,,,,,
11,CD007867,Arabi 2011,STD-Arabi-2011 0.706 0.175 120 120,-0.54501698851427,0.271630514565251,240,Emergency & Trauma,efficacy,DICH,1,1,yes,2011.0,Mortality in hospital,Hypocaloric nutrition (intervention) vs. Control,-2.00646451444006,"negative 
",negative,,,,,,,,,,,,,,,,,
12,CD002008,Gray-Donald 1995,STD-Gray_x002d_Donald-1995 0.333 1.12 25 25,-1.18562366565774,1.19182823655699,50,Genetics & Endocrinology,efficacy,DICH,1,2,no,1995.0,Mortality,Dietary advice compared with nutritional supplements,-0.994794072913413,"negative 
",negative,,,,,,,,,,,,,,,,,
13,CD004047,Stewart 1989,STD-Stewart-1989 1.875 0.558 12 18,0.916290731874155,0.815037247176909,30,Psychiatry & Mental Health,efficacy,DICH,1,2,no,1993.0,Non treatment response,MAOIs vs TCA,1.12423172689097,"negative 
",negative,,,,,,,,,,,,,,,,,
14,CD005307,Chuchalin 2008,STD-Chuchalin-2008 1.263 0.144 972 970,0.2572773370829,0.157883980487555,1942,Lungs,efficacy,DICH,1,2,no,2004.0,# patients with exacerbations requiring systemic steroids,Addition of ICS + LABA versus increased dose of ICS alone in steroid-naive patients as first line treatment,1.62953414455609,"negative 
",negative,,,,,,,,,,,,,,,,,
15,CD003552,Stewart 2007,STD-Stewart-2007 0.458 0.583 63 67,-0.828024649575629,0.628730182959136,130,Gynaecology & Urology,efficacy,DICH,1,12,no,2007.0,Pregnancy per woman (3 cycles),Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg,-1.31697932120661,"negative 
",negative,,,,,,,,,,,,,,,,,
16,CD001758,Karas 2011,STD-Karas-2011 6.321 0.785 116 136,1.84383861827294,0.785427685297199,252,Gynaecology & Urology,efficacy,DICH,1,9,yes,2011.0,Number of patients with recurrent full-thickness prolapse,Rectopexy versus no rectopexy,2.34756000175274,"negative 
",negative,,,,,,,,,,,,,,,,,
17,CD006478,Dire 1995,STD-Dire-1995 0.066 0.039 99 109,0.861968050134998,0.520771534108423,208,Skin & Wounds,efficacy,DICH,1,20,no,1995.0,Number of patients that developed wound infection,SSD cream (1%) vs bacitracin zinc ointment,1.65517505024677,"negative 
",negative,,,,,,,,,,,,,,,,,
18,CD000179,Hillman 1963,STD-Hillman-1963 1.714 0.357 588 576,0.554310735705729,0.366727554225349,1164,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1962.0,Pre-eclampsia,Pyridoxine (B6) versus control,1.51150555587954,"negative 
",negative,,,,,,,,,,,,,,,,,
19,CD003412,Rhodes 2004,STD-Rhodes-2004 4.906 1.078 53 52,1.67006253425054,1.11375094903241,105,Skin & Wounds,efficacy,DICH,1,5,no,2004.0,Early treatment failure (lesions measured),MALPDT vs surgery,1.49949370252069,"negative 
",negative,,,,,,,,,,,,,,,,,
20,CD005027,Yan 2013,STD-Yan-2013 1.641 0.234 22 19,1.7404661748405,0.772706945349796,41,Skin & Wounds,efficacy,DICH,1,17,yes,2013.0,Number of participants with significant clinical response at the end of the six-month treatment,"Acupuncture, hot herbal compress, and moxibustion plus Centella triterpenes tablets and vitamin E × Heparin sodium cream plus Centella triterpenes tablets and vitamin E",2.25242724336147,"positive 
",positive,,,,,,,,,,,,,,,,,
21,CD002003,IPPPSH 1985,STD-IPPPSH-1985 0.944 0.132 3185 3172,-0.0602612101033095,0.136686473644621,6357,Heart & Hypertension,efficacy,DICH,1,1,no,1985.0,Mortality,Beta-blocker versus placebo or no treatment,-0.440871788528146,"negative 
",negative,,,,,,,,,,,,,,,,,
22,CD001176,Kjaer 2019,STD-Kjaer-2019 1.167 0.598 6 7,0.287682072451781,1.11803398874989,13,Gastroenterology,efficacy,DICH,1,12,no,2019.0,Clinical improvement at 4 weeks,Adalimumab versus placebo,0.257310667964081,"positive 
",positive,,,,,,,,,,,,,,,,,
23,CD008414,Ewe 1989,STD-Ewe-1989 0.98 0.064 111 121,-0.10648348040245,0.335031425490626,232,Gastroenterology,efficacy,DICH,1,6,yes,1989.0,Clinical relapse at 18 to 36 months,Sulphasalazine versus placebo,-0.317831320588849,"negative 
",negative,,,,,,,,,,,,,,,,,
24,CD005067,Gholami 2000,STD-Gholami-2000 0.938 0.314 96 75,-0.0800427076735364,0.389498911050341,171,Skin & Wounds,efficacy,DICH,1,107,yes,2000.0,Participants complete cure,Topical garlic (twice a day) versus vehicle for 3 weeks,-0.205501749562507,"positive 
",positive,,,,,,,,,,,,,,,,,
25,CD003557,Bishop 1992,STD-Bishop-1992 5.806 1.049 31 30,1.94017947434633,1.11406886020899,61,Skin & Wounds,efficacy,DICH,1,18,yes,1992.0,Complete healing at 4 weeks,1% silver sulphadiazine cream versus placebo cream,1.74152563063505,"positive 
",positive,,,,,,,,,,,,,,,,,
26,CD003085,Li 2012,STD-Li-2012 0.633 0.231 94 92,-0.651541179727481,0.325571157137209,186,Neurology,efficacy,DICH,1,3,no,2012.0,DCI at 2–3 months,Delayed cerebral ischaemia (DCI),-2.0012251252739,"negative 
",negative,,,,,,,,,,,,,,,,,
27,CD000975,Brachman 1962,STD-Brachman-1962 0.183 0.505 379 414,-2.65398297983193,1.03528664387035,793,Infectious Diseases,efficacy,DICH,1,1,no,1962.0,Cases of anthrax,Any vaccine compared with placebo/control,-2.56352479339461,"negative 
",negative,,,,,,,,,,,,,,,,,
28,CD007677,Alborzi 2007,STD-Alborzi-2007 1.062 0.407 61 60,0.0606246218164348,0.408384714290717,121,Gynaecology & Urology,efficacy,DICH,1,2,yes,2007.0,Clinical pregnancy per woman randomised,Secondary outcomes,0.148449782019211,"positive 
",positive,,,,,,,,,,,,,,,,,
29,CD001773,Micic 1988,STD-Micic-1988 32.882 1.522 21 14,3.49293612909888,1.52249953713512,35,Oncology,efficacy,DICH,1,1,no,1988.0,Clinical improvement of RT cystitis with placental extract,The effect of placental extract on late radiation cystitis,2.29421161971026,"positive 
",positive,,,,,,,,,,,,,,,,,
30,CD001957,Ferley 1989,STD-Ferley-1989 1.668 0.242 228 234,0.590868331439527,0.278137739907051,462,Lungs,efficacy,DICH,1,2,no,1989.0,Absence of symptoms at 48 hours - patient assessment,Treatment: Oscillococcinum versus placebo,2.12437309527641,"positive 
",positive,,,,,,,,,,,,,,,,,
31,CD009278,MRC 1955,STD-MRC-1955 0.947 0.553 76 72,-0.0588405000229332,0.602304377180311,148,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1955.0,Miscarriage,Combined oestrogen and progestogen (other than progesterone) versus placebo,-0.0976923001927947,"negative 
",negative,,,,,,,,,,,,,,,,,
32,CD008666,Kirkwood 2010,STD-Kirkwood-2010 1.006 0.03 38283 37893,0.0062985629214469,0.0317493119386116,76176,Pregnancy & Childbirth,efficacy,DICH,1,4,no,2010.0,Perinatal mortality (infant mortality level),Vitamin A alone versus placebo or no treatment (subgroups),0.198384233763096,"negative 
",negative,,,,,,,,,,,,,,,,,
33,CD004776,Grossman 2003,STD-Grossman-2003 1.092 0.993 130 142,0.0896121586896879,1.00744992785888,272,Infectious Diseases,efficacy,DICH,1,2,no,2003.0,Death,Epoetin once-weekly versus Epoetin three times-weekly,0.0889494913957061,"negative 
",negative,,,,,,,,,,,,,,,,,
34,CD000244,Boxma 1996,STD-Boxma-1996 0.321 0.316 1105 1090,-1.16315080980568,0.322166430267352,2195,Emergency & Trauma,efficacy,DICH,1,2,yes,1996.0,Deep surgical site infection,Antibiotic agent (single dose) versus placebo or no treatment,-3.61040350740588,"negative 
",negative,,,,,,,,,,,,,,,,,
35,CD010134,Hallstrom 2000,STD-Hallstrom-2000 1.398 0.235 240 278,0.382495148829239,0.268231803165908,518,Emergency & Trauma,efficacy,DICH,1,1,yes,2000.0,Survival to hospital discharge,Bystander-provided CPR,1.42598731513078,"positive 
",positive,,,,,,,,,,,,,,,,,
36,CD003642,Zhang J 2003,STD-Zhang-J-2003 3 0.394 30 30,1.79175946922805,0.58925565098879,60,Genetics & Endocrinology,efficacy,DICH,1,4,no,2003.0,Normalisation of fasting blood glucose levels (< 7.2 mmol/L),Herbal medicine plus dietary and lifestyle modification versus dietary and lifestyle modification,3.04071665027128,"positive 
",positive,,,,,,,,,,,,,,,,,
37,CD003431,Jonas 2001,STD-Jonas-2001 3.148 0.59 24 26,1.14681439048599,0.589671449453553,50,Gastroenterology,efficacy,DICH,1,11,yes,2001.0,NON - Healing (persistence & recurrence),Diltiazem Oral versus Topical,1.94483621608056,"negative 
",negative,,,,,,,,,,,,,,,,,
38,CD009391,Gianaroli 1996b,STD-Gianaroli-1996b 2.663 0.454 85 82,0.979407788664349,0.454198863508482,167,Gynaecology & Urology,efficacy,DICH,1,1,yes,1996.0,Ongoing pregnancy per randomized woman,Brief co-incubation versus standard insemination,2.15634134594451,"positive 
",positive,,,,,,,,,,,,,,,,,
39,CD004982,Marchiori 2002,STD-Marchiori-2002 0.167 1.049 30 30,-1.98100146886658,1.114816618083,60,Heart & Hypertension,efficacy,DICH,1,17,yes,2002.0,Incidence of venous thromboembolism,High-dose unfractionated heparin (UFH) versus low-dose UFH,-1.77697518742862,"negative 
",negative,,,,,,,,,,,,,,,,,
40,CD004421,ADEBAR,STD-ADEBAR 0.725 0.187 661 645,-0.321197217064285,0.186967690535997,1306,Oncology,efficacy,DICH,1,11,yes,2005.0,Febrile neutropenia by sequential or concurrent anthracycline/taxane,Toxicities,-1.71792899694851,"negative 
",negative,,,,,,,,,,,,,,,,,
41,CD008983,Natori 2017,STD-Natori-2017 0.543 1.202 35 38,-0.635988766719997,1.24787400905847,73,Oncology,efficacy,DICH,1,2,yes,2017.0,All-cause mortality,Adjuvanted vaccine versus non-adjuvanted vaccine,-0.50965783572963,"negative 
",negative,,,,,,,,,,,,,,,,,
42,CD002977,Rego 2002,STD-Rego-2002 0.418 0.322 50 46,-1.29928298413026,0.460566186471838,96,Neonatal,efficacy,DICH,1,7,no,2002.0,Nasal hyperaemia,Hudson prong (short binasal) vs Argyle prong (short binasal) CPAP in preterm infants: broad inclusion criteria,-2.82105595741494,"negative 
",negative,,,,,,,,,,,,,,,,,
43,CD003999,Durmaz 2019,STD-Durmaz-2019 1.714 0.263 44 88,0.792445401542226,0.39567854979828,132,Psychiatry & Mental Health,efficacy,DICH,1,9,yes,2019.0,"Behavioural interventions, cessation at longest follow-up","Interventions for smokers, tests of adjuncts to cessation programmes",2.00275046991104,"positive 
",positive,,,,,,,,,,,,,,,,,
44,CD008541,Brandes 2007 Study 1,STD-Brandes-2007-Study-1 3.746 0.181 364 360,1.64530279480156,0.213413295501886,724,Anaesthesia & Pain,efficacy,DICH,1,1,no,2007.0,Pain-free at 2 h,Sumatriptan plus naproxen versus placebo,7.70946716760212,"positive 
",positive,,,,,,,,,,,,,,,,,
45,CD010777,Hong 2012,STD-Hong-2012 0.25 1.092 35 35,-1.47866768125091,1.14528155019716,70,Kidney & Transplant,efficacy,DICH,1,3,yes,2012.0,Need for dialysis,Need for dialysis,-1.29109534768665,"negative 
",negative,,,,,,,,,,,,,,,,,
46,CD004116,Bensoussan 1998,STD-Bensoussan-1998 1.507 0.303 38 35,0.674798041891749,0.487987000986003,73,Gastroenterology,efficacy,DICH,1,1,yes,1998.0,Global improvement of symptoms rated by patient,Herbal medicine versus placebo,1.38281970734525,"neutral 
",neutral,,,,,,,,,,,,,,,,,
47,CD000410,McFaul 1989a,STD-McFaul-1989a 2.484 0.751 19 20,0.961411167154625,0.797337197385674,39,Gynaecology & Urology,efficacy,DICH,1,3,no,1989.0,pregnancy rate (per cycle),Gonadotrophin administration modalities,1.20577739293604,"positive 
",positive,,,,,,,,,,,,,,,,,
48,CD003347,Buchali 1988,STD-Buchali-1988 0.737 0.368 19 22,-0.538996500732687,0.638755554190066,41,Anaesthesia & Pain,efficacy,DICH,1,1,no,1988.0,Pain relief,Radioisotopes versus placebo (data as published),-0.843822800752203,"positive 
",positive,,,,,,,,,,,,,,,,,
49,CD009889,Ansari 2003,STD-Ansari-2003 0.869 0.213 54 51,-0.259272275402715,0.392680358366996,105,Heart & Hypertension,efficacy,DICH,1,1,yes,2003.0,All-cause hospital admissions,Nurse-led titration versus usual care,-0.660262908185495,"negative 
",negative,,,,,,,,,,,,,,,,,
50,CD005536,Zar 2007,STD-Zar-2007 1 0.238 200 200,0.0,0.280056016805602,400,Lungs,efficacy,DICH,1,1,yes,2007.0,Hospital admission,Home-made spacers versus commercial spacers,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
51,CD000218,Chung 1978,STD-Chung-1978 2.129 1.609 30 21,0.782274960455953,1.65743072243107,51,Infectious Diseases,efficacy,DICH,1,4,no,1978.0,No parasitological cure (2 weeks),Oral versus oral plus intravaginal,0.47198048755156,"negative 
",negative,,,,,,,,,,,,,,,,,
52,CD005230,Zhu 2005,STD-Zhu-2005 0.609 0.244 36 36,-1.02252998221067,0.487118522205591,72,Gynaecology & Urology,efficacy,DICH,1,7,yes,2005.0,NOT CURED:  number of children not achieving 14 consecutive dry nights during treatment,Medicinal herbs vs other treatments,-2.09914001541314,"negative 
",negative,,,,,,,,,,,,,,,,,
53,CD006567,Ben-Rafael 1995,STD-Ben_x002d_Rafael-1995 0.982 0.304 101 110,-0.0183973651397161,0.304043023814215,211,Gynaecology & Urology,efficacy,DICH,1,2,no,1995.0,Clinical pregnancy rate per randomised woman,Fibrin sealant versus usual care,-0.0605090848950303,"positive 
",positive,,,,,,,,,,,,,,,,,
54,CD008591,Lam 2006,STD-Lam-2006 1 0.144 48 48,0.0,0.433012701892219,96,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2006.0,Response (> 50% improvement on 24-item HAM-D SIGH-SAD),Fluoxetine versus Light Therapy,0.0,"positive 
",positive,,,,,,,,,,,,,,,,,
55,CD009526,Ashrafinia 2009,STD-Ashrafinia-2009 0.554 0.365 63 63,-0.590780915031412,0.365175100291783,126,Gynaecology & Urology,efficacy,DICH,1,1,yes,2009.0,Menstrual regularity,LOD vs medical interventions,-1.61780174650288,"neutral 
",neutral,,,,,,,,,,,,,,,,,
56,CD009820,New Hope 1999,STD-New-Hope-1999 1.094 0.029 289 301,0.889096528854976,0.288016676534541,590,Public Health & Work,efficacy,DICH,1,22,yes,1999.0,Respondent has health insurance (%),Time point 1 Health insurance,3.08696197578805,"neutral 
",neutral,,,,,,,,,,,,,,,,,
57,CD003137,Bjermer 2003,STD-Bjermer-2003 0.912 0.123 743 747,-0.10892309664344,0.144853452934239,1490,Lungs,efficacy,DICH,1,1,no,2003.0,Participants with one or more exacerbations requiring systemic corticosteroids,Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,-0.751953746610993,"negative 
",negative,,,,,,,,,,,,,,,,,
58,CD002938,Zeegers 1995,STD-Zeegers-1995 0.667 0.495 62 62,-0.460524885291192,0.560805532393558,124,Emergency & Trauma,efficacy,DICH,1,2,no,1995.0,Numbers not returning to work,Elastic bandage versus Semi-rigid ankle support,-0.821184632978991,"negative 
",negative,,,,,,,,,,,,,,,,,
59,CD000511,Dunn 1991,STD-Dunn-1991 0.153 0.594 62 60,-2.20979206769974,0.653685175543636,122,Neonatal,efficacy,DICH,1,1,yes,1991.0,Effect on pneumothorax,Animal derived surfactant extract vs. control,-3.38051427564037,"negative 
",negative,,,,,,,,,,,,,,,,,
60,CD008735,Bezerra 2014,STD-Bezerra-2014 1 0.986 70 70,0.0,1.01459931239178,140,Hepato-Biliary,efficacy,DICH,1,1,yes,2014.0,All-cause mortality,Primary outcomes,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
61,CD002000,BAESIC study,STD-BAESIC-study 13.39 1.518 24 30,2.59452637480522,1.51782396715594,54,Heart & Hypertension,efficacy,DICH,1,1,yes,2004.0,Early postoperative non-thrombotic complications - by symptoms at time of intervention,Bypass surgery compared with angioplasty (PTA),1.70937238503802,"negative 
",negative,,,,,,,,,,,,,,,,,
62,CD000370,Farrell 1998,STD-Farrell-1998 1.121 0.127 538 533,0.114081455068927,0.126939640858045,1071,Hepato-Biliary,efficacy,DICH,1,6,yes,1998.0,Biochemical ETR,Effect of different formulations of interferon,0.898706300867057,"neutral 
",neutral,,,,,,,,,,,,,,,,,
63,CD005067,Layegh 2007,STD-Layegh-2007 0.6 0.618 29 58,-0.590868331439527,0.701874778809016,87,Skin & Wounds,efficacy,DICH,1,35,no,2007.0,Lesions cured,Azythromicin (500 mg/d for 5 d/month up to 4 months) versus IMMA (60 mg/kg/d for 20 d),-0.8418429458915,"positive 
",positive,,,,,,,,,,,,,,,,,
64,CD001256,Andrish 1974,STD-Andrish-1974 1.509 0.295 344 1453,0.426376783906284,0.306959967057319,1797,Emergency & Trauma,efficacy,DICH,1,10,yes,1974.0,Lower limb soft-tissue injuries by location,Insoles vs control (no insoles),1.38903058921252,"negative 
",negative,,,,,,,,,,,,,,,,,
65,CD004104,Avdeev 1998,STD-Avdeev-1998 0.333 0.613 29 29,-1.3609765531356,0.730004097869308,58,Lungs,efficacy,DICH,1,1,no,1998.0,Mortality,NIV vs usual care - Overall,-1.86434097713689,"negative 
",negative,,,,,,,,,,,,,,,,,
66,CD007458,Koury 2005,STD-Koury-2005 1.1 0.039 143 148,1.02616858802343,0.43347487905816,291,Public Health & Work,efficacy,DICH,1,2,yes,2005.0,Attendance rate at healthcare appointments,Mobile phone message text reminders plus postal reminders vs postal reminders,2.36730809003984,"neutral 
",neutral,,,,,,,,,,,,,,,,,
67,CD003004,Moppett 2014,STD-Moppett-2014 0.082 1.449 51 63,-2.61539137061951,1.47324469254287,114,Anaesthesia & Pain,efficacy,DICH,1,2,yes,2014.0,All-cause mortality,Advanced haemodynamic monitoring versus usual care,-1.77525931968928,"negative 
",negative,,,,,,,,,,,,,,,,,
68,CD001758,Solomon 2002,STD-Solomon-2002 0.301 1.664 20 19,-1.20126644272819,1.66418184358729,39,Gynaecology & Urology,efficacy,DICH,1,6,yes,2002.0,Number of patients with recurrent full-thickness prolapse,Laparoscopic versus open procedure,-0.721836046557723,"negative 
",negative,,,,,,,,,,,,,,,,,
69,CD001350,Huang 2005,STD-Huang-2005 1.222 1.484 10 12,0.200670695462152,1.48392055111458,22,Spine & Muscles,efficacy,DICH,1,23,no,2005.0,Unsatisfied - patient rating,MICROENDOSCOPIC DISCECTOMY V. OPEN DISCECTOMY,0.135230080418677,"negative 
",negative,,,,,,,,,,,,,,,,,
70,CD010747,Gu 2008,STD-Gu-2008 0.353 1.104 17 18,-1.16315080980568,1.20933866224478,35,Heart & Hypertension,efficacy,DICH,1,4,no,2008.0,Amputation rate,Route of injection: IM injection vs IA injection,-0.961807346543137,"negative 
",negative,,,,,,,,,,,,,,,,,
71,CD001245,Hillman 2002,STD-Hillman-2002 0.855 0.146 254 251,-0.216056349431155,0.200128431069588,505,Neurology,efficacy,DICH,1,1,no,2002.0,"Poor outcome (death, vegetative or severe disability on Glasgow Outcome Scale at end of follow-up): open versus blind studies",Antifibrinolytic treatment versus control treatment with or without placebo,-1.07958848363743,"negative 
",negative,,,,,,,,,,,,,,,,,
72,CD007876,Campo 2010,STD-Campo-2010 1.032 0.345 85 87,0.0317486983145803,0.344543979772097,172,Gynaecology & Urology,efficacy,DICH,1,1,no,2010.0,Cleavage-stage embryo transfer,Live birth or ongoing pregnancy per woman randomised,0.0921470122205615,"neutral 
",neutral,,,,,,,,,,,,,,,,,
73,CD004087,Chraemmer-Jorgensen 1992,STD-Chraemmer_x002d_Jorgensen-1992 0.307 1.683 12 12,-1.18199389760716,1.68333692064476,24,Anaesthesia & Pain,efficacy,DICH,1,2,no,1992.0,Myocardial ischaemia - by drug type,ECG evidence of myocardial ischaemia,-0.702173096253616,"negative 
",negative,,,,,,,,,,,,,,,,,
74,CD001350,Haines 2002,STD-Haines-2002 0.952 0.812 17 10,-0.0487901641694318,0.812110712602543,27,Spine & Muscles,efficacy,DICH,1,12,no,2002.0,Poor result at 6 mos to 2 yrs - pt rated,PERCUTANEOUS ENDOSCOPIC DISCECTOMY (ANY TYPE) V. MICRODISCECTOMY,-0.0600782176768432,"negative 
",negative,,,,,,,,,,,,,,,,,
75,CD007807,Agrawal 2012,STD-Agrawal-2012 4.5 0.574 30 28,1.50407739677627,0.573903371104474,58,Gynaecology & Urology,efficacy,DICH,1,1,no,2012.0,Live birth; antioxidants vs placebo or no treatment/standard treatment (natural conceptions and undergoing fertility treatments),Antioxidant(s) versus placebo or no treatment/standard treatment,2.62078508770856,"positive 
",positive,,,,,,,,,,,,,,,,,
76,CD005067,Stahl 2014,STD-Stahl-2014 1.146 0.089 23 23,2.08248568406106,1.54176780515372,46,Skin & Wounds,efficacy,DICH,1,76,no,2014.0,Participants complete cure,DAC-055 + MWT (for 15 min) versus DAC-055 alone for up to 75 d,1.35071291351387,"positive 
",positive,,,,,,,,,,,,,,,,,
77,CD004912,McGready 2005,STD-McGready-2005 0.239 0.442 39 41,-2.06352608637394,0.572274312814926,80,Infectious Diseases,efficacy,DICH,1,1,yes,2005.0,Treatment failure at day 63,Artesunate plus atovaquone-proguanil (AS+AP) vs quinine (QN),-3.60583384605152,"negative 
",negative,,,,,,,,,,,,,,,,,
78,CD006359,El-Toukhy 2004,STD-El_x002d_Toukhy-2004 2.618 0.404 117 117,0.962443175127006,0.404304777531047,234,Gynaecology & Urology,efficacy,DICH,1,1,no,2004.0,Live-Birth Rate,GnRH agonists versus control,2.38048924626695,"positive 
",positive,,,,,,,,,,,,,,,,,
79,CD009144,Guañabens 2003,STD-Gua_x00f1_abens-2003 0.333 1.597 16 16,-1.16113264564944,1.67086470317168,32,Hepato-Biliary,efficacy,DICH,1,2,yes,2003.0,All-cause mortality,Bisphosphonates vs another bisphosphonate (alendronate vs etidronate or ibandronate),-0.694929184538611,"negative 
",negative,,,,,,,,,,,,,,,,,
80,CD010085,Makrides 2010,STD-Makrides-2010 0.684 0.221 368 338,-0.42560001651722,0.246722181690568,706,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2010.0,Any allergies (with sensitisation): medically diagnosed IgE mediated,n-3 LCPUFA supplementation versus placebo or no supplementation - any allergy,-1.72501723842162,"negative 
",negative,,,,,,,,,,,,,,,,,
81,CD007342,Gonsalez 1998,STD-Gonsalez-1998 1.357 0.487 40 42,0.305204423143983,0.486957153541596,82,Hepato-Biliary,efficacy,DICH,1,2,no,1988.0,Laboratory identified infection,Post-exposure prophylaxis with doxycycline,0.626758270053655,"negative 
",negative,,,,,,,,,,,,,,,,,
82,CD000217,Bassily 1970,STD-Bassily-1970 413.727 1.5 60 20,6.02520699521827,1.49953882498623,80,Infectious Diseases,efficacy,DICH,1,1,no,1970.0,parasitological cure,ANY DRUG THERAPY VERSUS PLACEBO,4.01804000991679,"positive 
",positive,,,,,,,,,,,,,,,,,
83,CD011571,Caca-Biljanovska 2002,STD-Caca_x002d_Biljanovska-2002 2 0.548 10 10,1.25276296849537,0.944911182523068,20,Skin & Wounds,efficacy,DICH,1,1,no,2002.0,Proportion of participants achieving clear or almost clear skin (PASI 90 or 100 or PGA 0 or 1),Penicillin versus no treatment in guttate psoriasis,1.32579970653992,"positive 
",positive,,,,,,,,,,,,,,,,,
84,CD001433,Thomsen 1973,STD-Thomsen-1973 0.35 0.148 20 20,1.46633706879343,0.676664952450958,40,Skin & Wounds,efficacy,DICH,1,12,yes,1973.0,improvement,tetracycline antibiotic versus placebo,2.16700608400389,"positive 
",positive,,,,,,,,,,,,,,,,,
85,CD005279,Bansal 2005,STD-Bansal-2005 0.2 1.528 30 30,-1.67726050877286,1.57094704065546,60,Kidney & Transplant,efficacy,DICH,1,1,yes,2005.0,Failed catheter placement (overall),Ultrasound guided versus blind haemodialysis catheter insertion,-1.06767476265339,"negative 
",negative,,,,,,,,,,,,,,,,,
86,CD002296,Yeomans 1998,STD-Yeomans-1998 0.322 0.332 210 215,-1.25780076252533,0.360639987611213,425,Gastroenterology,efficacy,DICH,1,14,yes,1998.0,Endoscopic gastric ulcers,PPI vs H2-antagonist - 12 weeks or longer studies,-3.48769078785932,"negative 
",negative,,,,,,,,,,,,,,,,,
87,CD006654,Lecrubier 2006,STD-Lecrubier-2006 0.883 0.175 140 70,-0.207934132650681,0.297817915403353,210,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2006.0,Global state: 1a. No clinically significant response (as defined by the original studies),OLANZAPINE versus AMISULPRIDE,-0.698192156670842,"negative 
",negative,,,,,,,,,,,,,,,,,
88,CD008997,Benoist 2005,STD-Benoist-2005 0.884 0.53 32 27,-0.123379021160504,0.529521687840279,59,Gastroenterology,efficacy,DICH,1,1,no,2005.0,2 years OS,Primary management of stage IV colorectal cancer,-0.23300088361578,"negative 
",negative,,,,,,,,,,,,,,,,,
89,CD004823,Chao 2007,STD-Chao-2007 0.091 1.727 5 4,-2.39789527279837,1.72679419208491,9,Lungs,efficacy,DICH,1,1,no,2007.0,Subjects cured (of cough) at end of study,Thickened versus unthickened feeds (infants),-1.38863987601393,"positive 
",positive,,,,,,,,,,,,,,,,,
90,CD007483,Faye 2003 SEN,STD-Faye-2003-SEN 0.539 0.775 144 349,-0.630958836767327,0.788095515215526,493,Infectious Diseases,efficacy,DICH,1,7,yes,2003.0,Total Failure (P. falciparum) Day 28 PCR unadjusted,Artesunate plus mefloquine vs Artesunate plus amodiaquine,-0.800612139754119,"negative 
",negative,,,,,,,,,,,,,,,,,
91,CD012189,Bateman 2009,STD-Bateman-2009 0.351 0.371 71 63,-1.04817145734138,0.371391363119804,134,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2009.0,Repetition of SH at post-intervention,Interventions for multiple repetition of self-harm (SH)/probable personality disorder vs treatment as usual (TAU) or other alternative forms of psychotherapy,-2.822282803069,"negative 
",negative,,,,,,,,,,,,,,,,,
92,CD000361,Bussel 1990a,STD-Bussel-1990a 0.927 0.248 61 65,-0.115664390796099,0.376401419473317,126,Neonatal,efficacy,DICH,1,1,no,1990.0,"Sepsis, one or more episodes",IVIG vs placebo or no treatment,-0.307289996296887,"negative 
",negative,,,,,,,,,,,,,,,,,
93,CD011101,Keita 2003,STD-Keita-2003 2 0.986 18 6,0.693147180559945,0.986013297183269,24,Gynaecology & Urology,efficacy,DICH,1,4,yes,2003.0,Incidence of shoulder tip pain,Subdiaphragmatic intraperitoneal local anaesthetic versus control,0.702979546563976,"negative 
",negative,,,,,,,,,,,,,,,,,
94,CD009687,Buckley 2008,STD-Buckley-2008 1.376 0.169 108 110,0.531121523385893,0.279225780461544,218,Skin & Wounds,efficacy,DICH,1,10,no,2008.0,Number of participants achieving 'clearance' by IGA,Steroid plus vitamin D versus steroid,1.90212208381325,"positive 
",positive,,,,,,,,,,,,,,,,,
95,CD003316,Langhammer 2007,STD-Langhammer-2007 0.167 1.107 35 40,-1.79175946922806,1.10701860692512,75,Neurology,efficacy,DICH,1,5,no,2007.0,Case fatality,Mixed training versus control - end of intervention,-1.6185450344009,"negative 
",negative,,,,,,,,,,,,,,,,,
96,CD012318,Bernat 2014,STD-Bernat-2014 0.434 0.288 348 359,-0.898691283273077,0.30812838633265,707,Heart & Hypertension,efficacy,DICH,1,1,yes,2014.0,Short-term NACE,Transradial versus transfemoral approach,-2.91661308446559,"negative 
",negative,,,,,,,,,,,,,,,,,
97,CD003738,Laurell 2002,STD-Laurell-2002 1.133 0.501 60 60,0.125163142954006,0.50071843809507,120,"Oral Health, Eyes & ENT",efficacy,DICH,1,23,no,2002.0,YAG rate (2 years),Dexamethasone versus placebo,0.249967114113424,"negative 
",negative,,,,,,,,,,,,,,,,,
98,CD008842,Segovia 2006,STD-Segovia-2006 0.354 0.636 48 51,-1.16760516015506,0.700340053457026,99,Heart & Hypertension,efficacy,DICH,1,3,yes,2006.0,Mortality,Interleukin-2 receptor antagonist (IL-2 RA) versus monoclonal antibody,-1.66719746270618,"negative 
",negative,,,,,,,,,,,,,,,,,
99,CD004415,Szeimies 2008,STD-Szeimies-2008 2.447 0.204 34 35,4.62801079030435,1.4643983926496,69,Skin & Wounds,efficacy,DICH,1,30,no,2008.0,Participant complete clearance,0.1% resiquimod versus 0.01% resiquimod,3.16034954253855,"positive 
",positive,,,,,,,,,,,,,,,,,
100,CD005291,Blockeel 2008,STD-Blockeel-2008 0.415 0.383 72 67,-0.879525538049514,0.383487038476879,139,Gynaecology & Urology,efficacy,DICH,1,2,yes,2008.0,Live birth rate per woman randomised,Repeated IVF failure,-2.2934948246042,"positive 
",positive,,,,,,,,,,,,,,,,,
101,CD005055,Miller 2000,STD-Miller-2000 1.667 0.754 63 61,0.51082562376599,0.753535727058793,124,Anaesthesia & Pain,efficacy,DICH,1,1,yes,2000.0,Mortality prior to discharge,Inhaled nitric oxide versus placebo or conventional management,0.677904982368719,"negative 
",negative,,,,,,,,,,,,,,,,,
102,CD003250,Kennedy 1978,STD-Kennedy-1978 0.25 1.088 30 30,-1.49549365308488,1.15019315642297,60,Pregnancy & Childbirth,efficacy,DICH,1,17,no,1978.0,Vaginal delivery not achieved within 24 hours,IV oxytocin and amniotomy versus intracervical PG: all women,-1.30021087739365,"negative 
",negative,,,,,,,,,,,,,,,,,
103,CD006102,Brown 2007,STD-Brown-2007 0.417 0.759 20 25,-1.04454506739783,0.880257803810674,45,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2007.0,Psychosocial mood management versus control for smokers with current depression,Psychosocial mood management versus control for smokers with current depression. Abstinence at six months or greater follow-up,-1.18663539576242,"neutral 
",neutral,,,,,,,,,,,,,,,,,
104,CD002232,Angeli 2006,STD-Angeli-2006 0.546 0.49 61 55,-0.614556905966724,0.500456863091239,116,Hepato-Biliary,efficacy,DICH,1,15,no,2006.0,Death,Ciprofloxacin versus ceftazidime,-1.22799176370708,"negative 
",negative,,,,,,,,,,,,,,,,,
105,CD009490,Russell 2003,STD-Russell-2003 0.968 0.096 83 75,-0.122062365275758,0.361432772920142,158,Skin & Wounds,efficacy,DICH,1,5,yes,2003.0,Pressure ulcer improvement,Alternating-pressure mattress versus alternating-pressure mattress overlay,-0.337718033396842,"positive 
",positive,,,,,,,,,,,,,,,,,
106,CD009071,Skerk 2002,STD-Skerk-2002 1.005 0.104 46 45,0.0273989741881143,0.526333570112174,91,Gynaecology & Urology,efficacy,DICH,1,14,no,2002.0,Microbiological efficacy (pathogen eradication) at the end of treatment,Non-fluoroquinolone antibacterial agents: azithromycin versus clarithromycin in chlamydial prostatitis,0.0520562923285987,"positive 
",positive,,,,,,,,,,,,,,,,,
107,CD004316,Martin 2000,STD-Martin-2000 0.102 1.586 10 10,-2.28238238567653,1.58564993434418,20,Gynaecology & Urology,efficacy,DICH,1,25,yes,2000.0,Azoospermia,DSG 75 µg versus DSG 300 µg daily plus testosterone implants SC (both groups),-1.43939865681671,"negative 
",negative,,,,,,,,,,,,,,,,,
108,CD008138,Faergermann 1986,STD-Faergermann-1986 1.091 0.446 22 24,0.125163142954006,0.641252276247591,46,Skin & Wounds,efficacy,DICH,1,17,yes,1986.0,Failure to achieve complete resolution,Miconazole vs steroids,0.195185494991802,"negative 
",negative,,,,,,,,,,,,,,,,,
109,CD010356,Dronkers 2008,STD-Dronkers-2008 0.375 0.508 10 10,-2.23359222150709,1.04937623195424,20,Anaesthesia & Pain,efficacy,DICH,1,1,yes,2008.0,PPC; Atelectasis,"Preoperative inspiratory muscle training (IMT) versus usual care, non-exercise intervention",-2.1284951512076,"negative 
",negative,,,,,,,,,,,,,,,,,
110,CD000480,Feigin 2001,STD-Feigin-2001 0.698 0.849 15 15,-0.374693449441411,0.870388279778489,30,Neurology,efficacy,DICH,1,1,yes,2001.0,Death or dependency at one month: Rankin,Vinpocetine versus placebo,-0.430489998712722,"negative 
",negative,,,,,,,,,,,,,,,,,
111,CD003167,Leblanc 1998,STD-Leblanc-1998 1.898 0.623 191 292,0.621447947475251,0.612826559990315,483,"Oral Health, Eyes & ENT",efficacy,DICH,1,5,yes,1998.0,Incidence of visual field defect progression,Comparison of timolol and brimonidine,1.01406823406132,"negative 
",negative,,,,,,,,,,,,,,,,,
112,CD001905,Arya 2011,STD-Arya-2011 1.068 0.17 35 23,0.234193387500795,0.595759844593266,58,Neurology,efficacy,DICH,1,4,yes,2011.0,Seizure cessation,Intravenous lorazepam versus intranasal lorazepam,0.393100323269827,"positive 
",positive,,,,,,,,,,,,,,,,,
113,CD005067,Bumb 2013,STD-Bumb-2013 1.043 0.041 50 50,1.14028498506868,1.17261165453159,100,Skin & Wounds,efficacy,DICH,1,102,no,2013.0,Participants complete cure,Radiofrequency waves versus ILSSG,0.972431905023297,"positive 
",positive,,,,,,,,,,,,,,,,,
114,CD012367,Borch 2017,STD-Borch-2017 0.156 1.483 21 23,-1.99353819804457,1.54305100415577,44,Gynaecology & Urology,efficacy,DICH,1,5,yes,2017.0,Resolution of daytime urinary incontinence,Transcutaneous electrical nerve stimulation (TENS) versus anticholinergics,-1.29194575725335,"positive 
",positive,,,,,,,,,,,,,,,,,
115,CD000340,Bischoff 2003,STD-Bischoff-2003 0.76 0.286 45 44,-0.42720509474457,0.444638875900201,89,Emergency & Trauma,efficacy,DICH,1,9,no,2003.0,Number of participants falling,Vitamin D vs control,-0.960791145127976,"negative 
",negative,,,,,,,,,,,,,,,,,
116,CD000562,Bailer 2003,STD-Bailer-2003 1.053 0.074 40 41,0.538224597954106,0.766901648282319,81,Psychiatry & Mental Health,efficacy,DICH,1,9,yes,2003.0,Non-Abstinence rates for binge eating at end of therapy,Guided self-help versus specialist psychotherapy (CBT &/or IPT),0.701816978956302,"negative 
",negative,,,,,,,,,,,,,,,,,
117,CD000340,Gray-Donald 1995,STD-Gray_x002d_Donald-1995 0.099 1.449 22 24,-2.54099611643904,1.50915362953699,46,Emergency & Trauma,efficacy,DICH,1,8,no,1995.0,Number of participants falling,Nutritional supplementation vs control,-1.68372262883443,"negative 
",negative,,,,,,,,,,,,,,,,,
118,CD000337,Hansen 1994,STD-Hansen-1994 9.882 1.383 16 7,3.1876232813641,1.54350820613872,23,Emergency & Trauma,efficacy,DICH,1,1,no,1994.0,Non-union,Conservative treatment versus internal fixation for undisplaced intracapsular fractures,2.06518065060265,"negative 
",negative,,,,,,,,,,,,,,,,,
119,CD004947,Fonseca 2007,STD-Fonseca-2007 0.381 0.666 136 138,-1.0036439307779,0.688145651746868,274,Pregnancy & Childbirth,efficacy,DICH,1,4,no,2007.0,Perinatal death,"Progesterone versus placebo: ultrasound identified short cervix, singletons",-1.45847601918305,"negative 
",negative,,,,,,,,,,,,,,,,,
120,CD004197,Taccetti 2012,STD-Taccetti-2012 1.11 0.28 105 118,0.104140259252597,0.279588622232724,223,Genetics & Endocrinology,efficacy,DICH,1,5,yes,2009.0,Positive respiratory culture for P aeruginosa,Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,0.372476742511763,"negative 
",negative,,,,,,,,,,,,,,,,,
121,CD002834,Risi 2004,STD-Risi-2004 0.96 0.299 389 269,-0.0431968615329206,0.319823188727503,658,Oncology,efficacy,DICH,1,12,yes,2004.0,Uptake of screening,Photocomic vs placebo comic,-0.135064820361494,"positive 
",positive,,,,,,,,,,,,,,,,,
122,CD001737,Poskitt 1987,STD-Poskitt-1987 0.337 0.585 25 28,1.08756245248152,0.584809748552845,53,Skin & Wounds,efficacy,DICH,1,6,yes,1987.0,Proportion fully healed in trial,Autograft versus comparator graft,1.85968591524471,"positive 
",positive,,,,,,,,,,,,,,,,,
123,CD012371,Cohen 2011,STD-Cohen-2011 0.714 0.513 64 60,-0.336472236621213,0.512695955569325,124,Psychiatry & Mental Health,efficacy,DICH,1,4,yes,2011.0,PTSD diagnosis,CBT versus other therapies (short-term),-0.656280263119252,"negative 
",negative,,,,,,,,,,,,,,,,,
124,CD005187,Carman 2000,STD-Carman-2000 -0.013 0.021 258 269,-0.223029714442324,0.367514015222392,527,Lungs,efficacy,DICH,1,1,yes,2000.0,Influenza,HCWs offered vaccination versus HCWs offered no vaccination: experimental design; data for periods of high influenza activity (three C-RCTs; Carman 2000 and Potter 1997 152 days; Lemaitre 2009 118 days),-0.606860433084063,"negative 
",negative,,,,,,,,,,,,,,,,,
125,CD011564,Mobarhan 1984,STD-Mobarhan-1984 4.922 1.546 12 6,1.12986483217221,1.62760076464846,18,Hepato-Biliary,efficacy,DICH,1,1,yes,1984.0,All-cause mortality,Vitamin D versus placebo or no intervention,0.694190403883381,"negative 
",negative,,,,,,,,,,,,,,,,,
126,CD006309,Spinelli 2003,STD-Spinelli-2003 0.463 0.3 21 17,-2.02595285672885,0.778899853437515,38,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2003.0,Evidence of depression post-treatment - Clinical Global Impression Scale,All interventions versus usual care - all trials,-2.60104408517696,"negative 
",negative,,,,,,,,,,,,,,,,,
127,CD007462,Cordtz 1989,STD-Cordtz-1989 1.417 0.186 337 354,0.407824025210726,0.217478405222485,691,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1989.0,Surgical site infection,Drape versus no drape,1.87523917509655,"negative 
",negative,,,,,,,,,,,,,,,,,
128,CD004858,Romero 1978,STD-Romero-1978 1.869 0.445 148 83,0.695747962260003,0.487305017061881,231,Psychiatry & Mental Health,efficacy,DICH,1,9,no,1978.0,Rearrest within 10 years,PSYCHOTHERAPY - UNSPECIFIED: GROUP PSYCHOTHERAPY vs NO GROUP THERAPY,1.42774635577301,"negative 
",negative,,,,,,,,,,,,,,,,,
129,CD003041,Aberg 1983,STD-Aberg-1983 0.633 0.11 542 443,-0.616662015304079,0.147547404460612,985,Heart & Hypertension,efficacy,DICH,1,1,no,1983.0,Total deaths,Ceased v continued smoking,-4.17941621920364,"negative 
",negative,,,,,,,,,,,,,,,,,
130,CD004408,Burns 2013,STD-Burns-2013 0.989 0.147 166 167,-0.0168071183163813,0.228708128395311,333,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2013.0,Health service outcomes: 1a. Readmission to hospital - by 12 months,COMMUNITY TREATMENT ORDERS compared with SUPERVISED DISCHARGE (SECTION 17),-0.0734871927565729,"negative 
",negative,,,,,,,,,,,,,,,,,
131,CD004186,Aberg 1977,STD-Aberg-1977 4.313 0.855 29 29,1.76358859226136,1.13021279075268,58,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1977.0,responders (int-to-treat),overall efficacy,1.56040402895005,"positive 
",positive,,,,,,,,,,,,,,,,,
132,CD003232,Cole 1992,STD-Cole-1992 5 1.511 16 16,1.73864964391411,1.59046269300711,32,Kidney & Transplant,efficacy,DICH,1,1,yes,1992.0,Death,Plasma exchange as adjunctive therapy,1.09317222689884,"negative 
",negative,,,,,,,,,,,,,,,,,
133,CD000551,Combes 1995,STD-Combes-1995 1.281 0.746 77 74,0.259902508344705,0.781739387847749,151,Hepato-Biliary,efficacy,DICH,1,1,yes,1995.0,All-cause mortality,UDCA versus placebo or no intervention,0.332466947917588,"negative 
",negative,,,,,,,,,,,,,,,,,
134,CD006019,Gleave 2001,STD-Gleave-2001 0.475 0.246 247 253,-0.743636580482337,0.246145340662094,500,Gynaecology & Urology,efficacy,DICH,1,2,no,2001.0,Positive Surgical Margin Status (Case analysis only),Short-term versus Long-term Neo-adjuvant hormone therapy and prostatectomy,-3.02112799893781,"negative 
",negative,,,,,,,,,,,,,,,,,
135,CD012355,Covelli 2016,STD-Covelli-2016 0.201 1.551 310 313,-1.60622247558013,1.55126750910005,623,Lungs,efficacy,DICH,1,1,no,2016.0,Mortality all-cause,Once-daily long-acting beta2-agonists/inhaled corticosteroids combined inhalers (FF/VI) versus inhaled long-acting muscarinic antagonists (TIO),-1.03542584767469,"negative 
",negative,,,,,,,,,,,,,,,,,
136,CD000528,Barakat 2005 EGY,STD-Barakat-2005-EGY 3.209 0.279 45 38,2.72129542785223,0.552165933434065,83,Infectious Diseases,efficacy,DICH,1,14,no,2005.0,Parasitological failure at three to six weeks,Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg,4.92840152402698,"negative 
",negative,,,,,,,,,,,,,,,,,
137,CD007745,Adenusi 2003,STD-Adenusi-2003 1.069 0.066 113 103,0.360098432390253,0.35196888472125,216,Infectious Diseases,efficacy,DICH,1,2,yes,2003.0,Parasitological cure,Ivermectin versus thiabendazole,1.02309734758356,"positive 
",positive,,,,,,,,,,,,,,,,,
138,CD011998,Campbell 2008,STD-Campbell-2008 9 1.47 32 32,2.32856057939731,1.51263980256031,64,Kidney & Transplant,efficacy,DICH,1,1,yes,2008.0,All-cause mortality,Dietary intervention versus control,1.5394018955841,"negative 
",negative,,,,,,,,,,,,,,,,,
139,CD005192,Richard 1995,STD-Richard-1995 0.927 0.131 48 57,-0.247836163904581,0.425017933624499,105,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,1995.0,Urine positive for cocaine metabolites,Acupuncture versus no acupuncture,-0.583119309322,"negative 
",negative,,,,,,,,,,,,,,,,,
140,CD002999,Brandt 1997,STD-Brandt-1997 0.2 0.136 20 25,0.980829253011726,0.67700320038633,45,Lungs,efficacy,DICH,1,2,no,1997.0,12 months (point prevalence),Comparison among various psychosocial interventions,1.4487808217923,"neutral 
",neutral,,,,,,,,,,,,,,,,,
141,CD005215,Clark 2005,STD-Clark-2005 0.611 0.454 75 72,-0.560618964745853,0.514650909590303,147,Gynaecology & Urology,efficacy,DICH,1,4,no,2005.0,Initiation of sexual intercourse - cluster RCT,Educational interventions,-1.08931890393849,"neutral. 
",neutral,,,,,,,,,,,,,,,,,
142,CD003444,Zhang 1997,STD-Zhang-1997 0.185 0.61 66 57,-1.92237965164512,0.666251254849407,123,Psychiatry & Mental Health,efficacy,DICH,1,2,no,1997.0,Global state: 1. Not improved/worse - medium term,HERBAL MEDICINE + ANTIPSYCHOTCS versus ANTIPSYCHOTICS,-2.88536740104097,"negative 
",negative,,,,,,,,,,,,,,,,,
143,CD005461,Kenchaveeriah 2011,STD-Kenchaveeriah-2011 2.453 0.182 350 393,1.06612357914538,0.21195801944083,743,Pregnancy & Childbirth,efficacy,DICH,1,6,yes,2011.0,Caesarean section (overall),Partograph with latent phase versus partograph without latent phase (study carried out in a low-resource setting),5.02988083186443,"negative 
",negative,,,,,,,,,,,,,,,,,
144,CD004364,Azhar 2000,STD-Azhar-2000 2.8 0.425 22 22,1.78339121955754,0.674723721859797,44,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2000.0,Response at 2-4 months,PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone,2.64314290690985,"neutral 
",neutral,,,,,,,,,,,,,,,,,
145,CD003666,D'Angio 2005,STD-D_x0027_Angio-2005 1.042 0.393 71 74,0.0487901641694318,0.462987974312362,145,Neonatal,efficacy,DICH,1,2,yes,2005.0,Death in hospital,Volume-targeted ventilation (VTV) versus pressure-limited ventilation (PLV) - infants weighing less than 1000 g,0.105381061445269,"negative 
",negative,,,,,,,,,,,,,,,,,
146,CD003807,Huijgens 1999,STD-Huijgens-1999 0.143 1.505 101 101,-1.97591239935911,1.51845934641893,202,"Oral Health, Eyes & ENT",efficacy,DICH,1,3,no,1999.0,Oral candidiasis present,Comparison of drugs absorbed from the GI tract,-1.30126131069562,"negative 
",negative,,,,,,,,,,,,,,,,,
147,CD008879,Braga 2002a,STD-Braga-2002a 0.542 0.28 50 50,-0.965925847509151,0.429043481570702,100,Gastroenterology,efficacy,DICH,1,1,no,2002.0,Total complications,All immune enhancing nutrition trials compared to no nutrition or standard nutrition,-2.25134721537537,"negative 
",negative,,,,,,,,,,,,,,,,,
148,CD003455,Chruscielewska 2012,STD-Chruscielewska-2012 2.26 0.357 59 60,1.06677168281245,0.454268620850474,119,Oncology,efficacy,DICH,1,2,yes,2012.0,Endoscopy scores Gilinsky scale grade 6-9 at 8 weeks,Endoscopic argon plasma coagulation (APC) plus oral sucralfate versus APC plus placebo,2.34832791403302,"negative 
",negative,,,,,,,,,,,,,,,,,
149,CD012152,Hegarty 2016,STD-Hegarty-2016 0.764 0.106 277 138,-0.517017594013912,0.20994008880258,415,Neonatal,efficacy,DICH,1,1,no,2016.0,Hypoglycaemia,Dextrose gel versus control,-2.46269112756305,"negative 
",negative,,,,,,,,,,,,,,,,,
150,CD001909,Baulac 2010,STD-Baulac-2010 1.133 0.22 141 141,0.161864509804434,0.284780444273739,282,Neurology,efficacy,DICH,1,1,no,2010.0,Intention-to-treat analysis,Efficacy of add-on lamotrigine versus placebo - 50% responders,0.568383514595705,"neutral 
",neutral,,,,,,,,,,,,,,,,,
151,CD003850,Arrieta 2010,STD-Arrieta-2010 0.333 1.604 20 20,-1.14862270924277,1.66334879257286,40,Neonatal,efficacy,DICH,1,1,yes,2010.0,Invasive fungal infection,Systemic antifungal agent versus placebo or no drug,-0.690548316968497,"negative 
",negative,,,,,,,,,,,,,,,,,
152,CD010699,BENEFIT-EXT 2009,STD-BENEFIT_x002d_EXT-2009 1.116 0.279 359 184,0.121146835460356,0.30813011935382,543,Kidney & Transplant,efficacy,DICH,1,1,no,2005.0,Recipient and kidney survival,Any dosage belatacept versus calcineurin inhibitor (CNI),0.393167781567128,"positive 
",positive,,,,,,,,,,,,,,,,,
153,CD004316,Matsumoto 1990,STD-Matsumoto-1990 0.667 0.904 10 10,-0.405465108108164,0.903696114115064,20,Gynaecology & Urology,efficacy,DICH,1,27,yes,1990.0,Azoospermia,TE 100 mg IM weekly versus TE 300 mg IM weekly,-0.448674174620317,"negative 
",negative,,,,,,,,,,,,,,,,,
154,CD009400,Summers 2005a,STD-Summers-2005a 2.4 1.122 30 24,0.938269638592931,1.18905367046233,54,Gastroenterology,efficacy,DICH,1,1,yes,2005.0,Clinical remission (UCDAI < 3),Trichuris suis eggs versus placebo,0.789089392599168,"positive 
",positive,,,,,,,,,,,,,,,,,
155,CD001080,Braudo 1969,STD-Braudo-1969 1.599 0.317 44 43,0.700115849876039,0.464947507710478,87,Neonatal,efficacy,DICH,1,1,no,1969.0,Mortality,Digoxin vs placebo,1.5057954678015,"negative 
",negative,,,,,,,,,,,,,,,,,
156,CD002253,Saichua 2009,STD-Saichua-2009 0.964 0.193 26 28,0.111225635110224,0.577648102724622,54,Pregnancy & Childbirth,efficacy,DICH,1,13,yes,2009.0,Complete miscarriage,Sublingual powdery versus sublingual compact misoprostol,0.192549122182867,"negative 
",negative,,,,,,,,,,,,,,,,,
157,CD008120,Pollack 2006,STD-Pollack-2006 7.857 1.197 12 12,2.06142303617716,1.19739978025981,24,Psychiatry & Mental Health,efficacy,DICH,1,6,no,2006.0,Response - as defined by original study,Olanzapine versus placebo added to antidepressants for generalised anxiety disorder,1.72158294177228,"neutral 
",neutral,,,,,,,,,,,,,,,,,
158,CD000177,Hsu 1986,STD-Hsu-1986 0.431 1.173 43 37,-0.8754687373539,1.24594580635795,80,Neurology,efficacy,DICH,1,1,no,1985.0,"All cause case fatality, early (within 4 weeks)",Prostacyclin vs control in ischaemic stroke: all trials,-0.702653946011507,"negative 
",negative,,,,,,,,,,,,,,,,,
159,CD000180,Santos 2005,STD-Santos-2005 1.892 1.202 37 35,0.664159643686693,1.24819196972153,72,Pregnancy & Childbirth,efficacy,DICH,1,5,no,2005.0,Preterm birth,Increase in exercise in overweight women,0.532097353450261,"negative 
",negative,,,,,,,,,,,,,,,,,
160,CD001467,Elmerson 1988,STD-Elmerson-1988 0.816 0.221 101 122,-0.280124171572038,0.303231970026615,223,Emergency & Trauma,efficacy,DICH,1,16,no,1988.0,Non-union,Three Gouffon screws versus Rydell four-flanged nail,-0.923794979623854,"negative 
",negative,,,,,,,,,,,,,,,,,
161,CD000338,Trafton 1984,STD-Trafton-1984 7.553 1.495 37 40,2.10625279913049,1.52950683260499,77,Emergency & Trauma,efficacy,DICH,1,2,no,1984.0,Non-union,Harris nail versus extramedullary fixation implants,1.37707969276817,"negative 
",negative,,,,,,,,,,,,,,,,,
162,CD002057,Suchomski 2002,STD-Suchomski-2002 0.937 0.06 51 27,-1.03889305396649,1.12258659750432,78,Neonatal,efficacy,DICH,1,2,yes,2002.0,Death or BPD at 36 weeks' postmenstrual age,Inhaled versus systemic steroids among infants - outcomes including deaths (Infants randomised between 12 and 21 days of age),-0.925445801932879,"negative 
",negative,,,,,,,,,,,,,,,,,
163,CD003385,Fichter 1991 a,STD-Fichter-1991-a 1.231 0.199 20 20,0.767255152713667,0.729575369499423,40,Psychiatry & Mental Health,efficacy,DICH,1,3,yes,1991.0,Remission,Psychotherapy versus combination of psychotherapy and antidepressants,1.05164618323135,"positive 
",positive,,,,,,,,,,,,,,,,,
164,CD003718,Johnson 2004,STD-Johnson-2004 3.095 0.41 73 85,1.1296410309068,0.409757080832253,158,Gynaecology & Urology,efficacy,DICH,1,1,no,2004.0,Live birth,OSCM versus no intervention,2.75685542422452,"positive 
",positive,,,,,,,,,,,,,,,,,
165,CD007464,Postmus 2000,STD-Postmus-2000 0.714 0.372 60 60,-0.419853845560264,0.461700879210073,120,Oncology,efficacy,DICH,1,1,yes,2000.0,Early death (overall response outside the brain),Teniposide versus teniposide + whole brain radiotherapy,-0.909363322587982,"negative 
",negative,,,,,,,,,,,,,,,,,
166,CD002147,Escorsell 2000,STD-Escorsell-2000 1.638 0.334 105 114,0.498086597988561,0.338049790780118,219,Hepato-Biliary,efficacy,DICH,1,3,yes,2000.0,Mortality,Terlipressin versus endoscopic treatment,1.47341193981847,"negative 
",negative,,,,,,,,,,,,,,,,,
167,CD009200,Belfrage 1983,STD-Belfrage-1983 0.91 0.132 24 23,-0.562118918153541,0.797474082513471,47,Pregnancy & Childbirth,efficacy,DICH,1,5,no,1983.0,Satisfaction with pain,Local anaesthetic nerve block bupivacaine versus other local anaesthetic solution,-0.704874215324792,"negative 
",negative,,,,,,,,,,,,,,,,,
168,CD005955,Asplund 2000,STD-Asplund-2000 1.092 0.05 182 217,0.442520983551904,0.256016054622657,399,Spine & Muscles,efficacy,DICH,1,5,yes,2000.0,Discharge to preadmission residence/home from hospital - MDI versus usual care,Hospital outcomes - multidisciplinary intervention versus usual care,1.72848919261777,"positive 
",positive,,,,,,,,,,,,,,,,,
169,CD004161,Chue 2002,STD-Chue-2002 1.06 0.073 319 321,0.126796616961745,0.158683016419686,640,Psychiatry & Mental Health,efficacy,DICH,1,3,no,2002.0,Global state: 1. Moderate to severely ill at end of study period (CGI rating),RISPERIDONE DEPOT vs ORAL RISPERIDONE,0.79905600374014,"negative 
",negative,,,,,,,,,,,,,,,,,
170,CD003987,Dionne 1974,STD-Dionne-1974 1.92 0.484 53 56,0.667829372575655,0.497751353846888,109,Gynaecology & Urology,efficacy,DICH,1,36,no,1974.0,Gained >2.7 kg (cycle 6),Levonorgestrel 250 µg and EE 50 µg versus levonorgestrel 150 µg and EE 30 µg,1.34169272954119,"negative 
",negative,,,,,,,,,,,,,,,,,
171,CD006319,Ho 1998,STD-Ho-1998 2 1.241 52 51,0.693147180559945,1.24096736459909,103,Gastroenterology,efficacy,DICH,1,5,yes,1998.0,Recurrence,Fistulotomy Vs. Marsupialization fistulotomy,0.558553915544651,"negative 
",negative,,,,,,,,,,,,,,,,,
172,CD000515,BACASS 2008,STD-BACASS-2008 0.302 1.693 10 10,-1.19869574722509,1.69327136626103,20,Neurology,efficacy,DICH,1,1,no,2008.0,Death or any stroke between randomisation and 30 days after treatment,Endovascular treatment or endarterectomy for symptomatic carotid stenosis,-0.707917095339522,"negative 
",negative,,,,,,,,,,,,,,,,,
173,CD009199,Dieterich 1988,STD-Dieterich-1988 1 0.267 50 50,0.0,0.416666666666667,100,Anaesthesia & Pain,efficacy,DICH,1,5,no,1988.0,Any headache,Fluids versus less or no fluids,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
174,CD003350,Wang 1988,STD-Wang-1988 1.238 0.542 25 30,0.213574100298059,0.542388220451903,55,Anaesthesia & Pain,efficacy,DICH,1,1,no,1988.0,Improvement in pain rating (four hours),TENS stimulation versus no such treatment,0.393766111144736,"positive 
",positive,,,,,,,,,,,,,,,,,
175,CD010747,Losordo 2012,STD-Losordo-2012 3.214 0.668 7 9,2.16905370036952,1.15881713089561,16,Heart & Hypertension,efficacy,DICH,1,3,no,2012.0,Amputation rate,Low cell dose vs high cell dose,1.87178256390905,"negative 
",negative,,,,,,,,,,,,,,,,,
176,CD001467,Nordkild 1985,STD-Nordkild-1985 0.507 0.603 30 19,-0.842182759720433,0.748258050334315,49,Emergency & Trauma,efficacy,DICH,1,4,no,1985.0,Non-union,Sliding hip screw versus sliding nail plate,-1.12552448897029,"negative 
",negative,,,,,,,,,,,,,,,,,
177,CD012370,Decker 2008,STD-Decker-2008 0.963 0.226 75 78,-0.0571584138399486,0.341533131883705,153,Public Health & Work,efficacy,DICH,1,3,no,2008.0,Hospital readmissions at the time point closest to 90 days,Hospital readmissions in participants treated in short-stay unit vs usual care,-0.167358327798814,"negative 
",negative,,,,,,,,,,,,,,,,,
178,CD000208,Zeng 1995,STD-Zeng-1995 0.526 0.24 21 21,-2.34660197841082,0.862288043438189,42,Psychiatry & Mental Health,efficacy,DICH,1,12,no,1995.0,Tardive dyskinesia: 1. No clinically important improvement - medium term,ANXIOLYTIC - BUSPIRONE versus PLACEBO,-2.72136671297708,"negative 
",negative,,,,,,,,,,,,,,,,,
179,CD004818,Swift 1992,STD-Swift-1992 0.091 1.396 10 24,-3.04452243772342,1.50174501671825,34,Heart & Hypertension,efficacy,DICH,1,6,yes,1992.0,Improved contraction in at least one segment (post-HBOT echo),Improvement in left ventricular function,-2.02732314995564,"positive 
",positive,,,,,,,,,,,,,,,,,
180,CD009992,Budimulja 1998,STD-Budimulja-1998 0.999 0.023 86 89,-0.0350913198112695,1.01163185733661,175,Skin & Wounds,efficacy,DICH,1,4,no,1998.0,Mycological cure,Azoles versus allylamines,-0.034687835853308,"positive 
",positive,,,,,,,,,,,,,,,,,
181,CD007624,Tinetti 1999,STD-Tinetti-1999 1.153 0.18 144 148,0.202930685576121,0.256279633140049,292,Emergency & Trauma,efficacy,DICH,1,8,yes,1999.0,'Poor outcome': dead or incomplete recovery of self-care ADL,Home based rehabilitation versus usual care: post discharge,0.791833057858429,"negative 
",negative,,,,,,,,,,,,,,,,,
182,CD003167,Flammer 1992,STD-Flammer-1992 0.332 1.022 37 35,-1.21639532432449,1.17998352154219,72,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,yes,1992.0,Incidence of visual field defect progression,Comparison of timolol and carteolol,-1.03085789090911,"negative 
",negative,,,,,,,,,,,,,,,,,
183,CD011424,El-Khayat 2015,STD-El_x002d_Khayat-2015 1.294 0.304 166 166,0.291962115671558,0.343415096795012,332,Gynaecology & Urology,efficacy,DICH,1,2,no,2015.0,Live birth or ongoing pregnancy,Higher vs. lower degree of intentional endometrial injury,0.850172628973948,"positive 
",positive,,,,,,,,,,,,,,,,,
184,CD007529,Lees 2013,STD-Lees-2013 0.841 0.395 167 166,-0.186472170520268,0.42518039930698,333,Pregnancy & Childbirth,efficacy,DICH,1,5,yes,2013.0,Any perinatal death after randomisation,Early ductus venosus Doppler ultrasound versus CTG,-0.438571888130796,"negative 
",negative,,,,,,,,,,,,,,,,,
185,CD009031,Ahmed 2007,STD-Ahmed-2007 1.426 0.894 61 58,0.370373788296894,0.931896912485936,119,Oncology,efficacy,DICH,1,2,yes,2007.0,Treatment failure,Outpatients versus inpatients - children,0.397440729048969,"negative 
",negative,,,,,,,,,,,,,,,,,
186,CD005563,Chan 2013,STD-Chan-2013 0.645 0.138 450 452,-0.545293445734276,0.170314582625012,902,Psychiatry & Mental Health,efficacy,DICH,1,14,no,2013.0,Incident delirium,Bispectral index (BIS)-guided anaesthesia versus BIS-blinded anaesthesia/clinical judgement,-3.20168383311528,"negative 
",negative,,,,,,,,,,,,,,,,,
187,CD000218,Notowicz 1977,STD-Notowicz-1977 2.495 0.39 53 85,1.10900444643572,0.470466367466953,138,Infectious Diseases,efficacy,DICH,1,21,no,1977.0,No parasitological cure (1-3 weeks),Carnidazole 1.5g versus 2g,2.35724490234389,"negative 
",negative,,,,,,,,,,,,,,,,,
188,CD004310,Gebbia 1996,STD-Gebbia-1996 0.803 0.145 62 60,-0.57497707309691,0.377025030031131,122,Anaesthesia & Pain,efficacy,DICH,1,3,yes,1996.0,Appetite improvement,Megestrol acetate versus megestrol acetate (ITT),-1.52503687367768,"positive 
",positive,,,,,,,,,,,,,,,,,
189,CD000324,Yalcinkaya 2000,STD-Yalcinkaya-2000 0.681 0.418 48 52,-0.388073365396295,0.421179433669114,100,Gynaecology & Urology,efficacy,DICH,1,11,no,2000.0,primary treatment success,25 mg/m2 versus the standard 50 mg/m2 MTX both single dose im,-0.921396759608097,"positive 
",positive,,,,,,,,,,,,,,,,,
190,CD003220,Vargas 2006,STD-Vargas-2006 4.394 1.528 32 28,1.54161531609534,1.57094704065546,60,"Oral Health, Eyes & ENT",efficacy,DICH,1,11,yes,2006.0,Clinical failure,Sodium hypochlorite (NaOCl) pulpotomy versus ferric sulfate (FS) pulpotomy,0.981328635656691,"negative 
",negative,,,,,,,,,,,,,,,,,
191,CD008000,Liu 2001a,STD-Liu-2001a 0.413 0.442 22 20,-1.42444612708427,0.678854720416649,42,Kidney & Transplant,efficacy,DICH,1,1,yes,2001.0,Incidence of ESKD,Rheum officinale versus no treatment,-2.09830775900035,"negative 
",negative,,,,,,,,,,,,,,,,,
192,CD010529,Millar 1980,STD-Millar-1980 0.333 1.033 7 11,-1.09861228866811,1.03279555898864,18,Anaesthesia & Pain,efficacy,DICH,1,5,yes,1980.0,Pleurodesis failure,C. parvum,-1.0637267744876,"negative 
",negative,,,,,,,,,,,,,,,,,
193,CD000345,Gregorio 1996,STD-Gregorio-1996 1.114 0.536 34 30,0.109698917256425,0.541403278997103,64,Hepato-Biliary,efficacy,DICH,1,9,no,1996.0,Loss of HBeAg,Gluco+IFN versus Control+IFN (trials stratified according to length of follow-up),0.202619602636377,"positive 
",positive,,,,,,,,,,,,,,,,,
194,CD001338,Hoffman 2001,STD-Hoffman-2001 0.156 0.585 47 49,-2.31401378881767,0.663734408239693,96,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2001.0,Vaginal delivery not achieved in 24 hours,Oral misoprostol versus placebo/ no treatment (1): all women,-3.48635502407465,"negative 
",negative,,,,,,,,,,,,,,,,,
195,CD006686,BRAIN 2009,STD-BRAIN-2009 1.204 0.346 163 57,0.225161715470447,0.414461417427884,220,Emergency & Trauma,efficacy,DICH,1,1,no,2009.0,Mortality at end of follow-up period,Beta-2 receptor antagonist versus placebo,0.543263391964886,"negative 
",negative,,,,,,,,,,,,,,,,,
196,CD005167,Goldstein 1996,STD-Goldstein-1996 0.893 0.28 28 25,-0.22314355131421,0.551222417764512,53,Psychiatry & Mental Health,efficacy,DICH,1,7,no,1996.0,Relapse rates,Family intervention versus Individual intervention (subgroup analysis),-0.404815813223219,"negative 
",negative,,,,,,,,,,,,,,,,,
197,CD000978,Antunes 2007,STD-Antunes-2007 0.846 0.109 19 19,-2.11296423371848,1.54841932227753,38,"Oral Health, Eyes & ENT",efficacy,DICH,1,13,no,2007.0,Mucositis (any),Laser versus no treatment,-1.36459433392408,"negative 
",negative,,,,,,,,,,,,,,,,,
198,CD000314,Kelly 1997,STD-Kelly-1997 1.333 0.671 15 15,0.37469344944141,0.870388279778489,30,Emergency & Trauma,efficacy,DICH,1,1,no,1997.0,Functional grading: poor or fair,Manipulation versus control,0.430489998712722,"negative 
",negative,,,,,,,,,,,,,,,,,
199,CD007778,Xu 2009,STD-Xu-2009 0.833 0.548 30 30,-0.22314355131421,0.669576980886689,60,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2009.0,Global state: 1. Not improved - short term (CGI-SI),CHLORPROMAZINE LOW DOSE (=400 mg/day) vs MEDIUM DOSE (401-800 mg/day),-0.333260487866103,"negative 
",negative,,,,,,,,,,,,,,,,,
200,CD012621,Bermejo 2017,STD-Bermejo-2017 0.4 0.301 104 96,-0.915147221172077,0.30101712723018,200,Lungs,efficacy,DICH,1,4,yes,2017.0,Improvement in WHO functional class,Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo),-3.04018322675801,"positive 
",positive,,,,,,,,,,,,,,,,,
201,CD004325,Kirkley 1999,STD-Kirkley-1999 0.938 1.368 16 15,-0.0689928714869512,1.46222270468463,31,Emergency & Trauma,efficacy,DICH,1,1,yes,1999.0,Non return to pre-injury level of activity,Surgical versus non-surgical treatment,-0.0471835591568327,"negative 
",negative,,,,,,,,,,,,,,,,,
202,CD008615,Carpay 2004,STD-Carpay-2004 2.565 0.185 141 155,1.41293172064819,0.264014307682938,296,Anaesthesia & Pain,efficacy,DICH,1,4,no,2004.0,Pain-free at 2 h,Oral sumatriptan 50 mg versus placebo,5.35172405256543,"positive 
",positive,,,,,,,,,,,,,,,,,
203,CD003553,Reiter 1990,STD-Reiter-1990 0.585 0.358 132 128,-0.535657599467173,0.358072263107672,260,Gynaecology & Urology,efficacy,DICH,1,7,yes,1990.0,Proportion of women with intermenstrual bleeding within 12 cycles,Triphasic LNG 50-75-125 µg and EE 30-40-30 µg versus monophasic NET 1000 µg and EE 35 µg,-1.49594831729846,"negative 
",negative,,,,,,,,,,,,,,,,,
204,CD002251,Davies 2006,STD-Davies-2006 0.467 0.39 35 35,-1.09861228866811,0.543358164784606,70,Pregnancy & Childbirth,efficacy,DICH,1,9,yes,2006.0,Women with hypotension requiring intervention,Colloid: different volumes,-2.02189340267596,"negative 
",negative,,,,,,,,,,,,,,,,,
205,CD004385,Combes 2005,STD-Combes-2005 0.646 0.468 132 134,-0.468114505672941,0.499896304314252,266,Hepato-Biliary,efficacy,DICH,1,1,no,2005.0,Mortality,Methotrexate (with or without ursodeoxycholic acid) versus placebo (with or without ursodeoxycholic acid),-0.936423217441248,"negative 
",negative,,,,,,,,,,,,,,,,,
206,CD010628,Müller 2004,STD-M_x00fc_ller-2004 2.167 0.238 82 82,1.17087285589959,0.346521853784245,164,Psychiatry & Mental Health,efficacy,DICH,1,9,no,2004.0,Treatment response (post-treatment score on self report and clinician-rated scales),Best-case/worst-case analysis (based on comparison 'natural products versus placebo'),3.37892933191051,"neutral 
",neutral,,,,,,,,,,,,,,,,,
207,CD006409,Azoulay 2006,STD-Azoulay-2006 5.351 1.571 30 30,1.67726050877286,1.57094704065546,60,Hepato-Biliary,efficacy,DICH,1,13,no,2006.0,Mortality,Ischaemic pre-conditioning (IPC) versus control (continuous vascular occlusion),1.06767476265339,"negative 
",negative,,,,,,,,,,,,,,,,,
208,CD011782,EQUINOX,STD-EQUINOX 0.721 0.435 386 371,-0.336604871411513,0.447082184456815,757,Heart & Hypertension,efficacy,DICH,1,2,yes,2008.0,Recurrent VTE [6-months follow-up],Idrabiotaparinux versus idraparinux,-0.752892607028107,"negative 
",negative,,,,,,,,,,,,,,,,,
209,CD005183,SHEP,STD-SHEP 0.98 0.466 116 101,-0.0224463056522665,0.506171506187061,217,Heart & Hypertension,efficacy,DICH,1,9,no,1991.0,Stroke,Diuretic versus placebo,-0.0443452572456169,"negative 
",negative,,,,,,,,,,,,,,,,,
210,CD008121,Amore 2001,STD-Amore-2001 0.609 0.288 157 156,-0.495720517250865,0.288107872067603,313,Psychiatry & Mental Health,efficacy,DICH,1,11,no,2001.0,No clinically important response - as defined by original study,Amisulpride versus antidepressants for dysthymia,-1.72060733257072,"negative 
",negative,,,,,,,,,,,,,,,,,
211,CD004158,Stevinson 2003,STD-Stevinson-2003 1.833 0.662 20 22,0.747214401830221,0.807856162288417,42,Neurology,efficacy,DICH,1,11,no,2003.0,Iatrogenic symptoms (number of participants with no clinician-rated bruising),High-dose arnica oral tablets versus placebo,0.92493495341248,"negative 
",negative,,,,,,,,,,,,,,,,,
212,CD003643,Miller 1992,STD-Miller-1992 1 0.62 26 13,0.0,0.806225774829855,39,Neurology,efficacy,DICH,1,3,no,1992.0,Number of patients who improved after treatment,Plasma exchange or leukapheresis versus placebo,0.0,"positive 
",positive,,,,,,,,,,,,,,,,,
213,CD001338,Aalami-Harandi 2013 (T),STD-Aalami_x002d_Harandi-2013-_x0028_T_x0029_ 0.531 0.208 128 128,-0.889248720906394,0.285187396537037,256,Pregnancy & Childbirth,efficacy,DICH,1,15,no,2013.0,Vaginal delivery not achieved in 24 hours,Oral misoprostol versus oxytocin (4): all women,-3.11812068732465,"negative 
",negative,,,,,,,,,,,,,,,,,
214,CD005048,Heier 1995,STD-Heier-1995 2.111 0.808 22 20,0.747214401830221,0.807856162288417,42,Gastroenterology,efficacy,DICH,1,5,no,1995.0,Dysphagia improvement (2-point grade or more),Laser versus photodynamic therapy (PDT),0.92493495341248,"positive 
",positive,,,,,,,,,,,,,,,,,
215,CD004483,Donly 1999,STD-Donly-1999 0.643 0.952 30 30,-0.44183275227904,0.951884791392664,60,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,no,1999.0,Replacement (Failure) of restoration at 12 months,Vitremer versus amalgam for primary Class II restorations,-0.464166206114725,"negative 
",negative,,,,,,,,,,,,,,,,,
216,CD010564,Chiswick 2015,STD-Chiswick-2015 0.839 0.222 214 220,-0.209078421005865,0.263690804463553,434,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2015.0,"Large-for-gestational-age infant, defined as birthweight = 90th percentile for gestational age and infant sex",Metformin versus placebo,-0.792892347653951,"negative 
",negative,,,,,,,,,,,,,,,,,
217,CD004310,Loprinzi 1999a,STD-Loprinzi-1999a 0.818 0.187 79 159,-0.317201567289771,0.28893040473324,238,Anaesthesia & Pain,efficacy,DICH,1,2,no,1999.0,Appetite improvement,Megestrol acetate versus other drugs (ITT),-1.09784765498333,"positive 
",positive,,,,,,,,,,,,,,,,,
218,CD008121,Boyer 1999a,STD-Boyer-1999a 0.3 0.288 104 108,-1.20511500890471,0.287915019942369,212,Psychiatry & Mental Health,efficacy,DICH,1,10,no,1999.0,No clinically important response (as defined by original study),Amisulpride versus placebo for dysthymia,-4.18566217610299,"negative 
",negative,,,,,,,,,,,,,,,,,
219,CD003964,Chen 2008,STD-Chen-2008 0.522 0.252 45 47,-1.18269540587865,0.438215130508241,92,Kidney & Transplant,efficacy,DICH,1,7,yes,2008.0,Number of patients developing infection,Chinese medicinal herb (Huangqi granules) + baseline treatment versus baseline treatment,-2.69889221877611,"negative 
",negative,,,,,,,,,,,,,,,,,
220,CD002290,Barratt 1973,STD-Barratt-1973 0.267 0.71 15 14,-1.87180217690159,0.928782731664065,29,Kidney & Transplant,efficacy,DICH,1,2,yes,1973.0,Relapse at 6 months,Cyclophosphamide duration,-2.01532835730909,"negative 
",negative,,,,,,,,,,,,,,,,,
221,CD006263,Werth 2008,STD-Werth-2008 1.852 0.568 9 10,1.07044141170141,0.962387903181704,19,Skin & Wounds,efficacy,DICH,1,6,no,2008.0,Remission (<7.5mg prednisone) at 12 months,Dapsone vs placebo,1.11227646166632,"positive 
",positive,,,,,,,,,,,,,,,,,
222,CD003840,Feng 2005,STD-Feng-2005 0.15 0.557 25 15,-3.3787245258101,0.891882585015845,40,Gastroenterology,efficacy,DICH,1,5,yes,2005.0,Proportion not healed,H. pylori eradication vs. no treatment/placebo: peptic ulcer acute healing,-3.78830642348519,"negative 
",negative,,,,,,,,,,,,,,,,,
223,CD011689,Alwani 2014,STD-Alwani-2014 0.333 1.627 100 100,-1.10861237200269,1.63910559961192,200,Pregnancy & Childbirth,efficacy,DICH,1,8,no,2014.0,Death,Misoprostol vs Oxytocin,-0.67635201311323,"negative 
",negative,,,,,,,,,,,,,,,,,
224,CD001233,Matonhodze 2003,STD-Matonhodze-2003 1.142 0.125 174 176,0.230514812929189,0.216573821565396,350,Pregnancy & Childbirth,efficacy,DICH,1,34,yes,2003.0,Vaginal delivery not achieved in 24 hours,Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women,1.06437062089512,"negative 
",negative,,,,,,,,,,,,,,,,,
225,CD005284,Friedland 1990,STD-Friedland-1990 1.125 0.134 20 20,0.810930216216329,0.931694990624912,40,Kidney & Transplant,efficacy,DICH,1,14,yes,1990.0,Failure to achieve complete cure,Comparison of two intraperitoneal antibiotic regimens,0.87038164246479,"negative 
",negative,,,,,,,,,,,,,,,,,
226,CD005063,Kaim 1972,STD-Kaim-1972 0.14 1.046 103 130,-2.02640684502375,1.06262857833283,233,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1972.0,Alcohol withdrawal seizures,Benzodiazepine versus Placebo,-1.90697566990246,"negative 
",negative,,,,,,,,,,,,,,,,,
227,CD010112,Birch 2005,STD-Birch-2005 0.563 0.252 38 51,-1.09218139833782,0.446297144780477,89,Neonatal,efficacy,DICH,1,1,yes,2010.0,All allergic disease,Higher versus lower PUFA intake,-2.44720677940935,"negative 
",negative,,,,,,,,,,,,,,,,,
228,CD001860,Bowman 2000,STD-Bowman-2000 0.646 0.148 152 139,-0.730017716368273,0.243390853040768,291,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,no,2000.0,Active trachoma at 3 months,Oral versus topical antibiotics (individuals),-2.99936381029897,"negative 
",negative,,,,,,,,,,,,,,,,,
229,CD001021,Schuster 2013,STD-Schuster-2013 1.19 0.164 183 191,0.243506245833094,0.229287082425485,374,Genetics & Endocrinology,efficacy,DICH,1,2,yes,2008.0,Number of pulmonary exacerbations,Colistimethate sodium dry powder (CDPI) versus tobramycin for inhalation solution (TIS),1.06201467285987,"negative 
",negative,,,,,,,,,,,,,,,,,
230,CD005111,Lembo 2009,STD-Lembo-2009 1.682 0.182 78 77,0.979091633113185,0.331701925637793,155,Gastroenterology,efficacy,DICH,1,7,no,2009.0,"Symptom severity (responders) (short-term: up to 3 mons, closest to 8 wks)",Acupuncture versus no specific treatment,2.95172128178213,"neutral 
",neutral,,,,,,,,,,,,,,,,,
231,CD007345,Niederau 1994,STD-Niederau-1994 0.2 1.536 50 50,-1.64984745077198,1.56218453996289,100,Hepato-Biliary,efficacy,DICH,1,2,yes,1994.0,Cholangitis,Prophylactic antibiotics vs placebo (only including patients with biliary obstruction relieved at first ERCP),-1.056115592343,"negative 
",negative,,,,,,,,,,,,,,,,,
232,CD003556,Piaggessi 1998,STD-Piaggessi-1998 1.206 0.115 22 24,1.70952137099108,1.14028532682238,46,Skin & Wounds,efficacy,DICH,1,1,no,1998.0,Number of ulcers completely healed,Surgical debridement compared with conventional nonsurgical management,1.49920491896093,"positive 
",positive,,,,,,,,,,,,,,,,,
233,CD002114,Bø 1999,STD-B_x00f8_-1999 0.383 0.253 27 30,-3.89792408104864,1.09238559494002,57,Gynaecology & Urology,efficacy,DICH,1,1,yes,1999.0,No subjective improvement or cure,CONES versus CONTROL,-3.56826755964562,"negative 
",negative,,,,,,,,,,,,,,,,,
234,CD011006,Costa 1985,STD-Costa-1985 0.433 0.35 36 37,1.30683018976564,0.518557055893765,73,Oncology,efficacy,DICH,1,3,no,1985.0,Antidepressants versus placebo,Depression: efficacy as a dichotomous outcome at 6 to 12 weeks,2.52012806481486,"neutral 
",neutral,,,,,,,,,,,,,,,,,
235,CD011159,Smith 2014,STD-Smith-2014 1.394 0.09 211 220,0.738544414422368,0.197153883014759,431,Gynaecology & Urology,efficacy,DICH,1,4,yes,2013.0,Effective contraception use at 4 months,Voice messages and counsellor support vs standard care,3.74603027406303,"positive 
",positive,,,,,,,,,,,,,,,,,
236,CD008327,Salusky 1998,STD-Salusky-1998 1.062 0.213 16 17,0.22314355131421,0.785281265959316,33,Kidney & Transplant,efficacy,DICH,1,1,yes,1998.0,Bone disease on bone histology,Intraperitoneal versus oral calcitriol,0.284157487243265,"negative 
",negative,,,,,,,,,,,,,,,,,
237,CD001822,Gatchel 2003,STD-Gatchel-2003 0.22 0.804 22 48,-1.51412773262978,0.804344265205948,70,Spine & Muscles,efficacy,DICH,1,3,yes,2003.0,Proportion off work long term follow up,"Intense physical conditioning programme (PCP) versus care as usual (CaU), acute pain",-1.88243740662724,"negative 
",negative,,,,,,,,,,,,,,,,,
238,CD006020,Armstrong 2000,STD-Armstrong-2000 0.438 0.425 80 80,-0.958254930973187,0.484438616332481,160,Emergency & Trauma,efficacy,DICH,1,1,yes,2000.0,Medically attended or self-reported injuries - RCTs only,Intervention versus Control (n/N in clustered studies adjusted for clustering),-1.97807296665944,"negative 
",negative,,,,,,,,,,,,,,,,,
239,CD001971,Baier 1998,STD-Baier-1998 0.111 1.003 19 19,-2.78501124223834,1.12546286774228,38,Neonatal,efficacy,DICH,1,1,no,1998.0,Incidence of sepsis (all pathogens); number of patients with one or more episodes,Vancomycin versus control,-2.4745474258295,"negative 
",negative,,,,,,,,,,,,,,,,,
240,CD004970,Romeo 2005,STD-Romeo-2005 0.3 1.567 9 8,-1.33500106673234,1.70448325245358,17,"Oral Health, Eyes & ENT",efficacy,DICH,1,5,no,2005.0,Implant failure,Adjunctive implant surface smoothening to systemic antibiotics + resective surgery + 2 different local antibiotics (6 months),-0.783229207333439,"negative 
",negative,,,,,,,,,,,,,,,,,
241,CD002140,Curran 2003,STD-Curran-2003 0.914 0.072 201 201,-0.267217554831179,0.211449299180503,402,Oncology,efficacy,DICH,1,4,no,2003.0,Dose of radiotherapy,Subgroup analysis Concurrent vs Sequential,-1.26374292024997,"neutral 
",neutral,,,,,,,,,,,,,,,,,
242,CD009961,Walsh 1971,STD-Walsh-1971 0.036 0.994 15 16,-3.3322045101752,0.994029797388005,31,Genetics & Endocrinology,efficacy,DICH,1,1,yes,1968.0,Incidence of oral bleeding,Antifibrinolytic agents in people with haemophilia undergoing dental extractions,-3.35221793041937,"negative 
",negative,,,,,,,,,,,,,,,,,
243,CD006097,Sands 2007,STD-Sands-2007 0.902 0.163 52 27,-0.312928855186565,0.510456842639774,79,Gastroenterology,efficacy,DICH,1,5,no,2007.0,Failure to induce clinical remission at week 10,Three infusions of natalizumab (300 mg) and two infusions of infliximab versus placebo and two infusions of infliximab,-0.61303685061461,"negative 
",negative,,,,,,,,,,,,,,,,,
244,CD009071,Skerk 2004b,STD-Skerk-2004b 0.988 0.103 46 43,-0.0622131845015726,0.540101441128948,89,Gynaecology & Urology,efficacy,DICH,1,17,no,2004.0,Microbiological efficacy (pathogen eradication) at the end of treatment,Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in chlamydial prostatitis,-0.11518796241597,"positive 
",positive,,,,,,,,,,,,,,,,,
245,CD004551,Cavusoglu 2009,STD-Cavusoglu-2009 0.862 0.086 300 310,-0.280509275677795,0.162653379963602,610,Skin & Wounds,efficacy,DICH,1,3,no,2009.0,Minor infection,Sterile cleansing method compared with non-sterile cleansing,-1.7245831334127,"negative 
",negative,,,,,,,,,,,,,,,,,
246,CD012510,FAIR,STD-FAIR 0.34 0.411 62 57,-1.08001086271756,0.410586458846834,119,Heart & Hypertension,efficacy,DICH,1,3,no,2015.0,Binary restenosis,Drug-eluting balloon (DEB) versus uncoated balloon angioplasty at 12 months,-2.63041033002127,"negative 
",negative,,,,,,,,,,,,,,,,,
247,CD011353,Bowden 2007,STD-Bowden-2007 1.167 0.438 17 17,0.249460859631583,0.707412821790007,34,Kidney & Transplant,efficacy,DICH,1,1,yes,2007.0,Loss of patency by 6 months,Omega-3 fatty acids versus placebo,0.352638306725001,"negative 
",negative,,,,,,,,,,,,,,,,,
248,CD000184,Bujold 2003b,STD-Bujold-2003b 0.559 0.34 36 38,-0.887303195000903,0.504569841725564,74,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,2003.0,Cephalic presentation at birth (primary),Tocolytic drug 1 (A) vs tocolytic drug 2 (A),-1.75853394639371,"positive 
",positive,,,,,,,,,,,,,,,,,
249,CD001352,Amundsen 2000,STD-Amundsen-2000 0.094 1.149 13 17,-2.36712361413162,1.14867072934085,30,Spine & Muscles,efficacy,DICH,1,1,no,2000.0,Secondary surgery by 4 years,DECOMPRESSION vs CONSERVATIVE,-2.06075035575248,"negative 
",negative,,,,,,,,,,,,,,,,,
250,CD005511,Pecora 2001,STD-Pecora-2001 1.118 0.151 9 9,1.20983792377833,1.69987554938146,18,"Oral Health, Eyes & ENT",efficacy,DICH,1,8,no,2001.0,Calcium sulphate (CaS) versus no grafting - healing at 1 year,Grafting versus no grafting,0.711721469385543,"neutral 
",neutral,,,,,,,,,,,,,,,,,
251,CD007006,Jemmott 1998,STD-Jemmott-1998 0.521 0.396 172 164,-0.651214328931959,0.39578832941968,336,Infectious Diseases,efficacy,DICH,1,6,yes,1998.0,Unprotected sex in past 3m - 3m,Jemmott 1998: A+ Abstinence-focused vs. A+ Condom-focused vs. Attention,-1.64536010924525,"negative 
",negative,,,,,,,,,,,,,,,,,
252,CD011136,Frohlich 2011,STD-Frohlich-2011 0.062 0.818 30 30,-2.77258872223978,0.818317088384971,60,Anaesthesia & Pain,efficacy,DICH,1,7,yes,2011.0,Successful first attempt,VLS versus Macintosh,-3.38815938417192,"positive 
",positive,,,,,,,,,,,,,,,,,
253,CD008121,Cutler 2009,STD-Cutler-2009 0.448 0.234 152 157,-0.802373731251138,0.23350949904601,309,Psychiatry & Mental Health,efficacy,DICH,1,6,no,2009.0,Non-response to treatment - as defined by the original study,Quetiapine versus placebo for major depression,-3.43615028308995,"negative 
",negative,,,,,,,,,,,,,,,,,
254,CD010285,Asicioglu 2013,STD-A_x015f_icio_x011f_lu-2013 1.009 0.032 578 578,0.0394853294360957,0.140517249761082,1156,Infectious Diseases,efficacy,DICH,1,3,no,2013.0,Effectiveness of cure in mild-moderate PID,Regimens containing nitroimidazoles versus no nitroimidazoles,0.280999873703988,"positive 
",positive,,,,,,,,,,,,,,,,,
255,CD000493,Kondrackiene 2005,STD-Kondrackiene-2005 3.5 0.336 42 42,2.14006616349627,0.511424111524613,84,Pregnancy & Childbirth,efficacy,DICH,1,8,yes,2005.0,Pruritus score (> 50% reduction after 14 days treatment),UDCA versus cholestyramine,4.18452340292774,"positive 
",positive,,,,,,,,,,,,,,,,,
256,CD006774,Bloom 2004,STD-Bloom-2004 1.083 0.678 48 52,0.0870113769896297,0.737265627884961,100,Gastroenterology,efficacy,DICH,1,1,no,2004.0,Clinical remission,LMWH versus placebo,0.118019033708712,"positive 
",positive,,,,,,,,,,,,,,,,,
257,CD004834,Martínez 1997,STD-Mart_x00ed_nez-1997 1.82 0.201 51 49,1.33222713984962,0.424746226263573,100,Skin & Wounds,efficacy,DICH,1,16,yes,1997.0,Complete cure,Oral AL + IVSSG (20 mg/kg/d (4 doses) x 15d) vs IVSSG (same dose) in L. braziliensis; FU: 1 year,3.13652495884192,"positive 
",positive,,,,,,,,,,,,,,,,,
258,CD005284,Merchant 1992,STD-Merchant-1992 4.381 0.63 7 23,2.18480205733766,0.983192080250175,30,Kidney & Transplant,efficacy,DICH,1,5,yes,1992.0,Failure to achieve complete cure,Low versus high dose antibiotic,2.22215180657449,"negative 
",negative,,,,,,,,,,,,,,,,,
259,CD004876,Crocetti 2001,STD-Crocetti-2001 0.916 0.148 275 550,-0.0872969767741469,0.147765501400028,825,Lungs,efficacy,DICH,1,14,no,2001.0,Hospitalisations for influenza or pneumonia,Influenza vaccines versus no vaccination: case-control studies in community,-0.590780499825994,"negative 
",negative,,,,,,,,,,,,,,,,,
260,CD001132,FFSSG 1989,STD-FFSSG-1989 0.502 0.228 105 108,-0.973107206917816,0.313311727935475,213,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,yes,1989.0,Failure at 12 months,Regular-dose postoperative 5-Fluorouracil (5-FU) versus control,-3.10587545933876,"negative 
",negative,,,,,,,,,,,,,,,,,
261,CD002114,Olah 1990,STD-Olah-1990 1.944 0.328 24 30,1.18377009700842,0.574594404914223,54,Gynaecology & Urology,efficacy,DICH,1,3,no,1990.0,No subjective improvement or cure after treatment,CONES versus ELECTROSTIMULATION,2.06018382163873,"negative 
",negative,,,,,,,,,,,,,,,,,
262,CD013124,Reed 2018,STD-Reed-2018 2.167 0.477 127 127,0.832781985435727,0.510515559238132,254,Public Health & Work,efficacy,DICH,1,2,yes,2018.0,"Health status: high self-rated health (CDC 'Healthy Days Measure' and another similar 5-point scale, dichotomised) at 6 months",Interventions for involving patients in decision-making about their health care vs attention-control conditions for older patients with multi-morbidity,1.63125681551906,"positive 
",positive,,,,,,,,,,,,,,,,,
263,CD000521,Cao 2008,STD-Cao-2008 0.2 0.73 30 30,-1.94591014905531,0.828078671210825,60,Anaesthesia & Pain,efficacy,DICH,1,2,yes,2008.0,Incomplete or unsatisfactory analgesia,Regional (spinal or epidural) versus lumbar plexus nerve blocks,-2.34990975701618,"negative 
",negative,,,,,,,,,,,,,,,,,
264,CD009121,Kaiser 1998,STD-Kaiser-1998 0.333 1.594 15 15,-1.16530366316678,1.67336436944866,30,Anaesthesia & Pain,efficacy,DICH,1,1,no,1998.0,30-day mortality,30-day mortality,-0.696383695292095,"negative 
",negative,,,,,,,,,,,,,,,,,
265,CD005067,Nilforoushzadeh 2014a,STD-Nilforoushzadeh-2014a 0.609 0.155 60 60,-1.32311545949836,0.400164950461231,120,Skin & Wounds,efficacy,DICH,1,82,yes,2014.0,Partcipants complete cure,Ablative CO2 laser (25 kW for 1 session) versus 3 weeks fractional CO2 laser,-3.30642515785886,"positive 
",positive,,,,,,,,,,,,,,,,,
266,CD013210,Ewe 1999,STD-Ewe-1999 0.685 0.275 43 40,-0.628155041814233,0.454050610191944,83,Gastroenterology,efficacy,DICH,1,5,yes,1999.0,Clinical relapse,Direct evidence: budesonide versus placebo,-1.38344719226054,"negative 
",negative,,,,,,,,,,,,,,,,,
267,CD004865,Donato 2000,STD-Donato-2000 0.919 0.146 57 57,-0.224319330403222,0.387191235182919,114,Neonatal,efficacy,DICH,1,1,no,2000.0,Use of one or more red blood cell transfusions,Early (0-7 days) versus late (8-28 days) initiation of EPO,-0.579350228052677,"negative 
",negative,,,,,,,,,,,,,,,,,
268,CD006873,Ardizzone 2004,STD-Ardizzone-2004 1.296 0.407 71 69,0.304489190768162,0.477556555450225,140,Gastroenterology,efficacy,DICH,1,4,yes,2004.0,Clinical Recurrence within 12 months,5-ASA vs Azathioprine/6MP,0.637598180347665,"negative 
",negative,,,,,,,,,,,,,,,,,
269,CD006534,Gastpar 2006,STD-Gastpar-2006 0.858 0.356 127 131,-0.153469093977857,0.356263171702721,258,Psychiatry & Mental Health,efficacy,DICH,1,52,no,2006.0,Citalopram versus non-conventional ADs,SE - Infection,-0.43077451212363,"neutral 
",neutral,,,,,,,,,,,,,,,,,
270,CD002100,Mennigen 1989,STD-Mennigen-1989 0.941 1.4 51 48,-0.0618754037180875,1.4287325137144,99,Gastroenterology,efficacy,DICH,1,2,no,1989.0,Clinical anastomotic dehiscence,All studies stratified by level of anastomosis,-0.0433078992212646,"negative 
",negative,,,,,,,,,,,,,,,,,
271,CD001843,Porru 2001,STD-Porru-2001 0.311 1.124 30 28,-1.24703229378638,1.18651426116757,58,Gynaecology & Urology,efficacy,DICH,1,16,no,2001.0,Number of incontinent men,Prevention of UI after TURP:  pre or post-operative PFMT ± biofeedback versus no treatment,-1.05100489273451,"negative 
",negative,,,,,,,,,,,,,,,,,
272,CD002227,Feinstein 1959,STD-Feinstein-1959 0.065 1.024 116 113,-2.86801485079489,1.04190517825435,229,Heart & Hypertension,efficacy,DICH,1,2,no,1959.0,Rheumatic fever recurrences,Intramuscular versus oral penicillin,-2.75266397619798,"negative 
",negative,,,,,,,,,,,,,,,,,
273,CD002959,Newell 1966,STD-Newell-1966 0.571 0.394 224 270,-0.5923994908261,0.415184195983177,494,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1966.0,Neonatal tetanus deaths,Tetanus toxoid versus influenza vaccine,-1.42683535779407,"negative 
",negative,,,,,,,,,,,,,,,,,
274,CD005253,Rogahn 2000,STD-Rogahn-2000 0.328 1.623 61 60,-1.131673150929,1.64308659295771,121,Neonatal,efficacy,DICH,1,1,yes,2000.0,Mortality before hospital discharge,Iodine supplementation versus control,-0.688748332424697,"negative 
",negative,,,,,,,,,,,,,,,,,
275,CD001531,Nishioka 1991,STD-Nishioka-1991 2.435 0.391 23 24,1.54044504094715,0.636209010280352,47,Emergency & Trauma,efficacy,DICH,1,1,no,1991.0,Behaviour (observed) of 5 to 7 yr olds - post-test at less than 1 month,Direct education compared to No education,2.42128768385147,"neutral 
",neutral,,,,,,,,,,,,,,,,,
276,CD009362,Green 1974,STD-Green-1974 0.734 0.246 76 91,-0.438254930931155,0.345108924514112,167,Skin & Wounds,efficacy,DICH,1,2,yes,1974.0,Pressure ulcer,Active topical agent versus placebo/control,-1.26990320968427,"negative 
",negative,,,,,,,,,,,,,,,,,
277,CD008553,Keefe 1986,STD-Keefe-1986 1.231 1.364 13 16,0.22314355131421,1.46628782986152,29,Heart & Hypertension,efficacy,DICH,1,3,yes,1986.0,All-cause mortality,Lidocaine vs tocainide,0.15218263888563,"negative 
",negative,,,,,,,,,,,,,,,,,
278,CD003857,Palomba 2007,STD-Palomba-2007 1.319 0.626 30 32,0.276753001919591,0.625670527398337,62,Gynaecology & Urology,efficacy,DICH,1,2,yes,2007.0,Live birth rate,Open versus laparoscopic myomectomy,0.442330251786647,"positive 
",positive,,,,,,,,,,,,,,,,,
279,CD002786,Fiskerstrand 1984,STD-Fiskerstrand-1984 0.333 1.033 8 10,-1.09861228866811,1.03279555898864,18,Heart & Hypertension,efficacy,DICH,1,2,no,1984.0,Fistulae thromboses at one month,Ticlopidine versus placebo,-1.0637267744876,"negative 
",negative,,,,,,,,,,,,,,,,,
280,CD011746,Sharma 2010,STD-Sharma-2010 0.779 0.197 13 27,-1.26851132546351,0.857969178415583,40,Hepato-Biliary,efficacy,DICH,1,5,yes,2010.0,All-cause mortality at one year,Gemcitabine plus oxaliplatin versus best supportive care,-1.47850453999533,"negative 
",negative,,,,,,,,,,,,,,,,,
281,CD004961,De Grave 2012,STD-De-Grave-2012 1.025 0.345 51 61,0.0324352757531537,0.449087437085042,112,Emergency & Trauma,efficacy,DICH,1,3,yes,2012.0,Mortality at 1 year,ACE trochanteric nail versus the Gamma 3 nail,0.0722248566196512,"negative 
",negative,,,,,,,,,,,,,,,,,
282,CD002758,Lastayo 1998,STD-Lastayo-1998 0.441 1.172 17 15,-0.90078654533819,1.28039957705518,32,Emergency & Trauma,efficacy,DICH,1,6,no,1998.0,No improvement in pain,Rotator cuff repair (RCR) + continuous passive motion vs RCR + manual passive ROM exercises,-0.703519871046764,"negative 
",negative,,,,,,,,,,,,,,,,,
283,CD003233,Bhamik 2002,STD-Bhamik-2002 2.308 0.735 13 12,1.13943428318836,0.961769203083567,25,Kidney & Transplant,efficacy,DICH,1,1,yes,2002.0,Complete remission,Remission of proteinuria,1.18472735406289,"positive 
",positive,,,,,,,,,,,,,,,,,
284,CD004790,Lolekha 2002,STD-Lolekha-2002 1.489 0.549 47 50,0.454255272277596,0.624563339525596,97,Hepato-Biliary,efficacy,DICH,1,7,no,2002.0,Hepatitis B events,Four RV vaccinations versus three RV vaccinations,0.727316580288939,"negative 
",negative,,,,,,,,,,,,,,,,,
285,CD007818,Stein 1995,STD-Stein-1995 2.545 0.581 11 14,1.48160454092422,0.889330698283316,25,Neurology,efficacy,DICH,1,5,yes,1995.0,Fatigue - number of patients improved,Amantadine versus placebo,1.66597705868489,"positive 
",positive,,,,,,,,,,,,,,,,,
286,CD012041,Elamin 2012,STD-Elamin-2012 0.3 1.567 9 8,-1.33500106673234,1.70448325245358,17,Emergency & Trauma,efficacy,DICH,1,1,yes,2012.0,All-cause mortality (longest period reported),Omega-3 fatty acids and antioxidants versus placebo or standard nutrition,-0.783229207333439,"negative 
",negative,,,,,,,,,,,,,,,,,
287,CD000974,Azurin 1965i,STD-Azurin-1965i 0.711 0.168 145500 48934,-0.340773909175785,0.168371653795721,194434,Infectious Diseases,efficacy,DICH,1,1,yes,1964.0,"Cholera cases, by period of follow up",Injected cholera vaccine vs placebo (no booster),-2.02393871826687,"negative 
",negative,,,,,,,,,,,,,,,,,
288,CD008058,Ang 2000,STD-Ang-2000 1.066 0.161 17 22,0.316669609325033,0.81460753383066,39,Skin & Wounds,efficacy,DICH,1,1,yes,2000.0,Proportion completely healed in 10 days,MEBO vs silver sulphadiazine (SSD),0.388738866477096,"positive 
",positive,,,,,,,,,,,,,,,,,
289,CD011567,Bystritsky 1995,STD-Bystritsky-1995 2 0.754 11 11,0.944461608840852,1.00198216250004,22,Psychiatry & Mental Health,efficacy,DICH,1,4,yes,1995.0,Failure to respond,TCAs versus SSRIs,0.942593235875908,"negative 
",negative,,,,,,,,,,,,,,,,,
290,CD004767,Ohkuma 1990,STD-Ohkuma-1990 0.857 0.42 5 10,-0.441832752279039,1.14434427054266,15,Skin & Wounds,efficacy,DICH,1,11,yes,1990.0,Primary outcome: short-term clinical cure (up to 3 months after start of treatment),Topical: 10% povidone iodine versus 50% salicylic acid plaster,-0.386101249119304,"positive 
",positive,,,,,,,,,,,,,,,,,
291,CD003108,Fischl 1988,STD-Fischl-1988 0.643 0.241 60 60,-0.713766467762681,0.382530214596658,120,Infectious Diseases,efficacy,DICH,1,2,no,1988.0,Death,Cotrimoxazole and leucovorin vs control,-1.86590873224297,"negative 
",negative,,,,,,,,,,,,,,,,,
292,CD002807,Belenky 2001,STD-Belenky-2001 1.096 0.844 16 23,0.0918075492531229,0.844326944497082,39,Gynaecology & Urology,efficacy,DICH,1,3,no,2001.0,Pregnancy rate per couple,Testicular versus Testicular sperm retrieval techniques (obstructive and non-obstructive azoospermia),0.10873459606078,"positive 
",positive,,,,,,,,,,,,,,,,,
293,CD007339,Akriviadis 2000,STD-Akriviadis-2000 0.52 0.293 50 52,-0.998528830111127,0.432469739043057,102,Hepato-Biliary,efficacy,DICH,1,1,no,2000.0,Mortality using the fixed effect model,"All-cause mortality, pentoxifylline versus control",-2.30889872738983,"negative 
",negative,,,,,,,,,,,,,,,,,
294,CD001816,Eibl 1988,STD-Eibl-1988 0.08 1.46 88 91,-2.59943553353271,1.47541231366257,179,Neonatal,efficacy,DICH,1,1,yes,1988.0,Definite necrotizing enterocolitis (NEC) during study period,Oral immunoglobulin versus control,-1.76183668081219,"negative 
",negative,,,,,,,,,,,,,,,,,
295,CD007312,Flickinger 2001,STD-Flickinger-2001 0.718 0.444 44 43,-0.330741561912228,0.443514352465523,87,Neurology,efficacy,DICH,1,2,no,2001.0,Complete pain relief with no medication at final follow-up,One versus two isocentres,-0.745729106789027,"positive 
",positive,,,,,,,,,,,,,,,,,
296,CD002922,Clark 1984,STD-Clark-1984 2.857 1.603 20 19,1.09861228866811,1.66410058867569,39,Kidney & Transplant,efficacy,DICH,1,23,yes,1984.0,Death,Plasma exchange (PE) + immunosuppression (IS) versus IS alone,0.660183823107952,"negative 
",negative,,,,,,,,,,,,,,,,,
297,CD005283,Valeri (Tx) 1996,STD-Valeri-_x0028_Tx_x0029_-1996 0.224 1.06 25 28,-1.6519975268529,1.13364232786899,53,Kidney & Transplant,efficacy,DICH,1,3,no,1996.0,All-cause mortality,Transplant recipients,-1.45724756939722,"negative 
",negative,,,,,,,,,,,,,,,,,
298,CD006027,Al Waili 1999,STD-Al-Waili-1999 0.049 1.429 32 30,-3.35762613336851,1.47734356754647,62,Kidney & Transplant,efficacy,DICH,1,4,yes,1999.0,NSAID versus NSAID,Pain recurrence,-2.27274562744044,"neutral 
",neutral,,,,,,,,,,,,,,,,,
299,CD011943,Zoccali 2004,STD-Zoccali-2004 0.81 0.176 10 10,-1.82074700610131,1.61644212827482,20,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2004.0,Mental state: specific. 1a. Negative symptoms: clinically important change,Mirtazapine adjunct versus placebo adjunct - short term,-1.12639170574238,"negative 
",negative,,,,,,,,,,,,,,,,,
300,CD003079,"Clonazepam 1993, CA",STD-Clonazepam-1993_x002c_-CA 0.333 1.563 8 8,-1.22377543162212,1.70811213297709,16,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,1993.0,Tranquillisation or asleep: 1. sedation,Benzodiazepines versus antipsychotics,-0.71644911829599,"negative 
",negative,,,,,,,,,,,,,,,,,
301,CD008836,Huang 2004,STD-Huang-2004 4.742 0.836 44 38,1.55644538229359,0.836017183545168,82,Gastroenterology,efficacy,DICH,1,1,no,2004.0,Effective rate,Oral traditional Chinese medicine + conventional therapy versus conventional therapy,1.86173850601182,"neutral 
",neutral,,,,,,,,,,,,,,,,,
302,CD003220,Chen 2015,STD-Chen-2015 20.982 1.432 56 51,3.25936369764194,1.45888725384976,107,"Oral Health, Eyes & ENT",efficacy,DICH,1,21,yes,2015.0,Clinical failure,Vitapex pulpectomy versus zinc oxide and eugenol (ZOE) pulpectomy,2.23414365232201,"negative 
",negative,,,,,,,,,,,,,,,,,
303,CD002308,Afilalo 1999,STD-Afilalo-1999 0.323 0.887 28 26,-1.12986483217221,0.886611857624624,54,Lungs,efficacy,DICH,1,1,yes,1999.0,Admission to hospital,ICS versus placebo,-1.27436241964923,"negative 
",negative,,,,,,,,,,,,,,,,,
304,CD005937,MacDonald 1976,STD-MacDonald-1976 0.953 0.055 93 82,-0.407546274311989,0.477427052476701,175,Pregnancy & Childbirth,efficacy,DICH,1,4,no,1976.0,"Failure to suppress lactation as indicated by milk secretion, breast engorgement or breast pain at = 7 days",Pyridoxine versus placebo,-0.853630459769303,"negative 
",negative,,,,,,,,,,,,,,,,,
305,CD000535,BOA 2000,STD-BOA-2000 0.885 0.131 1351 1339,-0.121805217402441,0.131333023847995,2690,Heart & Hypertension,efficacy,DICH,1,5,no,2000.0,"Primary graft patency, 3 months","ASA or ASA/DIP versus vitamin K antagonists, all grafts",-0.927453079458663,"positive 
",positive,,,,,,,,,,,,,,,,,
306,CD004316,Qoubaitary 2006,STD-Qoubaitary-2006 0.286 0.945 10 10,-1.25276296849537,0.944911182523068,20,Gynaecology & Urology,efficacy,DICH,1,45,yes,2006.0,Azoospermia,Testosterone undecanoate (TU) 750 mg/8 wk IM versus TU 1000 mg/8 wk IM,-1.32579970653992,"negative 
",negative,,,,,,,,,,,,,,,,,
307,CD001415,Anhut 1994,STD-Anhut-1994 2.189 0.322 163 109,0.92640405786972,0.369817476692967,272,Neurology,efficacy,DICH,1,1,no,1994.0,Reduction in seizure frequency = 50%,Gabapentin versus placebo,2.50503049816341,"positive 
",positive,,,,,,,,,,,,,,,,,
308,CD006037,Elk 1998,STD-Elk-1998 0.2 1.454 6 6,-1.97716269255942,1.6661537672341,12,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1998.0,Preterm birth (< 37 weeks gestation),Any psychosocial intervention vs. control: neonatal outcomes,-1.18666279874133,"negative 
",negative,,,,,,,,,,,,,,,,,
309,CD009808,Altergott 2008,STD-Altergott-2008 1.045 1.404 66 69,0.0451204352804701,1.42481244300348,135,Emergency & Trauma,efficacy,DICH,1,1,no,2008.0,Infection,Prophylactic antibiotics versus no antibiotics following surgical repair,0.0316676314149509,"negative 
",negative,,,,,,,,,,,,,,,,,
310,CD008487,Shi 2009,STD-Shi-2009 1.024 0.061 45 45,0.311779624030842,0.7946905693698,90,Gastroenterology,efficacy,DICH,1,1,no,2009.0,Symptom scores of FD,Manual acupuncture compared with cisapride,0.392328330104744,"negative 
",negative,,,,,,,,,,,,,,,,,
311,CD005474,Gravem 1981,STD-Gravem-1981 0.966 0.115 29 28,-0.223143551314209,0.730296743340221,57,Psychiatry & Mental Health,efficacy,DICH,1,12,no,1981.0,Global state: Average endpoint global state score - Unwell,CIS-(Z) ZUCLOPENTHIXOL versus CIS(Z)/TRANS(E) ZUCLOPENTHIXOL - all short term,-0.30555189154151,"negative 
",negative,,,,,,,,,,,,,,,,,
312,CD001860,Attiah 1973,STD-Attiah-1973 0.724 0.097 152 76,-0.958762158983048,0.315289674939735,228,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,1973.0,Active trachoma at 3 months,Any antibiotic versus control (individuals),-3.04089297934133,"negative 
",negative,,,,,,,,,,,,,,,,,
313,CD009583,Wandless 1987,STD-Wandless-1987 1.8 0.481 25 25,0.810930216216329,0.650854139658888,50,Anaesthesia & Pain,efficacy,DICH,1,2,yes,1987.0,Number of patients with moderate/severe pain (1h postop),Nalbuphine versus morphine,1.24594769673177,"negative 
",negative,,,,,,,,,,,,,,,,,
314,CD008591,Lam 1995,STD-Lam-1995 1.616 0.286 36 32,0.869770716239262,0.501027083627361,68,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1995.0,Response (> 50% improvement on 29-item HAM-D SIGH-SAD),Fluoxetine versus Placebo,1.7359754485571,"positive 
",positive,,,,,,,,,,,,,,,,,
315,CD009508,Bø 1990,STD-B_x00f8_-1990 0.911 0.074 23 29,-1.92577524064625,1.57493172327937,52,Gynaecology & Urology,efficacy,DICH,1,1,yes,1990.0,Patients' perception of change in incontinence - not cured,More versus less contact with health professionals,-1.22276744583971,"negative 
",negative,,,,,,,,,,,,,,,,,
316,CD009670,Aimer 2017,STD-Aimer-2017 1.25 0.587 19 19,0.292136422801161,0.766873678056066,38,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2017.0,Subgroups by type of pharmacotherapy,Effect of increasing behavioural support. Abstinence at longest follow-up,0.380944647287533,"neutral 
",neutral,,,,,,,,,,,,,,,,,
317,CD012131,Das 1999,STD-Das-1999 1.077 0.153 16 16,0.479573080261886,0.990800172428821,32,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,yes,1999.0,Combined anatomical and functional success rate,Adjunctive intravitreal dexamethasone versus antibiotics alone,0.48402603633614,"positive 
",positive,,,,,,,,,,,,,,,,,
318,CD004305,Roski 2003,STD-Roski-2003 1.162 0.086 1024 1065,0.189302299009053,0.108007005978578,2089,Psychiatry & Mental Health,efficacy,DICH,1,4,yes,2003.0,Abstinence from smoking,Interventions directed at healthcare providers,1.75268536789733,"positive 
",positive,,,,,,,,,,,,,,,,,
319,CD005563,Sieber 2010,STD-Sieber-2010 0.478 0.315 57 57,-1.03987981500371,0.430741508238202,114,Psychiatry & Mental Health,efficacy,DICH,1,13,yes,2010.0,Incident delirium,Light versus deep propofol sedation,-2.41416207891591,"negative 
",negative,,,,,,,,,,,,,,,,,
320,CD005393,Huang 2006,STD-Huang-2006 9 1.493 300 296,2.19722457733622,1.49297273410651,596,Gastroenterology,efficacy,DICH,1,9,yes,2006.0,Proportion of patients complaining of difficulty voiding due to outlet obstruction or anal stenosis,Stenosis/Outlet obstruction,1.47171112180504,"negative 
",negative,,,,,,,,,,,,,,,,,
321,CD010655,Hammar 1987,STD-Hammar-1987 1.333 0.474 30 30,0.37469344944141,0.615457454896664,60,Pregnancy & Childbirth,efficacy,DICH,1,4,yes,1987.0,Frequency of leg cramps after treatment: never,Oral calcium versus oral vitamin C,0.608804794645508,"positive 
",positive,,,,,,,,,,,,,,,,,
322,CD000218,Chaudhuri 1980,STD-Chaudhuri-1980 5.571 1.532 34 38,1.77885606439215,1.5674001584609,72,Infectious Diseases,efficacy,DICH,1,16,no,1980.0,No parasitological cure (1 week),Tinidazole versus carnidazole,1.1349086924547,"negative 
",negative,,,,,,,,,,,,,,,,,
323,CD011611,Yoon 2009,STD-Yoon-2009 1.125 0.677 18 17,0.117783035656383,0.67700320038633,35,Psychiatry & Mental Health,efficacy,DICH,1,3,no,2009.0,Response rate,Cytidine versus placebo,0.173977073652194,"neutral 
",neutral,,,,,,,,,,,,,,,,,
324,CD003914,Lawson 1979,STD-Lawson-1979 1.022 0.154 148 135,0.0341913647482796,0.245950023291089,283,Oncology,efficacy,DICH,1,2,yes,1979.0,Overall failure (disregarding modifications),Treatment failure,0.139017530028095,"negative 
",negative,,,,,,,,,,,,,,,,,
325,CD008569,Pace 2001,STD-Pace-2001 13.6 1.007 35 34,3.09104245335832,1.07207772542416,69,Kidney & Transplant,efficacy,DICH,1,1,yes,2001.0,Stone-free rate,"Percussion, diuresis, and inversion therapy following shock wave lithotripsy versus no intervention following shock wave lithotripsy",2.88322607592221,"positive 
",positive,,,,,,,,,,,,,,,,,
326,CD008042,Ekbom 1991,STD-Ekbom-1991 4.5 0.504 39 39,2.01490302054227,0.617855995961868,78,Anaesthesia & Pain,efficacy,DICH,1,4,no,1991.0,Participants pain-free at 15 minutes,Sumatriptan versus placebo,3.26112076877315,"positive 
",positive,,,,,,,,,,,,,,,,,
327,CD010746,Chevrier 1999,STD-Chevrier-1999 6.25 1.487 27 24,1.94591014905531,1.53861851632414,51,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,yes,1999.0,Intraocular pressure (IOP) increase of = 5 mmHg within 2 hours after laser trabeculoplasty (LTP),Medication versus medication: brimonidine versus apraclonidine (regardless of timing),1.26471255116844,"negative 
",negative,,,,,,,,,,,,,,,,,
328,CD009510,BRAVO,STD-BRAVO 1.918 0.157 134 132,1.11542915352569,0.259102812655912,266,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,2011.0,15 or more letter gain at 6 months,Ranibizumab 0.3 mg versus sham,4.30496736832793,"positive 
",positive,,,,,,,,,,,,,,,,,
329,CD013105,Dieter 2014,STD-Dieter-2014 1.943 0.431 81 78,0.664159643686693,0.431433023517571,159,Gynaecology & Urology,efficacy,DICH,1,8,yes,2014.0,Postoperative infection - UTI,Prophylactic antibiotics for postoperative patients required urinary catheterisation,1.53942699673671,"negative 
",negative,,,,,,,,,,,,,,,,,
330,CD004568,Piya-Anant 1998,STD-Piya_x002d_Anant-1998 8.407 0.78 50 50,2.85726259928889,1.4751690815898,100,Gynaecology & Urology,efficacy,DICH,1,1,no,1998.0,Discontinuation - overall at 6 months,DMPA 25 mg / E2C 5 mg versus DMPA 150 mg,1.93690515544808,"negative 
",negative,,,,,,,,,,,,,,,,,
331,CD006023,Locatelli 2014,STD-Locatelli-2014 0.482 1.22 171 165,-0.735195416803445,1.22964113556205,336,Kidney & Transplant,efficacy,DICH,1,17,yes,2014.0,Death (all causes),Sevelamer versus colestilan,-0.597894292522507,"negative 
",negative,,,,,,,,,,,,,,,,,
332,CD001790,F-Dieterich(D),STD-F_x002d_Dieterich_x0028_D_x0029_ 1 0.415 50 50,0.0,0.416666666666667,100,Anaesthesia & Pain,efficacy,DICH,1,4,no,1988.0,Postural headache,Supplementary fluids versus no or less supplementary fluids,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
333,CD012983,Brookfield 1977,STD-Brookfield-1977 0.4 0.606 6 6,-2.30258509299405,1.39642400437689,12,Emergency & Trauma,efficacy,DICH,1,1,no,1977.0,Risk of acute mountain sickness,Spironolactone: spironolactone vs. placebo,-1.64891543383451,"negative 
",negative,,,,,,,,,,,,,,,,,
334,CD012744,Bardet 2011,STD-Bardet-2011 1.028 0.156 131 132,0.0444952398865511,0.253580293178461,263,"Oral Health, Eyes & ENT",efficacy,DICH,1,5,no,2011.0,Xerostomia (0 to 4 scale - grade 2 or above),Amifostine (intravenous versus subcutaneous),0.175468051278089,"negative 
",negative,,,,,,,,,,,,,,,,,
335,CD001433,Bhushan 2001,STD-Bhushan-2001 0.446 0.221 7 8,2.23359222150709,1.31384568203061,15,Skin & Wounds,efficacy,DICH,1,3,yes,2001.0,induction of remission,liarozole versus placebo,1.70004152851115,"positive 
",positive,,,,,,,,,,,,,,,,,
336,CD004778,Lau 1996,STD-Lau-1996 1.11 0.6 48 45,0.104140259252597,0.599629117928136,93,Gastroenterology,efficacy,DICH,1,1,yes,1996.0,Septic abdominal complications (presence or absence),Laparoscopic surgery versus open surgery,0.173674453322792,"negative 
",negative,,,,,,,,,,,,,,,,,
337,CD005963,Henderson 2004 a,STD-Henderson-2004-a 3 1.625 80 80,1.11111245143234,1.64063025793971,160,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2004.0,Death,ADVANCE DIRECTIVES versus USUAL CARE,0.677247323737445,"negative 
",negative,,,,,,,,,,,,,,,,,
338,CD000937,Austria 1997,STD-Austria-1997 1 0.996 265 265,0.0,1.00379508005252,530,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1997.0,Perinatal mortality,Magnesium supplementation versus no magnesium,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
339,CD001732,Abramowitz 1973,STD-Abramowitz-1973 1.61 0.154 44 28,3.32588204443572,1.08304590589427,72,Heart & Hypertension,efficacy,DICH,1,7,no,1973.0,Results: cosmetic and symptomatic improvement,Sclerotherapy versus graduated compression stockings,3.07085971733537,"positive 
",positive,,,,,,,,,,,,,,,,,
340,CD009110,Baker 1993,STD-Baker-1993 0.444 0.401 10 10,-2.60268968544438,1.23603308118261,20,Skin & Wounds,efficacy,DICH,1,2,yes,1993.0,Number of ulcers healed,Alginate dressings compared with foam dressings,-2.10567963355332,"positive 
",positive,,,,,,,,,,,,,,,,,
341,CD009431,Amarapurkar 2004,STD-Amarapurkar-2004 0.619 0.241 30 30,-1.11556184698188,0.542657133985171,60,Gastroenterology,efficacy,DICH,1,2,no,2004.0,Not symptom-free or no symptom improvement,Prokinetic versus prokinetic,-2.05573976110736,"negative 
",negative,,,,,,,,,,,,,,,,,
342,CD012047,Ekmekci 2013,STD-Ekmekci-2013 3.102 1.653 30 30,1.1319487089357,1.65328517110549,60,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,yes,2013.0,Postoperative vomiting (number of patients who vomit),Local injection versus no treatment/placebo,0.684666341124205,"negative 
",negative,,,,,,,,,,,,,,,,,
343,CD003017,See 2001,STD-See-2001 11 0.983 12 13,2.39789527279837,0.982806741383621,25,Psychiatry & Mental Health,efficacy,DICH,1,2,no,2001.0,Global improvement in symptoms,Famotidine versus placebo,2.43984414415244,"positive 
",positive,,,,,,,,,,,,,,,,,
344,CD006103,Walker 2014,STD-Walker-2014 1.43 0.118 655 655,0.438317932978743,0.144041430827414,1310,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2011.0,Continuous abstinence at 6m,Cytisine vs NRT,3.04299902091309,"positive 
",positive,,,,,,,,,,,,,,,,,
345,CD006934,Ravichandran 2003,STD-Ravichandran-2003 3.385 0.376 16 25,2.61901657873181,0.7934448032916,41,Gynaecology & Urology,efficacy,DICH,1,2,yes,2003.0,Recurrence of stricture requiring further surgery,Urethrotomy versus urethroplasty,3.30081760932436,"negative 
",negative,,,,,,,,,,,,,,,,,
346,CD003964,Guo 2008,STD-Guo-2008 0.464 0.4 36 31,-1.09596328049653,0.556613451109893,67,Kidney & Transplant,efficacy,DICH,1,4,yes,2008.0,Number of patients developing infection,Mannan peptide + baseline treatment versus baseline treatment,-1.96898454090747,"negative 
",negative,,,,,,,,,,,,,,,,,
347,CD005656,Pearson 2002,STD-Pearson-2002 2.732 0.752 41 28,1.14788333767489,0.832925308034621,69,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,yes,2002.0,Gain of three or more lines visual acuity,Intravitreal fluocinolone acetonide implant versus other treatment,1.3781347818371,"positive 
",positive,,,,,,,,,,,,,,,,,
348,CD007191,Abrams 1993,STD-Abrams-1993 1.013 0.519 53 46,0.0143887374520995,0.596877659121693,99,Infectious Diseases,efficacy,DICH,1,1,yes,1993.0,Development of MAC disease,Monotherapy versus no treatment or placebo,0.0241066778630524,"negative 
",negative,,,,,,,,,,,,,,,,,
349,CD012656,Leslie 2008 PAK,STD-Leslie-2008-PAK 5.227 1.502 74 55,1.69259572010774,1.52240543802179,129,Infectious Diseases,efficacy,DICH,1,3,yes,2008.0,Recurrence,0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen,1.11179037977367,"negative 
",negative,,,,,,,,,,,,,,,,,
350,CD003382,Evliyaoglu 2011,STD-Evliyao_x011f_lu-2011 11.5 0.681 25 25,4.88469407073841,1.04257207028537,50,Psychiatry & Mental Health,efficacy,DICH,1,2,no,2011.0,Global Assessment Questions,Tadalafil vs placebo,4.6852339612372,"neutral 
",neutral,,,,,,,,,,,,,,,,,
351,CD011261,Dehghan 2016,STD-Dehghan-2016 0.567 0.467 50 52,-0.676753370784269,0.551990284520905,102,Public Health & Work,efficacy,DICH,1,1,no,2016.0,Prevalence of MSD in thigh,Multi-faceted ergonomic interventions versus no intervention,-1.22602406194821,"negative 
",negative,,,,,,,,,,,,,,,,,
352,CD000175,Collins 1978,STD-Collins-1978 0.072 1.014 49 53,-2.94166505228372,1.05537471519536,102,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1978.0,Maternal hypotension,Prophylactic intravenous preloading before epidural anaesthesia in labour,-2.78731810600483,"negative 
",negative,,,,,,,,,,,,,,,,,
353,CD001755,Klarskov 1986,STD-Klarskov-1986 1.25 0.204 7 9,1.6094379124341,1.63299316185545,16,Gynaecology & Urology,efficacy,DICH,1,2,yes,1986.0,"Number not cured (worse, unchanged or improved) within first year",ANTERIOR REPAIR VS PELVIC FLOOR MUSCLE TRAINING,0.985575414538425,"negative 
",negative,,,,,,,,,,,,,,,,,
354,CD004931,Benjamin 1988,STD-Benjamin-1988 7 1.505 90 90,1.97962120639763,1.51927370177324,180,Genetics & Endocrinology,efficacy,DICH,1,5,no,1988.0,Gastric ulcers,Minor complications due to balloon usage,1.30300498461014,"negative 
",negative,,,,,,,,,,,,,,,,,
355,CD010136,Fouad 1996,STD-Fouad-1996 0.267 1.485 8 11,-1.49821227732388,1.61954012507201,19,"Oral Health, Eyes & ENT",efficacy,DICH,1,4,yes,1996.0,Incidence of endodontic flare-up,Endodontic flare-up,-0.92508500044558,"negative 
",negative,,,,,,,,,,,,,,,,,
356,CD002253,Jain 1996*,STD-Jain-1996_x002a_ 0.9 0.167 20 18,-0.510825623765991,0.816496580927726,38,Pregnancy & Childbirth,efficacy,DICH,1,8,no,1996.0,Complete miscarriage,Vaginal misoprostol plus laminaria tents versus vaginal misoprostol alone,-0.625631062882807,"negative 
",negative,,,,,,,,,,,,,,,,,
357,CD004048,Li 2008,STD-Li-2008 0.42 0.36 77 77,-0.866477026161936,0.359843564662956,154,Psychiatry & Mental Health,efficacy,DICH,1,5,no,2008.0,Efficacy - response (categorical): YMRS decrease by = 50% by end of trial,Lithium vs quetiapine,-2.40792697508295,"positive 
",positive,,,,,,,,,,,,,,,,,
358,CD001430,Kapoor 1998,STD-Kapoor-1998 1.307 0.369 22 23,0.44628710262842,0.612372435695794,45,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,yes,1998.0,Participants with normal visual acuity at 6 months,Total intravenous corticosteroid dose more than or equal to 3000 mg versus placebo,0.728783786816492,"positive 
",positive,,,,,,,,,,,,,,,,,
359,CD009458,Ørbo 2014,STD-_x00d8_rbo-2014 1.4 1.757 3 8,0.336472236621213,1.75662013130736,11,Gynaecology & Urology,efficacy,DICH,1,1,yes,2014.0,Regression rate,Levonorgestrel-releasing intrauterine system (LNG-IUS) versus medroxyprogesterone (MPA) 10 mg,0.191545246820549,"negative 
",negative,,,,,,,,,,,,,,,,,
360,CD009172,Beken 2014,STD-Beken-2014 1.333 0.73 40 40,0.315081046639896,0.798835488782351,80,Neonatal,efficacy,DICH,1,1,yes,2014.0,Death before discharge,MOFS-LE versus S-LE,0.394425449375274,"negative 
",negative,,,,,,,,,,,,,,,,,
361,CD004539,Solomkin 2001,STD-Solomkin-2001 1.689 0.577 259 270,0.524280516100174,0.576851496184833,529,Gastroenterology,efficacy,DICH,1,12,yes,2001.0,Mortality (all causes - ITT analysis),Fluoroquinolones alone versus other regimens,0.908865660516872,"negative 
",negative,,,,,,,,,,,,,,,,,
362,CD003063,Dani 2004,STD-Dani-2004 0.082 1.42 13 14,-3.02757287940965,1.53152449759831,27,Neonatal,efficacy,DICH,1,1,no,2004.0,Need for mechanical ventilation.,"Early surfactant, rapid extubation to NCPAP vs. selective surfactant, ventilation in babies with RDS.",-1.97683607683546,"negative 
",negative,,,,,,,,,,,,,,,,,
363,CD001892,Cianciaruso 2008a,STD-Cianciaruso-2008a 0.916 0.272 212 211,-0.0993819502854918,0.306831566574549,423,Kidney & Transplant,efficacy,DICH,1,1,yes,2008.0,Death (all causes),Low protein diet versus normal protein diet,-0.323897411843854,"negative 
",negative,,,,,,,,,,,,,,,,,
364,CD005624,EVOLVeS Study,STD-EVOLVeS-Study 0.618 0.665 36 29,-0.480814545349951,0.665133815147269,65,Heart & Hypertension,efficacy,DICH,1,3,yes,,Recurrence,Radiofrequency ablation versus surgery,-0.722883928617421,"negative 
",negative,,,,,,,,,,,,,,,,,
365,CD009880,Fortún 2001,STD-Fort_x00fa_n-2001 0.587 0.19 23 11,-2.88417978764824,1.50208811028225,34,Heart & Hypertension,efficacy,DICH,1,3,no,2001.0,Cure,Glycopeptides plus aminoglycosides versus beta-lactam plus aminoglycosides,-1.92011358581774,"positive 
",positive,,,,,,,,,,,,,,,,,
366,CD002948,Tao 2002,STD-Tao-2002 9 1.438 12 12,2.5828870581482,1.55559290337985,24,Spine & Muscles,efficacy,DICH,1,3,no,2002.0,ACR20 responders,Tripterygium wilfordii Hook F 180 mg versus placebo,1.6603875297556,"positive 
",positive,,,,,,,,,,,,,,,,,
367,CD004059,Mathews 1987,STD-Mathews-1987 1.875 0.609 16 6,1.20397280432594,1.00829889748361,22,Spine & Muscles,efficacy,DICH,1,1,no,1987.0,>50% improvement from baseline,Prolotherapy vs control - Between group differences in proportions,1.19406339462501,"positive 
",positive,,,,,,,,,,,,,,,,,
368,CD000218,DuBouchet 1997,STD-DuBouchet-1997 1.171 0.114 45 43,0.742595455973927,0.533633141943311,88,Infectious Diseases,efficacy,DICH,1,13,no,1997.0,No parasitological cure (2-3 weeks),Intravaginal: clotrimazole versus AVC suppositories,1.39158421320993,"negative 
",negative,,,,,,,,,,,,,,,,,
369,CD008709,Lee 2010 SEC,STD-Lee-2010-SEC 0.95 0.214 144 141,-0.0665543300001092,0.279409374235091,285,Gynaecology & Urology,efficacy,DICH,1,8,yes,2010.0,Number of women with urinary incontinence,One single-incision sling versus another,-0.238196482069751,"negative 
",negative,,,,,,,,,,,,,,,,,
370,CD004425,Monk 1987,STD-Monk-1987 1.475 0.624 39 39,0.397096858437648,0.635231381122678,78,Gynaecology & Urology,efficacy,DICH,1,24,no,1987.0,Women with self-assessed acne improvement at cycle 6,CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg,0.625121601731699,"neutral. 
",neutral,,,,,,,,,,,,,,,,,
371,CD002232,Ricart 2000,STD-Ricart-2000 0.556 0.766 24 24,-0.610909082322973,0.795979874054457,48,Hepato-Biliary,efficacy,DICH,1,9,no,2000.0,Death,Amoxicillin-clavulinic acid versus cefotaxime,-0.767493126693274,"negative 
",negative,,,,,,,,,,,,,,,,,
372,CD005124,Carroll 2005,STD-Carroll-2005 4.608 0.783 60 79,1.62627647679693,0.821408595263318,139,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,2005.0,High level of provider concern (adj for cluster),ALPHA versus standard care,1.97986298922961,"negative 
",negative,,,,,,,,,,,,,,,,,
373,CD001960,Loffeld 1989,STD-Loffeld-1989 1.038 0.395 26 24,0.0571584138399486,0.597858378316199,50,Gastroenterology,efficacy,DICH,1,5,no,1989.0,Individual symptom scores at end of treatment (Dichotomous),Bismuth vs. placebo,0.0956052736116684,"neutral 
",neutral,,,,,,,,,,,,,,,,,
374,CD001905,Ashrafi 2010,STD-Ashrafi-2010 1.222 0.07 49 49,3.14510967462859,1.46634120726434,98,Neurology,efficacy,DICH,1,5,yes,2010.0,Seizure cessation,Buccal midazolam versus rectal diazepam,2.14486891526169,"positive 
",positive,,,,,,,,,,,,,,,,,
375,CD006956,Maartense 2006,STD-Maartense-2006 0.062 1.492 30 30,-2.78400292352422,1.49246419240887,60,Gastroenterology,efficacy,DICH,1,1,yes,2006.0,Wound infection,Primary Outcomes,-1.86537334542732,"negative 
",negative,,,,,,,,,,,,,,,,,
376,CD006283,Pan 2004,STD-Pan-2004 0.487 1.203 38 37,-0.748717031714756,1.24723632708419,75,Neurology,efficacy,DICH,1,6,yes,2004.0,Number of participants without recovery,Electrotherapy plus acupuncture versus acupuncture,-0.600300853540019,"negative 
",negative,,,,,,,,,,,,,,,,,
377,CD001169,Hayden 1980,STD-Hayden-1980 1.528 0.498 9 11,0.782759339249632,0.918072515031979,20,Lungs,efficacy,DICH,1,7,no,1980.0,Viral nasal shedding or persistence in upper airways at 2 to 5 days,Oral or inhaled amantadine versus placebo or aspirin,0.852611668940298,"negative 
",negative,,,,,,,,,,,,,,,,,
378,CD005532,Glazebrook 1942,STD-Glazebrook-1942 0.267 0.577 335 1100,-2.38301819692474,1.43563450014528,1435,Lungs,efficacy,DICH,1,1,no,1942.0,The number of pneumonia cases during the follow-up,Vitamin C for preventing community-acquired pneumonia,-1.65990591385453,"negative 
",negative,,,,,,,,,,,,,,,,,
379,CD006173,Huh 2004,STD-Huh-2004 8.036 1.465 27 24,2.23889727373679,1.51841751183335,51,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2004.0,Incidence of postpartum haemorrhage (blood loss > 500 ml),Timing of oxytocics,1.47449384394515,"negative 
",negative,,,,,,,,,,,,,,,,,
380,CD009187,Lowe 1987,STD-Lowe-1987 40.733 1.417 44 46,4.26433550655858,1.45327324130758,90,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1987.0,Proportion of participants recruited into a smoking cessation programme,Recruitment: Head to head comparison of individual interventions,2.93429713377351,"positive 
",positive,,,,,,,,,,,,,,,,,
381,CD003628,Bion 1993,STD-Bion-1993 0.667 0.5 6 4,-1.09861228866811,1.4142135623731,10,Hepato-Biliary,efficacy,DICH,1,4,no,1993.0,Mortality,Non-randomised studies,-0.776836199212093,"negative 
",negative,,,,,,,,,,,,,,,,,
382,CD007891,INSPIRE,STD-INSPIRE 0.553 0.266 658 665,-0.608886836942206,0.277668133096303,1323,Lungs,efficacy,DICH,1,1,no,2008.0,Mortality (all-cause),Fluticasone/salmeterol (FPS) versus tiotropium (TIO),-2.19285817984388,"negative 
",negative,,,,,,,,,,,,,,,,,
383,CD004680,Voss 2012,STD-Voss-2012 0.667 0.29 100 100,-0.505548566665147,0.359484802611001,200,Kidney & Transplant,efficacy,DICH,1,12,yes,2012.0,Peritonitis rate (patient-month),Radiological versus surgical implantation,-1.40631415568407,"negative 
",negative,,,,,,,,,,,,,,,,,
384,CD008170,LIFE 2002,STD-LIFE-2002 0.885 0.067 4605 4588,-0.13358839007873,0.0735429421383423,9193,Heart & Hypertension,efficacy,DICH,1,3,no,2002.0,All-cause death,RAS inhibitors vs beta-blockers (ß-blockers),-1.81646785122406,"negative 
",negative,,,,,,,,,,,,,,,,,
385,CD007913,Chevallier 1995,STD-Chevallier-1995 0.829 0.135 61 59,-0.539813160639243,0.387828352495104,120,Oncology,efficacy,DICH,1,1,no,1995.0,Febrile neutropenia rates (total),Primary outcomes,-1.3918867900357,"negative 
",negative,,,,,,,,,,,,,,,,,
386,CD003000,George 1999,STD-George-1999 0.167 0.577 30 20,-2.60268968544438,0.760725774312731,50,Lungs,efficacy,DICH,1,1,no,1999.0,Hospital admission/re-admission (end of follow up),Education versus usual care,-3.42132444216939,"negative 
",negative,,,,,,,,,,,,,,,,,
387,CD001500,Cano 2012,STD-Cano-2012 2.914 0.434 105 48,1.0695360245866,0.434318982172,153,Gynaecology & Urology,efficacy,DICH,1,3,yes,2012.0,Improvement in symptoms (participant-assessed at end point),Oestrogen cream versus placebo or other regimens,2.46255878395626,"positive 
",positive,,,,,,,,,,,,,,,,,
388,CD010461,Esfahani 2016,STD-Esfahani-2016 2.475 0.311 102 101,1.12826098259024,0.376552135316924,203,Gynaecology & Urology,efficacy,DICH,1,4,yes,2016.0,Live birth per woman randomly assigned,Zeta sperm selection versus ICSI,2.99629420940779,"positive 
",positive,,,,,,,,,,,,,,,,,
389,CD008616,Charlesworth 2003,STD-Charlesworth-2003 3.174 0.191 427 389,1.36348590625493,0.217819687133689,816,Anaesthesia & Pain,efficacy,DICH,1,1,no,2003.0,Pain-free at 2 h,Zolmitriptan 1 mg versus placebo,6.25970004914237,"positive 
",positive,,,,,,,,,,,,,,,,,
390,CD005475,laser - Ma 1999,STD-laser-_x002d_-Ma-1999 0.2 1.539 60 60,-1.64305452323309,1.5600073534166,120,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1999.0,"Global state: Not improved, endpoint",ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS versus STANDARD DOSE ANTIPSYCHOTICS,-1.0532351143311,"negative 
",negative,,,,,,,,,,,,,,,,,
391,CD004236,Arrowsmith 2000,STD-Arrowsmith-2000 0.7 0.165 60 60,-0.826678573184468,0.376781482711512,120,Anaesthesia & Pain,efficacy,DICH,1,1,no,2000.0,Occurrence of pain for all pain scales combined,Amethocaine vs EMLA,-2.19405308147116,"negative 
",negative,,,,,,,,,,,,,,,,,
392,CD003711,Dong 2011,STD-Dong-2011 0.303 0.552 60 50,-1.37339095628398,0.620005854333053,110,Heart & Hypertension,efficacy,DICH,1,2,no,2011.0,Abnormal electrocardiogram,Herbal medicines plus supportive therapy versus supportive therapy,-2.21512578741914,"negative 
",negative,,,,,,,,,,,,,,,,,
393,CD004161,MacFadden 2010,STD-MacFadden-2010 1.049 0.119 177 172,0.087323828171675,0.215418098967708,349,Psychiatry & Mental Health,efficacy,DICH,1,5,no,2010.0,Global state: 1. Relapse (any reason),RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE,0.405369040902943,"negative 
",negative,,,,,,,,,,,,,,,,,
394,CD009899,Bahrami 2006,STD-Bahrami-2006 0.833 0.511 19 19,-0.256429528947677,0.717647765284833,38,Neurology,efficacy,DICH,1,6,yes,2006.0,Short-term improvement in CTS symptoms (Phalen's sign) (3 months or less),NERVE AND TENDON GLIDING EXERCISES PLUS SPLINT VERSUS SPLINT,-0.357319483668844,"positive 
",positive,,,,,,,,,,,,,,,,,
395,CD006680,Nakamura 1995,STD-Nakamura-1995 0.833 0.646 26 13,-0.231111720963387,0.825198388844998,39,Heart & Hypertension,efficacy,DICH,1,1,no,1995.0,Initial technical failure rates,Balloon angioplasty versus atherectomy,-0.280068071008798,"negative 
",negative,,,,,,,,,,,,,,,,,
396,CD003574,Stack 1997,STD-Stack-1997 6.5 1.42 21 10,2.17548459069981,1.5210523916409,31,Gastroenterology,efficacy,DICH,1,2,yes,1997.0,Remission rate,CDP571 versus placebo,1.4302496105035,"positive 
",positive,,,,,,,,,,,,,,,,,
397,CD003679,Taberner 1978b,STD-Taberner-1978b 0.224 0.688 48 48,-1.49502756125636,0.688107312482343,96,Gynaecology & Urology,efficacy,DICH,1,2,no,1978.0,Deep Vein Thrombosis,Oral warfarin (Acenocoumarol) vs placebo/control,-2.17266628930748,"negative 
",negative,,,,,,,,,,,,,,,,,
398,CD004740,Johnston 2006,STD-Johnston-2006 0.24 0.606 32 21,-1.42711635564015,0.605530070819498,53,"Oral Health, Eyes & ENT",efficacy,DICH,1,10,no,2006.0,Clinical cure,Topical spray: antiseptic/antibiotic/steroid vs antiseptic (acetic acid + neomycin + dexamethasone vs acetic acid),-2.35680509426848,"positive 
",positive,,,,,,,,,,,,,,,,,
399,CD005288,Sun2004,STD-Sun2004 5.59 1.461 60 30,1.79923893565935,1.49419646803294,90,Gynaecology & Urology,efficacy,DICH,1,1,no,2004.0,Reduction of pain,Chinese herbal medicine versus placebo,1.20415151163353,"positive 
",positive,,,,,,,,,,,,,,,,,
400,CD009071,Aliaev 2008,STD-Aliaev-2008 1.039 0.071 34 32,0.503905180921417,0.94819095753652,66,Gynaecology & Urology,efficacy,DICH,1,19,no,2008.0,Microbiological efficacy (pathogen eradication) at the end of treatment,Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin,0.531438500774786,"positive 
",positive,,,,,,,,,,,,,,,,,
401,CD013210,Herfarth 2006,STD-Herfarth-2006 0.929 0.128 37 42,-0.306031211119977,0.527684733956913,79,Gastroenterology,efficacy,DICH,1,3,yes,2006.0,Clinical relapse,Direct evidence: 5-ASA versus purine analogues,-0.579950852140751,"negative 
",negative,,,,,,,,,,,,,,,,,
402,CD008540,Sacks 2006,STD-Sacks-2006 0.923 0.322 13 9,-0.223143551314209,0.908295106229247,22,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2006.0,Caesarean section,Very tight versus tight-moderate glycaemic control,-0.245672964418559,"negative 
",negative,,,,,,,,,,,,,,,,,
403,CD003750,Pitkin 1971,STD-Pitkin-1971 4.773 0.471 44 49,1.56291789679921,0.471353500224749,93,Oncology,efficacy,DICH,1,3,yes,1971.0,Reduction of vaginal bleeding,Reduction of vaginal radiation symptoms that prevent intercourse,3.31580840293746,"negative 
",negative,,,,,,,,,,,,,,,,,
404,CD009687,De Cuyper 1995,STD-De-Cuyper-1995 0.757 0.477 76 74,-0.311033662982529,0.53277164242859,150,Skin & Wounds,efficacy,DICH,1,6,no,1995.0,Number of participants achieving 'clearance' by IGA,Steroid versus steroid: high versus moderate potency,-0.583802962118461,"positive 
",positive,,,,,,,,,,,,,,,,,
405,CD003998,Cinamon 2001,STD-Cinamon-2001 1.1 0.377 10 11,0.22314355131421,0.885061203156783,21,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,2001.0,"Hearing recovery: average speech frequencies (500, 1000, 2000 Hz)",Oral steroid versus oral placebo immediately post-treatment,0.252122170216381,"positive 
",positive,,,,,,,,,,,,,,,,,
406,CD000324,Tzafettas 1994,STD-Tzafettas-1994 5.755 0.764 20 16,1.94591014905531,0.899735410842437,36,Gynaecology & Urology,efficacy,DICH,1,7,no,1994.0,primary treatment success,MTX transvaginally under sonographic guidance versus MTX under laparoscopic guidance,2.16275821269869,"positive 
",positive,,,,,,,,,,,,,,,,,
407,CD001047,Pitt 1991,STD-Pitt-1991 0.266 0.289 72 204,-1.3244189574018,0.288678747527581,276,Emergency & Trauma,efficacy,DICH,1,1,no,1991.0,Drowning and near-drowning,Fencing versus no fencing - all pool types,-4.58786442973349,"negative 
",negative,,,,,,,,,,,,,,,,,
408,CD001541,Anderson 1990,STD-Anderson-1990 0.729 0.369 14 17,-0.644357016390513,0.731111352342316,31,Skin & Wounds,efficacy,DICH,1,3,yes,1990.0,Recurrence,Surgical procedures: Chem abln & surg vs surg proc,-0.881339093321611,"negative 
",negative,,,,,,,,,,,,,,,,,
409,CD002745,Monto 1995,STD-Monto-1995 0.519 0.64 54 14,-0.780158557549575,0.782139644975515,68,Lungs,efficacy,DICH,1,3,no,1995.0,RMT (proved and clinical infection),Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly,-0.997467092432066,"negative 
",negative,,,,,,,,,,,,,,,,,
410,CD000340,Ryan 1996,STD-Ryan-1996 0.312 1.097 16 15,-1.32175583998232,1.21792172709634,31,Emergency & Trauma,efficacy,DICH,1,6,no,1996.0,Number of participants falling,Home safety intervention plus fall prevention classes vs control,-1.08525516096468,"negative 
",negative,,,,,,,,,,,,,,,,,
411,CD004174,Mol 2016,STD-Mol-2016 1.535 0.203 256 262,0.511800757924197,0.241420010636869,518,Heart & Hypertension,efficacy,DICH,1,4,yes,2016.0,Cumulative incidence of any post-thrombotic syndrome,One year versus two years of compression stockings,2.11995996758538,"negative 
",negative,,,,,,,,,,,,,,,,,
412,CD002251,Hartley 2001,STD-Hartley-2001 0.895 0.107 20 20,-1.20983792377833,1.20199352814084,40,Pregnancy & Childbirth,efficacy,DICH,1,44,yes,2001.0,Women with hypotension requiring intervention,Lateral vs supine wedged position,-1.00652615463714,"negative 
",negative,,,,,,,,,,,,,,,,,
413,CD002071,Tan 2008,STD-Tan-2008 2.568 1.645 56 47,0.942958978956316,1.64491255581068,103,Heart & Hypertension,efficacy,DICH,1,5,yes,2008.0,"Reocclusion/restenosis, 24 hours",Clopidogrel plus aspirin versus LMWH followed by warfarin,0.573257815818414,"negative 
",negative,,,,,,,,,,,,,,,,,
414,CD005563,Li 2013,STD-Li-2013 0.5 0.342 40 40,-1.03609193168678,0.494347323890138,80,Psychiatry & Mental Health,efficacy,DICH,1,10,yes,2013.0,Incident delirium,Intravenous parecoxib sodium analgesia versus Morphine and Saline,-2.09587850811757,"negative 
",negative,,,,,,,,,,,,,,,,,
415,CD001534,Belet 2004,STD-Belet-2004 1.786 0.864 21 25,0.650587566141149,0.965591606093619,46,Kidney & Transplant,efficacy,DICH,1,2,yes,2004.0,Recurrence of symptomatic UTI,Comparison between two types of antibiotics,0.673770942120298,"negative 
",negative,,,,,,,,,,,,,,,,,
416,CD009744,AIM-HIGH 2011,STD-AIM_x002d_HIGH-2011 1.156 0.146 1693 1672,0.153236091202848,0.154489137197052,3365,Heart & Hypertension,efficacy,DICH,1,1,no,2011.0,Overall mortality,"Niacin versus control, maximum follow-up, available case analysis",0.99188909966786,"negative 
",negative,,,,,,,,,,,,,,,,,
417,CD000536,Cole 1993,STD-Cole-1993 1.08 1.443 13 14,0.0800427076735364,1.46978107562195,27,Heart & Hypertension,efficacy,DICH,1,18,no,1993.0,"Early graft thrombosis, 24 h and 1 month","Early graft thrombosis, ancrod versus heparin",0.0544589320145286,"negative 
",negative,,,,,,,,,,,,,,,,,
418,CD001233,Roberts 1986,STD-Roberts-1986 0.744 0.539 28 25,-0.373376793556664,0.680276786671132,53,Pregnancy & Childbirth,efficacy,DICH,1,25,yes,1986.0,Caesarean section,Laminaria tent versus oxytocin: all women,-0.548860112343017,"negative 
",negative,,,,,,,,,,,,,,,,,
419,CD006319,Ho 2001,STD-Ho-2001 0.384 1.645 46 54,-0.95838294735946,1.64525488353501,100,Gastroenterology,efficacy,DICH,1,2,no,2001.0,Recurrence,Ayurvedic seton Vs. Conventional fistulotomy,-0.58251335823436,"negative 
",negative,,,,,,,,,,,,,,,,,
420,CD001350,MacKay 1995,STD-MacKay-1995 1 1.021 50 50,0.0,1.02062072615966,100,Spine & Muscles,efficacy,DICH,1,15,no,1995.0,Poor result at 1yr - independent observer rated,GELFOAM V. NO INTERPOSITION MEMBRANE,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
421,CD008471,Barker 1984,STD-Barker-1984 0.889 0.405 9 8,-0.287682072451781,0.991631652042901,17,Emergency & Trauma,efficacy,DICH,1,1,no,1984.0,Proportion of fractures united,Electromagnetic stimulation versus sham,-0.290109812306934,"negative 
",negative,,,,,,,,,,,,,,,,,
422,CD000165,Betson 1997,STD-Betson-1997 1.026 0.379 443 422,0.0263662092685064,0.391315267345541,865,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1997.0,Smoking cessation (at longest follow up),Effect of advice versus control (subgroups by intensity),0.0673784323503648,"negative 
",negative,,,,,,,,,,,,,,,,,
423,CD003261,Bass 1997,STD-Bass-1997 2.571 0.496 7 9,2.484906649788,1.29099444873581,16,Skin & Wounds,efficacy,DICH,1,2,no,1997.0,Cure/improvement,Non-bullous impetigo: topical (Top) antibiotic (Ab) vs another topical (Top) antibiotic (Ab),1.9248004143018,"positive 
",positive,,,,,,,,,,,,,,,,,
424,CD006323,Chuchalin 2005,STD-Chuchalin-2005 0.731 0.08 64 60,-3.13926780531279,1.04606110650034,124,Lungs,efficacy,DICH,1,1,yes,2005.0,Failure to recover by day seven (complete resolution of all symptoms),"P. sidoides versus placebo, acute bronchitis in adults",-3.00103673275398,"negative 
",negative,,,,,,,,,,,,,,,,,
425,CD000526,Mayosi 2014,STD-Mayosi-2014 0.808 0.314 138 118,-0.247778773448598,0.364202619124626,256,Infectious Diseases,efficacy,DICH,1,1,no,2014.0,Deaths from all causes,Steroids versus placebo in HIV-negative people,-0.680332211899363,"negative 
",negative,,,,,,,,,,,,,,,,,
426,CD006418,Gray 2014,STD-Gray-2014 0.551 0.607 85 82,-0.636576829071551,0.646943703271639,167,Infectious Diseases,efficacy,DICH,1,1,no,2013.0,Active TB,Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral therapy (ART),-0.98397561619711,"negative 
",negative,,,,,,,,,,,,,,,,,
427,CD006260,Murthy 2005,STD-Murthy-2005 0.651 0.926 30 30,-0.44183275227904,0.951884791392664,60,Gynaecology & Urology,efficacy,DICH,1,3,yes,2005.0,Discontinuation of patch by cycle 3,Immediate versus conventional start of contraceptive patch (norelgestromin 150 µg + EE 20 µg),-0.464166206114725,"negative 
",negative,,,,,,,,,,,,,,,,,
428,CD008704,Dimidjian 2004,STD-Dimidjian-2004 1.157 0.234 43 45,0.267137543220149,0.429146490702767,88,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2006.0,Clinical response at post-treatment,Third wave CBT vs other psychological therapies,0.62248567565515,"positive 
",positive,,,,,,,,,,,,,,,,,
429,CD002010,Papaioannou 2008,STD-Papaioannou-2008 0.191 1.577 23 24,-1.65292302437384,1.57702176140147,47,Genetics & Endocrinology,efficacy,DICH,1,1,no,2008.0,Vertebral fractures,Bisphosphonates versus control (without lung transplantation),-1.04812949626321,"negative 
",negative,,,,,,,,,,,,,,,,,
430,CD010893,Hashkes 2012,STD-Hashkes-2012 0.867 0.193 7 7,-1.24171313230878,1.71867569769464,14,Genetics & Endocrinology,efficacy,DICH,1,2,yes,2012.0,Number of participants experiencing an attack,Rilonacept versus placebo,-0.722482510210836,"negative 
",negative,,,,,,,,,,,,,,,,,
431,CD003449,Sadeghi-Bazargani 2006,STD-Sadeghi_x002d_Bazargani-2006 0.377 0.338 24 22,-2.11107862662302,0.678604598923904,46,Gynaecology & Urology,efficacy,DICH,1,6,no,2006.0,Continued amenorrhea during treatment,Estrogen and progestin vs placebo (DMPA /Therapeutic for amenorrhea),-3.11091116973074,"negative 
",negative,,,,,,,,,,,,,,,,,
432,CD004920,Ables 2000,STD-Ables-2000 1 0.365 60 60,0.0,0.456435464587638,120,Emergency & Trauma,efficacy,DICH,1,1,no,2000.0,Mortality,Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
433,CD001363,Comstock 1962,STD-Comstock-1962 0.379 0.164 2480 2406,-1.00460065081894,0.169301518588934,4886,Infectious Diseases,efficacy,DICH,1,1,no,1962.0,Active tuberculosis,Isoniazid versus placebo,-5.93379586427762,"negative 
",negative,,,,,,,,,,,,,,,,,
434,CD008107,Walsh 2002,STD-Walsh-2002 -0.064 0.095 53 54,-0.264925085329165,0.395251007473455,107,Gastroenterology,efficacy,DICH,1,6,yes,2002.0,Risk difference plot for postoperative morbidity,Postoperative morbidity,-0.670270487158613,"negative 
",negative,,,,,,,,,,,,,,,,,
435,CD006942,Rahman 2011,STD-Rahman-2011 0.517 0.337 100 104,-0.659875252704844,0.337205237444335,204,Gynaecology & Urology,efficacy,DICH,1,3,no,2011.0,live birth rate per couple,Short versus long interval,-1.95689502839876,"positive 
",positive,,,,,,,,,,,,,,,,,
436,CD007003,Campistol 1999a,STD-Campistol-1999a 0.895 1.374 19 17,-0.117783035656384,1.45535409971441,36,Kidney & Transplant,efficacy,DICH,1,1,yes,1999.0,Mortality,Standard interferon versus placebo or control,-0.0809308440327316,"negative 
",negative,,,,,,,,,,,,,,,,,
437,CD004203,Hakvoort 2011,STD-Hakvoort-2011 2.786 0.481 42 45,1.2770950691549,0.580005030619362,87,Gynaecology & Urology,efficacy,DICH,1,2,yes,2011.0,Symptomatic UTI,Urethral vs intermittent catheterisation,2.20186895239709,"negative 
",negative,,,,,,,,,,,,,,,,,
438,CD002290,Dorresteijn 2007,STD-Dorresteijn-2007 5 1.017 12 12,2.06142303617716,1.19739978025981,24,Kidney & Transplant,efficacy,DICH,1,10,yes,2007.0,Relapse within 12 months,Mycophenolate mofetil versus cyclosporin,1.72158294177228,"negative 
",negative,,,,,,,,,,,,,,,,,
439,CD005228,Pace 2003,STD-Pace-2003 0.392 0.439 13 14,-2.11021320034659,0.886201746417561,27,Neurology,efficacy,DICH,1,19,no,2003.0,Abnormal median or sural sensory amplitude,Vitamin E - qualitative sensory nerve conduction study (NCS) amplitudes,-2.38118826652853,"negative 
",negative,,,,,,,,,,,,,,,,,
440,CD002096,Blum (OCAY) 1998,STD-Blum-_x0028_OCAY_x0029_-1998 0.915 0.062 164 164,-0.368712922498212,0.260249218951662,328,Gastroenterology,efficacy,DICH,1,4,no,1998.0,Global symptom scores (dichotomous),Follow-up between 3-12 months,-1.41676860350807,"neutral 
",neutral,,,,,,,,,,,,,,,,,
441,CD003244,Dekkers 1999,STD-Dekkers-1999 0.936 0.271 102 100,-0.0842603436177401,0.343860124042395,202,Gastroenterology,efficacy,DICH,1,4,no,1999.0,Oesophagitis persists at four weeks,Standard dose omeprazole versus standard dose rabeprazole,-0.245042497592281,"negative 
",negative,,,,,,,,,,,,,,,,,
442,CD003749,Ruckley 1991,STD-Ruckley-1991 1 0.178 98 93,0.0004579803148516,0.295760626296957,191,Heart & Hypertension,efficacy,DICH,1,2,no,1991.0,Failed primary stump healing,Skew flaps amputation versus long posterior flap amputation,0.0015484830438242,"negative 
",negative,,,,,,,,,,,,,,,,,
443,CD007504,Cheung 2008,STD-Cheung-2008 0.583 0.9 13 9,-0.538996500732687,0.899735410842437,22,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2008.0,Number relapsed,Medication versus placebo,-0.59906111756568,"negative 
",negative,,,,,,,,,,,,,,,,,
444,CD012390,Bourcier 1994,STD-Bourcier-1994 1.601 0.216 46 38,1.04439073450147,0.454839836247158,84,Gynaecology & Urology,efficacy,DICH,1,5,no,1994.0,Subjective cure,Electrical stimulation versus PFMT and vaginal cones,2.29617252331864,"neutral 
",neutral,,,,,,,,,,,,,,,,,
445,CD004197,Valerius 1991,STD-Valerius-1991 2.778 1.68 14 12,1.02165124753198,1.67950610023922,26,Genetics & Endocrinology,efficacy,DICH,1,2,yes,1991.0,Proportion colonised with P aeruginosa,Oral ciprofloxacin and inhaled colistin versus no treatment,0.6083045767958,"negative 
",negative,,,,,,,,,,,,,,,,,
446,CD001407,Burns 1993,STD-Burns-1993 0.724 0.454 43 40,-0.40084616225187,0.560360684079603,83,Gynaecology & Urology,efficacy,DICH,1,15,no,1993.0,self reported cure post treatment,PFMT versus PFMT with biofeedback,-0.715335985625513,"positive 
",positive,,,,,,,,,,,,,,,,,
447,CD011856,Alonso-Colmenero 2010,STD-Alonso_x002d_Colmenero-2010 1.333 0.244 53 53,0.475734303954721,0.400345362673705,106,Psychiatry & Mental Health,efficacy,DICH,1,4,no,2010.0,Active smoking. Subgroups by setting,Active smoking rates pre- and post-smoking ban,1.18830976529247,"negative 
",negative,,,,,,,,,,,,,,,,,
448,CD000215,Sotelo 1988,STD-Sotelo-1988 0.375 0.532 10 5,-2.23359222150709,1.31384568203061,15,Infectious Diseases,efficacy,DICH,1,2,no,1988.0,Symptoms not resolved after 3 months,Praziquantel vs placebo or no drug,-1.70004152851115,"negative 
",negative,,,,,,,,,,,,,,,,,
449,CD004352,Gummerus 1983,STD-Gummerus-1983 1.75 0.604 70 70,0.606135803570316,0.651061958558226,140,Pregnancy & Childbirth,efficacy,DICH,1,6,no,1983.0,Respiratory distress syndrome,Hexoprenaline versus salbutamol,0.930995576692271,"negative 
",negative,,,,,,,,,,,,,,,,,
450,CD006531,29060/356,STD-_x0032_9060_x002f_356 0.338 1.642 68 70,-1.08411928136554,1.64184460166646,138,Psychiatry & Mental Health,efficacy,DICH,1,15,no,,Abnormal white blood cells,SE - Abnormal laboratory values,-0.660305658809105,"negative 
",negative,,,,,,,,,,,,,,,,,
451,CD006137,Di Lorenzo 2004,STD-Di-Lorenzo-2004 37 1.416 40 40,4.19870457754634,1.45711696734449,80,Skin & Wounds,efficacy,DICH,1,9,no,2004.0,Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines,Desloratadine 5 to 20 mg versus placebo,2.88151512311208,"positive 
",positive,,,,,,,,,,,,,,,,,
452,CD003023,Jones 2005,STD-Jones-2005 0.682 0.119 66 64,-1.38101730401905,0.424910100734836,130,Psychiatry & Mental Health,efficacy,DICH,1,7,no,2005.0,Use of opioid and cocaine,CBT (Reinforcement-Based Therapy) versus Usual Care,-3.25013997462222,"negative 
",negative,,,,,,,,,,,,,,,,,
453,CD008303,Fuchs 2005,STD-Fuchs-2005 0.144 0.517 111 116,-2.18792218467391,0.552560228288986,227,Emergency & Trauma,efficacy,DICH,1,5,yes,2005.0,DVT,Mechanical + pharmacological prophylaxis vs Pharmacological,-3.95960851443987,"negative 
",negative,,,,,,,,,,,,,,,,,
454,CD006629,Casey 2003,STD-Casey-2003 0.606 0.717 103 104,-0.520875959619493,0.743931679278644,207,Psychiatry & Mental Health,efficacy,DICH,1,3,no,2003.0,Weight: gain (= 7% from baseline),Switching - techniques: to aripriprazole from previous regimen - three dfferent techniques - short term (up to 12 months),-0.700166391790926,"negative 
",negative,,,,,,,,,,,,,,,,,
455,CD010224,Kelly 1984,STD-Kelly-1984 1.165 1.093 79 23,0.159848700941896,1.1440226740707,102,Neurology,efficacy,DICH,1,6,no,1984.0,All Major Malformations,PB vs Controls,0.139725116088055,"negative 
",negative,,,,,,,,,,,,,,,,,
456,CD004826,Bousvaros 2005,STD-Bousvaros-2005 1.846 0.443 39 36,0.798507696217772,0.566012694531112,75,Gastroenterology,efficacy,DICH,1,4,no,2005.0,Relapses at end of study (PCDAI),Probiotics plus maintenance versus placebo plus maintenance (children),1.41075934150074,"negative 
",negative,,,,,,,,,,,,,,,,,
457,CD007428,Shen 2008,STD-Shen-2008 0.123 1.046 67 66,-2.20865327315984,1.07582196225112,133,Emergency & Trauma,efficacy,DICH,1,4,yes,2008.0,Treatment failure (re-operation for symptomatic delayed union),Three-dimensional (3D) plate versus superior plate for treating acute dislocated fractures,-2.0529914341387,"negative 
",negative,,,,,,,,,,,,,,,,,
458,CD004415,Jorizzo 2002,STD-Jorizzo-2002 7.826 1.439 45 23,2.21439238095858,1.48386675641606,68,Skin & Wounds,efficacy,DICH,1,9,no,2002.0,Participant complete clearance,0.5% 5-FU versus vehicle,1.49231214418937,"positive 
",positive,,,,,,,,,,,,,,,,,
459,CD002896,Handforth 1998,STD-Handforth-1998 1.492 0.296 94 102,0.496134908355987,0.365337298014011,196,Neurology,efficacy,DICH,1,1,no,1998.0,50% responders,High versus low stimulation,1.35801877074418,"neutral. 
",neutral,,,,,,,,,,,,,,,,,
460,CD001062,Coxon 1973,STD-Coxon-1973 1.055 0.415 200 211,0.0565703514883942,0.438302620468082,411,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1973.0,Admission for pre-eclampsia,Prophylactic abdominal decompression in pregnancy,0.129066879472407,"negative 
",negative,,,,,,,,,,,,,,,,,
461,CD001055,Cinciripini 2000,STD-Cinciripini-2000 0.571 0.696 42 40,-0.619039208406223,0.766515353757371,82,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,2000.0,Abstinence in late pregnancy,Smoking cessation interventions: counselling vs less intensive intervention,-0.807601837812855,"negative 
",negative,,,,,,,,,,,,,,,,,
462,CD005306,Charlton 1990,STD-Charlton-1990 0.553 0.27 27 19,-1.40431286662257,0.651795721325065,46,Lungs,efficacy,DICH,1,1,yes,1990.0,Number of patients with at least one acute care visits for asthma,Peak flow-based self-management plan versus Symptom-based self-management plan,-2.15452912726656,"negative 
",negative,,,,,,,,,,,,,,,,,
463,CD004509,Hofling 2007,STD-Hofling-2007 1.349 0.548 46 41,0.299516530098783,0.547765173537715,87,Gynaecology & Urology,efficacy,DICH,1,9,no,2007.0,Incidence of increased breast density,HT plus testosterone versus HT on mammographic findings,0.546797322225454,"negative 
",negative,,,,,,,,,,,,,,,,,
464,CD008687,Skillman 1984,STD-Skillman-1984 0.273 0.574 22 24,-1.84582669049833,0.743391941675028,46,Gastroenterology,efficacy,DICH,1,20,yes,1984.0,Clinically important upper GI bleeding,Antacids versus prostaglandin analogues,-2.48297914871026,"negative 
",negative,,,,,,,,,,,,,,,,,
465,CD005188,Chambers 1991,STD-Chambers-1991 2.301 0.22 198 161,0.833200170576365,0.220008366848658,359,Lungs,efficacy,DICH,1,3,yes,1991.0,Reminder (to physician) compared to no reminder,Provider- or system-based intervention,3.7871294738055,"neutral 
",neutral,,,,,,,,,,,,,,,,,
466,CD005064,Kaim 1972,STD-Kaim-1972 1.209 1.214 55 133,0.193066096076932,1.23537528966091,188,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,1972.0,Alcohol withdrawal seizures,Anticonvulsant versus Other Drugs,0.156281332233807,"negative 
",negative,,,,,,,,,,,,,,,,,
467,CD008039,Misra 2004,STD-Misra-2004 1.194 0.246 35 33,0.354171813720614,0.487189697314702,68,Anaesthesia & Pain,efficacy,DICH,1,3,no,2004.0,Headache relief at 2 hours,Ibuprofen 400 mg versus rofecoxib 25 mg,0.726969013656779,"positive 
",positive,,,,,,,,,,,,,,,,,
468,CD003092,Wilson 1978,STD-Wilson-1978 0.2 1.033 15 15,-1.94591014905531,1.17108008753824,30,Pregnancy & Childbirth,efficacy,DICH,1,23,yes,1978.0,Caesarean section,Extra-amniotic PGE2 vs oxytocin: all women,-1.66163712436257,"negative 
",negative,,,,,,,,,,,,,,,,,
469,CD003407,Aapro 2008,STD-Aapro-2008 4.927 0.17 231 232,2.58476217589245,0.236923912396165,463,Oncology,efficacy,DICH,1,1,yes,2008.0,Haematological response - overall,Haematologic response,10.9096720113688,"neutral 
",neutral,,,,,,,,,,,,,,,,,
470,CD008107,ACCORD 07 2011,STD-ACCORD-07-2011 1.955 0.334 113 111,0.670253360694093,0.334306571414186,224,Gastroenterology,efficacy,DICH,1,3,yes,2011.0,Odds ratio plot for tumor-free resection margin,Presence of tumor-free resection margin,2.0049063285199,"positive 
",positive,,,,,,,,,,,,,,,,,
471,CD006689,Filler 2006,STD-Filler-2006 1.018 0.067 135 118,0.0811206236130719,0.303220660428818,253,Infectious Diseases,efficacy,DICH,1,1,yes,2006.0,Maternal anaemia: (haemoglobin less than 11g/dl),Monthly sulfadoxine pyrimethamine (SP) compared to standard 2-dose SP,0.267530001083535,"negative 
",negative,,,,,,,,,,,,,,,,,
472,CD006897,Chen 2005,STD-Chen-2005 0.556 0.764 44 43,-0.586811530743913,0.764224683394521,87,Lungs,efficacy,DICH,1,1,no,2005.0,Treatment failure,Systemic corticosteroids for 7 or fewer days vs longer than 7 days,-0.7678521035691,"negative 
",negative,,,,,,,,,,,,,,,,,
473,CD011094,DART 1989,STD-DART-1989 0.873 0.087 1018 1015,-0.171386837457793,0.109564757827614,2033,Heart & Hypertension,efficacy,DICH,1,2,yes,1989.0,"Myocardial infarction (MI), overall",Secondary outcomes - higher omega-6 vs lower omega-6,-1.56425150619551,"negative 
",negative,,,,,,,,,,,,,,,,,
474,CD003277,Anonymous 1993,STD-Anonymous-1993 3.892 1.093 37 36,1.44513486114282,1.14406051364185,73,Neurology,efficacy,DICH,1,2,yes,1993.0,Number of participants in whom there was complete cessation of all seizures,Felbamate versus placebo,1.26316295677627,"positive 
",positive,,,,,,,,,,,,,,,,,
475,CD005207,AXIS-1 2010,STD-AXIS_x002d_1-2010 1.641 0.657 29 14,0.495321437230025,0.656574248344956,43,Neurology,efficacy,DICH,1,1,no,2010.0,"Functional outcome (death or dependency), end of trial",Colony stimulating factor (CSF),0.754402778480264,"negative 
",negative,,,,,,,,,,,,,,,,,
476,CD004549,Allaire 2000,STD-Allaire-2000 0.303 1.492 24 52,-1.24261059703135,1.53190490319958,76,Skin & Wounds,efficacy,DICH,1,1,yes,2000.0,Wound infection,Wound drain versus no drain,-0.81115387413148,"negative 
",negative,,,,,,,,,,,,,,,,,
477,CD009098,Brower 2004,STD-Brower-2004 0.91 0.143 276 273,-0.127833371509885,0.194184216355045,549,Emergency & Trauma,efficacy,DICH,1,1,yes,2004.0,Mortality before hospital discharge,High versus low levels of PEEP,-0.658309794222181,"negative 
",negative,,,,,,,,,,,,,,,,,
478,CD011082,Hill 2010,STD-Hill-2010 0.717 0.495 89 29,-0.390197635977376,0.587704237177401,118,Neonatal,efficacy,DICH,1,2,yes,2010.0,CRBSI,Silver-Alginate dressing versus control,-0.663935379896867,"negative 
",negative,,,,,,,,,,,,,,,,,
479,CD011481,Lecrubier 2005,STD-Lecrubier-2005 1.049 0.103 136 94,0.129211731480006,0.277877899058368,230,Psychiatry & Mental Health,efficacy,DICH,1,3,yes,2005.0,Benzodiazepine discontinuation,Lithium versus placebo,0.464994632239054,"negative 
",negative,,,,,,,,,,,,,,,,,
480,CD001359,Beasley 1997 (E003),STD-Beasley-1997-_x0028_E003_x0029_ 0.694 1.148 350 81,-0.368685856604868,1.16134197276846,431,Psychiatry & Mental Health,efficacy,DICH,1,3,no,1997.0,Death: deaths during study or within 30 days of study discontinuation,OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,-0.317465367867466,"negative 
",negative,,,,,,,,,,,,,,,,,
481,CD005431,Liu 2002,STD-Liu-2002 0.097 0.737 60 32,-2.72066866506142,0.809795972970034,92,"Oral Health, Eyes & ENT",efficacy,DICH,1,6,yes,2002.0,Risk of secondary hemorrhage,Aminomethylbenzoic acid versus placebo,-3.35969646166924,"negative 
",negative,,,,,,,,,,,,,,,,,
482,CD005951,Sprigg 2014 (TICH-1),STD-Sprigg-2014-_x0028_TICH_x002d_1_x0029_ 1.25 0.403 16 8,0.510825623765991,0.875595035770913,24,Neurology,efficacy,DICH,1,2,no,2014.0,Death or dependence (mRS 4 to 6) at day 90,Antifibrinolytic drugs vs placebo or open control,0.583403974322715,"negative 
",negative,,,,,,,,,,,,,,,,,
483,CD001067,Chatwani 1995,STD-Chatwani-1995 0.53 0.254 232 123,-0.753165190286198,0.303457944706727,355,Pregnancy & Childbirth,efficacy,DICH,1,5,no,1995.0,Treatment failure,Agent with longer half-life versus similar agent with shorter half-life,-2.48194256707988,"negative 
",negative,,,,,,,,,,,,,,,,,
484,CD004912,McGready 2001a,STD-McGready-2001a 0.212 0.3 64 65,-2.7243866204219,0.445168935645353,129,Infectious Diseases,efficacy,DICH,1,6,yes,2001.0,"Treatment failure at 48 hours (excludes new infections, detected by PCR)",Artesunate (AS) vs quinine plus clindamycin (QN+CLD),-6.11989382518888,"negative 
",negative,,,,,,,,,,,,,,,,,
485,CD006924,Brown 2012,STD-Brown-2012 0.965 1.415 377 364,-0.0351863091250441,1.41612654639503,741,Lungs,efficacy,DICH,1,1,yes,2012.0,All-cause mortality,"Formoterol and ICS versus same-dose ICS (Peto OR, OR, risk difference)",-0.0248468678273254,"negative 
",negative,,,,,,,,,,,,,,,,,
486,CD003717,Strevel 2007,STD-Strevel-2007 1.171 0.103 22 27,1.56291789679921,1.13713393805373,49,Public Health & Work,efficacy,DICH,1,3,yes,2007.0,Knowledge,Audio-visual informed consent versus placebo informed consent,1.3744360664094,"neutral 
",neutral,,,,,,,,,,,,,,,,,
487,CD010866,Ostergaard 2000,STD-Ostergaard-2000 0.459 0.522 169 186,-0.816279865963569,0.543302881223471,355,Infectious Diseases,efficacy,DICH,1,1,yes,2000.0,Prevalence of chlamydia infection (positivity) measured in the whole study population at least 12 months after start of screening,Offer of chlamydia screening vs usual care (inactive control),-1.5024397885124,"negative 
",negative,,,,,,,,,,,,,,,,,
488,CD001439,Richards 1981,STD-Richards-1981 0.27 0.431 67 62,-1.40649706843741,0.483045891539648,129,Gastroenterology,efficacy,DICH,1,7,yes,1981.0,Wound infection,"Per-operatively administered multiple agent, single dose Antibiotics vs Placebo",-2.91172555873393,"negative 
",negative,,,,,,,,,,,,,,,,,
489,CD001095,Meistrup-Larsen 1983,STD-Meistrup_x002d_Larsen-1983 2.383 0.575 46 55,0.88889175768604,0.598446437150509,101,Lungs,efficacy,DICH,1,1,no,1983.0,Treatment failure at 1 month or less,Short-acting antibiotic =< 48 hours in short treatment arm,1.48533219099521,"negative 
",negative,,,,,,,,,,,,,,,,,
490,CD003149,Vichinsky 1995,STD-Vichinsky-1995 0.839 0.399 110 120,-0.194705615993676,0.44302242755373,230,Genetics & Endocrinology,efficacy,DICH,1,1,yes,1995.0,Serious complications related to sickle cell disease,Aggressive versus conservative blood transfusion,-0.439493813143493,"negative 
",negative,,,,,,,,,,,,,,,,,
491,CD006611,Abroms 2014,STD-Abroms-2014 1.397 0.231 262 241,0.385548514204078,0.265753767637574,503,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2014.0,Long-term abstinence (all randomised)),Text messaging versus minimal smoking cessation support,1.45077346459251,"positive 
",positive,,,,,,,,,,,,,,,,,
492,CD000434,Wirbel 1999,STD-Wirbel-1999 0.9 0.386 32 32,-0.14981227822866,0.547762646987928,64,Emergency & Trauma,efficacy,DICH,1,15,no,1999.0,Neer score = 80 points (unsatisfactory or failure) at 6 months,Post-operative (percutaneous fixation) immobilisation for 1 week versus 3 weeks,-0.273498529066298,"negative 
",negative,,,,,,,,,,,,,,,,,
493,CD002778,Dahlstrom 1985,STD-Dahlstrom-1985 0.675 0.61 10 9,-0.624154309072994,0.962387903181704,19,"Oral Health, Eyes & ENT",efficacy,DICH,1,4,no,1985.0,Dysfunction score (3 months or less),Stabilisation splint (SS) versus bite plates,-0.648547542014512,"negative 
",negative,,,,,,,,,,,,,,,,,
494,CD010389,Komericki 2011,STD-Komericki-2011 1.042 0.18 20 25,0.154150679827259,0.681967275666043,45,Infectious Diseases,efficacy,DICH,1,2,yes,2011.0,Complete regression after treatment,Imiquimod versus any other patient-applied treatment,0.226038235744827,"positive 
",positive,,,,,,,,,,,,,,,,,
495,CD001732,Stanley 1991,STD-Stanley-1991 1.355 0.779 51 51,0.308735481649614,0.790849709117572,102,Heart & Hypertension,efficacy,DICH,1,4,no,1991.0,Results: successful sclerotherapy,Molefoam versus Sorbo pad to injection sites after sclerotherapy,0.390384516919277,"positive 
",positive,,,,,,,,,,,,,,,,,
496,CD004929,Adekunle 1979,STD-Adekunle-1979 1.861 0.343 84 86,0.756442030932259,0.412149759483642,170,Gastroenterology,efficacy,DICH,1,2,yes,1979.0,Does post-operative nasogastric decompression diminish the risk of pulmonary complications?,Pulmonary Complications,1.8353572057884,"negative 
",negative,,,,,,,,,,,,,,,,,
497,CD005428,Mountokalakis 1985,STD-Mountokalakis-1985 0.292 0.582 24 28,-1.65822807660353,0.725800051175056,52,Gynaecology & Urology,efficacy,DICH,1,3,yes,1985.0,Number of people with asymptomatic bacteriuria,CG: Antibiotic prophylaxis at catheterisation only versus antibiotic prophylaxis throughout catheterisation period,-2.28468994169798,"negative 
",negative,,,,,,,,,,,,,,,,,
498,CD001777,Randic 1991,STD-Randic-1991 3.4 0.499 200 200,1.28728883734444,0.519053191315001,400,Gynaecology & Urology,efficacy,DICH,1,9,yes,1991.0,Discontinuations due to pregnancy (10 years),Immediate insertion: Lippes Loop (plain) versus Lippes Loop with copper,2.48007113506642,"negative 
",negative,,,,,,,,,,,,,,,,,
499,CD011671,Alijani 1985,STD-Alijani-1985 0.278 0.432 29 29,-2.06109240301164,0.623001856442911,58,Kidney & Transplant,efficacy,DICH,1,1,yes,1985.0,Delayed graft function,Hypothermic machine perfusion versus static cold storage,-3.30832465697558,"negative 
",negative,,,,,,,,,,,,,,,,,
500,CD012235,Mikhael 2015,STD-Mikhael-2015 5 0.707 20 20,2.19722457733622,0.869226987360353,40,Skin & Wounds,efficacy,DICH,1,12,yes,2015.0,Complete healing of ulcer at 8 weeks,Intralesional pentoxifylline versus daily simple dressing,2.52779148517776,"positive 
",positive,,,,,,,,,,,,,,,,,
501,CD009864,Boguniewicz 1998,STD-Boguniewicz-1998 1.19 0.2 42 42,0.385662480811985,0.440524261136501,84,Skin & Wounds,efficacy,DICH,1,4,yes,1998.0,"Physician's assessment of global response of improvement, clear or excellent",Tacrolimus 0.03% versus tacrolimus 0.1%,0.875462522352392,"positive 
",positive,,,,,,,,,,,,,,,,,
502,CD006851,Ramos Macias 1992,STD-Ramos-Macias-1992 2.222 1.057 8 7,0.798507696217772,1.05672449894316,15,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,1992.0,House Brackmann Grades I & II,Steroids + acyclovir versus steroids alone,0.755644159869832,"neutral 
",neutral,,,,,,,,,,,,,,,,,
503,CD003455,Jensen 1997,STD-Jensen-1997 2.25 1.067 12 9,0.980829253011726,1.25277469819774,21,Oncology,efficacy,DICH,1,3,yes,1997.0,Severe bleeding episodes,Endoscopic bipolar electrocoagulation versus heater probe,0.782925496837348,"negative 
",negative,,,,,,,,,,,,,,,,,
504,CD000215,Baranwal 1998,STD-Baranwal-1998 0.657 0.413 31 32,-0.58551651636758,0.568376589992892,63,Infectious Diseases,efficacy,DICH,1,1,no,1998.0,Recurrence of seizures at trial's final follow-up time,Albendazole vs placebo or no drug,-1.03015593301424,"negative 
",negative,,,,,,,,,,,,,,,,,
505,CD008121,Cassano 2002,STD-Cassano-2002 1.55 0.295 138 139,0.437941696786073,0.295045922290188,277,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2002.0,No clinically important response to treatment (as defined by original study),Amisulpride versus antidepressants for major depression - all data short-term,1.4843170628718,"negative 
",negative,,,,,,,,,,,,,,,,,
506,CD002018,Sharp 2010,STD-Sharp-2010 2.114 0.225 129 125,1.02043839110677,0.297224318763291,254,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2010.0,Remission rate at post-treatment,Antidepressants versus treatment as usual,3.4332264444332,"positive 
",positive,,,,,,,,,,,,,,,,,
507,CD011627,Buckley 2014,STD-Buckley-2014 1.155 0.074 73 69,0.962810747509047,0.493146877911483,142,Gynaecology & Urology,efficacy,DICH,1,1,yes,2014.0,"Number of participants with IAD (residual, i.e. not healed)",Any topical skin care product versus another topical skin care product,1.95238130997935,"negative 
",negative,,,,,,,,,,,,,,,,,
508,CD006583,Santala 1999,STD-Santala-1999 0.135 2 50 50,-1.11861295537478,1.64519623968289,100,Gynaecology & Urology,efficacy,DICH,1,6,yes,1999.0,Transfundal vs infraumbilical insertion of the Veress needle,Comparisons of sites of entry,-0.679926763989197,"neutral 
",neutral,,,,,,,,,,,,,,,,,
509,CD007952,Malotte 1998,STD-Malotte-1998 1.084 0.034 200 204,0.789199200160904,0.342055492354045,404,Infectious Diseases,efficacy,DICH,1,5,yes,1998.0,Return for tuberculin skin test reading,Different values of cash incentive,2.30722563385721,"neutral 
",neutral,,,,,,,,,,,,,,,,,
510,CD001434,Kligman 1985b,STD-Kligman-1985b 1.412 0.377 44 43,0.460098100256333,0.499703929598517,87,Skin & Wounds,efficacy,DICH,1,10,yes,1985.0,Short term (2 weeks) treatment failure,Azoles vs Other antifungal topical skin treatments,0.920741409069956,"negative 
",negative,,,,,,,,,,,,,,,,,
511,CD003375,Antich 1986,STD-Antich-1986 2.47 0.772 13 16,0.944461608840852,0.801783725737273,29,Spine & Muscles,efficacy,DICH,1,1,no,1986.0,Number of patients improved for pain relief,Ultrasound + cryotherapy vs. cryotherapy - End of Treatment (4 treatments),1.17795058508126,"positive 
",positive,,,,,,,,,,,,,,,,,
512,CD006122,Garrel 1995,STD-Garrel-1995 0.314 0.82 24 16,-1.15745278869104,0.819671563409072,40,Emergency & Trauma,efficacy,DICH,1,1,yes,1995.0,Mortality at final follow-up,High-carbohydrate vs high-fat enteral feeding,-1.41209338027675,"negative 
",negative,,,,,,,,,,,,,,,,,
513,CD002830,Calver 2015,STD-Calver-2015 1.006 0.039 118 110,0.0762273653878833,0.491220443637923,228,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2015.0,Tranquillisation or asleep: 1. tranquillised/sleep within 120 minutes,Droperidol versus haloperidol,0.155179545914971,"neutral 
",neutral,,,,,,,,,,,,,,,,,
514,CD012236,EDIP-USA,STD-EDIP_x002d_USA 0.714 0.363 50 50,-0.441832752279039,0.473504328603603,100,Psychiatry & Mental Health,efficacy,DICH,1,12,no,2012.0,Prodromal symptoms: transition to psychosis,"Group C: other, family treatment vs enhanced care",-0.933112382693595,"negative 
",negative,,,,,,,,,,,,,,,,,
515,CD002963,Bolnick 2006,STD-Bolnick-2006 0.25 1.103 60 60,-1.43848011429046,1.13349296221878,120,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2006.0,Non reactive cardiotocography test,Fetal vibroacoustic stimulation versus mock or no stimulation,-1.26906841263017,"negative 
",negative,,,,,,,,,,,,,,,,,
516,CD004857,Kakkar 2009,STD-Kakkar-2009 0.444 0.761 30 30,-0.810930216216329,0.760725774312731,60,Psychiatry & Mental Health,efficacy,DICH,1,2,no,2009.0,"clinical response-categorical outcome, at least 50% reduction in YMRS",oxcarbazepine versus other mood stabilisers,-1.06599545276214,"positive 
",positive,,,,,,,,,,,,,,,,,
517,CD003557,Fischer 1984,STD-Fischer-1984 0.126 1.05 88 89,-2.15090050566198,1.0718395084554,177,Skin & Wounds,efficacy,DICH,1,23,yes,1984.0,Complete healing at 4 weeks,Chloramphenicol-containing ointment versus enzymatic cleanser,-2.00673747206948,"positive 
",positive,,,,,,,,,,,,,,,,,
518,CD003263,Nistico 2012,STD-Nistico-2012 1.2 0.516 20 20,0.251314428280906,0.71046597720222,40,Skin & Wounds,efficacy,DICH,1,10,yes,2012.0,Percentage repigmentation (>75%),TOPICAL CALCINEURIN INHIBITOR: tacrolimus plus vitamin E with MEL versus vitamin E with MEL,0.353731827202437,"positive 
",positive,,,,,,,,,,,,,,,,,
519,CD004308,Harrison 1992,STD-Harrison-1992 1.293 0.211 29 30,0.664976303593249,0.543175554070397,59,Anaesthesia & Pain,efficacy,DICH,1,1,yes,1992.0,Indometacin 50 mg,Participants with 50% pain reduction,1.22423827547119,"neutral 
",neutral,,,,,,,,,,,,,,,,,
520,CD010322,Nasr 2009,STD-Nasr-2009 0.021 1.426 210 210,-3.96585440942203,1.43270273212796,420,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2009.0,Distension of the bladder at the end of operation,Indwelling bladder catheter versus no catheter,-2.76809300386524,"negative 
",negative,,,,,,,,,,,,,,,,,
521,CD003256,Gill 1996,STD-Gill-1996 0.783 0.429 116 111,-0.268329343935966,0.470495479694253,227,Infectious Diseases,efficacy,DICH,1,6,yes,1996.0,Progression of KS,Liposomal daunorubicin versus ABV (RCT),-0.570312267633978,"negative 
",negative,,,,,,,,,,,,,,,,,
522,CD012066,Donohue 2015a,STD-Donohue-2015a 1.094 0.424 353 353,0.089939636768718,0.424380668940351,706,Lungs,efficacy,DICH,1,1,no,2015.0,Exacerbation,Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS),0.211931511850648,"negative 
",negative,,,,,,,,,,,,,,,,,
523,CD000459,Kazamatsuri 1973,STD-Kazamatsuri-1973 1.071 0.375 7 6,0.22314355131421,1.20415945787923,13,Psychiatry & Mental Health,efficacy,DICH,1,4,no,1973.0,Tardive dyskinesias: no clinically important improvement (medium term),Specific antipsychotic vs other drugs,0.185310632951562,"negative 
",negative,,,,,,,,,,,,,,,,,
524,CD006478,Noordenbos 1999,STD-Noordenbos-1999 0.429 0.136 14 14,3.09903184339179,1.52985578729208,28,Skin & Wounds,efficacy,DICH,1,2,no,1999.0,Number of patients that developed wound infection,SSD cream (1%) vs biosynthetic dressing with skin substitute (Transcyte® on Biobrane® mesh),2.02570194467626,"negative 
",negative,,,,,,,,,,,,,,,,,
525,CD007261,Thie 2001,STD-Thie-2001 0.735 0.454 21 18,-0.464305608131098,0.683446828289932,39,"Oral Health, Eyes & ENT",efficacy,DICH,1,3,no,2001.0,"Pain during function, after 90 days",Comparison 3. Glucosamine sulfate versus ibuprofren,-0.679358786831812,"negative 
",negative,,,,,,,,,,,,,,,,,
526,CD009491,Akil 2005,STD-Akil-2005 3.167 1.6 17 18,1.21302263984585,1.66773102787194,35,Emergency & Trauma,efficacy,DICH,1,3,yes,2005.0,Incomplete procedure,Oral midazolam versus chloral hydrate,0.727349086617222,"negative 
",negative,,,,,,,,,,,,,,,,,
527,CD007745,Datry 1994,STD-Datry-1994 2.207 0.277 29 24,2.07944154167984,0.647645307590848,53,Infectious Diseases,efficacy,DICH,1,1,yes,1994.0,Parasitological cure,Ivermectin versus albendazole,3.21077218858433,"positive 
",positive,,,,,,,,,,,,,,,,,
528,CD006283,Wen 2004,STD-Wen-2004 0.605 0.53 85 60,-0.553306618742158,0.583994830371137,145,Neurology,efficacy,DICH,1,4,no,2004.0,Incomplete recovery three months after randomisation,Exercise versus conventional treatment,-0.94745122724892,"negative 
",negative,,,,,,,,,,,,,,,,,
529,CD007949,Eid 2010a,STD-Eid-2010a 0.53 0.355 183 84,-0.71818325872127,0.404507888160884,267,Lungs,efficacy,DICH,1,1,no,2003.0,# participants with exacerbations requiring systemic steroids,LABA versus placebo: both groups receiving similar dose of ICS,-1.77544932927397,"negative 
",negative,,,,,,,,,,,,,,,,,
530,CD012191,Vogel 2010,STD-Vogel-2010 1.246 0.069 9754 9736,0.229625323676689,0.0724189968678327,19490,Oncology,efficacy,DICH,1,3,yes,2010.0,Overall breast cancer incidence,Tamoxifen versus raloxifene,3.17078851693795,"negative 
",negative,,,,,,,,,,,,,,,,,
531,CD004417,De la Poza Abad 2016,STD-De-la-Poza-Abad-2016 0.042 0.564 98 50,-3.1662658745959,0.564039578031806,148,Lungs,efficacy,DICH,1,4,yes,2012.0,Antibiotic use: delayed versus immediate antibiotics,Antibiotic use,-5.61355266175552,"neutral 
",neutral,,,,,,,,,,,,,,,,,
532,CD011426,Caro 1967,STD-Caro-1967 0.795 0.289 197 235,-0.255312834247602,0.320915685311665,432,Skin & Wounds,efficacy,DICH,1,1,no,1967.0,Surgical site infection,Topical antibiotic versus no topical antibiotic,-0.795576052942529,"negative 
",negative,,,,,,,,,,,,,,,,,
533,CD005193,Petersilia 1992 a,STD-Petersilia-1992-a 2.552 0.346 89 84,0.936990047887305,0.345761385984749,173,Psychiatry & Mental Health,efficacy,DICH,1,3,no,1992.0,Recidivism at 1 year.,RCT Community (Petersilia studies 1-4): intensive supervision vs. routine parole/probation.,2.70993258896942,"negative 
",negative,,,,,,,,,,,,,,,,,
534,CD000450,Finestone 2004a,STD-Finestone-2004a 1.044 0.309 204 213,0.0475023339850039,0.340328080644839,417,Emergency & Trauma,efficacy,DICH,1,7,yes,2004.0,Participants sustaining stress injury of bone in the foot,Prevention: custom-made versus prefabricated soft foot orthoses,0.139578062130514,"negative 
",negative,,,,,,,,,,,,,,,,,
535,CD003545,Bishop 1964,STD-Bishop-1964 0.655 0.202 14 14,-2.8207521236184,1.53494197185245,28,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1964.0,Global state: 1a. No substantial improvement (defined as slight improvement or worse) - by time period,TRIFLUOPERAZINE versus PLACEBO,-1.83769300426007,"negative 
",negative,,,,,,,,,,,,,,,,,
536,CD006439,Brooker 2002,STD-Brooker-2002 2.019 0.253 124 135,0.702729970155938,0.252629855677205,259,Gastroenterology,efficacy,DICH,1,3,yes,2002.0,Number of participants with at least one polyp (neoplastic or non-neoplastic) detected,Total number of participants with at least one polyp (neoplastic or non-neoplastic) detected,2.78165843966536,"negative 
",negative,,,,,,,,,,,,,,,,,
537,CD011880,Mathiesen 2012,STD-Mathiesen-2012 3.152 1.144 79 83,1.17459819564603,1.16562702011467,162,Pregnancy & Childbirth,efficacy,DICH,1,6,yes,2012.0,Major congenital malformation,Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different insulin types within similar insulin regimens),1.00769643751951,"negative 
",negative,,,,,,,,,,,,,,,,,
538,CD005563,Leung 2006,STD-Leung-2006 0.118 1.416 9 12,-2.6342840508626,1.55576819386638,21,Psychiatry & Mental Health,efficacy,DICH,1,8,yes,2006.0,Incident delirium,Gabapentinoids versus placebo,-1.69323685960947,"negative 
",negative,,,,,,,,,,,,,,,,,
539,CD004595,Elbourne 2002,STD-Elbourne-2002 1.003 0.298 314 315,0.0034071583216145,0.319456452533971,629,Neonatal,efficacy,DICH,1,4,yes,2002.0,Late diagnosed DDH,Infants with clinically unstable hips: Treatment guided by ultrasound surveillance versus treatment based on clinical assessment alone,0.0106654859984469,"negative 
",negative,,,,,,,,,,,,,,,,,
540,CD003940,Pons 1997,STD-Pons-1997 1.687 0.143 83 84,1.24653241874473,0.3297818046032,167,Infectious Diseases,efficacy,DICH,1,5,no,1997.0,Clinical cure,Treatment: Fluconazole vs Nystatin,3.77987020916629,"positive 
",positive,,,,,,,,,,,,,,,,,
541,CD006764,Egerman 1998,STD-Egerman-1998 1.485 0.609 99 84,0.419853845560264,0.645156343900092,183,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,1998.0,Neonatal death,Dexamethasone: oral versus intramuscular,0.650778450107408,"negative 
",negative,,,,,,,,,,,,,,,,,
542,CD006358,Jobs First 2003,STD-Jobs-First-2003 0.979 0.443 155 152,-0.0210534091978323,0.442554883425984,307,Psychiatry & Mental Health,efficacy,DICH,1,4,yes,2003.0,Below average achievement,Educational outcomes,-0.0475724254466472,"negative 
",negative,,,,,,,,,,,,,,,,,
543,CD006576,Cormio 2002,STD-Cormio-2002 0.611 0.897 72 66,-0.51082562376599,0.929242736582893,138,Gynaecology & Urology,efficacy,DICH,1,6,yes,2002.0,Bacteriuria,Quinolones versus other classes of antibiotics,-0.549722482248773,"negative 
",negative,,,,,,,,,,,,,,,,,
544,CD008946,Rook 2010,STD-Rook-2010 7 0.988 12 12,2.73436750941958,1.19739978025981,24,Skin & Wounds,efficacy,DICH,1,3,no,2010.0,Improvement,Topical hypericin versus placebo,2.2835877828759,"positive 
",positive,,,,,,,,,,,,,,,,,
545,CD004185,De Jonghe 1991,STD-De-Jonghe-1991 1.385 0.598 30 35,0.325422400434628,0.598252440785646,65,Psychiatry & Mental Health,efficacy,DICH,1,2,no,1991.0,Failure to respond - HDRS (-50%),Fluoxetine versus heterocyclics,0.54395498998261,"negative 
",negative,,,,,,,,,,,,,,,,,
546,CD009555,Chen 1998,STD-Chen-1998 0.927 0.087 94 82,-0.307100158308883,0.352630084323552,176,Psychiatry & Mental Health,efficacy,DICH,1,3,no,1998.0,Mental state: 1a. Clinically important response as (BPRS score > 30% change),CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day),-0.87088473718285,"positive 
",positive,,,,,,,,,,,,,,,,,
547,CD004834,Andersen 2005,STD-Andersen-2005 0.452 0.232 40 40,-1.85580183555515,0.503248731262534,80,Skin & Wounds,efficacy,DICH,1,26,yes,2005.0,Complete cure,IVPI for seven doses versus IVMA for 20 days in L. braziliensis; FU: 6 months,-3.68764334665957,"positive 
",positive,,,,,,,,,,,,,,,,,
548,CD013163,Nehra 2014,STD-Nehra-2014 1.111 1.337 9 10,0.117783035656383,1.49536320374386,19,Neonatal,efficacy,DICH,1,5,yes,2014.0,Parenteral nutrition-associated liver disease (PNALD)/cholestasis (conjugated bilirubin = 2 mg/dL),Fish oil lipid emulsion (LE) vs non-fish oil LE in preterm infants with surgical conditions (see Appendix 3),0.0787655034987461,"negative 
",negative,,,,,,,,,,,,,,,,,
549,CD003773,Augustine 2004,STD-Augustine-2004 0.964 0.151 40 40,-0.116410351844411,0.482708745526464,80,Kidney & Transplant,efficacy,DICH,1,1,yes,2004.0,Mortality,CRRT versus IRRT,-0.241160643811101,"negative 
",negative,,,,,,,,,,,,,,,,,
550,CD011455,Gunawansa 2011,STD-Gunawansa-2011 0.176 1.546 203 179,-1.74613330840128,1.55259389659077,382,Kidney & Transplant,efficacy,DICH,1,1,yes,2011.0,Major urological complications,Major urological complications,-1.12465552791074,"negative 
",negative,,,,,,,,,,,,,,,,,
551,CD008738,Alexander 1982,STD-Alexander-1982 0.137 1.062 127 122,-2.03725992764354,1.07679585018125,249,Skin & Wounds,efficacy,DICH,1,3,no,1982.0,Burn wound infection,Systemic antibiotic prophylaxis (perioperative),-1.89196487644396,"negative 
",negative,,,,,,,,,,,,,,,,,
552,CD004258,Brox 1993/7,STD-Brox-1993_x002f_7 2.455 0.349 44 28,1.56123581061622,0.535104435531039,72,Spine & Muscles,efficacy,DICH,1,3,no,1993.0,Good or excellent function (Neer score) at 2 and a half years,SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT,2.91762823656441,"positive 
",positive,,,,,,,,,,,,,,,,,
553,CD004055,Kircik 2013,STD-Kircik-2013 1.435 0.262 62 63,0.535895723054439,0.385415510828117,125,Skin & Wounds,efficacy,DICH,1,6,yes,2013.0,Primary: percentage of participants with investigator-rated good/excellent control at day 15,Corticosteroids creams/ointments: clobetasol propionate foam 0.05% versus vehicle,1.390436316128,"positive 
",positive,,,,,,,,,,,,,,,,,
554,CD002255,Ara 2008,STD-Ara-2008 0.251 0.284 45 44,-3.30688670219091,0.595157503701713,89,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2008.0,Birth within 48 hours after trial entry,Calcium channel blockers compared with placebo or no treatment,-5.55632195111883,"neutral 
",neutral,,,,,,,,,,,,,,,,,
555,CD002140,Atagi 2005,STD-Atagi-2005 0.882 0.196 23 23,-0.412845215405787,0.645876817005455,46,Oncology,efficacy,DICH,1,3,no,2005.0,Chemotherapy regime,Subgroup analysis Chemoradiotherapy vs Radiotherapy,-0.639201167367956,"neutral 
",neutral,,,,,,,,,,,,,,,,,
556,CD009582,Kryzhanovskaya 2009,STD-Kryzhanovskaya-2009 0.841 0.135 72 35,-0.550046336919272,0.456981300308786,107,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2009.0,Global state: No response (CGI-S),Atypical antipsychotics vs placebo (only short term),-1.20365173924535,"negative 
",negative,,,,,,,,,,,,,,,,,
557,CD007572,Mannon 2004,STD-Mannon-2004 0.922 0.16 31 8,-0.518793793415168,1.16169006603474,39,Gastroenterology,efficacy,DICH,1,1,no,2004.0,Failure to induce clinical remission (7 & 9 weeks),Briakinumab versus placebo,-0.446585374691197,"negative 
",negative,,,,,,,,,,,,,,,,,
558,CD000391,Dyer 1991,STD-Dyer-1991 9.974 1.072 12 12,2.5828870581482,1.55559290337985,24,Lungs,efficacy,DICH,1,9,no,1991.0,Side-effects: Hepatic,Methotrexate versus Placebo,1.6603875297556,"negative 
",negative,,,,,,,,,,,,,,,,,
559,CD003181,Zhou 1995,STD-Zhou-1995 0.65 0.188 64 48,-0.890315245470894,0.392002827571577,112,Hepato-Biliary,efficacy,DICH,1,2,no,1995.0,Risk of abnormal serum ALT at the end of treatment,Bile acids for chronic hepatitis B,-2.27119597832066,"negative 
",negative,,,,,,,,,,,,,,,,,
560,CD000324,Mottla 1992,STD-Mottla-1992 0.246 1.137 7 5,-1.67397643357167,1.35400640077266,12,Gynaecology & Urology,efficacy,DICH,1,6,no,1992.0,primary treatment success,local MTX versus laparoscopic salpingostomy,-1.23631353043562,"positive 
",positive,,,,,,,,,,,,,,,,,
561,CD001049,Vialet 2003,STD-Vialet-2003 1.25 0.5 10 10,0.405465108108164,0.903696114115064,20,Emergency & Trauma,efficacy,DICH,1,3,no,2003.0,Death,Mannitol versus hypertonic saline,0.448674174620317,"negative 
",negative,,,,,,,,,,,,,,,,,
562,CD000218,Antonelli 2000,STD-Antonelli-2000 0.037 1.398 16 17,-4.91789324239764,1.55411899916375,33,Infectious Diseases,efficacy,DICH,1,27,no,2000.0,No parasitological cure,Oral metronidazole versus intravaginal nonoxynol 9,-3.16442514700863,"negative 
",negative,,,,,,,,,,,,,,,,,
563,CD010529,Bayly 1978,STD-Bayly-1978 1.6 1.313 12 9,0.470003629245735,1.31339255365637,21,Anaesthesia & Pain,efficacy,DICH,1,4,yes,1978.0,Pleurodesis failure,Tetracycline,0.357854647445112,"negative 
",negative,,,,,,,,,,,,,,,,,
564,CD004834,Arévalo 2007,STD-Ar_x00e9_valo-2007 1.667 0.325 7 7,2.4567357728213,1.62519840058678,14,Skin & Wounds,efficacy,DICH,1,37,yes,2007.0,Complete cure,"7.5% imiquimod cream x 20 days plus IVMA for 20 days versus IVMA x 20 days in L. braziliensis, L. peruviana, L. mexicana and L. amazonensis; FU: 3 months",1.51165283693012,"positive 
",positive,,,,,,,,,,,,,,,,,
565,CD008307,Fassoulaki 2002,STD-Fassoulaki-2002 0.935 0.26 22 24,-0.154150679827259,0.595618925792242,46,Anaesthesia & Pain,efficacy,DICH,1,2,no,2002.0,Incidence of any pain at 3 months (all studies),Gabapentin versus placebo,-0.258807558242412,"negative 
",negative,,,,,,,,,,,,,,,,,
566,CD000565,Compton 1990,STD-Compton-1990 1 0.979 16 8,0.0,1.0,24,Emergency & Trauma,efficacy,DICH,1,1,no,1990.0,Death (all-cause mortality),Calcium channel blockers versus control,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
567,CD004287,Maloney 2013,STD-Maloney-2013 2.625 1.605 23 20,1.0055218656021,1.66129214737083,43,Skin & Wounds,efficacy,DICH,1,6,yes,2013.0,Dehiscence,Adhesive versus adhesive: octylcyanoacrylate versus butylcyanoacrylate,0.605264924169684,"negative 
",negative,,,,,,,,,,,,,,,,,
568,CD002227,Lue 1996,STD-Lue-1996 0.567 0.397 124 125,-0.628948391037668,0.437585506171799,249,Heart & Hypertension,efficacy,DICH,1,4,no,1996.0,Rheumatic fever recurrences,Three-weekly versus 4-weekly intramuscular penicillin,-1.43731540959846,"negative 
",negative,,,,,,,,,,,,,,,,,
569,CD003927,Kopelman 1989,STD-Kopelman-1989 0.287 1.62 49 42,-1.2748915310061,1.64650085709387,91,Pregnancy & Childbirth,efficacy,DICH,1,9,yes,1989.0,Very preterm birth (less than 34 weeks),Terbutaline versus ritodrine (primary outcomes),-0.774303593899323,"negative 
",negative,,,,,,,,,,,,,,,,,
570,CD005005,Marx 1999b,STD-Marx-1999b 8.667 0.589 80 80,2.51430562464278,0.635059369902061,160,Oncology,efficacy,DICH,1,9,no,1999.0,Wound dehiscence,Head and neck soft tissues,3.95916625091373,"negative 
",negative,,,,,,,,,,,,,,,,,
571,CD001449,England 1982,STD-England-1982 1.193 0.247 38 34,0.341749293722057,0.47418751688503,72,Pregnancy & Childbirth,efficacy,DICH,1,7,no,1982.0,Persistent high blood pressure,Labetalol versus methyldopa,0.720704956484369,"negative 
",negative,,,,,,,,,,,,,,,,,
572,CD008040,GL/MIG/001/92,STD-GL_x002f_MIG_x002f_001_x002f_92 0.879 0.106 286 288,-0.209643352027188,0.171843382039453,574,Anaesthesia & Pain,efficacy,DICH,1,2,no,1992.0,Headache relief at 2 hours,Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg,-1.2199675631329,"positive 
",positive,,,,,,,,,,,,,,,,,
573,CD007357,Friedrich 1983,STD-Friedrich-1983 1.438 0.237 40 40,0.707745979981098,0.454388002645313,80,Anaesthesia & Pain,efficacy,DICH,1,2,yes,1983.0,Participants with at least 50% pain relief over 4 to 6 hours,Etodolac 100 mg versus placebo,1.55758069284578,"positive 
",positive,,,,,,,,,,,,,,,,,
574,CD001310,Fynes 1999,STD-Fynes-1999 0.396 0.425 20 19,-1.6376087894008,0.702037850017464,39,Gynaecology & Urology,efficacy,DICH,1,4,yes,1999.0,"Number of people failing to achieve full continence (worse, unchanged or improved)",ELECTRICAL STIMULATION AS AN ADJUNCT versus ANY OTHER TREATMENT,-2.33265028283028,"negative 
",negative,,,,,,,,,,,,,,,,,
575,CD009099,Jeffcoate 2009,STD-Jeffcoate-2009 1.155 0.164 103 106,0.246405331845874,0.281172277031289,209,Skin & Wounds,efficacy,DICH,1,1,yes,2009.0,Number of ulcers healed,Fibrous-hydrocolloid (hydrofibre) dressing compared with basic wound contact dressing,0.876350024431656,"positive 
",positive,,,,,,,,,,,,,,,,,
576,CD009557,Dinsmore 2000,STD-Dinsmore-2000 1.857 0.593 14 13,0.916290731874155,0.85146931829632,27,Oncology,efficacy,DICH,1,1,yes,2000.0,Incidence of postoperative seroma,All trials analysis,1.07612888942086,"negative 
",negative,,,,,,,,,,,,,,,,,
577,CD012902,Bayston 1990,STD-Bayston-1990 1.026 0.555 78 80,0.0273989741881143,0.6006128001764,158,Neurology,efficacy,DICH,1,1,yes,1990.0,Number of participants experiencing shunt infection after administration of antibiotics,Treatment benefit of antibiotic prophylaxis versus no antibiotic prophylaxis,0.0456183654095738,"negative 
",negative,,,,,,,,,,,,,,,,,
578,CD009807,Ginsberg 1998,STD-Ginsberg-1998 4.891 1.535 45 44,1.63216616351166,1.56379679493836,89,Spine & Muscles,efficacy,DICH,1,3,yes,1998.0,Depression,MAOIs vs placebo (safety),1.04372011043544,"negative 
",negative,,,,,,,,,,,,,,,,,
579,CD007922,Choi 2006,STD-Choi-2006 3 1.605 21 21,1.14624033765736,1.66191419224295,42,Anaesthesia & Pain,efficacy,DICH,1,1,yes,2006.0,Mortality,Comparison 1: PEEP versus ZEEP,0.68971090264918,"negative 
",negative,,,,,,,,,,,,,,,,,
580,CD000545,Colombel 2010,STD-Colombel-2010 0.663 0.138 170 169,-0.681718484736323,0.225496171918002,339,Gastroenterology,efficacy,DICH,1,2,no,2010.0,Clinical remission through 26 weeks,Azathioprine versus Infliximab,-3.0231931608321,"positive 
",positive,,,,,,,,,,,,,,,,,
581,CD003719,ERLH Group 2001,STD-ERLH-Group-2001 1 0.355 133 126,0.0,0.355272182399276,259,Gynaecology & Urology,efficacy,DICH,1,2,yes,2001.0,Ongoing pregnancy/live birth rate per woman,rhLH versus uhCG for triggering ovulation,0.0,"positive 
",positive,,,,,,,,,,,,,,,,,
582,CD008138,Abeck 2004,STD-Abeck-2004 1.322 0.205 46 16,1.04731899428056,0.646515627143189,62,Skin & Wounds,efficacy,DICH,1,19,yes,2004.0,Failure to achieve complete resolution,Ciclopirox vs placebo,1.61994381931406,"negative 
",negative,,,,,,,,,,,,,,,,,
583,CD004415,Tarstedt 2005,STD-Tarstedt-2005 1.174 0.066 105 106,0.923762746712855,0.380851099469221,211,Skin & Wounds,efficacy,DICH,1,57,no,2005.0,Participant complete clearance,Single MAL-red light PDT versus multiple MAL-red light PDT (2 treatments 1 week apart),2.42552206886174,"positive 
",positive,,,,,,,,,,,,,,,,,
584,CD007079,Kumar 2009,STD-Kumar-2009 0.982 0.024 273 251,-0.2708749541354,0.349987508905049,524,Pregnancy & Childbirth,efficacy,DICH,1,2,no,2009.0,Low birthweight (< 2500 g),Calcium supplementation versus placebo or no treatment (infant outcomes),-0.773956061983023,"negative 
",negative,,,,,,,,,,,,,,,,,
585,CD000207,Jackson 1978,STD-Jackson-1978 0.84 0.39 4 2,-0.762140052046897,1.83095083286825,6,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1978.0,Tardive dyskinesia: 1. No clinically important improvement (50% or more change on any validated TD scale),CHOLINERGIC DRUGS versus PLACEBO,-0.41625369636659,"negative 
",negative,,,,,,,,,,,,,,,,,
586,CD001100,Columbus 1997,STD-Columbus-1997 1.071 0.365 510 511,0.0685789306745761,0.364975461088688,1021,Heart & Hypertension,efficacy,DICH,1,1,yes,1997.0,Incidence of recurrent venous thromboembolism during initial treatment,LMWH versus UFH in patients with venous thromboembolism,0.187900113804943,"negative 
",negative,,,,,,,,,,,,,,,,,
587,CD010591,Ciabatti 2009,STD-Ciabatti-2009 0.75 0.395 52 52,-0.360002734031407,0.4926461797253,104,"Oral Health, Eyes & ENT",efficacy,DICH,1,4,no,2009.0,Daily record chart symptom resolution at 4 weeks post-treatment (capsaicin 1 µg versus 2 µg/puff),Different doses of capsaicin,-0.730753122316192,"neutral 
",neutral,,,,,,,,,,,,,,,,,
588,CD003642,Cao FK 1997,STD-Cao-FK-1997 1.157 0.318 35 27,0.24294617861039,0.524871599611211,62,Genetics & Endocrinology,efficacy,DICH,1,2,no,1997.0,Normalisation of fasting blood glucose levels (< 7.2 mmol/L),Herbal medicines versus hypoglycemic drugs,0.462867830513877,"positive 
",positive,,,,,,,,,,,,,,,,,
589,CD012367,Kajbafzadeh 2011,STD-Kajbafzadeh-2011 0.963 0.277 10 11,-0.133531392624523,0.96670771669818,21,Gynaecology & Urology,efficacy,DICH,1,2,yes,2011.0,Resolution of daytime urinary incontinence at 12 months,Pelvic floor muscle training and urotherapy versus urotherapy alone,-0.138130057635832,"positive 
",positive,,,,,,,,,,,,,,,,,
590,CD002855,Cameron 1986 MI600GP1pv,STD-Cameron-1986-MI600GP1pv 7.6 1.011 20 19,2.484906649788,1.12422813026934,39,Gynaecology & Urology,efficacy,DICH,1,12,no,1986.0,failure to achieve complete abortion,mifepristone alone vs combined regimen mifepristone/prostaglandin,2.21032242734638,"negative 
",negative,,,,,,,,,,,,,,,,,
591,CD002302,Katz 2005,STD-Katz-2005 1.225 0.46 20 21,0.297251523467932,0.673137098304315,41,Skin & Wounds,efficacy,DICH,1,1,yes,2005.0,Skin maceration,Non-removable pressure relieving device versus another non-removable instant pressure relieving cast,0.441591355188611,"negative 
",negative,,,,,,,,,,,,,,,,,
592,CD001103,Andersen 2002,STD-Andersen-2002 1.034 0.278 58 60,0.0487901641694318,0.399900781345367,118,Skin & Wounds,efficacy,DICH,1,6,no,2002.0,Total number of ulcers healed,Foam compared with foam,0.12200567352054,"positive 
",positive,,,,,,,,,,,,,,,,,
593,CD011880,Schuster 1998,STD-Schuster-1998 0.489 0.841 47 46,-0.762140052046897,0.892206111855185,93,Pregnancy & Childbirth,efficacy,DICH,1,3,yes,1998.0,Macrosomia,Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen),-0.854219716632698,"negative 
",negative,,,,,,,,,,,,,,,,,
594,CD002086,Revuz 1985,STD-Revuz-1985 1.822 0.211 43 47,1.31317209629093,0.447542986128322,90,Skin & Wounds,efficacy,DICH,1,19,yes,1985.0,Global grade - good/very good response,Minocycline versus placebo plus combination erythromycin/tretinoin gel (strength unspecified),2.93418093231922,"positive 
",positive,,,,,,,,,,,,,,,,,
595,CD000307,Chouinard 1982,STD-Chouinard-1982 1 0.957 24 24,0.0,1.04446593573419,48,Psychiatry & Mental Health,efficacy,DICH,1,10,no,1982.0,Global state: 1. Needing additional antipsychotic treatment,FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
596,CD005283,Albright 2000,STD-Albright-2000 1.125 0.419 33 33,0.158605030176638,0.563717817509592,66,Kidney & Transplant,efficacy,DICH,1,1,no,2000.0,All-cause mortality,Membrane composition,0.281355361229006,"negative 
",negative,,,,,,,,,,,,,,,,,
597,CD006476,Essa 2011,STD-Essa-2011 1.069 0.117 40 35,0.334202088086673,0.578962183736736,75,Gastroenterology,efficacy,DICH,1,2,yes,2011.0,Successfully reduced intussusception,Enema plus dexamethasone versus enema alone,0.577243380439232,"positive 
",positive,,,,,,,,,,,,,,,,,
598,CD004068,Symon 2005,STD-Symon-2005 1.725 0.05 913 836,1.1337924716865,0.0996459656792558,1749,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2005.0,Total infant sleep >= 15 hrs per 24 hrs,Education on sleep enhancement versus usual care,11.378207476417,"positive 
",positive,,,,,,,,,,,,,,,,,
599,CD003486,Dargaville 2011,STD-Dargaville-2011 0.423 0.63 31 35,-1.0171968971826,0.728755553038641,66,Neonatal,efficacy,DICH,1,1,yes,2011.0,Death,Lung lavage versus standard care,-1.39579985763575,"negative 
",negative,,,,,,,,,,,,,,,,,
600,CD003881,Kuhn 2008,STD-Kuhn-2008 0.833 0.483 15 15,-0.287682072451781,0.760116950066092,30,Gynaecology & Urology,efficacy,DICH,1,5,yes,2008.0,"Number not cured (worse, unchanged or improved) within first year",One route of injection versus another route of injection,-0.378470802982051,"negative 
",negative,,,,,,,,,,,,,,,,,
601,CD004326,Meehan 2002,STD-Meehan-2002 4.063 0.77 17 16,1.58923520511658,0.902377811277357,33,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,2002.0,Syringing not necessary,'Active drops' versus saline: triethanolamine polypeptide (Cerumenex) versus saline in children,1.76116387754143,"positive 
",positive,,,,,,,,,,,,,,,,,
602,CD000360,Kerin 1984,STD-Kerin-1984 4.565 1.583 14 7,1.51846613422837,1.5830363674871,21,Gynaecology & Urology,efficacy,DICH,1,1,no,1984.0,Pregnancy rate per couple (all cycles),Intra-uterine insemination (IUI) versus timed intercourse (TI) both in natural cycles (NC),0.959211149797384,"positive 
",positive,,,,,,,,,,,,,,,,,
603,CD010182,Armstrong 1997,STD-Armstrong-1997 0.304 0.759 23 21,-1.43508452528932,0.883715101688537,44,Skin & Wounds,efficacy,DICH,1,2,yes,1997.0,Proportion of ulcers healed at 6 and 12 weeks,Hydrocolloid dressings compared with alginate dressings,-1.62392214702144,"positive 
",positive,,,,,,,,,,,,,,,,,
604,CD004889,Gines 2002,STD-Gines-2002 1.324 0.531 35 35,0.280713403135688,0.53117643692883,70,Hepato-Biliary,efficacy,DICH,1,2,no,2002.0,24-month mortality,TIPS versus paracentesis - mortality,0.528474878815642,"negative 
",negative,,,,,,,,,,,,,,,,,
605,CD003940,Just-Nubling 1991a,STD-Just_x002d_Nubling-1991a 0.2 0.462 22 11,-3.80666248977032,1.18556128291858,33,Infectious Diseases,efficacy,DICH,1,23,no,1991.0,Clinical Episode,Prevention: Fluconazole vs No treatment,-3.21085256799141,"negative 
",negative,,,,,,,,,,,,,,,,,
606,CD010289,Litkowski 2005,STD-Litkowski-2005 4.471 0.301 62 63,2.56152469658017,0.444016613215238,125,Anaesthesia & Pain,efficacy,DICH,1,1,no,2005.0,Participants with =50% pain relief at 6 hours,Ibuprofen 400 mg + oxycodone 5 mg versus placebo,5.76898390812794,"positive 
",positive,,,,,,,,,,,,,,,,,
607,CD000314,Sorensen 1986,STD-Sorensen-1986 1.262 0.091 31 58,1.62099873483518,0.790193165777106,89,Emergency & Trauma,efficacy,DICH,1,11,no,1986.0,Anatomical grading,Above-elbow versus below-elbow plaster cast,2.05139553850864,"neutral 
",neutral,,,,,,,,,,,,,,,,,
608,CD002253,Lelaidier 1993,STD-Lelaidier-1993 5 1.522 23 23,1.6983853984506,1.57767703266427,46,Pregnancy & Childbirth,efficacy,DICH,1,19,no,1993.0,Complete miscarriage,Mifepristone versus placebo,1.0765101876285,"negative 
",negative,,,,,,,,,,,,,,,,,
609,CD001533,Abeyagunawardena 2008,STD-Abeyagunawardena-2008 0.489 0.499 18 22,-1.07044141170141,0.71046597720222,40,Kidney & Transplant,efficacy,DICH,1,10,yes,2008.0,Number with relapse with infection,Daily prednisolone treatment during viral infections,-1.50667512034392,"negative 
",negative,,,,,,,,,,,,,,,,,
610,CD004539,Smith 1980,STD-Smith-1980 1.6 0.865 23 35,0.470003629245736,0.86482175427464,58,Gastroenterology,efficacy,DICH,1,11,yes,1980.0,Mortality (all causes),Clindamycin regimens versus nitroimidazole regimens,0.543468786397431,"negative 
",negative,,,,,,,,,,,,,,,,,
611,CD002251,Eldaba 2015,STD-Eldaba-2015 0.047 0.574 100 100,-4.05146283473884,0.622129720767001,200,Pregnancy & Childbirth,efficacy,DICH,1,33,yes,2015.0,Women with hypotension requiring intervention,Granisetron vs control,-6.51224768645345,"negative 
",negative,,,,,,,,,,,,,,,,,
612,CD001689,Burrows 2001,STD-Burrows-2001 2.85 1.617 39 37,1.07229498035074,1.64903224932303,76,Pregnancy & Childbirth,efficacy,DICH,1,3,yes,2001.0,Symptomatic thromboembolic events,Caesarean section: LMWH or UFH versus no treatment or placebo,0.650257131593965,"negative 
",negative,,,,,,,,,,,,,,,,,
613,CD010226,Bishop 1964,STD-Bishop-1964 23 1.398 14 14,4.55687989686031,1.56257362216786,28,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1964.0,Global state: 1. clinical improvement (as defined by each study),TRIFLUOPERAZINE versus PLACEBO,2.91626572483557,"positive 
",positive,,,,,,,,,,,,,,,,,
614,CD007062,Laohapojanart 2007,STD-Laohapojanart-2007 2 0.913 3 3,1.38629436111989,1.73205080756888,6,Pregnancy & Childbirth,efficacy,DICH,1,4,no,2007.0,Respiratory distress syndrome,Nifedipine versus Terbutaline,0.800377422568629,"negative 
",negative,,,,,,,,,,,,,,,,,
615,CD003244,Cordova 1996,STD-Cordova-1996 1.667 0.577 10 10,0.847297860387203,0.936050466689952,20,Gastroenterology,efficacy,DICH,1,5,no,1996.0,Oesophagitis persists at four weeks,Standard dose omeprazole versus standard dose lansoprazole,0.905183951655306,"negative 
",negative,,,,,,,,,,,,,,,,,
616,CD004055,Veien 1995,STD-Veien-1995 2.217 0.314 23 24,1.73460105538811,0.642643132755989,47,Skin & Wounds,efficacy,DICH,1,40,yes,1995.0,Primary: participant- and investigator-rated good/excellent control of symptoms,Other oral interventions: oral ranitidine versus placebo,2.69916687345468,"positive 
",positive,,,,,,,,,,,,,,,,,
617,CD003576,Hamilton 1991,STD-Hamilton-1991 1.286 1.148 14 9,0.287682072451781,1.30703226177984,23,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1991.0,Abortion,Bed rest versus no bed rest (placebo and activity),0.220103268193267,"negative 
",negative,,,,,,,,,,,,,,,,,
618,CD004015,Kidane 2000,STD-Kidane-2000 0.603 0.088 6283 7294,-0.527178661247103,0.0911255337274264,13577,Public Health & Work,efficacy,DICH,1,3,yes,2000.0,Mortality among children < 5 years old - unadjusted,LHW interventions to reduce mortality/morbidity in children under five compared with usual care,-5.78519147908635,"negative 
",negative,,,,,,,,,,,,,,,,,
619,CD000402,CHART 1996,STD-CHART-1996 3.745 2.333 259 83,-0.0314367734235637,1.63783735044858,342,Gynaecology & Urology,efficacy,DICH,1,1,yes,1996.0,Endometrial hyperplasia at 1 year,Unopposed estrogen versus placebo,-0.019194075293834,"negative 
",negative,,,,,,,,,,,,,,,,,
620,CD007701,Gaffaney 2009,STD-Gaffaney-2009 0.646 0.148 43 44,-1.61221183931683,0.535985729058513,87,Pregnancy & Childbirth,efficacy,DICH,1,6,yes,2009.0,Vaginal delivery not achieved within 24 hours,Oral misoprostol versus placebo,-3.00793799519394,"negative 
",negative,,,,,,,,,,,,,,,,,
621,CD010095,Raborn 1998,STD-Raborn-1998 1.079 0.28 114 123,0.0923733201310149,0.340286210385854,237,Skin & Wounds,efficacy,DICH,1,1,no,1998.0,Incidence of HSL during use of the preventative intervention (by clinical evaluation),Oral aciclovir (short-term) versus placebo,0.271457723856256,"negative 
",negative,,,,,,,,,,,,,,,,,
622,CD005195,Algotar 2013,STD-Algotar-2013 1.048 0.217 234 232,0.0555698511548106,0.256419070785336,466,Oncology,efficacy,DICH,1,1,yes,2013.0,Any cancer risk,Randomised controlled trials: highest versus lowest selenium exposure,0.216714969696351,"negative 
",negative,,,,,,,,,,,,,,,,,
623,CD004834,Convit 1987,STD-Convit-1987 0.929 0.074 58 44,-0.607989372219638,0.637588640407291,102,Skin & Wounds,efficacy,DICH,1,34,yes,1987.0,Complete cure,Vaccine vs IMMA (50 mg/kg in 2-3 series of 20 daily injections) in L. braziliensis; FU: 6 months,-0.953576230328156,"positive 
",positive,,,,,,,,,,,,,,,,,
624,CD004732,Hidar 2007,STD-Hidar-2007 1.561 0.906 147 153,0.452931645347088,0.920271858927605,300,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,2007.0,Postoperative febrile morbidity (including endometritis),Methods of performing the uterine incision: blunt versus sharp dissection,0.492171569686908,"negative 
",negative,,,,,,,,,,,,,,,,,
625,CD006099,De Salvo 1998,STD-De-Salvo-1998 0.333 1.133 40 40,-1.15125602215353,1.17728560086386,80,Skin & Wounds,efficacy,DICH,1,4,no,1998.0,Wound Infection,Suction drain compared with open drain,-0.977890174914879,"negative 
",negative,,,,,,,,,,,,,,,,,
626,CD009096,Bremner 1997,STD-Bremner-1997 0.5 0.995 334 167,-0.699189495015908,1.00452608440666,501,Heart & Hypertension,efficacy,DICH,1,1,no,1997.0,Total mortality,All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs),-0.696039163013766,"negative 
",negative,,,,,,,,,,,,,,,,,
627,CD008265,Brown 1993,STD-Brown-1993 1.107 0.112 84 85,0.297790461772542,0.325301156315475,169,Neurology,efficacy,DICH,1,1,yes,1993.0,Overall improvement at 3 months or less,Endoscopic versus open or mini-open carpal tunnel release,0.91543007453606,"positive 
",positive,,,,,,,,,,,,,,,,,
628,CD009436,Lin 2013,STD-Lin-2013 1.8 0.506 36 36,0.725937003382936,0.616770794269863,72,Skin & Wounds,efficacy,DICH,1,15,yes,2013.0,Secondary outcome: number of participants with remission (short-term data),Wet cupping plus herbal medicine versus western drugs,1.17699639822003,"positive 
",positive,,,,,,,,,,,,,,,,,
629,CD004250,Ang 2009,STD-Ang-2009 0.455 0.468 28 28,-1.0907382322372,0.6270652926055,56,Spine & Muscles,efficacy,DICH,1,13,yes,2009.0,Pain Prevelance during previous week: 6 weeks of treatment + 46 weeks follow-up,Chronic MND: Cervical/Scapulothoracic Strengthening + Cervical/Scapulothoracic Endurance Training,-1.73943326970802,"negative 
",negative,,,,,,,,,,,,,,,,,
630,CD001084,Aktulga 1980,STD-Aktulga-1980 3.01 0.857 14 14,1.20397280432594,0.945750730607407,28,Spine & Muscles,efficacy,DICH,1,10,no,1980.0,Aphtas not improved,Colchicine vs placebo,1.27303396694464,"negative 
",negative,,,,,,,,,,,,,,,,,
631,CD008175,Coburn 2004,STD-Coburn-2004 0.345 1.611 27 28,-1.09861228866811,1.65511145829939,55,Kidney & Transplant,efficacy,DICH,1,1,yes,2004.0,All-cause mortality,Vitamin D versus placebo/no treatment,-0.663769369222374,"negative 
",negative,,,,,,,,,,,,,,,,,
632,CD007855,Robertson 1968,STD-Robertson-1968 0.618 0.319 82 78,-0.604446410143294,0.39831797581406,160,Pregnancy & Childbirth,efficacy,DICH,1,5,no,1968.0,Symptomatic infection,Cycloserine versus sulphadimidine,-1.51749719280924,"negative 
",negative,,,,,,,,,,,,,,,,,
633,CD003220,Cuadros-Fernández 2016,STD-Cuadros_x002d_Fern_x00e1_ndez-2016 0.5 1.206 45 45,-0.716136698784644,1.24337568203691,90,"Oral Health, Eyes & ENT",efficacy,DICH,1,7,no,2016.0,Clinical failure,Biodentine pulpotomy versus Mineral trioxide aggregate (MTA) pulpotomy,-0.575961641465804,"negative 
",negative,,,,,,,,,,,,,,,,,
634,CD008023,Burger 1997,STD-Burger-1997 1.209 0.138 72 95,0.430931714545225,0.317098545439068,167,Gynaecology & Urology,efficacy,DICH,1,2,yes,1997.0,"Cholinergic agent plus sedative versus placebo, spontaneous voiding",Cholinergic agent plus sedative versus placebo,1.35898357385569,"neutral 
",neutral,,,,,,,,,,,,,,,,,
635,CD005067,Ben Salah 2009,STD-Ben-Salah-2009 1.338 0.128 50 42,1.22750330173613,0.519438793809564,92,Skin & Wounds,efficacy,DICH,1,72,no,2009.0,Participants complete cure,"WR279,396 (twice a day for 20 d) versus vehicle (twice a day for 20 d)",2.36313366726736,"positive 
",positive,,,,,,,,,,,,,,,,,
636,CD000208,O'Brien 2014,STD-O_x0027_Brien-2014 0.632 0.157 46 46,-1.47113324105692,0.488300114268773,92,Psychiatry & Mental Health,efficacy,DICH,1,15,no,2014.0,Tardive dyskinesia: 1. No clinically important improvement - medium term,ENZYME INHIBITOR - VMAT2 INHIBITORS versus PLACEBO,-3.01276448247393,"negative 
",negative,,,,,,,,,,,,,,,,,
637,CD002240,Berg 1983,STD-Berg-1983 2.7 0.767 14 15,0.993251773010283,0.767390962214756,29,Gynaecology & Urology,efficacy,DICH,1,4,yes,1983.0,Children not cured or improved,Behaviour modifications + laxatives versus behaviour modifications alone,1.29432300081262,"negative 
",negative,,,,,,,,,,,,,,,,,
638,CD003991,Gupta 1977,STD-Gupta-1977 1.845 0.503 50 50,0.612259521420845,0.502752053958637,100,Gynaecology & Urology,efficacy,DICH,1,1,yes,1977.0,Azoospermia at 2 months,Vasectomy with clips versus conventional vasectomy,1.21781605186882,"positive 
",positive,,,,,,,,,,,,,,,,,
639,CD004258,Saunders 1995,STD-Saunders-1995 2 0.365 12 12,1.94591014905531,0.971008312455224,24,Spine & Muscles,efficacy,DICH,1,4,no,1995.0,Excellent or good result,LASER VERSUS PLACEBO,2.00400977426755,"positive 
",positive,,,,,,,,,,,,,,,,,
640,CD001842,Beisland 1984,STD-Beisland-1984 0.333 1.576 10 10,-1.19869574722509,1.69327136626103,20,Gynaecology & Urology,efficacy,DICH,1,6,yes,1984.0,Number cured (subjective),Adrenergic agonist vs other drugs,-0.707917095339522,"neutral 
",neutral,,,,,,,,,,,,,,,,,
641,CD005647,Mayanja-Kizza 1998,STD-Mayanja_x002d_Kizza-1998 2.679 0.53 28 30,1.28401551199947,0.666346076762739,58,Infectious Diseases,efficacy,DICH,1,14,no,1998.0,Mortality,Two weeks of FLU versus two weeks of 5FC + FLU,1.92694990902852,"negative 
",negative,,,,,,,,,,,,,,,,,
642,CD004443,DeMaria 1985,STD-DeMaria-1985 0.94 0.843 10 13,-0.0645385211375715,0.861200712184254,23,Emergency & Trauma,efficacy,DICH,1,1,no,1985.0,Death rate,Naloxone versus control,-0.0749401622925777,"negative 
",negative,,,,,,,,,,,,,,,,,
643,CD003449,Weisberg 2009,STD-Weisberg-2009 0.04 1.427 40 37,-3.55965145704947,1.46607766807234,77,Gynaecology & Urology,efficacy,DICH,1,13,yes,2009.0,Continued irregular bleeding during treatment (# women),Antiprogestin and estrogen vs placebo (Implanon/Therapeutic),-2.42801014882782,"negative 
",negative,,,,,,,,,,,,,,,,,
644,CD001792,Strelec 1994,STD-Strelec-1994 2 0.428 30 30,0.980829253011726,0.58925565098879,60,Anaesthesia & Pain,efficacy,DICH,1,9,no,1994.0,Number of participants affected by PDPH of any severity,Caffeine 300 mg versus placebo,1.66452243837775,"negative 
",negative,,,,,,,,,,,,,,,,,
645,CD003437,Watkins 2007,STD-Watkins-2007 0.682 0.278 127 127,-0.383159350593866,0.278119660364654,254,Neurology,efficacy,DICH,1,3,yes,2007.0,Depression: Meeting study criteria for depression at end of treatment,Psychological interventions versus standard care and/or attention control,-1.37767804725308,"negative 
",negative,,,,,,,,,,,,,,,,,
646,CD001841,HOPE HYP 2000,STD-HOPE-HYP-2000 0.791 0.081 2212 2143,-0.266615477800256,0.0926697918131974,4355,Heart & Hypertension,efficacy,DICH,1,3,no,2000.0,Total mortality,First-line ACE inhibitor vs Placebo,-2.87704841657242,"negative 
",negative,,,,,,,,,,,,,,,,,
647,CD011385,Forbes 1972,STD-Forbes-1972 -0.643 0.144 14 14,-3.09104245335832,1.00378073182133,28,Genetics & Endocrinology,efficacy,DICH,1,1,no,1972.0,Number of people with postoperative bleedings,Antifibrinolytic therapy versus placebo in hemophilia,-3.0794000675324,"negative 
",negative,,,,,,,,,,,,,,,,,
648,CD000157,Morales 1986,STD-Morales-1986 3.359 0.421 78 82,1.30686722748857,0.472685789400127,160,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1986.0,Caesarean section,Oxytocin for prelabour rupture of membranes at or near term from 34 weeks onwards) for nulliparas,2.76476944472369,"negative 
",negative,,,,,,,,,,,,,,,,,
649,CD001004,Bassiouny 2007,STD-Bassiouny-2007 2.455 0.685 20 20,0.897941593205959,0.684607090736627,40,Lungs,efficacy,DICH,1,9,no,2007.0,Reduction in AHI below 10,RAUP versus submucosal channeling technique,1.31161596973789,"positive 
",positive,,,,,,,,,,,,,,,,,
650,CD001886,Camarasa 2006,STD-Camarasa-2006 0.229 1.091 35 32,-1.58045037556085,1.14678945339594,67,Emergency & Trauma,efficacy,DICH,1,6,yes,2006.0,No. Exposed to Allogeneic Blood,Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),-1.37815217159586,"neutral. 
",neutral,,,,,,,,,,,,,,,,,
651,CD004175,Furusho 1991,STD-Furusho-1991 0.973 0.415 49 53,-0.0330398540782002,0.5092807919651,102,Heart & Hypertension,efficacy,DICH,1,1,yes,1991.0,Coronary artery lesions within day 30 of illness,ASA + IVIG versus IVIG alone,-0.0648755158244105,"negative 
",negative,,,,,,,,,,,,,,,,,
652,CD000324,Lundorff 1991a,STD-Lundorff-1991a 0.282 0.735 48 57,-1.36827585561721,0.84181827531719,105,Gynaecology & Urology,efficacy,DICH,1,1,no,1991.0,primary treatment success,laparoscopic salpingostomy versus salpingostomy by open surgery,-1.6253815054106,"positive 
",positive,,,,,,,,,,,,,,,,,
653,CD012656,Carmona-Fonseca 2009 COL,STD-Carmona_x002d_Fonseca-2009-COL 3.876 0.31 63 66,2.07558797236385,0.428188869946089,129,Infectious Diseases,efficacy,DICH,1,5,no,2009.0,Recurrence,1.17 mg/kg/day primaquine for 3 days versus standard 14-day regimen; follow-up 4 months,4.84736553900893,"negative 
",negative,,,,,,,,,,,,,,,,,
654,CD010735,Conrad-Hengerer 2013,STD-Conrad_x002d_Hengerer-2013 0.329 1.641 73 73,-1.11231113302627,1.64136078066092,146,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,2013.0,Intraoperative complications,Laser-assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery,-0.677676197781687,"negative 
",negative,,,,,,,,,,,,,,,,,
655,CD008337,Chew 1994,STD-Chew-1994 1.183 0.385 31 33,0.238891908282349,0.54808468816126,64,Gastroenterology,efficacy,DICH,1,18,yes,1994.0,H. pylori persistence,PPI dual therapy (PPI + one antibiotic) 14 days versus 7 days,0.435866780157269,"negative 
",negative,,,,,,,,,,,,,,,,,
656,CD006946,Kvist 2007,STD-Kvist-2007 0.2 0.824 140 70,-1.66915714713572,0.850077050740819,210,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2007.0,Breast abscess,Acupuncture versus usual care,-1.96353630024607,"negative 
",negative,,,,,,,,,,,,,,,,,
657,CD001888,Abuzakuk 2007,STD-Abuzakuk-2007 1.083 0.349 52 52,0.105360515657826,0.459235708430253,104,Emergency & Trauma,efficacy,DICH,1,1,no,2007.0,No. exposed to allogeneic blood (All Studies),Cell salvage - blood transfused (all studies),0.229425790990789,"negative 
",negative,,,,,,,,,,,,,,,,,
658,CD004879,ca Kawai 2003,STD-ca-Kawai-2003 0.202 0.339 999 303,-1.65619967834214,0.351580640486354,1302,Lungs,efficacy,DICH,1,8,no,2003.0,Influenza,Inactivated vaccines (cohort studies by age group),-4.71072490240378,"negative 
",negative,,,,,,,,,,,,,,,,,
659,CD009346,Baek 2008,STD-Baek-2008 0.025 0.806 60 60,-8.47630175004016,1.64316837693998,120,Anaesthesia & Pain,efficacy,DICH,1,1,yes,2008.0,Pain,Non-pharmacological interventions versus placebo,-5.15851075823726,"negative 
",negative,,,,,,,,,,,,,,,,,
660,CD003557,Morias 1979,STD-Morias-1979 1.312 0.108 30 29,3.0122615755052,1.4867967793292,59,Skin & Wounds,efficacy,DICH,1,7,yes,1979.0,Frequency of complete healing,Levamisole versus placebo,2.02600760062465,"positive 
",positive,,,,,,,,,,,,,,,,,
661,CD005563,Beaussier 2006,STD-Beaussier-2006 0.9 0.366 26 26,-0.165985137474261,0.576571453093956,52,Psychiatry & Mental Health,efficacy,DICH,1,11,yes,2006.0,Incident delirium,Intrathecal morphine and PCA morphine versus PCA morphine,-0.287883030947099,"negative 
",negative,,,,,,,,,,,,,,,,,
662,CD005960,Eriksson 2001,STD-Eriksson-2001 0.987 0.285 77 72,-0.0173917427118691,0.379403521770406,149,Emergency & Trauma,efficacy,DICH,1,1,no,2001.0,Functional assessment - single hop test: participants with < 90% of opposite side,Patella tendon versus hamstring tendon autografts for ACL reconstruction,-0.0458396976145983,"negative 
",negative,,,,,,,,,,,,,,,,,
663,CD000223,Moser 1973,STD-Moser-1973 0.379 0.507 40 38,-1.01160091167848,0.535028420979121,78,Lungs,efficacy,DICH,1,1,no,1973.0,Frequency of unsatisfactory response,Doxapram vs. placebo,-1.89074238304428,"negative 
",negative,,,,,,,,,,,,,,,,,
664,CD010168,Dandapat 1992,STD-Dandapat-1992 0.575 0.503 40 46,-0.664976303593249,0.596949919464947,86,Gastroenterology,efficacy,DICH,1,1,yes,1992.0,Intra-peritoneal abscess,Drain use versus no drain use,-1.11395660156764,"negative 
",negative,,,,,,,,,,,,,,,,,
665,CD006542,Loo 2008,STD-Loo-2008 5.602 0.471 44 29,3.05635689537043,0.647620077441923,73,"Oral Health, Eyes & ENT",efficacy,DICH,1,4,yes,2008.0,Periodontal healing at 48 months,Thymosin alpha 1 versus saline soaking prior to replantation,4.71936711326636,"positive 
",positive,,,,,,,,,,,,,,,,,
666,CD003263,Rath 2008,STD-Rath-2008 7.407 1.006 27 20,2.41381072810427,1.10066121416135,47,Skin & Wounds,efficacy,DICH,1,13,no,2008.0,Percentage repigmentation (> 75%),ORAL: oral minipulses of betamethasone (OMP) plus NB-UVB versus OMP,2.19305513544736,"positive 
",positive,,,,,,,,,,,,,,,,,
667,CD004224,Crowther 2012b,STD-Crowther-2012b 0.343 0.678 10 12,-1.7227665977411,0.983797307811494,22,Pregnancy & Childbirth,efficacy,DICH,1,2,no,2012.0,Vaginal birth,Secondary maternal outcomes,-1.75113977651909,"neutral 
",neutral,,,,,,,,,,,,,,,,,
668,CD009957,Foden-Shroff 1998,STD-Foden_x002d_Shroff-1998 1.293 0.296 173 175,0.290732969285037,0.334768442125867,348,Oncology,efficacy,DICH,1,1,no,1998.0,Number of participants who experienced prolonged vaginal discharge,Prolonged vaginal discharge,0.868459904520292,"negative 
",negative,,,,,,,,,,,,,,,,,
669,CD010328,Arts 2011,STD-Arts-2011 0.319 1.629 166 159,-1.14785300477127,1.63675954890682,325,Spine & Muscles,efficacy,DICH,1,5,yes,2011.0,Surgical site and other infections,Secondary outcomes - complications of surgery,-0.701296048975499,"negative 
",negative,,,,,,,,,,,,,,,,,
670,CD002091,VASCA 1966,STD-VASCA-1966 0.9 0.272 295 287,-0.105010238800809,0.272775496760723,582,Neurology,efficacy,DICH,1,2,no,1966.0,All ischaemic or haemorrhagic strokes,Intervention versus control: history of stroke,-0.384969471407189,"negative 
",negative,,,,,,,,,,,,,,,,,
671,CD009439,Shipley 2003,STD-Shipley-2003 1.161 0.654 33 45,0.149035579160488,0.654233886329635,78,Emergency & Trauma,efficacy,DICH,1,10,no,2003.0,Baseline measures of knowledge of suicide (Shipley 2003 - dichotomous),"Experimental group comparisons, gatekeeper training programs: baseline measures of suicide-related outcomes",0.227801681133644,"neutral 
",neutral,,,,,,,,,,,,,,,,,
672,CD004966,Dorsey 2002,STD-Dorsey-2002 0.634 0.391 59 54,-0.566175718849155,0.482104171249977,113,Infectious Diseases,efficacy,DICH,1,1,no,2002.0,Treatment failure by day 28,Sulfadoxine-pyrimethamine (SP) plus artesunate (AS) versus SP plus amodiaquine (AQ),-1.1743846094117,"negative 
",negative,,,,,,,,,,,,,,,,,
673,CD006117,Sogaard 1999,STD-Sogaard-1999 0.074 1.487 79 69,-2.60698707065693,1.48657346745439,148,Psychiatry & Mental Health,efficacy,DICH,1,28,no,1999.0,Sertraline versus newer ADs,SE - Dismenorrea,-1.75368868591549,"neutral 
",neutral,,,,,,,,,,,,,,,,,
674,CD003124,Zanini 1974,STD-Zanini-1974 -0.115 0.158 19 11,-0.693147180559945,0.924211375534118,30,Lungs,efficacy,DICH,1,2,yes,1974.0,Cough after 6 to 7 days,Cough (AC or CC versus placebo),-0.749987718079496,"negative 
",negative,,,,,,,,,,,,,,,,,
675,CD003989,Endrikat 2001,STD-Endrikat-2001 0.131 2 35 34,-1.15659954631846,1.65066242067233,69,Gynaecology & Urology,efficacy,DICH,1,7,no,2001.0,Pregnancy per woman,EE 20 µg and gestodene 75 µg (23-day) versus EE 30 µg and gestodene 75 µg (21-day),-0.700688118802248,"negative 
",negative,,,,,,,,,,,,,,,,,
676,CD001960,Blum 2000,STD-Blum-2000 0.823 0.045 395 203,-0.858590092911604,0.221386655114503,598,Gastroenterology,efficacy,DICH,1,8,no,2000.0,Global symptom assessment at the end of treatment (dichotomous),PPI vs placebo,-3.87823779381613,"neutral 
",neutral,,,,,,,,,,,,,,,,,
677,CD010127,Hamilton-Reeves 2016,STD-Hamilton_x002d_Reeves-2016 0.306 0.71 14 15,-1.65822807660353,0.92259984619036,29,Gynaecology & Urology,efficacy,DICH,1,2,no,2016.0,Complications at 90 days,Immunonutrition compared to standard oral nutritional supplements,-1.79734267618921,"negative 
",negative,,,,,,,,,,,,,,,,,
678,CD010410,Smith 2011,STD-Smith-2011 1.481 0.644 18 16,0.510825623765991,0.828962898554264,34,Gastroenterology,efficacy,DICH,1,1,no,2011.0,Clinical remission (CDAI < 150),Low dose naltrexone versus placebo,0.616222541029141,"positive 
",positive,,,,,,,,,,,,,,,,,
679,CD003078,Dryden 1992,STD-Dryden-1992 0.429 0.33 40 40,-1.33684608570591,0.493578567396981,80,Kidney & Transplant,efficacy,DICH,1,2,yes,1992.0,Number of patients with peritonitis,Double bag systems versus standard systems,-2.70847677352792,"negative 
",negative,,,,,,,,,,,,,,,,,
680,CD002863,Fr Caribbean 1990,STD-Fr-Caribbean-1990 2.924 1.625 78 76,1.0856250931413,1.6409271123051,154,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1990.0,Maternal death,Beta-blocker versus placebo/no beta-blocker,0.661592513768793,"negative 
",negative,,,,,,,,,,,,,,,,,
681,CD000360,Bensdorp 2015,STD-Bensdorp-2015 1.257 0.677 18 18,0.228841572428848,0.677322843086097,36,Gynaecology & Urology,efficacy,DICH,1,9,yes,2015.0,Live birth rate per couple (all cycles),In vitro fertilisation (IVF) versus intra-uterine insemination (IUI) in cycles with ovarian hyperstimulation (OH),0.337861884867448,"positive 
",positive,,,,,,,,,,,,,,,,,
682,CD009029,Sack 2007,STD-Sack-2007 0.758 0.389 330 341,-0.288448649721976,0.404694994380433,671,Infectious Diseases,efficacy,DICH,1,3,no,2007.0,ETEC diarrhoea,ETEC killed whole cell vaccine with recombinant cholera B-subunit (ETEC WC-rCTB) versus placebo,-0.712755664703924,"negative 
",negative,,,,,,,,,,,,,,,,,
683,CD011745,MRC-TMH 1985 Betablocker arm,STD-MRC_x002d_TMH-1985-Betablocker-arm 0.684 0.325 4403 4327,-0.382006293013962,0.326249213151075,8730,Heart & Hypertension,efficacy,DICH,1,2,no,1985.0,Sudden cardiac death,"Subgroup analysis, first-line diuretic versus others",-1.17090333896703,"negative 
",negative,,,,,,,,,,,,,,,,,
684,CD004587,EUCATAX,STD-EUCATAX 0.243 0.797 211 211,-1.41542263404291,0.796687389990327,422,Heart & Hypertension,efficacy,DICH,1,13,no,,Mortality: 12 months,Unselected Patients: Mortality,-1.7766349158107,"negative 
",negative,,,,,,,,,,,,,,,,,
685,CD005509,Belch 1979,STD-Belch-1979 0.288 0.875 24 25,-1.24521576285999,0.874501452868193,49,Heart & Hypertension,efficacy,DICH,1,1,no,1979.0,Incidence of DVT in general,Treatment versus no treatment,-1.42391503041638,"negative 
",negative,,,,,,,,,,,,,,,,,
686,CD003431,Simpson 2003,STD-Simpson-2003 0.105 1.613 7 8,-2.25606507735915,1.61272000076449,15,Gastroenterology,efficacy,DICH,1,27,yes,2003.0,Non-healing of the fissure,GTN Dose Comparisons,-1.39891926452806,"negative 
",negative,,,,,,,,,,,,,,,,,
687,CD012314,Nikkhah 2017,STD-Nikkhah-2017 0.943 0.155 135 135,-0.0942009173500393,0.250654647596797,270,"Oral Health, Eyes & ENT",efficacy,DICH,1,8,yes,2017.0,BCVA: loss of 15 or more letters,Extended targeted PRP versus standard PRP,-0.375819551934146,"negative 
",negative,,,,,,,,,,,,,,,,,
688,CD001820,AICLA 1983b,STD-AICLA-1983b 1.01 0.396 202 204,0.0104712998672954,0.420877842009694,406,Neurology,efficacy,DICH,1,2,no,1983.0,vascular death,Dipyridamole plus aspirin versus placebo,0.024879665361557,"negative 
",negative,,,,,,,,,,,,,,,,,
689,CD003220,Al-Ostwani 2016,STD-Al_x002d_Ostwani-2016 1 1.369 16 16,0.0,1.46059348668044,32,"Oral Health, Eyes & ENT",efficacy,DICH,1,19,no,2016.0,Clinical failure,Metapex versus zinc oxide eugenol (ZOE) pulpectomy,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
690,CD000427,Walsh 1987,STD-Walsh-1987 0.182 0.683 16 16,-2.73436750941958,0.928621377277985,32,Neonatal,efficacy,DICH,1,1,no,1987.0,Hypoxemia end of first suction (TcPO2 <40mmHg),Suctioning with preoxygenation vs without preoxygenation,-2.94454508190914,"negative 
",negative,,,,,,,,,,,,,,,,,
691,CD002033,Egger 1995,STD-Egger-1995 0.692 0.324 43 46,-0.533758144071098,0.464182484526878,89,Oncology,efficacy,DICH,1,2,no,1995.0,Colonisation,Fluconazole versus nystatin,-1.14988859309316,"negative 
",negative,,,,,,,,,,,,,,,,,
692,CD002999,Tashkin 2001,STD-Tashkin-2001 0.067 0.033 204 200,0.631876355166904,0.313231566957153,404,Lungs,efficacy,DICH,1,4,no,2001.0,6 months (continuous abstinence),Comparison among various combinations of psychosocial and pharmacological interventions,2.01728185094876,"positive 
",positive,,,,,,,,,,,,,,,,,
693,CD007935,Cicerone 2008,STD-Cicerone-2008 1.429 0.25 34 34,0.713349887877465,0.492805380304581,68,Public Health & Work,efficacy,DICH,1,2,yes,2008.0,Return to work,Cognitive rehabilitation versus conventional treatment,1.44752861147047,"positive 
",positive,,,,,,,,,,,,,,,,,
694,CD010971,Groß 2013,STD-Gro_x03b2_-2013 103.571 1.56 15 14,4.64026150579936,1.5603460523088,29,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2013.0,Treatment success: postintervention,Cognitive behavioural therapy (CBT) versus control,2.97386691813222,"positive 
",positive,,,,,,,,,,,,,,,,,
695,CD007645,Marsh 2005,STD-Marsh-2005 0.462 0.391 22 22,-1.34855403313704,0.645910872102997,44,Neonatal,efficacy,DICH,1,2,no,2005.0,Oxygen desaturation >10% at speculum insertion,Oxygen desaturation >10%,-2.08783299891878,"negative 
",negative,,,,,,,,,,,,,,,,,
696,CD009536,Hogh 2009,STD-Hogh-2009 0.9 0.459 42 42,-0.105360515657826,0.45918031408866,84,Heart & Hypertension,efficacy,DICH,1,2,no,2009.0,Antibiotic vs Placebo,Referral to AAA surgery,-0.229453468332884,"neutral 
",neutral,,,,,,,,,,,,,,,,,
697,CD007207,Vimala 2005,STD-Vimala-2005 0.476 0.553 30 30,-0.743336925083801,0.553354454025073,60,Gynaecology & Urology,efficacy,DICH,1,13,yes,2005.0,Need for additional mechanical dilation,Misoprostol versus prostaglandin F2a,-1.34332871033531,"negative 
",negative,,,,,,,,,,,,,,,,,
698,CD004767,Burke 2004,STD-Burke-2004 17.882 1.409 16 15,3.67037598254938,1.51760094236276,31,Skin & Wounds,efficacy,DICH,1,4,yes,2004.0,Primary outcome: short-term clinical cure (up to 3 months after start of treatment),Topical: 10% lemon myrtle oil versus vehicle,2.41853828637913,"positive 
",positive,,,,,,,,,,,,,,,,,
699,CD010529,Mejer 1977,STD-Mejer-1977 14.529 1.542 14 9,2.67617499257176,1.54167323728617,23,Anaesthesia & Pain,efficacy,DICH,1,12,yes,1977.0,Pain,Mepacrine,1.73588989407552,"negative 
",negative,,,,,,,,,,,,,,,,,
700,CD002053,Kaltenbach 1986,STD-Kaltenbach-1986 1.1 0.322 20 16,0.200670695462151,0.672324476737388,36,Neonatal,efficacy,DICH,1,6,no,1986.0,Treatment failure,Phenobarbitone titration with loading dose versus phenobarbitone titration alone (all infants),0.298472987977402,"negative 
",negative,,,,,,,,,,,,,,,,,
701,CD002761,Mastrosimone 1989,STD-Mastrosimone-1989 6.429 1.206 12 10,1.86075234071501,1.20580605984887,22,Anaesthesia & Pain,efficacy,DICH,1,10,no,1989.0,Therapeutic effectiveness index (>70% improvement),Metoclopramide vs. placebo,1.54316054851161,"positive 
",positive,,,,,,,,,,,,,,,,,
702,CD002855,Baird 1995 GP0.5 M600po,STD-Baird-1995-GP0.5-M600po 0.611 0.346 391 386,-0.514569922298982,0.360454370503431,777,Gynaecology & Urology,efficacy,DICH,1,3,no,1995.0,failure to achieve complete abortion,combined regimen mifepristone/prostaglandin: type of prostaglandin,-1.42755911540289,"negative 
",negative,,,,,,,,,,,,,,,,,
703,CD002922,Sun 2015,STD-Sun-2015 0.952 1.397 42 40,-0.0500104205746617,1.43179302608424,82,Kidney & Transplant,efficacy,DICH,1,4,yes,2015.0,Death,Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA,-0.0349285264445193,"negative 
",negative,,,,,,,,,,,,,,,,,
704,CD010640,Anker 2009,STD-Anker-2009 0.527 1.405 110 58,-0.648296614394593,1.42362852302689,168,Emergency & Trauma,efficacy,DICH,1,2,yes,2009.0,Mortality,Parenteral iron vs inactive control,-0.455383271624958,"negative 
",negative,,,,,,,,,,,,,,,,,
705,CD010450,Angle 2002,STD-Angle-2002 0.111 1.474 40 40,-2.30121429086027,1.5080818414532,80,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,2002.0,Need for additional pain relief,Non-opioid analgesics versus placebo,-1.52592135758547,"negative 
",negative,,,,,,,,,,,,,,,,,
706,CD008492,Awab 2010 AFG,STD-Awab-2010-AFG 0.412 0.232 264 265,-1.03232015633184,0.265083892975949,529,Infectious Diseases,efficacy,DICH,1,1,yes,2009.0,Parasite clearance,ACT versus Chloroquine,-3.89431490816949,"positive 
",positive,,,,,,,,,,,,,,,,,
707,CD001687,Netherlands 1997,STD-Netherlands-1997 0.975 0.35 110 132,-0.0287601521752627,0.39793598094262,242,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1997.0,Hypertension,Low vs normal salt intake in pregnancy,-0.0722733141826895,"negative 
",negative,,,,,,,,,,,,,,,,,
708,CD001067,Morales 1989,STD-Morales-1989 1.459 0.736 37 72,0.405465108108165,0.792118034381339,109,Pregnancy & Childbirth,efficacy,DICH,1,8,no,1988.0,Treatment failure,Continued oral versus no treatment (tx) after intravenous antibiotic course,0.51187460770899,"negative 
",negative,,,,,,,,,,,,,,,,,
709,CD004961,Vaquero 2012,STD-Vaquero-2012 8.719 1.469 31 30,2.30076525627706,1.51372809441847,61,Emergency & Trauma,efficacy,DICH,1,8,no,2012.0,Mortality (12 months),PFNA versus Gamma 3 nail,1.51993298186155,"negative 
",negative,,,,,,,,,,,,,,,,,
710,CD007917,Liu 2011,STD-Liu-2011 1.6 0.354 10 10,1.38629436111989,1.01242283656583,20,Skin & Wounds,efficacy,DICH,1,34,yes,2011.0,Investigator's global assessment of improvement,Blue LED versus red LED,1.36928397014655,"neutral 
",neutral,,,,,,,,,,,,,,,,,
711,CD005457,Attilakos 2010,STD-Attilakos-2010 1.016 0.46 186 189,0.0168071183163812,0.483143348595323,375,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2010.0,Severe postpartum haemorrhage (> 1000 ml),Carbetocin versus oxytocin,0.0347870220406546,"negative 
",negative,,,,,,,,,,,,,,,,,
712,CD010607,Bondok 2006,STD-Bondok-2006 0.077 1.435 20 20,-2.91122559417937,1.50718020120104,40,Pregnancy & Childbirth,efficacy,DICH,1,12,yes,2006.0,Hospital readmission,Hydrocortisone vs metoclopramide,-1.93157101709502,"negative 
",negative,,,,,,,,,,,,,,,,,
713,CD003654,NICS-EH,STD-NICS_x002d_EH 0.995 0.995 215 214,-0.0047058910374131,1.00469488742246,429,Heart & Hypertension,efficacy,DICH,1,2,no,1999.0,CCBs vs other classes of antihypertensive agents,Myocardial infarction,-0.004683900651158,"neutral 
",neutral,,,,,,,,,,,,,,,,,
714,CD005984,Hanai 2012,STD-Hanai-2012 1.607 0.402 32 30,0.678758443107845,0.565392551295152,62,Gastroenterology,efficacy,DICH,1,3,yes,2012.0,Relapse at 24 months,Elemental diet versus 6-mercaptopurine,1.20050828676997,"negative 
",negative,,,,,,,,,,,,,,,,,
715,CD009162,Wang 2008,STD-Wang-2008 1.954 0.208 34 31,2.20905903498322,0.643106083141552,65,Heart & Hypertension,efficacy,DICH,1,13,yes,2007.0,Rate of resolution of phlebitis: recovery,Aloe vera plus routine treatment versus routine treatment plus dexamethasone for treatment of phlebitis,3.43498388973719,"positive 
",positive,,,,,,,,,,,,,,,,,
716,CD001552,Gerritsen 2002,STD-Gerritsen-2002 1.379 0.123 87 89,0.840817279381358,0.3179999632804,176,Neurology,efficacy,DICH,1,1,yes,2002.0,Improvement in clinical symptoms at three months,Surgical versus non-surgical treatment - primary outcomes,2.64407980022299,"positive 
",positive,,,,,,,,,,,,,,,,,
717,CD004305,Hughes 1991,STD-Hughes-1991 2.375 0.665 32 38,0.990398704027877,0.753015914196351,70,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1991.0,Full versus no financial coverage,Interventions directed at individuals: abstinence from smoking,1.31524272642348,"neutral 
",neutral,,,,,,,,,,,,,,,,,
718,CD004663,Allaire 2000,STD-Allaire-2000 3.846 1.201 26 50,1.40691364832263,1.24982992040196,76,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2000.0,Wound infection,Closure of subcutaneous tissue versus non-closure of subcutaneous tissue,1.12568408337524,"negative 
",negative,,,,,,,,,,,,,,,,,
719,CD001825,Gonzalez DV 2004,STD-Gonzalez-DV-2004 4.815 1.537 53 51,1.6094379124341,1.56167696770373,104,Emergency & Trauma,efficacy,DICH,1,1,no,2004.0,All wound infections,Drains versus no drain,1.03058311399738,"negative 
",negative,,,,,,,,,,,,,,,,,
720,CD011802,Knox 2007,STD-Knox-2007 1.857 1.24 58 53,0.619039208406224,1.23979349574351,111,Lungs,efficacy,DICH,1,1,no,2007.0,Exacerbation requiring OCS,ICS dose reduction versus no change in ICS dose (no concomitant LABA),0.499308320725609,"negative 
",negative,,,,,,,,,,,,,,,,,
721,CD007605,Jiang 2007,STD-Jiang-2007 0.111 1.448 15 15,-2.49571756589222,1.54068000343797,30,Hepato-Biliary,efficacy,DICH,1,7,yes,2007.0,Death (during length of initial hospital stay; ITT),Enteral nutrition via nasojejunal tube plus intravenous glutamine-dipeptide supplementation versus standard parenteral nutrition,-1.61988054646203,"negative 
",negative,,,,,,,,,,,,,,,,,
722,CD009701,Merrill 1999,STD-Merrill-1999 0.979 0.277 404 412,-0.0225685542109049,0.294757909040963,816,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1999.0,Vaginal delivery not achieved within 24 hours,High- versus low-dose oxytocin,-0.0765664076134035,"negative 
",negative,,,,,,,,,,,,,,,,,
723,CD009864,Reitamo 2002a,STD-Reitamo-2002a 0.954 0.102 191 186,-0.0959547173709501,0.206095497283744,377,Skin & Wounds,efficacy,DICH,1,1,yes,2002.0,"Physician's assessment of global response of improvement, clear or excellent",Tacrolimus 0.1% versus steroids,-0.465583764010349,"positive 
",positive,,,,,,,,,,,,,,,,,
724,CD002253,Gilles 2004,STD-Gilles-2004 1.141 0.153 41 39,0.423483613610843,0.485459571613328,80,Pregnancy & Childbirth,efficacy,DICH,1,6,no,2004.0,Complete miscarriage,Vaginal misoprostol wet versus dry vaginal preparations,0.872335490684589,"negative 
",negative,,,,,,,,,,,,,,,,,
725,CD003576,Harrison 1993,STD-Harrison-1993 2.5 0.365 20 20,1.94591014905531,0.71046597720222,40,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1993.0,Abortion,Bed rest versus human chorionic gonadotrophin,2.73892094976625,"negative 
",negative,,,,,,,,,,,,,,,,,
726,CD004737,Atkinson 1996,STD-Atkinson-1996 1.409 0.133 323 320,0.467216154392372,0.180294386775618,643,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1996.0,Endometritis,Manual placental removal versus cord traction,2.59140710228454,"negative 
",negative,,,,,,,,,,,,,,,,,
727,CD007101,Deisenhofer 2009,STD-Deisenhofer-2009 1.12 0.104 50 48,0.559615787935422,0.509824121556282,98,Heart & Hypertension,efficacy,DICH,1,15,yes,2009.0,Sinus rhythm remaining,Comparision of sinus rhythm between CFAE+PV(A)I and PV(A)I,1.09766439890515,"positive 
",positive,,,,,,,,,,,,,,,,,
728,CD009665,Ferrari 1991,STD-Ferrari-1991 6.686 0.353 109 106,2.52387507565893,0.414613577120902,215,Anaesthesia & Pain,efficacy,DICH,1,3,no,1991.0,Pain-free at 1 h,Subcutaneous sumatriptan 8 mg versus placebo,6.0872948087828,"positive 
",positive,,,,,,,,,,,,,,,,,
729,CD003521,Freeman 1986,STD-Freeman-1986 1.064 0.497 29 36,0.0776509342300661,0.622482794151023,65,Pregnancy & Childbirth,efficacy,DICH,1,6,yes,1986.0,Use of pharmacological analgesia,Hypnosis compared with control,0.12474390450578,"negative 
",negative,,,,,,,,,,,,,,,,,
730,CD010605,Hallay 2001,STD-Hallay-2001 0.778 0.864 9 7,-0.336472236621213,1.15881713089561,16,Gastroenterology,efficacy,DICH,1,1,no,2001.0,All-cause mortality,Immunonutrition vs control (other EN or placebo or no intervention),-0.290358355645954,"negative 
",negative,,,,,,,,,,,,,,,,,
731,CD010292,Arnold 2004,STD-Arnold-2004 0.114 0.057 104 103,0.670941668647455,0.343900462841404,207,Anaesthesia & Pain,efficacy,DICH,1,1,no,2004.0,Self-reported pain relief of 50% or greater,SNRIs versus placebo in parallel and cross-over design trials,1.95097634677181,"positive 
",positive,,,,,,,,,,,,,,,,,
732,CD006117,Behan 1995,STD-Behan-1995 0.333 0.907 20 20,-1.09861228866811,0.906764700582363,40,Psychiatry & Mental Health,efficacy,DICH,1,13,no,1995.0,Sertraline versus TCAs,SE - Participants with at least one TEAE,-1.21157372796111,"neutral 
",neutral,,,,,,,,,,,,,,,,,
733,CD004182,LaRusso 1988b,STD-LaRusso-1988b 1.136 0.43 39 31,0.167432944300204,0.564806664394551,70,Hepato-Biliary,efficacy,DICH,1,1,no,1988.0,Mortality,D-penicillamine versus placebo,0.296442933228638,"negative 
",negative,,,,,,,,,,,,,,,,,
734,CD006761,Altomare 2008,STD-Altomare-2008 0.431 1.231 146 127,-0.841567185678218,1.23081133880223,273,Gastroenterology,efficacy,DICH,1,3,no,2008.0,Postoperative bleeding,Complications,-0.683749945379276,"negative 
",negative,,,,,,,,,,,,,,,,,
735,CD003991,Song 2006,STD-Song-2006 0.138 0.387 144 144,-1.98348682430889,0.387433081465322,288,Gynaecology & Urology,efficacy,DICH,1,4,yes,2006.0,Azoospermia at 3rd month,Intra-vas device versus no-scalpel vasectomy,-5.11955978773697,"positive 
",positive,,,,,,,,,,,,,,,,,
736,CD000227,Aloia 1988,STD-Aloia-1988 0.6 0.645 17 17,-0.664976303593249,0.829515062006253,34,Emergency & Trauma,efficacy,DICH,1,10,no,1988.0,Persons sustaining new vertebral deformity,"Calcitriol [1,25(OH)2D3] plus vitamin D plus calcium versus vitamin D plus calcium",-0.801644640405862,"negative 
",negative,,,,,,,,,,,,,,,,,
737,CD007453,Collins 1991,STD-Collins-1991 1.636 0.812 11 12,0.628608659422374,1.02875329080073,23,Neonatal,efficacy,DICH,1,2,yes,1991.0,All-cause mortality,Insulin infusion versus No glucose reduction,0.611039269612538,"negative 
",negative,,,,,,,,,,,,,,,,,
738,CD004484,Shovelton 1971,STD-Shovelton-1971 1.056 0.132 36 38,0.22314355131421,0.5444525428617,74,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,1971.0,Success at 24 months,"Pulp capping with Ledermix, glycerrhetinic acid, calcium hydroxide and zinc oxide eugenol",0.409849406049871,"positive 
",positive,,,,,,,,,,,,,,,,,
739,CD003711,Yang YX 2008,STD-Yang-YX-2008 1.22 0.652 83 81,0.210240146478302,0.689788029620351,164,Heart & Hypertension,efficacy,DICH,1,1,no,2008.0,Number of patients that died of cardiac failure,Herbal medicines versus supportive therapy,0.304789496845886,"negative 
",negative,,,,,,,,,,,,,,,,,
740,CD011946,Asilian 2011,STD-Asilian-2011 4 0.595 32 32,1.75785791755237,0.707919081030704,64,Skin & Wounds,efficacy,DICH,1,2,no,2011.0,Participant-reported scar improvement (short-term),Fractional laser versus non-fractional non-ablative laser,2.48313396920026,"positive 
",positive,,,,,,,,,,,,,,,,,
741,CD007372,Biem 2003,STD-Biem-2003 0.796 0.198 149 150,-0.306942884978745,0.265911686892109,299,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,2003.0,Vaginal delivery or labour not achieved within 24 hours,Outpatient versus inpatient induction with controlled release PGE,-1.15430385390802,"negative 
",negative,,,,,,,,,,,,,,,,,
742,CD005231,Australia NNCG-017,STD-Australia-NNCG_x002d_017 1.444 0.423 218 218,0.38704905295172,0.444631224510707,436,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2001.0,Reduction in cigarettes/day of > 50% of baseline or cessation,Nicotine replacement therapy to assist smoking reduction versus placebo,0.870494539328961,"positive 
",positive,,,,,,,,,,,,,,,,,
743,CD003436,Mohr 2013,STD-Mohr-2013 0.146 0.05 108 105,1.10266908936372,0.401475997043698,213,Neurology,efficacy,DICH,1,1,no,2013.0,Death or dependence,Intervention versus conservative management for unruptured brain AVMs,2.74653801842033,"negative 
",negative,,,,,,,,,,,,,,,,,
744,CD004228,Chang 1999,STD-Chang-1999 1.111 0.092 123 127,0.3068182552048,0.26752954329844,250,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1999.0,Women who were abstinent following the intervention,Brief alcohol reduction intervention versus alcohol assessment only,1.14685747010203,"positive 
",positive,,,,,,,,,,,,,,,,,
745,CD012537,Reiff 2006,STD-Reiff-2006 0.841 0.146 97 87,-0.352220593589352,0.29652546337094,184,Anaesthesia & Pain,efficacy,DICH,1,3,no,2006.0,Participant-reported pain relief of 30% or greater,Rofecoxib versus naproxen,-1.18782579271697,"positive 
",positive,,,,,,,,,,,,,,,,,
746,CD005967,Anh 1989,STD-Anh-1989 0.331 0.738 19 22,-1.37792611144937,0.87655424186731,41,Infectious Diseases,efficacy,DICH,1,1,yes,1989.0,Death: participant age,Artesunate vs quinine,-1.57198042703438,"negative 
",negative,,,,,,,,,,,,,,,,,
747,CD001841,ATTMH 1980,STD-ATTMH-1980 0.708 0.26 1721 1706,-0.351322524377668,0.264120228794426,3427,Heart & Hypertension,efficacy,DICH,1,1,no,1980.0,Total mortality,First-line thiazide vs placebo,-1.33016136621294,"negative 
",negative,,,,,,,,,,,,,,,,,
748,CD003244,Earnest 1998,STD-Earnest-1998 0.384 0.212 71 66,-1.83971386235009,0.378947857380036,137,Gastroenterology,efficacy,DICH,1,1,no,1998.0,Oesophagitis persists at four weeks,Standard dose PPI versus placebo,-4.85479420590863,"negative 
",negative,,,,,,,,,,,,,,,,,
749,CD003715,Anonymous 1990,STD-Anonymous-1990 0.927 0.153 125 123,-0.127476883715817,0.258614257679601,248,Gastroenterology,efficacy,DICH,1,1,no,1990.0,"Relapse, drop-outs classed as relapse, grouped by length of follow-up",5-ASA compared to placebo,-0.492922876177031,"negative 
",negative,,,,,,,,,,,,,,,,,
750,CD001324,Chen 2002b,STD-Chen-2002b 3 1.621 50 50,1.11861295537478,1.64519623968289,100,Gynaecology & Urology,efficacy,DICH,1,11,no,2002.0,Observed number of pregnancy (all women),Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses),0.679926763989197,"negative 
",negative,,,,,,,,,,,,,,,,,
751,CD003160,HPS 2002,STD-HPS-2002 1 0.254 10269 10267,-0.0001953697378498,0.254384549002784,20536,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2002.0,Number of cases of dementia,Incidence of dementia,-0.0007680094511075,"negative 
",negative,,,,,,,,,,,,,,,,,
752,CD002849,Cinciripini 1995 H,STD-Cinciripini-1995-H 0.48 0.633 25 28,-0.893817876022097,0.754495904073753,53,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1995.0,Long term abstinence,Buspirone versus placebo/NRT,-1.1846557034917,"positive 
",positive,,,,,,,,,,,,,,,,,
753,CD001256,Bensel 1976,STD-Bensel-1976 0.668 0.416 372 414,-0.416267041140978,0.427830415443523,786,Emergency & Trauma,efficacy,DICH,1,15,no,1976.0,Lower limb soft-tissue injuries by location,Footwear: tropical combat boot vs leather combat boot,-0.972972061159894,"negative 
",negative,,,,,,,,,,,,,,,,,
754,CD009351,Arthurs 1979,STD-Arthurs-1979 1.176 0.117 21 21,1.54881329061766,1.1656858622338,42,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1979.0,"Satisfaction with pain relief (first stage, considerable to complete)",Inhaled analgesia using one type of delivery system versus a different delivery system,1.32867124908736,"positive 
",positive,,,,,,,,,,,,,,,,,
755,CD010461,Parmegiani 2012,STD-Parmegiani-2012 1.133 0.292 50 50,0.18400364297694,0.429377054525379,100,Gynaecology & Urology,efficacy,DICH,1,2,yes,2012.0,Live birth per woman randomly assigned,HA-ICSI versus viscous medium containing HA (SpermSlow),0.428536273742741,"positive 
",positive,,,,,,,,,,,,,,,,,
756,CD008183,720-04378,STD-_x0037_20_x002d_04378 13.51 1.454 50 52,2.73027333788692,1.48167664590022,102,Anaesthesia & Pain,efficacy,DICH,1,1,no,1999.0,Participants with =50% pain relief over 6 hours,Gabapentin 250 mg versus placebo,1.8426917542647,"positive 
",positive,,,,,,,,,,,,,,,,,
757,CD004316,Kamischke 2002,STD-Kamischke-2002 1 1.468 14 14,0.0,1.46759877141069,28,Gynaecology & Urology,efficacy,DICH,1,20,yes,2002.0,Azoospermia,Testostone undecanoate 1000 mg + NETE 200 mg IM versus testosterone undecanoate 1000 mg + NETE 400 mg IM,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
758,CD005937,Iliya 1966,STD-Iliya-1966 0.067 0.398 102 90,-4.74414130190843,0.529764713897147,192,Pregnancy & Childbirth,efficacy,DICH,1,5,no,1966.0,"Failure to suppress lactation as indicated by milk secretion, breast engorgement or breast pain at = 7 days",Combined oestrogen and androgen preparations versus placebo,-8.95518553323184,"negative 
",negative,,,,,,,,,,,,,,,,,
759,CD007575,Pongrojpaw 2007a,STD-Pongrojpaw-2007a 0.076 0.438 85 85,-4.01780448509977,0.529417693413134,170,Pregnancy & Childbirth,efficacy,DICH,1,13,yes,2007.0,Drowsiness,Ginger versus dimenhydrinate,-7.58910126179793,"negative 
",negative,,,,,,,,,,,,,,,,,
760,CD007258,Collis 2005,STD-Collis-2005 1 0.698 150 150,0.0,0.716727723851245,300,Skin & Wounds,efficacy,DICH,1,1,yes,2005.0,Haematoma,Drain compared with no drain,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
761,CD001352,Bridwell 1993,STD-Bridwell-1993 0.239 0.796 34 9,-1.43074612369072,0.796484370078067,43,Spine & Muscles,efficacy,DICH,1,3,no,1993.0,Poor result 18-24 months - Surgeon rating,LAMINECTOMY + FUSION ANY TYPE vs LAMINECTOMY,-1.79632667939295,"negative 
",negative,,,,,,,,,,,,,,,,,
762,CD004275,Bing 2005,STD-Bing-2005 0.455 0.397 15 15,-1.70474809223843,0.800567980192245,30,Gastroenterology,efficacy,DICH,1,1,yes,2005.0,Prevalence rate of nocturnal gastric acid breakthrough,H2RAs vs control,-2.12942327749488,"negative 
",negative,,,,,,,,,,,,,,,,,
763,CD001735,Laurent 1998,STD-Laurent-1998 0.4 0.57 80 80,-0.998528830111127,0.6143643943317,160,Skin & Wounds,efficacy,DICH,1,7,yes,1997.0,Pressure ulcer incidence,AP and CLP in ICU/post ICU (factorial design),-1.62530387392863,"negative 
",negative,,,,,,,,,,,,,,,,,
764,CD004484,Fitzgerald 1991,STD-Fitzgerald-1991 1.455 0.704 22 24,0.44183275227904,0.828557744824063,46,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,no,1991.0,Clinical symptoms at 12 months following indirect pulp capping,"Life, Dycal and Cavitec following three modalities",0.533255231803861,"neutral 
",neutral,,,,,,,,,,,,,,,,,
765,CD009440,Gao 2002,STD-Gao-2002 1.375 0.115 34 34,2.62103882411258,1.08257549250373,68,Kidney & Transplant,efficacy,DICH,1,2,yes,2002.0,Uraemic pruritus improvement,Manual acupuncture versus routine care/conventional medicine,2.42111413223549,"positive 
",positive,,,,,,,,,,,,,,,,,
766,CD008615,GL/MIG/001/92,STD-GL_x002f_MIG_x002f_001_x002f_92 1.075 0.098 242 227,0.135955636236029,0.185235920904474,469,Anaesthesia & Pain,efficacy,DICH,1,17,no,1992.0,Headache relief at 2 hours,Oral sumatriptan 100 mg versus paracetamol 1000 mg + metoclopramide 10 mg,0.733959350714384,"positive 
",positive,,,,,,,,,,,,,,,,,
767,CD008808,Le Guen 2014,STD-Le-Guen-2014 0.15 1.481 20 21,-2.0485643031154,1.54549306940317,41,Emergency & Trauma,efficacy,DICH,1,1,yes,2014.0,Incidence of delirium and confusion,Ear plugs or eye mask versus usual care or both,-1.32550856660037,"negative 
",negative,,,,,,,,,,,,,,,,,
768,CD005220,Ahonen 2004,STD-Ahonen-2004 1.529 0.271 83 83,0.571486668157141,0.360528005394784,166,Anaesthesia & Pain,efficacy,DICH,1,3,no,2004.0,Pain-free,Triptans vs placebo in adolescents,1.58513807417361,"positive 
",positive,,,,,,,,,,,,,,,,,
769,CD006028,Sezai 2006b,STD-Sezai-2006b 0.333 1.604 20 20,-1.14862270924277,1.66334879257286,40,Kidney & Transplant,efficacy,DICH,1,1,yes,2006.0,Mortality - low versus high dose studies,ANP for preventing AKI,-0.690548316968497,"negative 
",negative,,,,,,,,,,,,,,,,,
770,CD000155,Cosson 2002,STD-Cosson-2002 0.692 0.501 41 45,-0.367724780125317,0.500533902981794,86,Gynaecology & Urology,efficacy,DICH,1,4,no,2002.0,Live births,GnRH versus oral contraception,-0.734665080496441,"positive 
",positive,,,,,,,,,,,,,,,,,
771,CD001992,Besinger 1991,STD-Besinger-1991 0.545 0.856 22 18,-0.693147180559945,0.974679434480896,40,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,1991.0,Birth less than 48 hours after trial entry,COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic),-0.711154002063363,"negative 
",negative,,,,,,,,,,,,,,,,,
772,CD009651,Günal 1997,STD-G_x00fc_nal-1997 1.421 0.177 12 16,2.48127688173742,1.53257127193397,28,Emergency & Trauma,efficacy,DICH,1,2,no,1997.0,Patient-rated knee function score,Patellectomy with vastus medialis obliquus (VMO) advancement versus simple patellectomy for comminuted fractures,1.61902870501172,"positive 
",positive,,,,,,,,,,,,,,,,,
773,CD000536,Edmondson 1994,STD-Edmondson-1994 0.394 0.347 94 106,-0.992276638852077,0.376854989823312,200,Heart & Hypertension,efficacy,DICH,1,15,no,1994.0,"Occlusion in all bypasses, 6 months","Occlusion in all bypasses, low molecular weight heparin (LMWH) versus ASA/DIP",-2.63304630600037,"negative 
",negative,,,,,,,,,,,,,,,,,
774,CD008735,Davenport 2007,STD-Davenport-2007 1.031 0.227 34 37,0.0637158143861078,0.475649755659014,71,Hepato-Biliary,efficacy,DICH,1,2,no,2007.0,Infants who did not clear jaundice at six months,Secondary outcomes,0.133955318231646,"negative 
",negative,,,,,,,,,,,,,,,,,
775,CD000377,McDougle 1998,STD-McDougle-1998 0.062 0.926 11 13,-3.4628909506675,1.55233321478941,24,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1998.0,Global effect. No important clinical response - 12 weeks,ANY ANTIPSYCHOTIC DRUG vs PLACEBO,-2.23076522339135,"negative 
",negative,,,,,,,,,,,,,,,,,
776,CD009223,Davies 1977,STD-Davies-1977 0.217 0.925 6 13,-2.81341071676004,1.27801930084539,19,Pregnancy & Childbirth,efficacy,DICH,1,4,yes,1977.0,Satisfaction with pain relief (as defined by trialists),Non-opioid versus same non-opioid in different dose,-2.2013835901375,"neutral 
",neutral,,,,,,,,,,,,,,,,,
777,CD009396,Hollister 1960,STD-Hollister-1960 0.8 0.354 20 20,-0.405465108108164,0.639009650422694,40,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1960.0,Response to treatment - medium term,Comparison 1: TRIFLUOPERAZINE versus LOW-POTENCY ANTIPSYCHOTIC DRUGS,-0.634521102834607,"neutral 
",neutral,,,,,,,,,,,,,,,,,
778,CD003987,Koetsawang 1977,STD-Koetsawang-1977 1.746 0.294 116 112,0.566788518062346,0.300203749979246,228,Gynaecology & Urology,efficacy,DICH,1,42,no,1977.0,Gained >2.5 kg (cycle 12),Lynestrenol 2 mg and EE 40 µg versus lynestrenol 1 mg and EE 40 µg,1.88801278498863,"negative 
",negative,,,,,,,,,,,,,,,,,
779,CD012744,Watanabe 2010,STD-Watanabe-2010 0.17 0.68 16 15,-2.95751106073379,0.955163683531604,31,"Oral Health, Eyes & ENT",efficacy,DICH,1,12,no,2010.0,Xerostomia (grade 2 or above),Polaprezinc versus azulene oral rinse,-3.09633951931542,"negative 
",negative,,,,,,,,,,,,,,,,,
780,CD006283,Mosforth 1958,STD-Mosforth-1958 1.302 0.333 44 42,0.376846302802512,0.473620713981743,86,Neurology,efficacy,DICH,1,1,no,1958.0,Incomplete recovery after 6 and 12 months,Electrostimulation versus control,0.795671075351316,"negative 
",negative,,,,,,,,,,,,,,,,,
781,CD000494,Ghana 2007,STD-Ghana-2007 0.336 1.63 224 226,-1.09416783690769,1.63571256626937,450,Pregnancy & Childbirth,efficacy,DICH,1,6,yes,2007.0,Maternal death,Rectal misoprostol versus injectable uterotonics (subgroups by dose),-0.668924271581037,"negative 
",negative,,,,,,,,,,,,,,,,,
782,CD003527,Wang 1997,STD-Wang-1997 0.444 0.543 30 30,-1.02450431651439,0.668723931971705,60,Spine & Muscles,efficacy,DICH,1,3,yes,1997.0,Still with symptoms after treatment,ACUPUNCTURE PLUS VITAMIN B12 INJECTION VS INJECTION ALONE,-1.53202879025681,"negative 
",negative,,,,,,,,,,,,,,,,,
783,CD001261,Levine 1990ii CHL,STD-Levine-1990ii-CHL 0.351 0.244 35870 33982,-1.04689523972797,0.244263526947672,69852,Infectious Diseases,efficacy,DICH,1,2,no,1990.0,Cumulative incidence of typhoid fever at 2.5 to 3 years,Ty21a vaccine: liquid formulation versus enteric capsules (3 doses),-4.28592533977551,"negative 
",negative,,,,,,,,,,,,,,,,,
784,CD011088,EINSTEIN CHOICE,STD-EINSTEIN-CHOICE 0.281 0.329 921 468,-1.26777576088455,0.329384883269559,1389,Heart & Hypertension,efficacy,DICH,1,2,no,,Recurrent VTE,Extended VTE prophylaxis versus another extended VTE prophylaxis,-3.84891907697853,"negative 
",negative,,,,,,,,,,,,,,,,,
785,CD008846,von Seidlein 2003 GMB,STD-von-Seidlein-2003-GMB 0.971 0.063 769 607,-0.0500587430171507,0.109909825396832,1376,Infectious Diseases,efficacy,DICH,1,3,no,1999.0,Parasitaemia Prevalence: Cluster-randomized trials,MDA versus no MDA in areas of high endemicity (Stratified by study design),-0.455452848154495,"neutral 
",neutral,,,,,,,,,,,,,,,,,
786,CD005497,Hu 2005,STD-Hu-2005 1.195 0.244 974 974,0.17824005502543,0.244327109972114,1948,Gynaecology & Urology,efficacy,DICH,1,1,yes,2005.0,Pregnancy (at twelve-month follow-up),Advance provision vs. standard provision of emergency contraception,0.729514031602032,"negative 
",negative,,,,,,,,,,,,,,,,,
787,CD003281,Nilsson 2015,STD-Nilsson-2015 1.172 0.145 43 52,0.47907692545141,0.443668116782649,95,Anaesthesia & Pain,efficacy,DICH,1,3,no,2015.0,Nausea,Acupoint PC6 stimulation and antiemetic combination vs antiemetic,1.07980922525048,"negative 
",negative,,,,,,,,,,,,,,,,,
788,CD000221,Tulandi 1985,STD-Tulandi-1985 1.378 0.55 37 30,0.329382801650725,0.561877240237881,67,Gynaecology & Urology,efficacy,DICH,1,5,no,1985.0,Pregnancy rate (total),Laser versus electrosurgery for microsurgical salpingostomy,0.586218444283799,"positive 
",positive,,,,,,,,,,,,,,,,,
789,CD007387,Benedetti-Panici 1997,STD-Benedetti_x002d_Panici-1997 2.286 0.258 55 55,1.40475642395963,0.412973457017004,110,Oncology,efficacy,DICH,1,1,no,1997.0,Short-term lymphocyst formation: both asymptomatic and symptomatic within 4 weeks after surgery,Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy,3.40156588780907,"negative 
",negative,,,,,,,,,,,,,,,,,
790,CD009753,ACCORD 2010,STD-ACCORD-2010 0.993 0.12 1757 1745,-0.007393749024938,0.129835675882664,3502,Heart & Hypertension,efficacy,DICH,1,1,yes,2010.0,"Combined CVD death, non-fatal MI, or non-fatal stroke",Fibrates versus placebo,-0.0569469752798914,"negative 
",negative,,,,,,,,,,,,,,,,,
791,CD006580,Moudgil 2000,STD-Moudgil-2000 0.798 0.234 151 143,-0.225646681532328,0.234231176283584,294,Lungs,efficacy,DICH,1,2,yes,2000.0,Asthma exacerbations during follow-up,Adult studies,-0.963350332404674,"negative 
",negative,,,,,,,,,,,,,,,,,
792,CD006055,Wathne 1989,STD-Wathne-1989 0.5 1.148 11 11,-0.798507696217772,1.30809445802324,22,Infectious Diseases,efficacy,DICH,1,12,no,1989.0,Clinical failure,Cefadroxil versus metronidazole,-0.610435807078074,"negative 
",negative,,,,,,,,,,,,,,,,,
793,CD012432,Ristow 2016,STD-Ristow-2016 1.055 0.105 16 18,0.628608659422375,1.27638813323639,34,"Oral Health, Eyes & ENT",efficacy,DICH,1,4,yes,2017.0,Healing of MRONJ (defined as mucosal integrity) at 1 year,Autofluorescence-guided bone surgery (experimental) versus tetracycline fluorescence-guided bone surgery (control) for treatment of MRONJ,0.492490209720523,"positive 
",positive,,,,,,,,,,,,,,,,,
794,CD006546,Akin 2011,STD-Akin-2011 0.589 0.102 2701 480,-0.529350597659895,0.101930459676127,3181,Psychiatry & Mental Health,efficacy,DICH,1,4,no,2011.0,Reunification,Permanency,-5.19325233440377,"positive 
",positive,,,,,,,,,,,,,,,,,
795,CD004039,Descos 1983,STD-Descos-1983 0.131 1.096 59 31,-2.15090050566198,1.14205009362435,90,Hepato-Biliary,efficacy,DICH,1,1,yes,1983.0,All-cause mortality,Plasma expanders versus no plasma expander,-1.88336791675749,"negative 
",negative,,,,,,,,,,,,,,,,,
796,CD005067,Mapar 2010,STD-Mapar-2010 0.231 0.547 18 18,-2.56494935746154,0.822753351207442,36,Skin & Wounds,efficacy,DICH,1,73,yes,2010.0,Participants complete cure,IL metronidazole (2.5 mg to 10 mg each lesion) versus ILMA (150 mg to 600 mg each lesion) for up to 8 weeks,-3.11751918566763,"positive 
",positive,,,,,,,,,,,,,,,,,
797,CD011867,Beard 1963,STD-Beard-1963 1.122 0.149 163 49,0.262453914384625,0.327720296645072,212,Public Health & Work,efficacy,DICH,1,1,no,1963.0,"Obtaining competitive employment, short-term follow-up (= 1 year)",Any intervention to improve obtaining employment compared to another intervention in adults with severe mental illness,0.800847298966251,"positive 
",positive,,,,,,,,,,,,,,,,,
798,CD003964,Kang 2003,STD-Kang-2003 0.679 0.174 22 16,-2.14843441316679,1.12387509897463,38,Kidney & Transplant,efficacy,DICH,1,5,yes,2003.0,Number of patients developing infection,BCG vaccine injection + baseline treatment versus baseline treatment,-1.91163094113119,"negative 
",negative,,,,,,,,,,,,,,,,,
799,CD008738,Durtschi 1982,STD-Durtschi-1982 1.634 0.394 25 26,0.757366773294239,0.598185911019454,51,Skin & Wounds,efficacy,DICH,1,2,no,1982.0,Burn wound infection,Systemic antibiotic prophylaxis (general),1.26610600373971,"negative 
",negative,,,,,,,,,,,,,,,,,
800,CD006949,Arora 1985,STD-Arora-1985 0.952 0.49 7 5,-0.117783035656383,1.19023807142381,12,Skin & Wounds,efficacy,DICH,1,9,no,1985.0,Change in ENL severity (proportion improved),Levamisole versus placebo,-0.0989575434395968,"positive 
",positive,,,,,,,,,,,,,,,,,
801,CD007796,Cao 2010,STD-Cao-2010 1.389 0.17 30 30,1.20397280432594,0.615539510420646,60,Neurology,efficacy,DICH,1,3,yes,2010.0,Global symptom improvement,Chinese herbal medicine vs conventional medicine,1.95596348234928,"positive 
",positive,,,,,,,,,,,,,,,,,
802,CD004425,Maloney 2001,STD-Maloney-2001 1.857 0.176 280 275,0.626396499996132,0.178469161595967,555,Gynaecology & Urology,efficacy,DICH,1,2,no,2001.0,"Clinician assessment of no, minimal or mild acne at cycle 6",NA 1 mg / EE 20-30-35 µg versus placebo,3.50983046255476,"positive 
",positive,,,,,,,,,,,,,,,,,
803,CD000940,Holcomb 1991,STD-Holcomb-1991 1.129 0.165 25 24,0.498991166118988,0.672071924922406,49,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1991.0,Preterm birth,Magnesium versus placebo or no treatment,0.74246691107741,"negative 
",negative,,,,,,,,,,,,,,,,,
804,CD006066,Lund 1994,STD-Lund-1994 1.288 0.216 2029 2015,0.258767563747773,0.221067223013864,4044,Pregnancy & Childbirth,efficacy,DICH,1,9,yes,1994.0,Caesarean section (main outcome),Continuous CTG versus intermittent CTG,1.17053790344824,"negative 
",negative,,,,,,,,,,,,,,,,,
805,CD001880,Hoikka 1980,STD-Hoikka-1980 2.842 0.747 19 18,1.30625165344635,0.897825007220084,37,Emergency & Trauma,efficacy,DICH,1,6,no,1980.0,Participants with complications at end of study,Vitamin D versus control or lower dose supplementation,1.45490673899903,"negative 
",negative,,,,,,,,,,,,,,,,,
806,CD010683,Capussotti 2012,STD-Capussotti-2012 0.969 1.436 33 32,-0.0317486983145803,1.43649158177698,65,Hepato-Biliary,efficacy,DICH,1,1,yes,2012.0,Mortality (perioperative),Anterior approach vs conventional approach,-0.0221015554266641,"negative 
",negative,,,,,,,,,,,,,,,,,
807,CD006750,Andres 2009,STD-Andres-2009 5.256 1.533 38 40,1.71342762595815,1.56591462675928,78,Kidney & Transplant,efficacy,DICH,1,4,yes,2009.0,Death,Low dose CNI versus standard dose CNI,1.09420245310828,"negative 
",negative,,,,,,,,,,,,,,,,,
808,CD006055,Eriksson 2005,STD-Eriksson-2005 0.897 0.122 91 96,-0.267879445155601,0.298416299122048,187,Infectious Diseases,efficacy,DICH,1,6,no,2005.0,Clinical cure 1,Clindamycin ovule + lactobacilli versus clindamycin ovule alone,-0.897670287929021,"positive 
",positive,,,,,,,,,,,,,,,,,
809,CD001132,Khaw 2002,STD-Khaw-2002 0.633 0.161 182 186,-0.660811799917009,0.229681973073712,368,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,yes,2002.0,Failure at 12 months,"Regular dose intraoperative 5-Fluorouracil (5-FU) versus placebo or control, primary trabeculectomy",-2.8770729851965,"negative 
",negative,,,,,,,,,,,,,,,,,
810,CD005341,Clift 1978,STD-Clift-1978 0.456 1.615 29 40,-0.806701880106808,1.65102435701222,69,Oncology,efficacy,DICH,1,1,yes,1978.0,All-cause mortality up to 30 days,Prophylactic granulocytes versus no prophylactic granulocytes,-0.488606892248796,"negative 
",negative,,,,,,,,,,,,,,,,,
811,CD001744,NOTT 1980,STD-NOTT-1980 0.529 0.38 101 102,-0.653803002995124,0.393108146724163,203,Lungs,efficacy,DICH,1,1,yes,1980.0,Mortality,Continuous oxygen therapy versus nocturnal oxygen therapy,-1.66316319934699,"negative 
",negative,,,,,,,,,,,,,,,,,
812,CD001360,O'Brien 1972,STD-O_x0027_Brien-1972 1.071 0.313 50 50,0.0971637484536477,0.440958551844098,100,Psychiatry & Mental Health,efficacy,DICH,1,4,no,1972.0,Global impression: 1. Returned to hospital (long term),INDIVIDUAL PSYCHODYNAMIC PSYCHOTHERAPY versus GROUP PSYCHOTHERAPY,0.220346669879304,"negative 
",negative,,,,,,,,,,,,,,,,,
813,CD003992,Cornely 2003,STD-Cornely-2003 3 1.599 17 17,1.15745278869104,1.66865682044439,34,Oncology,efficacy,DICH,1,1,no,2003.0,Mortality,Oral versus intravenous antibiotic therapy,0.693643398996082,"negative 
",negative,,,,,,,,,,,,,,,,,
814,CD009015,Baykara 1998,STD-Baykara-1998 8.143 1.136 20 20,2.09714111877924,1.13610158746593,40,Anaesthesia & Pain,efficacy,DICH,1,1,yes,1998.0,Nausea and vomiting,Induction and maintenance: sevoflurane + nitrous oxide (N2O) versus propofol + N2O,1.84590985693181,"negative 
",negative,,,,,,,,,,,,,,,,,
815,CD002003,AASK 2002,STD-AASK-2002 1.438 0.31 441 217,0.391820234162382,0.332599183341208,658,Heart & Hypertension,efficacy,DICH,1,3,yes,2002.0,Mortality,Beta-blocker versus calcium-channel blocker (CCB),1.17805531037766,"negative 
",negative,,,,,,,,,,,,,,,,,
816,CD003575,Fine 1999,STD-Fine-1999 10.8 1.362 4 5,4.59511985013459,2.0985805688704,9,Gastroenterology,efficacy,DICH,1,1,no,1999.0,Clinical response,Bismuth subsalicylate versus placebo,2.18963232496144,"neutral 
",neutral,,,,,,,,,,,,,,,,,
817,CD009029,McKenzie 2008,STD-McKenzie-2008 1.014 0.164 17 16,0.0741079721537216,0.902783647956871,33,Infectious Diseases,efficacy,DICH,1,5,no,2008.0,ETEC diarrhoea,Live attenuated ETEC vaccine (PTL-003) versus placebo,0.0820882969263329,"negative 
",negative,,,,,,,,,,,,,,,,,
818,CD008844,Ellis 2006,STD-Ellis-2006 0.179 1.564 12 6,-1.91959284073794,1.71128163914794,18,Heart & Hypertension,efficacy,DICH,1,1,yes,2006.0,Mortality,GCSF versus placebo,-1.12172818127922,"negative 
",negative,,,,,,,,,,,,,,,,,
819,CD010140,Langgartner 2004,STD-Langgartner-2004 0.19 0.739 43 45,-1.89195963432657,0.802939038481386,88,Skin & Wounds,efficacy,DICH,1,8,yes,2004.0,Catheter colonisation,Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus chlorhexidine (in alcohol),-2.35629299816443,"negative 
",negative,,,,,,,,,,,,,,,,,
820,CD004834,Correia 1996,STD-Correia-1996 1.22 0.131 15 16,2.08406048753613,1.55701781904403,31,Skin & Wounds,efficacy,DICH,1,23,yes,1996.0,Complete cure,IMAS for 20 days versus IMMA for 20 days in L. braziliensis; FU: 1 year,1.33849494979813,"positive 
",positive,,,,,,,,,,,,,,,,,
821,CD009069,"Phase2 trial (ph2,2v)",STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_ 0.063 0.588 193 175,-3.02680997659957,0.607805941693001,368,Oncology,efficacy,DICH,1,4,no,2003.0,"Incident HPV16/18 infection, 3 doses",Infection with HPV vaccine types in hrHPV DNA negative women at baseline,-4.97989533989845,"negative 
",negative,,,,,,,,,,,,,,,,,
822,CD003431,Colak 2003,STD-Colak-2003 1.111 0.489 37 52,0.105360515657827,0.489490694090439,89,Gastroenterology,efficacy,DICH,1,5,yes,2003.0,NON - Healing,GTN versus Patch GTN,0.215245186333124,"negative 
",negative,,,,,,,,,,,,,,,,,
823,CD004185,Alves 1999,STD-Alves-1999 3.086 0.624 47 40,1.12678316563481,0.624245576422084,87,Psychiatry & Mental Health,efficacy,DICH,1,4,no,1999.0,Failure to respond - HDRS (-50%),Fluoxetine versus SNRIs,1.80503187878889,"negative 
",negative,,,,,,,,,,,,,,,,,
824,CD002251,Pouliou 2006,STD-Pouliou-2006 0.75 0.281 30 30,-0.538996500732687,0.522319308773341,60,Pregnancy & Childbirth,efficacy,DICH,1,23,yes,2006.0,Women with hypotension requiring intervention,Ephedrine: IM vs IV,-1.03192911247817,"negative 
",negative,,,,,,,,,,,,,,,,,
825,CD002071,Heinz 1996,STD-Heinz-1996 8.333 1.66 6 7,2.12026353620009,1.65998661306516,13,Heart & Hypertension,efficacy,DICH,1,9,no,1996.0,"Early occlusion, 72 hours",Taprostene versus ASA/DIP,1.27727749098231,"negative 
",negative,,,,,,,,,,,,,,,,,
826,CD006784,Rodriguez 1989,STD-Rodriguez-1989 0.21 0.42 49 24,-2.30591288308672,0.601124822352834,73,Infectious Diseases,efficacy,DICH,1,1,yes,1987.0,Diarrhoea on follow up,Antibiotic versus no drug or placebo,-3.83599678027145,"negative 
",negative,,,,,,,,,,,,,,,,,
827,CD000314,Vang Hansen 1998,STD-Vang-Hansen-1998 1.125 0.427 37 37,0.152874355467654,0.553451131940379,74,Emergency & Trauma,efficacy,DICH,1,19,no,1998.0,Pain (mild with stenuous use),Early mobilisation (3-4 weeks) versus 5-6 weeks plaster immobilisation,0.276220151419118,"negative 
",negative,,,,,,,,,,,,,,,,,
828,CD004767,Ormerod 1999,STD-Ormerod-1999 3.5 0.532 16 14,2.39789527279837,0.870388279778489,30,Skin & Wounds,efficacy,DICH,1,15,no,1999.0,Primary outcome: short-term clinical cure (up to 3 months after start of treatment),Topical: 5% sodium nitrite in 5% salicylic acid versus 5% salicylic acid alone,2.75497192288553,"positive 
",positive,,,,,,,,,,,,,,,,,
829,CD007356,Greenwald 2011 (TAME),STD-Greenwald-2011-_x0028_TAME_x0029_ 1.818 0.589 33 18,0.776528789498997,0.737209780774486,51,Spine & Muscles,efficacy,DICH,1,5,yes,2011.0,ACR 20,Benefits - RTX (2 x 500 mg) + MTX + TNFi versus MTX + TNFi,1.0533348983558,"positive 
",positive,,,,,,,,,,,,,,,,,
830,CD006115,Davidson 1999,STD-Davidson-1999 0.739 0.302 95 87,-0.302432882209929,0.30217235480071,182,Psychiatry & Mental Health,efficacy,DICH,1,5,no,1999.0,CGI,Buspirone vs Venlafaxine XR,-1.00086218148378,"neutral 
",neutral,,,,,,,,,,,,,,,,,
831,CD005002,Bordeaux 1991,STD-Bordeaux-1991 1.85 0.425 49 136,0.701244390792564,0.490701633749883,185,Oncology,efficacy,DICH,1,4,yes,1991.0,Loco-regional recurrence,Preoperative vs postoperative chemotherapy (Subgroup Local treatment),1.42906471583096,"negative 
",negative,,,,,,,,,,,,,,,,,
832,CD004767,Al-Mutairi 2010,STD-Al_x002d_Mutairi-2010 0.6 0.136 37 37,-3.94481282825113,1.46137854101645,74,Skin & Wounds,efficacy,DICH,1,2,no,2010.0,Primary outcome: short-term clinical cure (up to 3 months after start of treatment),Topical: 5% imiquimod versus cryospray,-2.69937782547933,"positive 
",positive,,,,,,,,,,,,,,,,,
833,CD001824,Serrao 1992,STD-Serrao-1992 0.714 0.447 14 14,-0.587786664902119,0.772544753930409,28,Spine & Muscles,efficacy,DICH,1,2,no,1992.0,General improvement at 2 months,epidural corticosteroid injections versus other treatments,-0.760844807904898,"positive 
",positive,,,,,,,,,,,,,,,,,
834,CD004252,Berry 1988b,STD-Berry-1988b 0.839 0.166 57 51,-0.41593640797546,0.392749219372539,108,Spine & Muscles,efficacy,DICH,1,4,no,1988.0,Pain (dichotomous),Non-benzodiazepines + analgesics/NSAIDs versus placebo + analgesics/NSAIDs for acute low back pain,-1.059038153252,"negative 
",negative,,,,,,,,,,,,,,,,,
835,CD001384,Chay 1992,STD-Chay-1992 2 0.548 10 10,1.25276296849537,0.944911182523068,20,Lungs,efficacy,DICH,1,1,no,1992.0,Reduction of bronchodilator use,Ketotifen versus Placebo,1.32579970653992,"positive 
",positive,,,,,,,,,,,,,,,,,
836,CD012150,Rahman 2015,STD-Rahman-2015 1.07 0.191 191 143,0.0900462806847837,0.254799698610984,334,Public Health & Work,efficacy,DICH,1,4,yes,2015.0,"Anaemia (as defined by trialists), randomised studies",Wheat flour or wheat flour products fortified with folic acid plus other vitamins and minerals versus unfortified wheat flours or wheat flour products (not containing folic acid nor any other vitamins and minerals),0.353400263719551,"negative 
",negative,,,,,,,,,,,,,,,,,
837,CD005939,Spinapolice 1983,STD-Spinapolice-1983 0.053 1.41 16 16,-3.73289633953071,1.51631215514291,32,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1983.0,Pre-eclampsia,Rest alone versus unrestricted activity,-2.46182577041922,"negative 
",negative,,,,,,,,,,,,,,,,,
838,CD000340,Kenny 2001,STD-Kenny-2001 0.485 0.208 84 87,-1.1973600792829,0.328420726290669,171,Emergency & Trauma,efficacy,DICH,1,13,no,2001.0,Number of participants with syncope,Cardiac pacing vs control,-3.64581155643378,"negative 
",negative,,,,,,,,,,,,,,,,,
839,CD007006,McBride 2000b,STD-McBride-2000b 0.954 0.409 61 41,-0.0475889628237978,0.40929593585986,102,Infectious Diseases,efficacy,DICH,1,10,yes,2000.0,Intercourse in past month - 6m,McBride 2000b: A+ vs. No Treatment,-0.116270303842186,"neutral 
",neutral,,,,,,,,,,,,,,,,,
840,CD009412,Lim 2010,STD-Lim-2010 1.043 0.097 62 62,0.184773540041241,0.430435247859339,124,Psychiatry & Mental Health,efficacy,DICH,1,1,no,2007.0,Specific behaviour: 1a. Agitation - Various measures,RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL,0.429271396708717,"negative 
",negative,,,,,,,,,,,,,,,,,
841,CD001754,Hilton 1989,STD-Hilton-1989 0.5 1.14 10 10,-0.810930216216329,1.31761569173682,20,Gynaecology & Urology,efficacy,DICH,1,6,yes,1989.0,"Number with incontinence (worse, unchanged or improved) within the first year (women's observations)",Sling versus bladder neck (needle) suspension,-0.615452761607138,"negative 
",negative,,,,,,,,,,,,,,,,,
842,CD004473,Gao 1996,STD-Gao-1996 1.067 0.242 105 42,0.102278849120418,0.379589671999014,147,Heart & Hypertension,efficacy,DICH,1,1,yes,1996.0,ECG improvement,Suxiao jiuxin wan vs nitroglycerin (xiaoxintong),0.26944581653603,"positive 
",positive,,,,,,,,,,,,,,,,,
843,CD011445,Sims 1978,STD-Sims-1978 0.83 0.223 46 42,-0.357674444271816,0.428854385445787,88,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1978.0,Birth < 48 hours after trial entry,Ethanol versus other tocolytic drug,-0.834023054002396,"negative 
",negative,,,,,,,,,,,,,,,,,
844,CD010109,Cui 2009,STD-Cui-2009 0.768 0.261 25 24,-0.590868331439527,0.581407076009734,49,Emergency & Trauma,efficacy,DICH,1,1,yes,2009.0,All-cause mortality at the end of the follow-up period,All-cause mortality at the end of the follow-up period,-1.01627303110022,"negative 
",negative,,,,,,,,,,,,,,,,,
845,CD005288,Miao 2001,STD-Miao-2001 2.676 0.553 36 17,1.42921940583692,0.718482437587056,53,Gynaecology & Urology,efficacy,DICH,1,4,no,2001.0,Reduction of pain,Chinese herbal medicine versus acupuncture,1.98921968174588,"positive 
",positive,,,,,,,,,,,,,,,,,
846,CD003212,Barrington 2001,STD-Barrington-2001 0.333 0.509 27 27,-1.52605630349505,0.665941634732027,54,Neonatal,efficacy,DICH,1,1,yes,2001.0,Respiratory failure post extubation,NIPPV versus NCPAP to prevent extubation failure,-2.29157665462549,"negative 
",negative,,,,,,,,,,,,,,,,,
847,CD004685,Friedlander 2002,STD-Friedlander-2002 0.863 0.171 115 62,-0.268953087345504,0.316768116768394,177,Skin & Wounds,efficacy,DICH,1,4,yes,2002.0,"Primary outcome: complete cure, i.e. clinical and mycological cure","Terbinafine, short-term versus long-term for treating Trichophyton and Microsporum infections; 12-20 weeks follow-up",-0.849053528774645,"positive 
",positive,,,,,,,,,,,,,,,,,
848,CD004705,Audrain 1997,STD-Audrain-1997 0.764 0.282 156 137,-0.316218379716716,0.331063637191699,293,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1997.0,Smoking cessation - feedback on smoking exposure,All interventions,-0.955158900563918,"positive 
",positive,,,,,,,,,,,,,,,,,
849,CD004584,Ding 2004,STD-Ding-2004 1.239 0.119 62 58,0.760475465728288,0.414701476769082,120,Neurology,efficacy,DICH,1,1,yes,2004.0,Improvement,Effects,1.83379010765313,"positive 
",positive,,,,,,,,,,,,,,,,,
850,CD006325,Jaffe 1985,STD-Jaffe-1985 0.444 0.477 15 15,-1.41706601978664,0.786566506207116,30,Oncology,efficacy,DICH,1,1,no,1985.0,Response rate,MTX versus cisplatin,-1.80158449235252,"neutral 
",neutral,,,,,,,,,,,,,,,,,
851,CD003244,Van Rensburg 2001,STD-Van-Rensburg-2001 0.802 0.213 177 173,-0.276719685799583,0.266927450690872,350,Gastroenterology,efficacy,DICH,1,9,no,2001.0,Oesophagitis persists at eight weeks,Pantoprazole versus pantoprazole plus cisapride,-1.03668500591965,"negative 
",negative,,,,,,,,,,,,,,,,,
852,CD005535,Aubier 1999a,STD-Aubier-1999a 0.347 0.57 171 83,-1.11772668469143,0.60169687881817,254,Lungs,efficacy,DICH,1,1,no,1999.0,# patients with exacerbations requiring oral steroids,Long-acting beta2 versus placebo: both groups receiving similar dose ICS,-1.85762420255,"negative 
",negative,,,,,,,,,,,,,,,,,
853,CD000218,Barnes 1957,STD-Barnes-1957 0.593 0.234 25 21,-1.52696169060986,0.684894108361413,46,Infectious Diseases,efficacy,DICH,1,26,no,1957.0,No parasitological cure,Oral plus intravaginal versus intravaginal,-2.22948580221119,"negative 
",negative,,,,,,,,,,,,,,,,,
854,CD003031,Bajaj 2005,STD-Bajaj-2005 0.36 0.291 30 30,-2.4567357728213,0.631450836352411,60,Neurology,efficacy,DICH,1,8,yes,2005.0,Recurrent seizure @ 6 months,Intermittent oral clobazam versus placebo,-3.89062082332916,"negative 
",negative,,,,,,,,,,,,,,,,,
855,CD003809,Sonesson 2019,STD-Sonesson-2019 0.973 0.23 75 73,-0.0408219945202553,0.347610893576904,148,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,yes,2019.0,Number of participants with new DLs,Professionally-applied F varnish versus non-F (placebo) varnish,-0.117435889595399,"negative 
",negative,,,,,,,,,,,,,,,,,
856,CD010266,Tan 2011,STD-Tan-2011 -0.143 0.125 21 21,-0.8754687373539,0.788810637746615,42,Skin & Wounds,efficacy,DICH,1,4,yes,2011.0,Surgical site infection,Amoxicillin versus ampicillin,-1.10985919238468,"negative 
",negative,,,,,,,,,,,,,,,,,
857,CD012975,Paraiso 2006,STD-Paraiso-2006 0.855 0.619 29 31,-0.183922838160928,0.726953601312724,60,Gynaecology & Urology,efficacy,DICH,1,2,yes,2006.0,Awareness of prolapse (subjective failure),Site-specific repair versus midline fascial plication,-0.253004920573752,"negative 
",negative,,,,,,,,,,,,,,,,,
858,CD004293,Koshisawa 1993,STD-Koshisawa-1993 0.743 0.566 46 41,-0.340545562008849,0.647787263799262,87,Kidney & Transplant,efficacy,DICH,1,13,yes,1993.0,50% increase in serum creatinine,Mizoribine versus other treatments,-0.525705862155354,"negative 
",negative,,,,,,,,,,,,,,,,,
859,CD003412,Sterry 2002,STD-Sterry-2002 0.756 0.289 54 49,-0.411895998438455,0.424407012641611,103,Skin & Wounds,efficacy,DICH,1,22,no,2002.0,Early treatment failure within 6 months measured histologically,Imiquimod 5% cream with and without occlusion for sBCC,-0.97052118878695,"negative 
",negative,,,,,,,,,,,,,,,,,
860,CD010061,Asbagh 2015,STD-Asbagh-2015 0.5 0.5 16 16,-1.09861228866811,0.763762615825973,32,Neonatal,efficacy,DICH,1,2,yes,2015.0,Failure of ductal closure after 4 to 5 days of treatment,Prophylactic administration of paracetamol (oral or IV) versus placebo (IV) or no intervention,-1.43842113492294,"negative 
",negative,,,,,,,,,,,,,,,,,
861,CD007125,Crotty 2003,STD-Crotty-2003 0.627 0.597 34 32,-0.548565951748838,0.698900234984607,66,Emergency & Trauma,efficacy,DICH,1,2,yes,2002.0,"'Poor outcome', mortality, institutional care and unable to walk (12 months)",Accelerated discharge and multidisciplinary home-based rehabilitation versus usual inpatient rehabilitation,-0.784898794261988,"negative 
",negative,,,,,,,,,,,,,,,,,
862,CD001933,Roland 2003,STD-Roland-2003 0.574 0.296 103 98,-0.554996842079128,0.296333629667111,201,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,2003.0,Number of subjects without resolution of symptoms at 8 days,Topical ciprofloxacin and topical dexamethasone vs topical ciprofloxacin,-1.87287835910689,"negative 
",negative,,,,,,,,,,,,,,,,,
863,CD006602,Feltes 2003,STD-Feltes-2003 0.547 0.205 639 648,-0.650390812574356,0.22056081893728,1287,Lungs,efficacy,DICH,1,1,no,2003.0,Hospitalisation for RSV infection,Palivizumab versus placebo,-2.94880484987366,"negative 
",negative,,,,,,,,,,,,,,,,,
864,CD012189,Beautrais 2010,STD-Beautrais-2010 0.873 0.251 153 174,-0.136143363073175,0.250641414636315,327,Psychiatry & Mental Health,efficacy,DICH,1,5,yes,2010.0,Repetition of SH at post-intervention,Remote contact interventions vs treatment as usual (TAU),-0.543179838298954,"negative 
",negative,,,,,,,,,,,,,,,,,
865,CD003080,Bond-Indiana,STD-Bond_x002d_Indiana 0.892 0.104 43 43,-0.625235974943734,0.569207101147486,86,Psychiatry & Mental Health,efficacy,DICH,1,8,no,1995.0,Not in competitive employment,SUPPORTED EMPLOYMENT (ALL APPROACHES) versus PRE-VOCATIONAL TRAINING,-1.09843319537528,"negative 
",negative,,,,,,,,,,,,,,,,,
866,CD011334,Ashby 2012,STD-Ashby-2012 3 1.543 6 6,1.26566637333128,1.73272357931985,12,Skin & Wounds,efficacy,DICH,1,2,yes,2012.0,Proportion of wounds healed,NPWT compared with standard dressings: medium-term follow-up,0.730449096692093,"positive 
",positive,,,,,,,,,,,,,,,,,
867,CD002147,Colin 1987,STD-Colin-1987 0.618 0.694 27 27,-0.496436886313891,0.712575592590203,54,Hepato-Biliary,efficacy,DICH,1,2,no,1987.0,Mortality,Terlipressin versus balloon tamponade,-0.696679610522933,"negative 
",negative,,,,,,,,,,,,,,,,,
868,CD004389,Alvarez 2006,STD-Alvarez-2006 2.626 0.289 65 64,1.43556541012667,0.40511372831235,129,Infectious Diseases,efficacy,DICH,1,2,no,2006.0,P. vivax parasitaemia > 30 days after starting primaquine,Primaquine: 3 days versus 14 days,3.54361086726694,"negative 
",negative,,,,,,,,,,,,,,,,,
869,CD010031,Arca 2002,STD-Arca-2002 0.784 0.249 17 16,-0.741937344729377,0.75907211527659,33,Skin & Wounds,efficacy,DICH,1,1,yes,2002.0,Clinical cure,Azole versus terbinafine,-0.977426689503712,"positive 
",positive,,,,,,,,,,,,,,,,,
870,CD006069,Moya 2005,STD-Moya-2005 0.803 0.144 527 258,-0.279283962675856,0.183879050273917,785,Neonatal,efficacy,DICH,1,1,no,2005.0,Mortality at 28 days,Protein containing synthetic surfactant vs animal derived sufactant (all patients),-1.51884601459393,"negative 
",negative,,,,,,,,,,,,,,,,,
871,CD008121,Keitner 2009,STD-Keitner-2009 0.441 0.446 64 33,-0.818310323513951,0.446216017644876,97,Psychiatry & Mental Health,efficacy,DICH,1,9,no,2009.0,No clinically important response (as defined by original study),Risperidone added to antidepressants versus placebo added to antidepressants for major depression,-1.8338882764294,"negative 
",negative,,,,,,,,,,,,,,,,,
872,CD009665,Dahlof 1998,STD-Dahlof-1998 3.168 0.304 47 63,1.76692254608112,0.442967771085489,110,Anaesthesia & Pain,efficacy,DICH,1,2,no,1998.0,Pain-free at 2 h,Subcutaneous sumatriptan 6 mg versus placebo,3.98882867200764,"positive 
",positive,,,,,,,,,,,,,,,,,
873,CD003774,Hertz 1998 Heart/lung,STD-Hertz-1998-Heart_x002f_lung 0.578 0.301 37 35,-0.91735967906306,0.493710152151999,72,Kidney & Transplant,efficacy,DICH,1,8,yes,1998.0,IV doses given at different frequencies,Different ganciclovir regimens,-1.85809361031861,"neutral 
",neutral,,,,,,,,,,,,,,,,,
874,CD004539,Leaper 1987,STD-Leaper-1987 0.096 1.545 24 19,-2.34122288569946,1.54503613965854,43,Gastroenterology,efficacy,DICH,1,6,yes,1987.0,Mortality (all causes),"Broad spectrum penicillins, aminoglycosides and antianaerobes versus other regimens",-1.51531917319221,"negative 
",negative,,,,,,,,,,,,,,,,,
875,CD000324,Fujishita 1995b,STD-Fujishita-1995b 5.964 0.772 14 12,2.01490302054227,0.891316130474729,26,Gynaecology & Urology,efficacy,DICH,1,12,no,1995.0,primary treatment success,MTX in lipiodol suspensions versus MTX in saline both under laparoscopic guidance,2.26059301705793,"positive 
",positive,,,,,,,,,,,,,,,,,
876,CD001338,Dallenbach 2003 (T),STD-Dallenbach-2003-_x0028_T_x0029_ 1.158 0.17 100 100,0.248386168501818,0.28814794345295,200,Pregnancy & Childbirth,efficacy,DICH,1,5,yes,2003.0,Vaginal delivery not achieved within 24 hours,Oral misoprostol versus vaginal PG (2): all women,0.862009166282235,"negative 
",negative,,,,,,,,,,,,,,,,,
877,CD006761,Thorbeck 2002,STD-Thorbeck-2002 0.193 1.561 56 56,-1.6454778489173,1.56078433452462,112,Gastroenterology,efficacy,DICH,1,4,no,2002.0,Symptoms of incontinence at follow-up,Incontinence,-1.05426343186516,"negative 
",negative,,,,,,,,,,,,,,,,,
878,CD001209,Bailey 1971,STD-Bailey-1971 0.2 0.566 25 25,-2.39789527279837,0.738548945875996,50,Kidney & Transplant,efficacy,DICH,1,1,no,1971.0,Patients with at least one microbiological recurrence during prophylaxis,Antibiotic versus placebo,-3.2467655477515,"negative 
",negative,,,,,,,,,,,,,,,,,
879,CD007114,Mourits 2000,STD-Mourits-2000 1.933 0.314 30 29,1.20397280432594,0.547722557505166,59,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,yes,2000.0,Success - composite outcomes score,Radiotherapy versus other intervention or sham radiotherapy,2.19814354517356,"positive 
",positive,,,,,,,,,,,,,,,,,
880,CD006613,Blair 1986,STD-Blair-1986 5.4 1.524 24 26,1.7730673362159,1.57549366660138,50,Gastroenterology,efficacy,DICH,1,1,yes,1986.0,Mortality,Transfusion vs no transfusion,1.12540429314497,"negative 
",negative,,,,,,,,,,,,,,,,,
881,CD007249,Davidson 2015,STD-Davidson-2015 1.372 0.292 96 95,0.316310720083372,0.292116721517679,191,Gynaecology & Urology,efficacy,DICH,1,17,no,2015.0,Any LARC initiation (immediate),Theory-based video versus control video,1.08282305251132,"neutral 
",neutral,,,,,,,,,,,,,,,,,
882,CD009065,Zhang 2012,STD-Zhang-2012 1.231 0.104 34 34,1.59393372589814,0.833493574337282,68,Emergency & Trauma,efficacy,DICH,1,6,yes,2012.0,Cure rate (30 days),Acupuncture plus electrophysiotherapy versus electrophysiotherapy alone,1.912352746289,"positive 
",positive,,,,,,,,,,,,,,,,,
883,CD000163,Ghahiry 2012,STD-Ghahiry-2012 1 0.189 52 60,0.0,0.378932373372537,112,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2012.0,Postoperative adhesions,Non-closure of both parietal and visceral peritoneum versus closure of both peritoneal layers,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
884,CD004125,Aasboe 1998,STD-Aasboe-1998 0.281 0.515 38 40,-1.62924053973028,0.621352099354745,78,Anaesthesia & Pain,efficacy,DICH,1,1,no,1998.0,Nausea,PRIMARY ANALYSIS: Placebo versus Drug,-2.62208905614417,"negative 
",negative,,,,,,,,,,,,,,,,,
885,CD009613,Hanson 1984,STD-Hanson-1984 1.193 0.55 54 46,0.199896701615462,0.623316919796232,100,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1984.0,Hypertensive disorders of pregnancy,Self-monitoring at home versus hospitalisation,0.320698340229253,"negative 
",negative,,,,,,,,,,,,,,,,,
886,CD008106,Bitar 2012,STD-Bitar-2012 0.096 1.457 21 18,-2.59112886304331,1.52895368385395,39,Emergency & Trauma,efficacy,DICH,1,1,yes,2012.0,Number of participants sustaining recurrent patellar dislocation,Surgical versus non-surgical management,-1.69470723044532,"negative 
",negative,,,,,,,,,,,,,,,,,
887,CD003594,Kleinknecht 1980,STD-Kleinknecht-1980 1 0.447 15 15,0.0,0.74535599249993,30,Kidney & Transplant,efficacy,DICH,1,10,yes,1980.0,Complete remission,Chlorambucil versus indomethacin,0.0,"positive 
",positive,,,,,,,,,,,,,,,,,
888,CD011501,Biton 2014,STD-Biton-2014 1.312 0.3 99 99,0.334065496590648,0.367406795270099,198,Neurology,efficacy,DICH,1,1,no,2014.0,50% or greater reduction in seizure frequency (responder rate),Brivaracetam vs placebo,0.909252362480284,"positive 
",positive,,,,,,,,,,,,,,,,,
889,CD000551,Battezzati 1993,STD-Battezzati-1993 0.333 1.619 44 44,-1.12134053974567,1.64685369190045,88,Hepato-Biliary,efficacy,DICH,1,2,yes,1993.0,Mortality - completed patient's course plus case scenarios,Influence of missing data - UDCA versus placebo or no intervention,-0.680898701117553,"negative 
",negative,,,,,,,,,,,,,,,,,
890,CD002752,Aldamiz-Echevarria 2007,STD-Aldamiz_x002d_Echevarria-2007 1.086 0.281 137 142,0.0973784328683839,0.331713291951684,279,Heart & Hypertension,efficacy,DICH,1,1,no,2007.0,All-cause mortality - main analysis,Case management vs usual care,0.293562046595852,"negative 
",negative,,,,,,,,,,,,,,,,,
891,CD008831,Chen 2014,STD-Chen-2014 0.5 0.428 30 30,-0.980829253011726,0.58925565098879,60,Oncology,efficacy,DICH,1,2,yes,2014.0,Any diarrhoea,Probiotics versus placebo for prevention of diarrhoea induced by chemotherapy alone,-1.66452243837775,"negative 
",negative,,,,,,,,,,,,,,,,,
892,CD009992,Dobson 1991,STD-Dobson-1991 2.562 0.286 34 28,2.28765944277737,0.605081517185438,62,Skin & Wounds,efficacy,DICH,1,3,no,1991.0,Mycological cure,Naftifine 1% cream once or twice daily versus placebo cream once or twice daily,3.78074586283599,"positive 
",positive,,,,,,,,,,,,,,,,,
893,CD003470,Marchese 1998,STD-Marchese-1998 0.455 0.424 18 18,-1.40749656877049,0.714625293905352,36,Emergency & Trauma,efficacy,DICH,1,2,yes,1998.0,Clinical results: number of patients who are reasonably to very satisfied after 2 months,NSAIDs: Tenoxicam (oral) versus laser therapy,-1.96955884541768,"positive 
",positive,,,,,,,,,,,,,,,,,
894,CD006077,Becker 2005,STD-Becker-2005 0.961 0.172 251 255,-0.0510769248274994,0.217802004216509,506,Spine & Muscles,efficacy,DICH,1,3,no,2005.0,Acute gout attacks,Allopurinol versus febuxostat,-0.234510811832226,"negative 
",negative,,,,,,,,,,,,,,,,,
895,CD003940,Vazquez 2006,STD-Vazquez-2006 1.324 0.66 135 143,-0.290083033989319,0.681825895882977,278,Infectious Diseases,efficacy,DICH,1,16,no,2006.0,Clinical cure,Treatment: Posaconazole vs Fluconazole,-0.425450302989235,"positive 
",positive,,,,,,,,,,,,,,,,,
896,CD008687,Cioffi 1994,STD-Cioffi-1994 0.143 1.499 50 50,-2.00715377429603,1.52530944319218,100,Gastroenterology,efficacy,DICH,1,15,yes,1994.0,Clinically important upper GI bleeding,H2 receptor antagonist + antacids versus sucralfate,-1.31589939553212,"negative 
",negative,,,,,,,,,,,,,,,,,
897,CD009951,Laitinen 2008,STD-Laitinen-2008 0.384 0.447 38 73,-1.23474446299269,0.539570536293786,111,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2008.0,Diagnosis of gestational diabetes,Primary maternal and infant outcomes: probiotics versus placebo or diet,-2.28838377920694,"negative 
",negative,,,,,,,,,,,,,,,,,
898,CD001118,Orleans 2000,STD-Orleans-2000 1.059 0.14 216 219,0.0837182662595588,0.205692629123224,435,Psychiatry & Mental Health,efficacy,DICH,1,5,no,2000.0,Long-term abstinence,Self-help plus NRT vs NRT alone,0.407006641980379,"positive 
",positive,,,,,,,,,,,,,,,,,
899,CD004389,Leslie 2008,STD-Leslie-2008 5.227 1.502 74 55,1.69259572010774,1.52240543802179,129,Infectious Diseases,efficacy,DICH,1,4,no,2008.0,P. vivax parasitaemia > 30 days after starting primaquine,Primaquine: weekly for 8 weeks versus daily for 14 days,1.11179037977367,"negative 
",negative,,,,,,,,,,,,,,,,,
900,CD004510,Al-Asseri 2001,STD-Al_x002d_Asseri-2001 2.667 0.243 36 36,2.77258872223978,0.637377439199098,72,Public Health & Work,efficacy,DICH,1,2,no,2001.0,Effect of TFU on compliance in cardiac surgery patients compared to usual care,Effect of TFU on compliance,4.34999507626705,"neutral 
",neutral,,,,,,,,,,,,,,,,,
901,CD012314,Han 1995,STD-Han-1995 1.102 0.256 50 58,0.152305660853689,0.401503963787634,108,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,yes,1995.0,BCVA: loss of 15 or more ETDRS letters,Diode versus argon laser,0.379337876062034,"negative 
",negative,,,,,,,,,,,,,,,,,
902,CD011680,Bulger 2014,STD-Bulger-2014 0.344 0.937 32 11,-1.20397280432594,1.06978710239208,43,Skin & Wounds,efficacy,DICH,1,2,yes,2014.0,Mortality within 30 days,AB 103 versus placebo,-1.12543215527072,"negative 
",negative,,,,,,,,,,,,,,,,,
903,CD009836,ALTS 2003,STD-ALTS-2003 1.341 0.124 673 675,0.35071932265361,0.148175474691467,1348,Oncology,efficacy,DICH,1,1,yes,2003.0,Occurrence of CIN2+,Occurence of CIN2+ at different lengths of follow-up: immediate colposcopy versus cytological surveillance,2.36691883986796,"negative 
",negative,,,,,,,,,,,,,,,,,
904,CD002249,Homburg 2012,STD-Homburg-2012 0.676 0.239 143 159,-0.391324079351906,0.238860927036548,302,Gynaecology & Urology,efficacy,DICH,1,3,yes,2012.0,Live birth/ongoing pregnancy,Antioestrogen versus gonadotropin,-1.63829255879941,"positive 
",positive,,,,,,,,,,,,,,,,,
905,CD002093,Andersen 1981,STD-Andersen-1981 2.154 0.73 20 20,0.767255152713667,0.729575369499423,40,Gastroenterology,efficacy,DICH,1,1,no,1981.0,Mortality at 6 months,Chemotherapy versus best supportive care for advanced pancreatic cancer,1.05164618323135,"negative 
",negative,,,,,,,,,,,,,,,,,
906,CD003582,Dodd 2012a,STD-Dodd-2012a 1.092 0.119 116 119,0.193548619387738,0.262344062366013,235,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2006.0,Caesarean birth - all,Elective birth at 37 weeks versus expectant management,0.737766342573845,"negative 
",negative,,,,,,,,,,,,,,,,,
907,CD006964,Steiner 2006,STD-Steiner-2006 1.355 0.181 298 300,0.304037262165189,0.181449006841058,598,Gynaecology & Urology,efficacy,DICH,1,7,yes,2006.0,Change in comprehension: categories versus stratified,Communicating pregnancy risk (three charts),1.67560719928058,"neutral 
",neutral,,,,,,,,,,,,,,,,,
908,CD007325,Copernicus 2012,STD-Copernicus-2012 4.554 0.323 114 73,2.20851858395498,0.402940580124553,187,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,no,2010.0,Gain of 15 letters or more at 6 months,Anti-VEGF versus sham intravitreal injection,5.48100313766438,"neutral. 
",neutral,,,,,,,,,,,,,,,,,
909,CD011530,Madhi 2011,STD-Madhi-2011 1.594 0.298 273 274,0.50636807091097,0.322205924344767,547,Lungs,efficacy,DICH,1,3,no,2011.0,Mortality in HIV-infected children,Effect of antibiotic prophylaxis on survival,1.57156660586149,"negative 
",negative,,,,,,,,,,,,,,,,,
910,CD008486,Lehur 2008,STD-Lehur-2008 0.409 0.236 39 54,-2.17475172148416,0.487967097366091,93,Gastroenterology,efficacy,DICH,1,7,yes,2008.0,Successful treatment,EMG biofeedback versus STARR procedure,-4.45675893563902,"positive 
",positive,,,,,,,,,,,,,,,,,
911,CD003431,Gough 1983,STD-Gough-1983 0.983 0.434 43 46,-0.0169495583137737,0.434229097531642,89,Gastroenterology,efficacy,DICH,1,6,yes,1983.0,NON - Healing in acute and ?chronic? fissure,Dilator & Normal Care versus Normal Care Alone for acute and chronic fissure,-0.0390336769463924,"negative 
",negative,,,,,,,,,,,,,,,,,
912,CD003363,Gregson 2007,STD-Gregson-2007 1.44 0.43 634 632,0.370940216979292,0.437320969573741,1266,Infectious Diseases,efficacy,DICH,1,1,yes,2007.0,HIV incidence (person/years),Interventions to increase condom use versus standard care,0.848210451332459,"negative 
",negative,,,,,,,,,,,,,,,,,
913,CD001333,Schottenfield 2008,STD-Schottenfield-2008 0.372 0.543 43 44,-1.17865499634165,0.629962813865348,87,Psychiatry & Mental Health,efficacy,DICH,1,4,yes,2008.0,retention and abstinence,naltrexone + psychotherapy vs buprenorphine + psychotherapy,-1.87099138298277,"positive 
",positive,,,,,,,,,,,,,,,,,
914,CD001318,Berget 1987,STD-Berget-1987 1.979 0.595 94 93,0.727436254038577,0.630764506002774,187,Oncology,efficacy,DICH,1,2,yes,1987.0,Residual Disease (All Grades of CIN),Laser ablation versus cryotherapy,1.15326123635019,"negative 
",negative,,,,,,,,,,,,,,,,,
915,CD012470,Boyer 2002,STD-Boyer-2002 0.743 1.39 35 26,-0.307484699747961,1.43854501657261,61,Emergency & Trauma,efficacy,DICH,1,7,no,2002.0,Second or subsequent reduction for unacceptable loss of alignment,Above-elbow cast (forearm pronated versus neutral versus supinated) for displaced fractures,-0.213747012575634,"negative 
",negative,,,,,,,,,,,,,,,,,
916,CD001100,Prandoni 2004,STD-Prandoni-2004 1 0.385 360 360,0.0,0.385535328702769,720,Heart & Hypertension,efficacy,DICH,1,6,yes,2004.0,Incidence of recurrent venous thromboembolism at the end of follow-up,LMWH versus subcutaneous UFH in patients with venous thromboembolism,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
917,CD011226,Bale 1998a,STD-Bale-1998a 0.132 1.486 26 24,-2.15500194691387,1.53946801287908,50,Skin & Wounds,efficacy,DICH,1,3,yes,1998.0,Wound infection,One brand of hydrogel dressings compared with another hydrogel dressing,-1.3998354814035,"negative 
",negative,,,,,,,,,,,,,,,,,
918,CD001548,Black 2002,STD-Black-2002 2.346 0.252 100 50,1.49328077322635,0.38207927477695,150,Anaesthesia & Pain,efficacy,DICH,1,3,yes,2002.0,Participants with at least 50% pain relief over 4 to 6 hours,Ibuprofen 200 mg versus placebo,3.90830089933064,"positive 
",positive,,,,,,,,,,,,,,,,,
919,CD005298,Winston-Salem 1980,STD-Winston_x002d_Salem-1980 0.46 0.263 455 123,-0.877275594390575,0.302482725923439,578,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1980.0,Vomiting,Antacids versus placebo or no treatment,-2.9002502265621,"negative 
",negative,,,,,,,,,,,,,,,,,
920,CD011403,De Vita 2012,STD-De-Vita-2012 0.518 0.825 28 29,-0.732367893713227,0.910198625829296,57,Kidney & Transplant,efficacy,DICH,1,1,yes,2012.0,Death,Rituximab versus no rituximab,-0.804624257750285,"negative 
",negative,,,,,,,,,,,,,,,,,
921,CD000181,Hall 1985,STD-Hall-1985 1.926 1.175 30 29,0.693147180559945,1.25356634105602,59,Lungs,efficacy,DICH,1,1,no,1985.0,Mortality,Ribavirin versus placebo,0.552940165875889,"negative 
",negative,,,,,,,,,,,,,,,,,
922,CD004508,Amatyakul 2001,STD-Amatyakul-2001 0.571 0.596 53 53,-0.622794689556954,0.659548661250428,106,Gynaecology & Urology,efficacy,DICH,1,1,yes,2001.0,Postoperative ileus,Early versus delayed oral fluids and food after major abdominal gynaecologic surgery,-0.944274056104075,"negative 
",negative,,,,,,,,,,,,,,,,,
923,CD011612,Heresco-Levy 2013,STD-Heresco_x002d_Levy-2013 5.333 1.202 13 13,1.67397643357167,1.20185042515466,26,Psychiatry & Mental Health,efficacy,DICH,1,7,no,2013.0,Response rate,D-cycloserine versus Placebo,1.39283258426792,"positive 
",positive,,,,,,,,,,,,,,,,,
924,CD007101,Oral 2009,STD-Oral-2009 1 0.321 50 50,0.0,0.445435403187374,100,Heart & Hypertension,efficacy,DICH,1,10,yes,2009.0,Recurrence of AF,Comparison of recurrence of AF between CFAE plus PVAI and PVAI alone,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
925,CD012276,Altintas 2011,STD-Altintas-2011 0.888 0.263 30 41,-0.219473822425247,0.48307934540186,71,Emergency & Trauma,efficacy,DICH,1,1,yes,2011.0,In-hospital mortality,Enteral (EN) versus parenteral nutrition (PN),-0.454322513504843,"negative 
",negative,,,,,,,,,,,,,,,,,
926,CD005608,Browning 1983,STD-Browning-1983 0.947 0.274 13 20,-0.149035579160488,0.738092284054115,33,"Oral Health, Eyes & ENT",efficacy,DICH,1,1,yes,1983.0,Treatment failure (persistent discharge) at 2-4 weeks,Systemic antibiotic vs topical antiseptic,-0.201919979899913,"negative 
",negative,,,,,,,,,,,,,,,,,
927,CD005067,Ranawaka 2010,STD-Ranawaka-2010 0.874 0.049 64 83,-3.22381933776063,1.46537443057123,147,Skin & Wounds,efficacy,DICH,1,65,no,2010.0,Lesions cured,IL 7% HSCS (0.2 mL to 7 mL per lesion) versus ILSSG (max 2 mL) max 5 injections,-2.19999699087415,"positive 
",positive,,,,,,,,,,,,,,,,,
928,CD004685,Dastghaib 2005,STD-Dastghaib-2005 1.036 0.17 19 21,0.158605030176639,0.761030003788725,40,Skin & Wounds,efficacy,DICH,1,9,yes,2005.0,"Primary outcome: complete cure, i.e. clinical and mycological cure",Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up,0.208408379941706,"positive 
",positive,,,,,,,,,,,,,,,,,
929,CD007545,HKCS 1992,STD-HKCS-1992 0.81 0.279 165 167,-0.244050236133523,0.322395417531429,332,Infectious Diseases,efficacy,DICH,1,1,no,1992.0,Active TB,Rifampicin versus INH,-0.756990400180646,"negative 
",negative,,,,,,,,,,,,,,,,,
930,CD009069,"CVT (ph3,2v)",STD-CVT-_x0028_ph3_x002c_2v_x0029_ 0.059 1.455 1733 1729,-2.84015982640272,1.45561149184534,3462,Oncology,efficacy,DICH,1,1,no,2004.0,"CIN2+ associated with HPV16/18, at least 1 dose",High-grade cervical lesions in hrHPV DNA negative women at baseline,-1.95117985967679,"negative 
",negative,,,,,,,,,,,,,,,,,
931,CD003449,Abdel-Aleem 2012,STD-Abdel_x002d_Aleem-2012 0.88 0.163 34 34,-0.415515443961666,0.529054808029367,68,Gynaecology & Urology,efficacy,DICH,1,22,no,2012.0,Women who stopped bleeding within10 days of starting treatment.,Matrix metalloproteinase inhibitor vs placebo (DMPA/Therapeutic),-0.785392057033535,"positive 
",positive,,,,,,,,,,,,,,,,,
932,CD006962,Alderson 1992,STD-Alderson-1992 0.333 0.483 20 20,-1.79175946922805,0.721687836487032,40,Emergency & Trauma,efficacy,DICH,1,4,no,1992.0,Complication rate total,Ultrasound guidance vs anatomical landmarks for internal jugular vein cannulation for central vein catheterization in children,-2.48273474851651,"negative 
",negative,,,,,,,,,,,,,,,,,
933,CD000562,Banasiak 2005,STD-Banasiak-2005 0.618 0.139 49 46,-1.89933974162419,0.553969156536735,95,Psychiatry & Mental Health,efficacy,DICH,1,8,yes,2005.0,Number not abstinent from binge eating at end of treatment,Guided (non specialist) self-help versus waiting-list control group,-3.42860197036664,"negative 
",negative,,,,,,,,,,,,,,,,,
934,CD006534,Bougerol 1997a,STD-Bougerol-1997a 2.515 0.545 158 158,0.922300037037999,0.544718822985074,316,Psychiatry & Mental Health,efficacy,DICH,1,14,no,1997.0,Citalopram versus other SSRIs,SE - Abdominal pain,1.69316718666664,"neutral 
",neutral,,,,,,,,,,,,,,,,,
935,CD012390,Smith 1996,STD-Smith-1996 2 1.13 9 9,0.826678573184468,1.32960789064188,18,Gynaecology & Urology,efficacy,DICH,1,3,yes,1996.0,Subjective cure,Electrical stimulation versus PFMT,0.621746139597128,"neutral 
",neutral,,,,,,,,,,,,,,,,,
936,CD002943,Davis 1997 (1),STD-Davis-1997-_x0028_1_x0029_ 1.915 0.071 2737 1185,0.675690795151419,0.0741229764772501,3922,Oncology,efficacy,DICH,1,5,yes,1997.0,Attendance to the mammogram invitation during the following 12 months,Phone calls of invitation compared with control,9.11580763838867,"positive 
",positive,,,,,,,,,,,,,,,,,
937,CD011033,Verstraete 1998,STD-Verstraete-1998 1.111 0.369 63 70,0.128617377822094,0.451127353542507,133,Heart & Hypertension,efficacy,DICH,1,1,yes,1998.0,Ulcer healing (8 weeks) - iloprost 200 mcg,Oral prostacyclin analogue (iloprost) versus placebo,0.285102148677346,"positive 
",positive,,,,,,,,,,,,,,,,,
938,CD002256,Santiago 2000,STD-Santiago-2000 0.751 0.139 49 52,-0.944113237473454,0.446969902154742,101,Pregnancy & Childbirth,efficacy,DICH,1,2,no,2000.0,Cure rates,Intravenous and oral cephradine versus intravenous and oral cefuroxime,-2.11225237520937,"positive 
",positive,,,,,,,,,,,,,,,,,
939,CD003216,Arias 2008,STD-Arias-2008 1.312 0.248 264 273,0.305381649551182,0.277744767888658,537,Skin & Wounds,efficacy,DICH,1,1,yes,2008.0,Incidence of pressure ulcers,Prevention with mixed nutritional supplements: mixed nutritional supplement versus standard hospital diet,1.09950459867385,"negative 
",negative,,,,,,,,,,,,,,,,,
940,CD011442,Aasebø 1993,STD-Aaseb_x00f8_-1993 7.658 1.051 12 7,2.39789527279837,1.56476351199945,19,Lungs,efficacy,DICH,1,2,yes,1993.0,Reversal of erectile dysfunction,Two different types of pharmacological intervention for sexual dysfunction,1.53243301905369,"positive 
",positive,,,,,,,,,,,,,,,,,
941,CD001544,Moral 2009,STD-Moral-2009 0.075 1.542 31 19,-2.59253731398037,1.54209804424569,50,Gastroenterology,efficacy,DICH,1,2,yes,2009.0,Anastomotic leakage for colorectal surgery,Mechanical bowel preparation versus rectal enema,-1.68117541141717,"negative 
",negative,,,,,,,,,,,,,,,,,
942,CD004785,Kaiser 1974,STD-Kaiser-1974 0.124 0.775 12 6,-4.60183128472258,1.70513030066677,18,Lungs,efficacy,DICH,1,5,no,1974.0,Rifampin versus placebo,Failure to eradicate (follow-up between three to four weeks),-2.69881503068891,"negative 
",negative,,,,,,,,,,,,,,,,,
943,CD006555,Donchin 1990,STD-Donchin-1990 0.444 0.269 33 28,-1.79175946922806,0.571699070175758,61,Spine & Muscles,efficacy,DICH,1,1,no,1990.0,Number of subjects with recurrent LBP,Post-treatment Exercise vs No Intervention,-3.13409547557461,"negative 
",negative,,,,,,,,,,,,,,,,,
944,CD000265,Hendricks 1985,STD-Hendricks-1985 0.909 0.177 11 10,-0.693147180559945,1.31233464566864,21,Skin & Wounds,efficacy,DICH,1,15,yes,1985.0,Complete healing in trial period (varying lengths),Single-layer compression stocking vs paste bandage system,-0.528178679765622,"neutral 
",neutral,,,,,,,,,,,,,,,,,
945,CD006126,Silicone Study 1992b,STD-Silicone-Study-1992b 1.063 0.195 63 67,0.111225635110224,0.353119061254056,130,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,yes,1992.0,Visual acuity = 5/200 at last follow-up examination,Silicone oil versus perfluropropane (C3F8),0.314980547114112,"negative 
",negative,,,,,,,,,,,,,,,,,
946,CD006185,Chang 2012,STD-Chang-2012 4.6 1.159 24 24,1.52605630349505,1.15908509647461,48,Neurology,efficacy,DICH,1,1,yes,2012.0,"Independent walking at the end of intervention phase, all electromechanical devices used",Electromechanical- and robotic-assisted gait training plus physiotherapy versus physiotherapy (or usual care),1.31660419768711,"positive 
",positive,,,,,,,,,,,,,,,,,
947,CD007963,Novartis 2004,STD-Novartis-2004 0.529 0.432 70 74,-0.741937344729377,0.496815254219712,144,Neurology,efficacy,DICH,1,3,no,2004.0,Reduction in participant-reported pain scores by at least 50% from baseline,Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy,-1.49338680410417,"positive 
",positive,,,,,,,,,,,,,,,,,
948,CD006102,Hall 1994,STD-Hall-1994 1.954 0.583 29 17,0.898591154774754,0.746587894162016,46,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,1994.0,Psychosocial mood management versus control for smokers with past depression,Psychosocial mood management versus control for smokers with past depression. Abstinence at six months or greater follow-up,1.20359727475001,"neutral 
",neutral,,,,,,,,,,,,,,,,,
949,CD004631,Kriegs-Au 2004,STD-Kriegs_x002d_Au-2004 2.812 1.097 16 15,1.17272026082183,1.21724483226875,31,Spine & Muscles,efficacy,DICH,1,2,no,2004.0,Pain - number of participants with frequent or constant pain,Trapeziectomy with ligament reconstruction and tendon interposition (T and LRTI) versus trapeziectomy and ligament reconstruction (T and LR),0.963421843932635,"negative 
",negative,,,,,,,,,,,,,,,,,
950,CD012189,Brown 2005,STD-Brown-2005 0.415 0.47 50 52,-0.880358722648092,0.469540919702413,102,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2005.0,Repetition of SH at 6 months,Cognitive behavioural therapy (CBT)-based psychotherapy vs. treatment as usual (TAU),-1.87493503911448,"negative 
",negative,,,,,,,,,,,,,,,,,
951,CD009362,Chiew 2010,STD-Chiew-2010 1.019 0.431 54 55,0.0219789067187752,0.515929815846329,109,Skin & Wounds,efficacy,DICH,1,1,yes,2010.0,Pressure ulcer,Fatty acid versus other topical intervention or standard care,0.0426005748140783,"negative 
",negative,,,,,,,,,,,,,,,,,
952,CD011701,Heikkinen 1989,STD-Heikkinen-1989 1.714 0.498 15 36,0.728238500371215,0.690897895117529,51,Infectious Diseases,efficacy,DICH,1,2,yes,1989.0,Recurrence of BV after the fourth week,Any antibiotic treatment versus no intervention,1.05404648866,"negative 
",negative,,,,,,,,,,,,,,,,,
953,CD004387,Amukoye 1997,STD-Amukoye-1997 9.013 1.042 152 137,2.25941292112884,1.05564918164019,289,Infectious Diseases,efficacy,DICH,1,2,yes,1997.0,Parasitaemia,One-dose regimen (with 1.2 mg chlorproguanil) versus sulfadoxine-pyrimethamine,2.14030660983257,"negative 
",negative,,,,,,,,,,,,,,,,,
954,CD000978,Puataweepong 2009,STD-Puataweepong-2009 0.612 0.184 30 31,-1.77601111225992,0.648818625245614,61,"Oral Health, Eyes & ENT",efficacy,DICH,1,2,no,2009.0,Mucositis (moderate plus severe),Aloe vera versus placebo,-2.73729982949795,"negative 
",negative,,,,,,,,,,,,,,,,,
955,CD000192,Hauth 1992,STD-Hauth-1992 0.878 0.135 457 449,-0.13043131831083,0.135306600861414,906,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1992.0,use of extra haemostatic sutures,Single versus two layer closure of uterine incision at CS,-0.96396862740217,"negative 
",negative,,,,,,,,,,,,,,,,,
956,CD004874,Harris 1998,STD-Harris-1998 1.024 0.328 125 63,0.024097551579061,0.328212701210316,188,Lungs,efficacy,DICH,1,3,yes,1998.0,Cure rate,Azithromycin versus co-amoxyclavulanic acid,0.0734205333620512,"positive 
",positive,,,,,,,,,,,,,,,,,
957,CD012037,Bung 1993,STD-Bung-1993 1.5 0.846 17 17,0.474457979595116,0.985610760609162,34,Pregnancy & Childbirth,efficacy,DICH,1,4,yes,1993.0,Caesarean section,Insulin versus exercise,0.481384739856,"negative 
",negative,,,,,,,,,,,,,,,,,
958,CD006169,Francioli 1988,STD-Francioli-1988 0.846 0.912 13 11,-0.200670695462151,1.09636681909852,24,Pregnancy & Childbirth,efficacy,DICH,1,4,no,1988.0,Birth before 7 days of trial entry,IV hexoprenaline plus IV magnesium sulphate versus IV hexoprenaline,-0.183032441302038,"negative 
",negative,,,,,,,,,,,,,,,,,
959,CD002294,Wong 2012,STD-Wong-2012 1.49 0.213 151 135,0.529517756778143,0.279199714868532,286,Psychiatry & Mental Health,efficacy,DICH,1,3,no,2012.0,Smoking cessation at time of surgery,Varenicline versus placebo,1.8965555069692,"positive 
",positive,,,,,,,,,,,,,,,,,
960,CD012294,Gunter 1995,STD-Gunter-1995 1.328 0.301 49 47,0.417795720565643,0.44062281114423,96,Anaesthesia & Pain,efficacy,DICH,1,2,no,1995.0,Participants using rescue medication in the PACU,Ketorolac versus opioid,0.948193579630368,"negative 
",negative,,,,,,,,,,,,,,,,,
961,CD001719,Rossi 1990,STD-Rossi-1990 1.5 0.837 15 15,0.485507815781701,0.996789718842316,30,Psychiatry & Mental Health,efficacy,DICH,1,2,no,1990.0,Global impression: no important improvement (CGI),Bromperidol decanoate vs other depot antipsychotics,0.487071452086781,"negative 
",negative,,,,,,,,,,,,,,,,,
962,CD004901,Dickinson 2002,STD-Dickinson-2002 1.853 0.252 51 99,0.896088024556636,0.37335497772755,150,Pregnancy & Childbirth,efficacy,DICH,1,17,no,2002.0,Vaginal birth not achieved in 24 hours,Vaginal misoprostol - low (< 800 mcg cumulative dose) versus moderate (800 mcg -2400 mcg cumulative dose),2.40009663192583,"negative 
",negative,,,,,,,,,,,,,,,,,
963,CD005275,Larsen 2002,STD-Larsen-2002 1.086 0.435 58 63,0.0971637484536479,0.511027302603341,121,Spine & Muscles,efficacy,DICH,1,1,yes,2002.0,Insoles vs placebo/No intervention,Prevention trials,0.190134163005898,"neutral 
",neutral,,,,,,,,,,,,,,,,,
964,CD000227,Falch 1987,STD-Falch-1987 1.162 0.544 47 39,0.173953307123438,0.630292715778173,86,Emergency & Trauma,efficacy,DICH,1,12,no,1987.0,Persons sustaining new non-vertebral fracture,"Calcitriol [1,25(OH)2D3] versus vitamin D (with or without calcium in each group)",0.27598812864063,"negative 
",negative,,,,,,,,,,,,,,,,,
965,CD010649,Bilecen 2017,STD-Bilecen-2017 5 1.539 60 60,1.64305452323309,1.5600073534166,120,Emergency & Trauma,efficacy,DICH,1,3,no,2017.0,All-cause mortality,Fibrinogen: therapeutic trials: intervention vs inactive control,1.0532351143311,"negative 
",negative,,,,,,,,,,,,,,,,,
966,CD009435,Strauss 2001,STD-Strauss-2001 1.059 0.056 241 251,0.207255539293822,0.201818670969727,492,Skin & Wounds,efficacy,DICH,1,3,yes,2001.0,Improvement in acne severity assessed by physician's global evaluation,Standard oral isotretinoin versus other formulations of oral isotretinoin,1.02693937234831,"positive 
",positive,,,,,,,,,,,,,,,,,
967,CD006189,Buchbinder 2004,STD-Buchbinder-2004 2 0.222 23 23,3.17805383034795,1.10439891782678,46,Spine & Muscles,efficacy,DICH,1,1,yes,2004.0,Patient reported success,ORAL STEROID VS PLACEBO,2.87763214817492,"positive 
",positive,,,,,,,,,,,,,,,,,
968,CD003552,Veres 2004,STD-Veres-2004 0.139 2 76 78,-1.0856250931413,1.6409271123051,154,Gynaecology & Urology,efficacy,DICH,1,6,no,2004.0,Pregnancy per woman,Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg,-0.661592513768793,"negative 
",negative,,,,,,,,,,,,,,,,,
969,CD007179,Sarmadian 2009,STD-Sarmadian-2009 0.778 0.452 40 40,-0.31383478526224,0.562609410503782,80,Infectious Diseases,efficacy,DICH,1,4,yes,2009.0,Total treatment failure,Doxycycline plus rifampicin (DR) versus doxycycline plus quinolone (DQ),-0.557820006923134,"negative 
",negative,,,,,,,,,,,,,,,,,
970,CD004690,Barrett 1996,STD-Barrett-1996 3 0.712 28 13,1.09861228866811,0.712000312109794,41,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,1996.0,Remission of anxiety diagnoses (ITT analysis),CBT versus wait-list,1.54299411107379,"positive 
",positive,,,,,,,,,,,,,,,,,
971,CD009902,Angeles-Agdeppa 2008,STD-Angeles_x002d_Agdeppa-2008 0.569 0.162 112 59,-1.10766212418803,0.333722131975782,171,Public Health & Work,efficacy,DICH,1,1,no,2008.0,"Anaemia (defined as haemoglobin (Hb) below the WHO cut-off, adjusted for altitude as appropriate)",Rice fortified with iron alone or in combination with other micronutrients versus unfortified rice (no micronutrients added).,-3.31911497038024,"negative 
",negative,,,,,,,,,,,,,,,,,
972,CD011883,Bjørndal 1980,STD-Bj_x00f8_rndal-1980 1.069 0.368 12 11,0.154150679827259,0.842332362861483,23,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1980.0,Global state: 1a. Clinically relevant response as defined by trials,Antipsychotic dose increase versus antipsychotic dose maintenance,0.183004579455542,"positive 
",positive,,,,,,,,,,,,,,,,,
973,CD006023,Spiegel 2007,STD-Spiegel-2007 0.175 1.59 20 10,-1.86774537620598,1.6794970414878,30,Kidney & Transplant,efficacy,DICH,1,10,yes,2007.0,Hospitalisation,Magnesium versus calcium,-1.11208613654443,"negative 
",negative,,,,,,,,,,,,,,,,,
974,CD011823,Wagena 2005,STD-Wagena-2005 0.573 0.572 64 11,-0.705569700558502,0.75950763778375,75,Psychiatry & Mental Health,efficacy,DICH,1,119,no,2005.0,Six-Month Abstinence,Placebo - SLC6A4 (Promoter) - non-Hispanic white,-0.92898302197113,"positive 
",positive,,,,,,,,,,,,,,,,,
975,CD008138,Dreno 2002,STD-Dreno-2002 0.939 0.051 66 63,-0.864104978703584,0.714007209627127,129,Skin & Wounds,efficacy,DICH,1,22,yes,2002.0,Failure to achieve complete resolution,Lithium vs placebo,-1.21021884240475,"negative 
",negative,,,,,,,,,,,,,,,,,
976,CD008478,Bigrigg 1994,STD-Bigrigg-1994 1.152 0.14 229 229,0.204390877674233,0.202435982290523,458,Oncology,efficacy,DICH,1,1,no,1994.0,Total pregnancy rates,Fertility outcomes,1.0096568572523,"positive 
",positive,,,,,,,,,,,,,,,,,
977,CD010623,Johnson+Vakil,STD-Johnson_x002b_Vakil 2.959 1.493 519 169,1.08494020069971,1.49333914147004,688,Gastroenterology,efficacy,DICH,1,1,no,2003.0,Number of participants with worsening scores in corporal atrophy,Atrophy (proton pump inhibitor (PPI) versus control),0.726519630116771,"negative 
",negative,,,,,,,,,,,,,,,,,
978,CD003989,Hampton 2001,STD-Hampton-2001 1.41 0.328 1141 1673,0.336185717350833,0.32268840267675,2814,Gynaecology & Urology,efficacy,DICH,1,17,no,2001.0,Pregnancy per woman,EE 20 µg and norethindrone acetate 1 mg versus EE 25 µg and norgestimate 180-215-250 µg,1.04182770301666,"negative 
",negative,,,,,,,,,,,,,,,,,
979,CD000535,CASPAR 2010,STD-CASPAR-2010 0.95 0.165 425 426,-0.0511887035012435,0.16466186077274,851,Heart & Hypertension,efficacy,DICH,1,10,no,2010.0,Primary graft patency at 24 months,"Clopidogrel and ASA versus ASA alone, all grafts",-0.310871644842471,"positive 
",positive,,,,,,,,,,,,,,,,,
980,CD002232,Terg 1997,STD-Terg-1997 1 0.498 40 40,0.0,0.500783085836134,80,Hepato-Biliary,efficacy,DICH,1,8,yes,1997.0,Death,IV + oral ciprofloxacin versus IV ciprofloxacin,0.0,"negative 
",negative,,,,,,,,,,,,,,,,,
981,CD008445,Chouhan 2006,STD-Chouhan-2006 0.958 0.644 24 23,-0.0512932943875506,0.77629348763684,47,Neurology,efficacy,DICH,1,1,yes,2006.0,Death or dependency in activities of daily living 3 months post-operatively in all participants,Intraoperative mild hypothermia compared with control (no hypothermia),-0.0660746163718254,"negative 
",negative,,,,,,,,,,,,,,,,,
982,CD003420,Cho 1992,STD-Cho-1992 1.585 0.319 79 84,0.460318802089054,0.319111300991604,163,Genetics & Endocrinology,efficacy,DICH,1,8,no,1992.0,Number of participants with relapse,Discontinuation of ATD based on normal TSH and TBII versus 24 month therapy,1.44250235155779,"negative 
",negative,,,,,,,,,,,,,,,,,
983,CD003993,Cheng 2004,STD-Cheng-2004 1.278 0.351 18 23,0.441832752279039,0.636209010280352,41,Oncology,efficacy,DICH,1,2,no,2004.0,Overall survival,Synthetic thymic peptides versus no treatment or placebo,0.694477357502908,"negative 
",negative,,,,,,,,,,,,,,,,,
984,CD001088,Baker 2006,STD-Baker-2006 17 1.445 65 65,2.96347853889412,1.46639201400713,130,Psychiatry & Mental Health,efficacy,DICH,1,3,yes,2006.0,Lost to treatment,Cognitive behaviour therapy + motivational interviewing versus treatment as usual,2.02093199539187,"negative 
",negative,,,,,,,,,,,,,,,,,
985,CD007699,Farahmand 2011,STD-Farahmand-2011 0.581 0.24 66 66,-0.859468396007459,0.370429996053838,132,Heart & Hypertension,efficacy,DICH,1,1,no,2011.0,Therapeutic INR,10 mg nomogram versus 5 mg nomogram,-2.32019114316688,"positive 
",positive,,,,,,,,,,,,,,,,,
986,CD003815,Astrand 1999,STD-Astrand-1999 3 1.128 33 33,1.16315080980568,1.18233525984243,66,"Oral Health, Eyes & ENT",efficacy,DICH,1,3,no,1999.0,Early implant failure,Turned versus roughened implants,0.983774103092125,"negative 
",negative,,,,,,,,,,,,,,,,,
987,CD012371,Berger 2009,STD-Berger-2009 0.196 0.528 84 82,-1.62860782854182,0.528003087212722,166,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2009.0,PTSD diagnosis,All psychotherapies versus control (medium-term),-3.08446648889703,"negative 
",negative,,,,,,,,,,,,,,,,,
988,CD005011,Diprose 2005,STD-Diprose-2005 0.333 1.576 10 10,-1.19869574722509,1.69327136626103,20,Emergency & Trauma,efficacy,DICH,1,1,yes,2005.0,Death,rFVIIa used prophylactically versus placebo,-0.707917095339522,"negative 
",negative,,,,,,,,,,,,,,,,,
989,CD012136,Neto 1990,STD-Neto-1990 0.127 1.473 34 39,-2.16865120489216,1.50976049211559,73,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1990.0,Episiotomy infection with wound dehiscence,Comparison 1. Antibiotic prophylaxis versus no treatment,-1.43642068806112,"negative 
",negative,,,,,,,,,,,,,,,,,
990,CD008940,McRae-Clark 2015,STD-McRae_x002d_Clark-2015 1.977 0.593 88 87,0.729961153682662,0.632098246138276,175,Psychiatry & Mental Health,efficacy,DICH,1,6,no,2015.0,Participants abstinent at end of treatment,Buspirone versus placebo,1.15482230514365,"positive 
",positive,,,,,,,,,,,,,,,,,
991,CD001333,Krupitsky 2006,STD-Krupitsky-2006 1.667 0.279 70 70,0.711496319228142,0.383497988352882,140,Psychiatry & Mental Health,efficacy,DICH,1,3,yes,2006.0,retention and abstinence,naltrexone + psychotherapy vs benzodiazepines + psychosocial therapy,1.85528044693013,"positive 
",positive,,,,,,,,,,,,,,,,,
992,CD009946,Cai 2006,STD-Cai-2006 0.308 0.503 27 27,-1.67509188265554,0.66470287288473,54,Lungs,efficacy,DICH,1,1,yes,2006.0,Clinically suspected pneumonia,Semirecumbent position (30º to 60º) versus 0° to 10° supine position,-2.52006114459208,"negative 
",negative,,,,,,,,,,,,,,,,,
993,CD006531,Hicks 2002,STD-Hicks-2002 2.25 0.932 20 20,0.810930216216329,0.931694990624912,40,Psychiatry & Mental Health,efficacy,DICH,1,53,yes,2002.0,Paroxetine versus newer or non-conventional ADs,SE - Influenza-like symptoms,0.87038164246479,"neutral 
",neutral,,,,,,,,,,,,,,,,,
994,CD009490,Ferrell 1993,STD-Ferrell-1993 1.305 0.208 43 41,0.571486668157141,0.442008135983057,84,Skin & Wounds,efficacy,DICH,1,3,yes,1993.0,Pressure ulcers completely healed,Low-air-loss versus low-tech overlay,1.2929324635306,"positive 
",positive,,,,,,,,,,,,,,,,,
995,CD009261,Frazee 2018,STD-Frazee-2018 0.72 0.708 25 24,-0.382992252256106,0.8238858408711,49,Skin & Wounds,efficacy,DICH,1,1,yes,2018.0,Mortality,Negative pressure wound therapy versus standard dressing,-0.464860825683284,"negative 
",negative,,,,,,,,,,,,,,,,,
996,CD002922,MyLupus 2011,STD-MyLupus-2011 4.651 1.534 42 39,1.58443661022868,1.56525008024945,81,Kidney & Transplant,efficacy,DICH,1,16,yes,2011.0,Death,Standard versus reduced dose oral corticosteroids,1.01225780482067,"negative 
",negative,,,,,,,,,,,,,,,,,
997,CD007959,Siproudhis 2007,STD-Siproudhis-2007 1.062 0.174 22 22,0.242946178610389,0.698562950691225,44,Gynaecology & Urology,efficacy,DICH,1,1,no,2007.0,Failure (number of participants with Wexner's >8),Injectable versus placebo injection,0.347779936468138,"negative 
",negative,,,,,,,,,,,,,,,,,
998,CD001136,Benigo 1986,STD-Benigo-1986 0.804 0.322 136 147,-0.220163909977115,0.324571549780057,283,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1986.0,Febrile Morbidity,Extended spectrum penicillin vs 2nd/3rd Generation Cephalosporin,-0.678321652425502,"negative 
",negative,,,,,,,,,,,,,,,,,
999,CD003414,Mounce 2015,STD-Mounce-2015 0.769 0.351 80 79,-0.262906784486223,0.35083716832733,159,Gynaecology & Urology,efficacy,DICH,1,2,yes,2015.0,Live birth rate per woman,Natural cycle FET versus HT + GnRHa FET,-0.74936981660088,"positive 
",positive,,,,,,,,,,,,,,,,,
0,CD000004,Blecher 1967,STD-Blecher-1967 0.362 0.353 42 38,-1.55227949859415,0.509869905232146,80,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1967.0,Unchanged or worsening pre-eclampsia,Abdominal decompression for suspected fetal compromise/pre-eclampsia,-3.04446189638785,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
1,CD000006,Banninger 1978,STD-Banninger-1978 0.441 0.282 80 73,-1.13370360847938,0.379196674468605,153,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1978.0,Short-term pain: pain at day 3 or less (women experiencing any pain),Synthetic sutures versus catgut,-2.9897509256064,"negative 
",negative,negative,neutral.,0.0,negative,1.0,"negative, because it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
2,CD000006,Gemynthe 1996,STD-Gemynthe-1996 1.016 0.035 155 153,0.182521376956474,0.411034252051126,308,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,1996.0,Short-term pain: at 3 days or less,Fast-absorbing synthetic versus standard absorbable synthetic material,0.444053934789288,"negative 
",negative,neutral,neutral.,0.0,positive,0.0,neutral. this,0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,negative,1.0
3,CD000006,Saint 1993,STD-Saint-1993 0.989 0.026 418 418,-0.0893709058995314,0.211484847970904,836,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1993.0,Short-term pain: pain at 3 days or less,Glycerol impregnated catgut (softgut) versus chromic catgut,-0.422587749226493,"negative 
",negative,negative,"neutral.

the outcome """,0.0,negative.,1.0,"negative, because it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
4,CD000007,Abu Dhabi 1997,STD-Abu-Dhabi-1997 0.529 0.172 827 821,-0.692206245543344,0.18600035093523,1648,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1997.0,PPH clinically estimated blood loss greater than or equal to 500mls,Active vs expectant management (all women),-3.72153193293913,"negative 
",negative,negative,negative.,1.0,negative.,1.0,this would be considered a,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
5,CD000009,Aycicegi-Dinn 2011,STD-Aycicegi_x002d_Dinn-2011 0.319 1.117 24 23,-1.23837423104327,1.19449219093425,47,Psychiatry & Mental Health,efficacy,DICH,1,8,no,2011.0,Short-term smoking cessation,Electrostimulation vs sham stimulation,-1.03673698366726,"positive 
",positive,positive,positive.,1.0,positive,1.0,this would be considered a,0.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
6,CD000009,Cai 2000,STD-Cai-2000 0.992 0.239 160 170,-0.0101523714640182,0.28942396888688,330,Psychiatry & Mental Health,efficacy,DICH,1,7,no,2000.0,Short-term smoking cessation,Laser therapy vs sham laser,-0.0350778530992579,"positive 
",positive,positive,positive,1.0,positive,1.0,positive,1.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
7,CD000009,Clavel 1985,STD-Clavel-1985 0.855 0.189 224 205,-0.197034109841127,0.238346626665503,429,Psychiatry & Mental Health,efficacy,DICH,1,3,no,1985.0,NRT,Acupuncture vs other intervention,-0.82667043623674,"neutral 
",neutral,neutral,"based on the outcome """,0.0,"the outcome ""nrt",0.0,the abbreviation,0.0,negative,0.0,"negative 
",1.0,1.0,0.0,neutral,negative,neutral,1.0
8,CD000009,Clavel 1992,STD-Clavel-1992 0.858 0.182 272 243,-0.189777857470409,0.224675246072811,515,Psychiatry & Mental Health,efficacy,DICH,1,2,no,1990.0,Short-term smoking cessation,Acupuncture vs sham acupuncture,-0.844676308528033,"positive 
",positive,positive,positive,1.0,positive.,1.0,positive,1.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
9,CD000009,Lamontagne 1980,STD-Lamontagne-1980 1.4 0.513 25 25,0.441832752279039,0.669636243353583,50,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1980.0,Short-term smoking cessation,Acupuncture vs waiting list/no intervention,0.659810093411778,"positive 
",positive,positive,positive,1.0,positive,1.0,positive,1.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
10,CD000009,Li 2009,STD-Li-2009 2.5 0.383 70 70,1.1314021114911,0.459487793372212,140,Psychiatry & Mental Health,efficacy,DICH,1,5,no,2009.0,Short-term smoking cessation,Acupressure vs sham acupressure,2.46231157347547,"positive 
",positive,positive,positive,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
11,CD000009,Tian 1996,STD-Tian-1996 13 0.711 60 60,3.09903184339179,0.764927893646039,120,Psychiatry & Mental Health,efficacy,DICH,1,4,no,1996.0,Short-term smoking cessation,Acupressure vs waiting list/no intervention,4.05140388935252,"positive 
",positive,positive,positive,1.0,positive,1.0,positive,1.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
12,CD000009,Yeh 2009,STD-Yeh-2009 0.967 0.657 30 29,-0.0392207131532814,0.760566590418971,59,Psychiatry & Mental Health,efficacy,DICH,1,6,no,2009.0,Short-term smoking cessation,Continuous auricular stimulation vs sham stimulation,-0.0515677570476452,"positive 
",positive,positive,positive,1.0,positive,1.0,positive,1.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
13,CD000010,Kamolratanakul 1999,STD-Kamolratanakul-1999 1.135 0.044 414 422,0.446479824178497,0.154930393353026,836,Infectious Diseases,efficacy,DICH,1,5,no,1999.0,Cure,Active TB: Direct observation of treatment vs self-supervision,2.88180914354966,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
14,CD000010,Krishnaswami 1981,STD-Krishnaswami-1981 1.325 0.131 75 75,0.745718067569283,0.343356809389702,150,Infectious Diseases,efficacy,DICH,1,2,no,1981.0,Completion of treatment,Active TB: Intensive vs routine defaulter action,2.17184586755322,"positive 
",positive,positive,positive,1.0,positive,1.0,this would be considered a,0.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
15,CD000010,Liefooghe 1999,STD-Liefooghe-1999 1.131 0.07 504 515,0.221918811418314,0.126275790603506,1019,Infectious Diseases,efficacy,DICH,1,3,no,1999.0,Completed treatment,Active TB:Counselling/health education vs. routine care,1.75741375569857,"positive 
",positive,positive,positive.,1.0,positive,1.0,this would be considered a,0.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
16,CD000010,Malotte 1998,STD-Malotte-1998 2.6 0.145 204 100,2.50567520186153,0.292276320923085,304,Infectious Diseases,efficacy,DICH,1,11,no,1998.0,Keeping first appointment,TB evaluation: Incentive ($5) vs routine care,8.57296682108202,"neutral 
",positive,positive,neutral.,0.0,positive,1.0,"neutral

",0.0,negative,0.0,"**positive** 
",1.0,0.0,1.0,neutral,positive,positive,1.0
17,CD000010,Morisky 1990,STD-Morisky-1990 1.072 0.052 43 45,1.41039191269895,1.13938569751948,88,Infectious Diseases,efficacy,DICH,1,4,no,1990.0,Completion of treatment,Active TB: Incentive plus health education vs routine care,1.23785292001599,"positive 
",positive,positive,positive,1.0,positive,1.0,"positive

completion",1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
18,CD000010,Paramasivan 1993,STD-Paramasivan-1993 1.205 0.071 100 100,0.997807589546144,0.381356312221252,200,Infectious Diseases,efficacy,DICH,1,1,no,1993.0,Completion of treatment,Active TB: Defaulter action vs no defaulter action,2.61647062751972,"positive 
",positive,positive,positive,1.0,positive,1.0,the completion of treatment for,0.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
19,CD000010,Sanmarti 1993,STD-Sanmarti-1993 1.312 0.078 80 77,1.79175946922805,0.526279105579632,157,Infectious Diseases,efficacy,DICH,1,9,no,1993.0,Completion of treatment,Prophylaxis: Health education vs no health education,3.40458028873226,"neutral 
",positive,positive,"the outcome ""completion of",0.0,positive,1.0,"positive

in",1.0,negative,0.0,"**positive** 
",1.0,0.0,1.0,neutral,positive,positive,1.0
20,CD000010,Tanke 1997,STD-Tanke-1997 1.051 0.025 376 325,0.537339000164863,0.264012265967145,701,Infectious Diseases,efficacy,DICH,1,19,no,1997.0,Keeping first appointment,TB Evaluation: Reminders vs no reminders,2.03528043743139,"positive 
",positive,positive,neutral.,0.0,positive,1.0,positive. keeping,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
21,CD000010,Tulsky 2000,STD-Tulsky-2000 1.679 0.321 43 38,0.796004565999653,0.479596216966232,81,Infectious Diseases,efficacy,DICH,1,7,no,2000.0,Completion of preventive therapy,Prophylaxis: Incentive ($5) vs routine care,1.65973904263657,"positive 
",positive,positive,neutral.,0.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
22,CD000010,White 1998,STD-White-1998 1.106 0.45 31 30,0.133531392624523,0.595662374668967,61,Infectious Diseases,efficacy,DICH,1,8,no,1998.0,Keeping first appointment,Prophylaxis: Incentive ($5) plus health education vs health education alone,0.224172951495772,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
23,CD000010,Wurtele 1980,STD-Wurtele-1980 1.102 0.034 629 653,0.366062083519659,0.127404050228936,1282,Infectious Diseases,efficacy,DICH,1,17,no,1980.0,Keeping first appointment,TB Evaluation: Verbal contract vs no contract,2.87323741169822,"positive 
",positive,positive,neutral,0.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
24,CD000012,Begley 2009,STD-Begley-2009 1.237 0.149 1059 549,0.240453099890958,0.16737008325693,1608,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,2009.0,No analgesia/anesthesia,Alternative versus conventional birth settings - all trials,1.43665519674647,"negative 
",positive,neutral,negative,0.0,"i would respond with """,0.0,neutral. the,0.0,negative,0.0,"neutral 
",0.0,0.0,0.0,negative,neutral,neutral,0.0
25,CD000013,Amin 2003,STD-Amin-2003 0.294 0.484 80 80,-1.39812881876689,0.536684151636802,160,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2003.0,"Caesarean section, overall","Transcervical amnioinfusion for intrapartum umbilical cord compression (potential, or diagnosed by EFM)*",-2.60512410232876,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

this",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
26,CD000013,Vergani 1996,STD-Vergani-1996 0.127 0.717 37 33,-2.55681923137829,0.807856162288417,70,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,1996.0,Suspicious/ominous fetal heart rate pattern,"Transabdominal amnioinfusion for cord compression (potential, or diagnosed by fetal heart rate monitor)",-3.16494365053251,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
27,CD000014,Choudhary 2010,STD-Choudhary-2010 0.043 1.015 146 146,-3.30004360297731,1.0288366701739,292,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2010.0,Meconium aspiration syndrome,Amnioinfusion for meconium-stained liquor in labour,-3.20754858243876,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as me",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
28,CD000015,Fraser 1993,STD-Fraser-1993 0.335 0.331 462 463,-1.21291884403288,0.387434539910941,925,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1991.0,Cessation of contractions,Amniotomy to shorten spontaneous labour,-3.13064200293473,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative. cess,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,positive,0.0
29,CD000015,Johnson 1997,STD-Johnson-1997 1.217 0.305 529 411,0.199036263063436,0.30953251608831,940,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1997.0,Use of oxytocin,Amniotomy to shorten spontaneous labour in multiparae,0.643022147006522,"neutral 
",negative,neutral,negative.,1.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",0.0,0.0,1.0,neutral,negative,positive,0.0
30,CD000016,Brazil 1983-84,STD-Brazil-1983_x002d_84 0.935 0.496 36 30,-0.0682082500265335,0.500032319576001,66,Infectious Diseases,efficacy,DICH,1,1,no,1983.0,Parasitological conversion,Amodiaquine vs chloroquine in symptomatic participants,-0.136407682776126,"negative 
",positive,positive,"neutral.

parasit",0.0,"in this context, """,0.0,neutral. par,0.0,negative,0.0,"**negative** 
",1.0,0.0,0.0,negative,negative,positive,1.0
31,CD000016,Cameroon-Centre 1994,STD-Cameroon_x002d_Centre-1994 0.896 0.555 54 52,-0.111552485905748,0.558407105536944,106,Infectious Diseases,efficacy,DICH,1,2,no,1994.0,Parasitological conversion on day 7,Amodiaquine vs chloroquine in asymptomatic participants,-0.199769101789066,"negative 
",positive,positive,"neutral.

the outcome """,0.0,negative.,0.0,neutral. this,0.0,negative,0.0,"**negative** 
",1.0,0.0,0.0,negative,negative,positive,1.0
32,CD000016,Cameroon-Hévécam2001,STD-Cameroon_x002d_H_x00e9_v_x00e9_cam2001 0.129 1.164 61 62,-2.01204995155986,1.52276337715625,123,Infectious Diseases,efficacy,DICH,1,3,no,2001.0,Parasitological conversion,Amodiaquine vs sulphadoxine-pyrimethamine in symptomatic participants,-1.32131490797825,"negative 
",positive,positive,"neutral.

parasit",0.0,"in this context, """,0.0,neutral. par,0.0,negative,0.0,"**positive** 
",1.0,0.0,1.0,negative,positive,positive,1.0
33,CD000018,Amoroso 1998,STD-Amoroso-1998 0.332 0.663 389 388,-1.11691345305051,0.670577095080808,777,Emergency & Trauma,efficacy,DICH,1,1,no,1998.0,Ankle sprain by intervention type,Any intervention v no intervention/control,-1.66560036309609,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because an",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
34,CD000018,Holme 1999,STD-Holme-1999 0.238 0.728 29 38,-1.70474809223843,0.815464999238573,67,Emergency & Trauma,efficacy,DICH,1,13,no,1999.0,Re-injury (recurrent ankle sprain),Rehabilitation: supervised programme (emphasis on balance training) v control,-2.09052270033687,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative. a re,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
35,CD000018,Simon 1969,STD-Simon-1969 1.027 0.688 73 75,0.0285733724440557,0.727033190896703,148,Emergency & Trauma,efficacy,DICH,1,9,no,1969.0,Ankle injury,Adhesive tape v cloth wrap,0.0393013314960409,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as an",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
36,CD000018,Wester 1996,STD-Wester-1996 0.462 0.4 24 24,-1.26566637333128,0.624543345216639,48,Emergency & Trauma,efficacy,DICH,1,14,no,1996.0,Recurrent ankle sprain,Rehabilitation: wobble board (ankle disk) exercises v control,-2.02654688905899,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as recur",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
37,CD000019,ACTOBAT 1995,STD-ACTOBAT-1995 1.229 0.179 699 698,0.224813869668154,0.194880886688445,1397,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1995.0,Death prior to hospital discharge,TRH + steroids versus steroids alone (intention-to-treat),1.15359629919769,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because death",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
38,CD000019,Ballard 1992b,STD-Ballard-1992b 0.761 0.481 91 89,-0.300104592450338,0.527610666943927,180,Pregnancy & Childbirth,efficacy,DICH,1,3,yes,1992.0,Death prior to hospital discharge,TRH + steroids versus steroids alone (timing of delivery subgroups),-0.568799327330947,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because death",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
39,CD000019,Campos 1993,STD-Campos-1993 0.747 0.56 66 69,-0.320211715749433,0.612682313877395,135,Pregnancy & Childbirth,efficacy,DICH,1,4,yes,1993.0,Death prior to hospital discharge,TRH + steroids versus steroids alone (optimally treated variously defined),-0.522639071663347,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because death",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
40,CD000020,Huchet 1987,STD-Huchet-1987 0.172 1.079 927 955,-1.76722490526431,1.08111068862228,1882,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1987.0,Incidence of Rhesus D alloimmunisation during pregnancy,Anti-D administration in pregnancy,-1.63463826957106,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
41,CD000021,International 1966,STD-International-1966 0.045 0.212 3389 1476,-3.73425004005463,0.4213003511728,4865,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1969.0,Immunisation after 6 months,"Anti-D prophylaxis postpartum (overall, irrespective of ABO status)",-8.86362907047043,"negative 
",positive,positive,neutral.,0.0,negative,0.0,"negative, because imm",0.0,negative,0.0,"negative 
",1.0,0.0,0.0,negative,negative,neutral,0.0
42,CD000021,MRC 1974,STD-MRC-1974 3.355 0.634 898 902,1.39746766171802,0.791981506486565,1800,Pregnancy & Childbirth,efficacy,DICH,1,7,no,1974.0,Immunisation after 6 months,"Dosage comparison, up to 50 ug versus more than 50 ug anti-D",1.76452057310977,"negative 
",positive,neutral,"neutral. the outcome """,0.0,positive,1.0,positive,1.0,negative,0.0,"negative 
",0.0,0.0,0.0,negative,negative,positive,1.0
43,CD000022,Abele-Horn 1997,STD-Abele_x002d_Horn-1997 1.17 0.593 58 30,0.157185583522413,0.593452345731122,88,Lungs,efficacy,DICH,1,1,no,1997.0,Overall mortality,Topical plus systemic versus no prophylaxis,0.264866395175779,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
44,CD000022,Bergmans 2001,STD-Bergmans-2001 0.714 0.283 87 139,-0.337364695404233,0.283419028162946,226,Lungs,efficacy,DICH,1,2,no,2001.0,Overall mortality,Topical versus control,-1.19033890416938,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
45,CD000023,Brink 1951,STD-Brink-1951 0.659 0.087 277 198,-0.90917743967985,0.192294479578258,475,Lungs,efficacy,DICH,1,1,no,1951.0,Symptom of sore throat on day 3,Antibiotics versus placebo for the treatment of sore throats: symptom of sore throat,-4.72804753248178,"negative 
",negative,negative,"neutral.

the outcome """,0.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
46,CD000023,Catanzaro 1954,STD-Catanzaro-1954 0.733 0.34 650 220,-0.325422400434628,0.358057437019716,870,Lungs,efficacy,DICH,1,4,no,1954.0,Incidence of acute rheumatic fever within 2 months. Rheumatic fever defined by clinical diagnosis,Antibiotics versus placebo for the treatment of sore throat: incidence of complications,-0.908855303057728,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
47,CD000023,Nelson 1984,STD-Nelson-1984 1.271 0.263 17 18,0.65232518603969,0.712974987873581,35,Lungs,efficacy,DICH,1,2,no,1984.0,Symptom of fever on day 3,Antibiotics versus control for the treatment of sore throat: symptom of fever,0.914934180209075,"negative 
",negative,negative,negative.,1.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,positive,0.0
48,CD000024,ARGIS-1 2004,STD-ARGIS_x002d_1-2004 1.277 0.366 83 46,0.246674048724404,0.368612074642891,129,Neurology,efficacy,DICH,1,1,no,2004.0,Dead or dependent at end of follow up (if > 1 month),Anticoagulant versus control in acute presumed ischaemic stroke,0.669196875776195,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
49,CD000025,Denmark 2000,STD-Denmark-2000 0.934 0.216 14 17,-0.262364264467491,0.822753351207442,31,Pregnancy & Childbirth,efficacy,DICH,1,9,no,2000.0,Other antihypertensive therapy,Magnesium chloride versus methyl dopa,-0.318885683154562,"neutral 
",neutral,neutral,neutral,1.0,i would classify this outcome,0.0,neutral. this,1.0,negative,0.0,"negative 
",1.0,1.0,0.0,neutral,negative,neutral,1.0
50,CD000025,India 2008,STD-India-2008 0.2 1.524 25 25,-1.69111594344837,1.57536309394497,50,Pregnancy & Childbirth,efficacy,DICH,1,6,no,2008.0,Eclampsia,Magnesium sulphate versus phenytoin,-1.07347693363409,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as e",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
51,CD000025,Magpie Trial 2002,STD-Magpie-Trial-2002 0.576 0.556 1297 1345,-0.554297995148075,0.559136484154963,2642,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2002.0,Maternal death,Magnesium sulphate versus none/placebo (subgroups by severity of pre-eclampsia),-0.99134649742236,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
52,CD000025,Mexico 1992,STD-Mexico-1992 3 1.602 19 19,1.15125602215353,1.66493326352823,38,Pregnancy & Childbirth,efficacy,DICH,1,7,no,1992.0,Eclampsia,Magnesium sulphate versus diazepam,0.69147277393801,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as e",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
53,CD000025,Nimodipine SG 2003,STD-Nimodipine-SG-2003 0.329 0.434 831 819,-1.13067422112777,0.439252678467964,1650,Pregnancy & Childbirth,efficacy,DICH,1,8,no,2003.0,Eclampsia,Magnesium sulphate versus nimodipine,-2.57408611615384,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as e",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
54,CD000026,Benhamou 1991a,STD-Benhamou-1991a 0.984 0.684 63 62,-0.0170944333593002,0.730883391419396,125,Oncology,efficacy,DICH,1,1,no,1991.0,Death,Antifungals versus placebo or no treatment,-0.0233887287082859,"negative 
",negative,negative,negative.,1.0,negative,1.0,this is considered a negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
55,CD000027,Read 1977,STD-Read-1977 0.045 0.72 15 15,-4.51085950651685,1.28388147753274,30,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1977.0,Failure to obtain relief,Antihistamines versus aspirin for itching in late pregnancy,-3.5134547740228,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
56,CD000028,Carter 1970,STD-Carter-1970 0.919 0.412 22 26,-0.1261512853269,0.616001988671047,48,Heart & Hypertension,efficacy,DICH,1,1,no,1970.0,Total mortality,Antihypertensive drug therapy vs control in adults 60 years or older,-0.204790386471084,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as higher",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
57,CD000029,CAST 1997,STD-CAST-1997 0.95 0.03 10554 10552,-0.0508720416143071,0.0299284077992531,21106,Neurology,efficacy,DICH,1,1,no,1997.0,Death or dependence at end of follow-up,Antiplatelet drug versus control in acute presumed ischaemic stroke,-1.6997911133641,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
58,CD000031,Ahluwalia 2002,STD-Ahluwalia-2002 1.947 0.27 300 300,0.732679570633765,0.294990857831945,600,Psychiatry & Mental Health,efficacy,DICH,1,1,yes,2002.0,Bupropion versus placebo/control. Subgroups by length of follow-up,Bupropion. Abstinence at 6m or greater follow-up,2.48373653345952,"neutral 
",neutral,neutral,based on the study's,0.0,positive.,0.0,neutral. the,1.0,negative,0.0,"positive 
",1.0,1.0,0.0,neutral,positive,neutral,1.0
59,CD000031,Berlin 1995,STD-Berlin-1995 1.571 0.434 44 44,0.566395474920802,0.53953340127956,88,Psychiatry & Mental Health,efficacy,DICH,1,6,yes,1995.0,MAOIs versus placebo,Monoamine oxidase inhibitors (MAOIs) versus placebo. Abstinence at 6m or greater follow-up,1.04978760087426,"neutral 
",neutral,neutral,based on the study outcome,0.0,positive,0.0,neutral. the,1.0,negative,0.0,"neutral. 
",1.0,1.0,1.0,neutral,neutral,neutral,1.0
60,CD000031,Cinciripini 2005,STD-Cinciripini-2005 1.223 0.327 71 76,0.253332592437143,0.410169991428498,147,Psychiatry & Mental Health,efficacy,DICH,1,7,yes,1999.0,Venlafaxine versus placebo,Venlafaxine versus placebo. Abstinence at 6m or greater follow-up,0.617628294929287,"neutral 
",neutral,neutral,based on the study's,0.0,positive,0.0,"neutral

",1.0,negative,0.0,"neutral. 
 ",1.0,1.0,1.0,neutral,neutral,positive,0.0
61,CD000031,Covey 2002,STD-Covey-2002 0.706 0.431 68 66,-0.405465108108164,0.500757002704481,134,Psychiatry & Mental Health,efficacy,DICH,1,5,yes,2000.0,SSRI versus placebo/control,Selective Serotonin Reuptake Inhibitors (SSRIs) versus placebo. Abstinence at 6m or greater follow-up.,-0.80970431949695,"neutral 
",neutral,neutral,based on the study outcome,0.0,positive,0.0,neutral. the,1.0,negative,0.0,"neutral. 
",1.0,1.0,1.0,neutral,neutral,neutral,1.0
62,CD000031,Da Costa 2002,STD-Da-Costa-2002 3.912 0.542 68 76,1.54044504094715,0.594841137477881,144,Psychiatry & Mental Health,efficacy,DICH,1,2,yes,2002.0,Nortriptyline versus placebo,Nortriptyline. Abstinence at 6m or greater follow-up,2.58967469445475,"neutral 
",neutral,neutral,based on the study design,0.0,positive,0.0,neutral. the,1.0,negative,0.0,"neutral. 
",1.0,1.0,1.0,neutral,neutral,neutral,1.0
63,CD000031,Parsons 2009,STD-Parsons-2009 0.507 0.687 71 72,-0.723000143709626,0.727913042543171,143,Psychiatry & Mental Health,efficacy,DICH,1,8,yes,2009.0,St John's wort versus placebo,St John's wort versus placebo. Abstinence at 6m or greater follow-up,-0.993250706408034,"neutral 
",neutral,neutral,neutral.,1.0,positive,0.0,"neutral

",1.0,negative,0.0,"neutral 
",1.0,1.0,1.0,neutral,neutral,neutral,1.0
64,CD000031,Sood 2012,STD-Sood-2012 0.7 0.553 80 40,-0.398639143037764,0.620586175777029,120,Psychiatry & Mental Health,efficacy,DICH,1,9,yes,2012.0,SAMe versus placebo,SAMe versus placebo. Abstinence at 6m or greater follow-up,-0.642359044718701,"neutral 
",neutral,neutral,based on the study's,0.0,positive,0.0,neutral. the,1.0,negative,0.0,"neutral 
",1.0,1.0,1.0,neutral,neutral,neutral,1.0
65,CD000032,Ceesay 1997,STD-Ceesay-1997 0.418 0.429 652 545,-0.889857474806,0.436970427145016,1197,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,1997.0,Stillbirth,Balanced protein/energy supplementation versus control or no intervention in pregnancy,-2.03642493754088,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as still",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
66,CD000032,Kafatos 1989,STD-Kafatos-1989 0.373 0.831 223 208,-1.00124745435012,0.842289139934864,431,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1989.0,Stillbirth,Nutritional education during pregnancy versus no nutritional education (or normal care),-1.1887217902721,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as still",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
67,CD000033,Bohn 1989,STD-Bohn-1989 1 0.365 41 41,0.0,0.498482545817653,82,Emergency & Trauma,efficacy,DICH,1,1,yes,1989.0,Death at the end of follow-up,Barbiturate vs no barbiturate,0.0,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
68,CD000033,Pérez-Bárcena 2008,STD-P_x00e9_rez_x002d_B_x00e1_rcena-2008 1.778 0.28 21 21,1.45083288225746,0.675976659689108,42,Emergency & Trauma,efficacy,DICH,1,3,no,2008.0,Death at the end of follow-up (6 months),Pentobarbital vs Thiopental,2.14627659322545,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
69,CD000033,Schwartz 1984,STD-Schwartz-1984 0.8 0.414 15 14,-0.405465108108164,0.750661084306402,29,Emergency & Trauma,efficacy,DICH,1,2,yes,1984.0,Death at the end of follow-up (1 year),Barbiturate vs Mannitol,-0.540144036483265,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
70,CD000034,Laurin 1987,STD-Laurin-1987 0.43 0.551 49 58,-0.968115799738741,0.620006378092995,107,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1987.0,Operative delivery for fetal distress,Bed rest in hospital versus ambulatory management,-1.56146103321784,"negative 
",negative,negative,negative,1.0,negative.,1.0,negative. operative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,positive,0.0
71,CD000035,Kulier 1997,STD-Kulier-1997 0.427 0.366 13 10,-2.66722820658196,1.19837853414984,23,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1997.0,No improvement in fetal heart rate abnormality,Tocolytics versus no treatment,-2.22569758267087,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
72,CD000035,Magann 1993,STD-Magann-1993 0.286 0.746 23 23,-1.52469668397901,0.867742006863901,46,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1993.0,No improvement in fetal heart rate abnormality,Terbutaline versus Magnesium sulphate,-1.75708525335705,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
73,CD000036,Cabero 1988,STD-Cabero-1988 1.171 0.228 44 54,0.283721671235684,0.409636245885491,98,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1988.0,Low birthweight for gestational age,Ritodrine versus control,0.692618570952814,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
74,CD000037,Campbell 1978,STD-Campbell-1978 1.833 0.298 50 50,0.911517453121497,0.436827144275454,100,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1978.0,Forceps delivery,Prophylactic tocolytics in 2nd stage of labour,2.08667768261835,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"the outcome ""forceps",0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
75,CD000038,Alfirevic 1995,STD-Alfirevic-1995 3.041 1.625 72 73,1.12620024518694,1.64141954503702,145,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1995.0,Perinatal deaths including major malformations,Biophysical profile versus conventional fetal monitoring (CTG),0.686113582960617,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative. perin,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
76,CD000039,Bath 2000,STD-Bath-2000 2 0.707 16 18,0.693147180559945,0.707106781186547,34,Neurology,efficacy,DICH,1,1,no,2000.0,"Death or dependency, end of trial by intervention",Blood pressure lowering therapy in acute stroke,0.980258143468547,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
77,CD000039,COSSACS 2010,STD-COSSACS-2010 1.105 0.15 379 384,0.099490477838031,0.149938232147918,763,Neurology,efficacy,DICH,1,2,no,2005.0,"Death or dependency, end of trial by C/S",Blood pressure altering by continue or stop prestroke antihypertensives (C/S),0.663543089796344,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
78,CD000040,USA 1989,STD-USA-1989 2.981 0.523 36 36,1.15745278869104,0.562923722082412,72,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1989.0,Preterm labour.,Routine transfusion versus selective transfusion.,2.05614498605477,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
79,CD000044,Harrison 1979,STD-Harrison-1979 0.838 0.814 16 14,-0.182321556793955,0.82663978450915,30,Gynaecology & Urology,efficacy,DICH,1,1,no,1979.0,Pregnancy per patient,Bromocriptine vs Placebo,-0.220557442565162,"positive 
",positive,positive,negative.,0.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,neutral,0.0
80,CD000046,Ingelman 1953,STD-Ingelman-1953 1.79 0.612 25 20,0.606135803570315,0.632797677328939,45,Pregnancy & Childbirth,efficacy,DICH,1,6,no,1953.0,Single injection given before symptoms subsided,Oxytocin versus placebo,0.957866669373433,"neutral 
",neutral,neutral,neutral,1.0,positive,0.0,neutral. the,1.0,negative,0.0,"negative 
",1.0,1.0,0.0,neutral,negative,neutral,1.0
81,CD000046,Kee 1989,STD-Kee-1989 3.603 0.534 35 35,1.38629436111989,0.593616839704664,70,Pregnancy & Childbirth,efficacy,DICH,1,5,no,1989.0,Total Improvement Rating (all outcomes measured by the researcher),Use of Serrapeptase (Danzen) versus placebo,2.33533530115082,"neutral 
",positive,positive,based on the study's,0.0,positive.,1.0,"positive

the",1.0,negative,0.0,"**positive** 
",1.0,0.0,1.0,neutral,positive,neutral,0.0
82,CD000046,Murata 1965,STD-Murata-1965 8.02 0.543 35 24,2.26868354131836,0.62341753687826,59,Pregnancy & Childbirth,efficacy,DICH,1,8,no,1965.0,Improvement in symptoms (pain and swelling) measured by researcher,Use of Kimotab (Bromelain and trypsin protease complex) versus placebo,3.63910767200858,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
83,CD000047,Rabinovici 1987,STD-Rabinovici-1987 3.667 0.592 27 27,1.70474809223843,0.72691752689634,54,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1987.0,Maternal febrile morbidity,Effect of caesarean delivery of the second twin,2.34517401102853,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as mater",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
84,CD000048,LeBard 1989,STD-LeBard-1989 0.341 1.045 11 15,-1.29098418131557,1.20037872811421,26,Neonatal,efficacy,DICH,1,1,no,1989.0,Postoperative apnoea/bradycardia,Caffeine vs placebo with induction of general anesthesia,-1.07548072210818,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as ap",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
85,CD000049,Janssens 1985,STD-Janssens-1985 0.496 0.53 50 50,-0.72676379135893,0.553122098585887,100,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1985.0,Preterm birth (< 38 weeks),Flunarizine versus no treatment,-1.31393013082821,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
86,CD000050,Ford-London,STD-Ford_x002d_London 0.127 0.847 35 38,-2.65324196460721,1.48754307456957,73,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1995.0,Number lost to follow up,CASE MANAGEMENT vs STANDARD CARE,-1.78364042693348,"negative 
",neutral,negative,negative,0.0,negative,0.0,"negative

l",0.0,negative,0.0,"negative 
",0.0,0.0,0.0,negative,negative,negative,0.0
87,CD000051,Bung 1987,STD-Bung-1987 0.664 0.342 30 31,-0.653141845946246,0.537570701927193,61,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1987.0,Non-cephalic births,Cephalic version by postural management,-1.21498780272945,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as c",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
88,CD000052,Chou 1995,STD-Chou-1995 0.913 0.651 71 81,-0.0971028304188448,0.691435657072421,152,Lungs,efficacy,DICH,1,1,no,1995.0,Hospital admission,Spacer (chamber) versus nebuliser (multiple-treatment studies),-0.140436538708437,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as hospital",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
89,CD000052,Ferrés 1989,STD-Ferr_x00e9_s-1989 0.585 0.84 41 48,-0.57251919277133,0.893514576472202,89,Lungs,efficacy,DICH,1,2,no,1989.0,Hospital admission,Spacer (chamber) versus nebuliser (single-treatment studies),-0.640749695468613,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as hospital",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
90,CD000053,Abden Abdi 1989 SOM,STD-Abden-Abdi-1989-SOM 0.915 0.141 100 101,-0.179133610317767,0.282427619799725,201,Infectious Diseases,efficacy,DICH,1,9,yes,1989.0,Parasitological failure,Metrifonate 3 doses 2 weeks apart: 7.5 mg/kg versus 5 mg/kg,-0.634263782149901,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because """,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
91,CD000053,Basra 2012 GAB,STD-Basra-2012-GAB 0.574 0.186 30 14,-2.43141796483701,1.10038704479453,44,Infectious Diseases,efficacy,DICH,1,14,yes,2009.0,Parasitological failure at six weeks,Mefloquine versus placebo,-2.20960249971955,"negative 
",negative,negative,negative,1.0,negative,1.0,"negative

par",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
92,CD000053,Borrmann 2001 GAB,STD-Borrmann-2001-GAB 0.337 0.197 89 30,-2.38262780066758,0.515154943084714,119,Infectious Diseases,efficacy,DICH,1,1,yes,2001.0,Parasitological failure,Praziquantel 40 mg/kg single dose versus placebo,-4.62507024857524,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
93,CD000053,Davis 1981 ZMB,STD-Davis-1981-ZMB 0.168 1.498 45 53,-1.8416491387309,1.52561275816975,98,Infectious Diseases,efficacy,DICH,1,2,yes,1981.0,Parasitological failure at four to six weeks,Praziquantel 40 mg/kg single dose versus lower doses,-1.20715373470021,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
94,CD000053,Jewsbury 1976 ZWE,STD-Jewsbury-1976-ZWE 0.407 0.164 55 38,-4.74183555147433,1.44923056022399,93,Infectious Diseases,efficacy,DICH,1,7,yes,1976.0,Parasitological failure,Metrifonate multiple doses versus placebo,-3.27196767831163,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
95,CD000053,Kardaman 1985 SDN,STD-Kardaman-1985-SDN 0.714 0.211 110 101,-0.483646405649522,0.301781047827557,211,Infectious Diseases,efficacy,DICH,1,3,yes,1985.0,Parasitological failure,Praziquantel 40 mg/kg single dose versus 2 x 20 mg/kg split dose,-1.60264008999626,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
96,CD000053,Keiser 2010 CIV,STD-Keiser-2010-CIV 0.154 0.558 26 20,-3.13549421592915,0.802170967356439,46,Infectious Diseases,efficacy,DICH,1,12,yes,2008.0,Parasitological failure,Praziquantel versus artesunate,-3.90876053051658,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
97,CD000053,Rey 1984 NER,STD-Rey-1984-NER 0.752 0.21 50 62,-0.53467683958817,0.384862471874114,112,Infectious Diseases,efficacy,DICH,1,8,yes,1984.0,Parasitological failure at one month,Metrifonate multiple doses versus single dose,-1.38926728029502,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because """,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
98,CD000053,Sacko 2009 MLI,STD-Sacko-2009-MLI 1.16 0.098 150 150,0.357600441459675,0.235231531400485,300,Infectious Diseases,efficacy,DICH,1,4,yes,2009.0,Praziquantel 40 mg/single dose versus praziquantel 2 x 40 mg/kg: parasitological failure,Praziquantel 40 mg/kg single dose versus praziquantel 2 x 40 mg/kg or 3 x 40 mg/kg,1.52020623821411,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because """,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
99,CD000053,van den Biggelaar 02 GAB,STD-van-den-Biggelaar-02-GAB 2.707 0.313 41 21,2.91777073208428,0.700937045185045,62,Infectious Diseases,efficacy,DICH,1,5,yes,,Parasitological failure,Praziquantel 40 mg/kg single dose versus multiple doses,4.16267160100519,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
100,CD000053,Wilkins 1987 GMB,STD-Wilkins-1987-GMB 0.448 0.264 33 39,-1.75785791755237,0.520429048943587,72,Infectious Diseases,efficacy,DICH,1,10,yes,1987.0,Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose: parasitological failure,Praziquantel versus metrifonate,-3.37770906739474,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
101,CD000054,Martin 1997,STD-Martin-1997 7.426 2 202 203,1.10848891216402,1.63601450199471,405,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1997.0,Neonatal death,Antibiotic therapy versus placebo or no therapy,0.677554453712052,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as ne",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
102,CD000055,Canadian Trial,STD-Canadian-Trial 0.363 0.089 1391 1396,-1.05758548217283,0.0953946120934783,2787,Pregnancy & Childbirth,efficacy,DICH,1,1,no,,Not complied with allocated procedure,Chorion villus sampling vs amniocentesis,-11.0864278281932,"neutral 
",neutral,neutral,negative,0.0,negative,0.0,"negative

this",0.0,negative,0.0,"negative 
",1.0,1.0,0.0,neutral,negative,neutral,1.0
103,CD000055,Danish Trial,STD-Danish-Trial 1.931 0.197 1443 1074,0.714200589757778,0.218001980391916,2517,Pregnancy & Childbirth,efficacy,DICH,1,2,no,,Number of abnormal karyotypes,Transabdominal CVS vs amniocentesis,3.27611973282909,"negative 
",negative,negative,negative,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
104,CD000056,Connaughton 1974,STD-Connaughton-1974 1.292 0.506 31 31,0.260883879297057,0.511512755603708,62,Gynaecology & Urology,efficacy,DICH,1,1,no,1974.0,Ovulation following all dose ranges,Clomiphene citrate in oligo-amenorrheic women vs placebo,0.510024190871156,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
105,CD000057,Battacharya 2008,STD-Battacharya-2008 0.789 0.285 192 193,-0.238222788150325,0.28626354111431,385,Gynaecology & Urology,efficacy,DICH,1,1,yes,2008.0,Live birth per woman randomised,Clomiphene versus placebo or no treatment in unexplained subfertility,-0.832179980807261,"positive 
",positive,positive,positive.,1.0,positive,1.0,this is considered a positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
106,CD000058,Glassman 1988,STD-Glassman-1988 5.182 0.745 33 38,1.90954250488444,0.824957911384305,71,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1988.0,Smoking Cessation,Clonidine vs placebo,2.31471506428754,"positive 
",positive,positive,positive,1.0,positive,1.0,this is a positive health,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
107,CD000059,Essock 1996 (H/CPZ/Flu),STD-Essock-1996-_x0028_H_x002f_CPZ_x002f_Flu_x0029_ 0.645 0.805 138 89,-0.450927482184922,0.828071241531076,227,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1996.0,Death,CLOZAPINE versus TYPICAL ANTIPSYCHOTICS - OVERALL,-0.544551554949755,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
108,CD000060,Benito Fernandez 2000,STD-Benito-Fernandez-2000 0.667 0.231 51 51,-0.723918839226699,0.405662778132638,102,Lungs,efficacy,DICH,1,1,no,2000.0,Primary outcome: hospital admissions,Anticholinergic and beta2-agonists versus beta2-agonists alone (all protocols),-1.78453355409897,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as hospital",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
109,CD000061,Daya 1995a,STD-Daya-1995a 1.723 0.362 115 117,0.554114618819437,0.37060024678788,232,Gynaecology & Urology,efficacy,DICH,1,1,no,1995.0,pregnancy per cycle start,FSH vs hMG in IVF: clinical pregnancy,1.49518146202583,"positive 
",positive,positive,positive.,1.0,positive,1.0,this outcome is considered a,0.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
110,CD000062,Flint 1989,STD-Flint-1989 0.139 0.162 503 498,-2.60217206795214,0.257972984299229,1001,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1989.0,Antenatal clinic waiting time > 15 min,Continuity of caregivers during pregnancy and childbirth,-10.0869944774288,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative. prolong,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
111,CD000063,Athens 1993,STD-Athens-1993 1.1 0.168 746 682,0.104976261050519,0.184716749383225,1428,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1993.0,Cesarean delivery,Continuous electronic fetal heart rate monitoring versus intermittent auscultation,0.568309378554126,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

c",1.0,negative,1.0,"neutral 
",1.0,1.0,0.0,negative,neutral,negative,1.0
112,CD000064,Bauer 1973,STD-Bauer-1973 0.425 0.616 28 26,-0.890067536775052,0.64297192893037,54,Neurology,efficacy,DICH,1,1,yes,1973.0,All deaths,Corticosteroids versus placebo,-1.38430232600627,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
113,CD000065,AMSTERDAM 1980,STD-AMSTERDAM-1980 0.507 0.429 64 58,-0.69203791810566,0.439307169019123,122,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1979.0,RDS,Corticosteroids versus placebo or no treatment,-1.57529393306016,"negative 
",negative,negative,based on the context of,0.0,negative.,1.0,the outcome 'rds,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
114,CD000066,Buchanan 2010,STD-Buchanan-2010 0.801 0.13 122 123,-0.442698178555468,0.257122736074076,245,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,2010.0,Presence of stretch marks,Topical preparations with active ingredients compared with other topical preparations with active ingredient,-1.72173875136397,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
115,CD000066,de Buman 1987,STD-de-Buman-1987 0.75 0.342 60 30,-0.405465108108164,0.488762609953839,90,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1987.0,Presence of stretch marks,Topical preparations with active ingredients compared with placebo or no treatment,-0.829574725747655,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
116,CD000067,Candy 1995,STD-Candy-1995 5.542 0.691 24 19,2.47653840011748,0.854547892654552,43,Gastroenterology,efficacy,DICH,1,1,no,1995.0,Maintenance of remission,Azathioprine versus placebo,2.89806858270332,"positive 
",positive,positive,neutral.,0.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
117,CD000067,Mantzaris 2004,STD-Mantzaris-2004 1.016 0.164 16 20,0.0800427076735361,0.850150816182876,36,Gastroenterology,efficacy,DICH,1,4,no,2004.0,Maintenance of remission,Azathioprine + infliximab versus infliximab,0.0941511860600486,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
118,CD000067,Mantzaris 2009,STD-Mantzaris-2009 1.654 0.195 38 39,1.32422193247751,0.498766952500267,77,Gastroenterology,efficacy,DICH,1,3,no,2009.0,Maintenance of remission,Azathioprine versus budesonide,2.65499132578717,"positive 
",positive,positive,neutral.,0.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
119,CD000067,Maté-Jiménez 2000,STD-Mat_x00e9__x002d_Jim_x00e9_nez-2000 2.125 1.247 15 1,1.22377543162212,1.70811213297709,16,Gastroenterology,efficacy,DICH,1,2,no,2000.0,Maintenance of remission,Azathioprine or 6-mercaptopurine versus mesalazine or sulfasalazine,0.71644911829599,"positive 
",positive,positive,neutral.,0.0,positive,1.0,positive,1.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
120,CD000069,Iffland 1989,STD-Iffland-1989 0.161 2.009 14 17,-0.969400557188104,1.67219563583754,31,Gynaecology & Urology,efficacy,DICH,1,1,no,1989.0,Live birth/ongoing pregnancies per woman randomised following treatment,Danazol versus placebo in unexplained subfertility,-0.579717191225995,"positive 
",positive,positive,positive.,1.0,positive,1.0,this is considered a positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
121,CD000070,Li 1987,STD-Li-1987 0.764 0.369 85 73,-0.270656122861854,0.36966338556474,158,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1987.0,Induction or elective Caesarean,Dietary regulation for 'gestational diabetes',-0.73216913936004,"negative 
",negative,negative,negative,1.0,negative.,1.0,"negative

ind",1.0,negative,1.0,"**negative** 
",1.0,1.0,1.0,negative,negative,negative,1.0
122,CD000071,AbuRahma 1996,STD-AbuRahma-1996 2.954 1.161 134 130,1.08322736982863,1.16134355773995,264,Neurology,efficacy,DICH,1,1,no,1996.0,Ipsilateral stroke,Perioperative events: synthetic versus vein (< 30 days),0.932736366090202,"negative 
",negative,negative,negative,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
123,CD000071,AbuRahma 2002,STD-AbuRahma-2002 16.123 1.468 100 100,2.7802464923067,1.46764395180007,200,Neurology,efficacy,DICH,1,2,no,2002.0,Ipsilateral Stroke,Perioperative events: Dacron versus other synthetic patch (< 30 days),1.89436033780313,"negative 
",negative,negative,negative,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
124,CD000071,Hayes 2001,STD-Hayes-2001 1.559 0.541 137 139,0.443783972410301,0.541395488317236,276,Neurology,efficacy,DICH,1,3,no,2001.0,Ipsilateral stroke,Events during long-term (> 1 year) follow-up: synthetic versus vein,0.81970386157016,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as an",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
125,CD000073,Chester 1992,STD-Chester-1992 0.297 0.897 338 336,-1.40124232255576,1.12070487071451,674,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1992.0,Perinatal deaths,Doppler ultrasound in high risk pregnancies,-1.25032232764582,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
126,CD000074,Peliowski 1990,STD-Peliowski-1990 0.455 0.429 11 10,-1.94591014905531,1.00888906370182,21,Neonatal,efficacy,DICH,1,1,no,1990.0,Failed treatment in first 48 hours,Doxapram vs placebo,-1.92876523204183,"negative 
",negative,negative,negative,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
127,CD000075,Eyal 1985,STD-Eyal-1985 1.556 1.116 9 7,0.538996500732687,1.3451854182691,16,Neonatal,efficacy,DICH,1,1,no,1985.0,Failed treatment in the first 48 hrs,Doxapram vs aminophylline,0.400685655235718,"negative 
",negative,negative,negative,1.0,negative,1.0,"the outcome ""failed treatment",0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
128,CD000076,Abraham 1987,STD-Abraham-1987 0.333 0.549 14 14,-1.88706964903238,0.857527571191466,28,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1987.0,Global impression: 1a. Not improved,ECT versus PLACEBO or SHAM ECT,-2.2005935580712,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
129,CD000076,Bagadia 1981,STD-Bagadia-1981 1.125 0.211 20 18,0.405465108108165,0.718795288428261,38,Psychiatry & Mental Health,efficacy,DICH,1,2,no,1981.0,Global impression: 1. Not improved - at end of course of ECT,ECT with or without ANTIPSYCHOTIC DRUGS versus ANTIPSYCHOTIC DRUGS with or without SHAM ECT,0.564089824510073,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
130,CD000076,Baker 1960,STD-Baker-1960 2.533 0.41 24 19,1.7227665977411,0.6774426702154,43,Psychiatry & Mental Health,efficacy,DICH,1,9,no,1960.0,Global impression: Not improved,ECT - NUMBER OF TREATMENTS: 12 versus 20 TREATMENTS,2.5430441179522,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
131,CD000076,Chanpattana 2000,STD-Chanpattana-2000 1 0.282 23 23,0.0,0.590326052690247,46,Psychiatry & Mental Health,efficacy,DICH,1,7,no,2000.0,Global impression: not improved,ECT - DOSE: THRESHOLD versus SUPRATHRESHOLD ECT,0.0,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
132,CD000076,Doongaji 1973,STD-Doongaji-1973 0.905 0.431 35 19,-0.143100843640673,0.619346222713713,54,Psychiatry & Mental Health,efficacy,DICH,1,6,no,1973.0,Global impression: 1. Not improved,ECT - ELECTRODE PLACEMENT: UNILATERAL versus BILATERAL ECT,-0.231051451341168,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
133,CD000077,Copenhagen Trial,STD-Copenhagen-Trial 1.37 0.262 581 579,0.331146557916953,0.274947842853416,1160,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1997.0,Not complied with allocated procedure,Early amniocentesis vs chorion villus sampling,1.20439773042154,"neutral 
",neutral,neutral,negative,0.0,negative,0.0,"negative

the",0.0,negative,0.0,"negative 
",1.0,1.0,0.0,neutral,negative,neutral,1.0
134,CD000078,Zlatnik 1993,STD-Zlatnik-1993 0.556 1.181 18 20,-0.635988766719997,1.27058218347627,38,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1993.0,Birth injury to infant,Planned immediate caesarean section versus planned vaginal delivery in singletons (infant outcomes),-0.5005490986659,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
135,CD000080,Campbell 1975,STD-Campbell-1975 0.629 0.556 51 51,-0.474457979595116,0.569042637953892,102,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1975.0,Pre-eclampsia,Energy/protein restriction in pregnant women with high weight-for-height or weight gain,-0.833782827418919,"negative 
",negative,negative,negative,1.0,negative.,1.0,"negative, as pre",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
136,CD000081,Belizan 1993,STD-Belizan-1993 0.796 0.343 1298 1308,-0.231723139740679,0.347639848163177,2606,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1993.0,Severe perineal/vaginal trauma,Restrictive versus routine episiotomy (where non-instrumental was intended),-0.666560927825257,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as severe",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
137,CD000081,Murphy 2008b,STD-Murphy-2008b 1.299 0.439 90 85,0.292811300505197,0.491481771527902,175,Pregnancy & Childbirth,efficacy,DICH,1,4,yes,2008.0,Severe perineal/vaginal trauma,Restrictive versus routine episiotomy (operative vaginal birth was intended),0.59577245275021,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
138,CD000083,Brocks 1984,STD-Brocks-1984 0.643 0.178 31 34,-1.56370190311142,0.603932826944376,65,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1984.0,Vaginal cephalic birth not achieved (CS + breech vaginal birth) (not prespecified),External cephalic version at term versus no ECV attempt,-2.5891983898657,"negative 
",negative,negative,negative,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
139,CD000084,Akhtar 2013,STD-Akhtar-2013 0.676 0.213 63 60,-0.689220987844664,0.369574907824927,123,Pregnancy & Childbirth,efficacy,DICH,1,3,yes,2013.0,Non-cephalic presentation at the birth,External cephalic version (ECV) commenced before term versus ECV at term,-1.86490200836675,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as non",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
140,CD000084,Mensink 1980,STD-Mensink-1980 1.04 0.247 50 52,0.0645385211375714,0.40568871482127,102,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1980.0,Non-cephalic presentation at the birth,External cephalic version (ECV) before term versus no ECV,0.159083846258835,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as non",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
141,CD000084,Van Veelen 1989,STD-Van-Veelen-1989 0.589 0.135 89 90,-1.31765976276032,0.322559544340141,179,Pregnancy & Childbirth,efficacy,DICH,1,2,yes,1989.0,Non-cephalic presentation at the birth,External cephalic version (ECV) commenced before term versus no ECV,-4.08501247562167,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as non",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
142,CD000087,Gadir 1990,STD-Gadir-1990 0.535 0.523 29 30,-0.641853886172395,0.534756872121062,59,Gynaecology & Urology,efficacy,DICH,1,1,no,1990.0,Pregnancy per patient,Daily FSH vs HMG for PCOD Patients,-1.20027234736889,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
143,CD000088,Bloch 1995,STD-Bloch-1995 1.744 0.498 32 31,0.710388986994452,0.62693772453268,63,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1995.0,Service utilisation: 1. Hospital admission,ANY FAMILY-BASED INTERVENTIONS (> 5 sessions) vs STANDARD CARE,1.13310933318613,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

h",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
144,CD000088,Leff 1989,STD-Leff-1989 4.364 1.037 11 12,1.83827948486295,1.21809943508986,23,Psychiatry & Mental Health,efficacy,DICH,1,3,no,1989.0,Global state: 1. Relapse,GROUP FAMILY-BASED INTERVENTIONS vs INDIVIDUAL FAMILY-BASED INTERVENTIONS (> 5 sessions),1.50913745783598,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as rel",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
145,CD000088,Schooler 1997,STD-Schooler-1997 0.978 0.071 272 256,-0.0564304364058583,0.177687343768397,528,Psychiatry & Mental Health,efficacy,DICH,1,2,no,1997.0,Service utilisation: Hospital Admission by 19-24 months,BEHAVIOURAL FAMILY-BASED vs SUPPORTIVE FAMILY-BASED INTERVENTIONS (> 5 sessions),-0.317582756369028,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as hospital",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
146,CD000089,Gustafsson 1986,STD-Gustafsson-1986 0.122 0.958 9 8,-2.63905732961526,1.28173988892331,17,Lungs,efficacy,DICH,1,1,no,1986.0,General paediatric assessment - no improvement,FAMILY THERAPY & DRUG THERAPY vs DRUG THERAPY ALONE,-2.05896481214463,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because there",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
147,CD000091,AISS 1994,STD-AISS-1994 0.749 0.157 64 68,-0.66865616055165,0.356307499518462,132,Neurology,efficacy,DICH,1,1,yes,1994.0,Death or dependency at the end of follow-up,Fibrinogen depleting agents versus control,-1.87662668188381,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
148,CD000092,Acton 1988,STD-Acton-1988 1.695 0.199 203 217,0.53130075846847,0.201135984797292,420,Gynaecology & Urology,efficacy,DICH,1,1,no,1988.0,Pregnancy rate (overall),OIL SOLUBLE VERSUS WATER SOLUBLE CONTRAST MEDIA FOR TUBAL FLUSHING,2.6415002715895,"positive 
",positive,positive,"the outcome ""pregn",0.0,positive,1.0,"positive, as a",1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,neutral,0.0
149,CD000092,Ogata 1993,STD-Ogata-1993 3.023 0.389 105 85,1.2476478678286,0.456264896389867,190,Gynaecology & Urology,efficacy,DICH,1,3,no,1993.0,Pregnancy rate,OIL SOLUBLE CONTRAST MEDIUM VERSUS NO TREATMENT FOR TUBAL FLUSHING,2.73448138943066,"positive 
",positive,positive,positive.,1.0,positive,1.0,"positive, as pregnancy",1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
150,CD000093,Barton 2010,STD-Barton-2010 1.196 0.15 100 110,0.330241686870577,0.278144082149491,210,Emergency & Trauma,efficacy,DICH,1,8,no,2010.0,Number of patients transfused,Long Gamma nail versus sliding hip screw (SHS),1.18730437950891,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
151,CD000093,Davis 1988,STD-Davis-1988 0.694 0.353 116 114,-0.417986614906206,0.402593499340213,230,Emergency & Trauma,efficacy,DICH,1,10,no,1988.0,Fracture fixation complications,Kuntscher-Y nail versus sliding hip screw (SHS),-1.03823488355182,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
152,CD000093,Varela-Egocheaga 2009,STD-Varela_x002d_Egocheaga-2009 1.429 0.267 40 40,0.619039208406224,0.458137653866291,80,Emergency & Trauma,efficacy,DICH,1,13,no,2009.0,Number of patients transfused,Gamma nail versus percutaneous compression plate (PCCP),1.35120788082372,"negative 
",negative,negative,negative,1.0,negative.,1.0,negative. a higher,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
153,CD000094,Angeleri 1992,STD-Angeleri-1992 0.343 0.608 55 57,-1.17865499634165,0.696066481744773,112,Neurology,efficacy,DICH,1,1,no,1992.0,Case fatality at the end of scheduled follow-up,Ganglioside versus control. Intention-to-treat analysis,-1.69330807796865,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
154,CD000096,Albizzati 1979,STD-Albizzati-1979 1.481 0.493 46 47,0.398907707562005,0.500171969050657,93,Neurology,efficacy,DICH,1,1,no,1979.0,Death within the scheduled treatment period,CI and/or PICH stroke: intravenous glycerol versus avoid glycerol,0.797541110348798,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as death",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
155,CD000097,Bachus 1990,STD-Bachus-1990 1.712 0.646 33 26,0.56531380905006,0.678568010927825,59,Gynaecology & Urology,efficacy,DICH,1,1,no,1990.0,Pregnancy per cycle,GnRH-a + HMG/FSH vs HMG/FSH,0.833098230311639,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
156,CD000098,Cavenee 1993,STD-Cavenee-1993 2.485 0.53 84 164,0.85015092936961,0.505820818921781,248,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1993.0,Failure to achieve microbiological cure,Any penicillin versus any other antibiotic,1.68073534652411,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
157,CD000098,Ramus 2001,STD-Ramus-2001 1.218 1.021 43 52,0.198450938723838,1.02195413003835,95,Pregnancy & Childbirth,efficacy,DICH,1,4,no,2001.0,Failure to achieve microbiological cure,Ceftriaxone versus cefixime,0.194187716347299,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative. failure,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
158,CD000099,Owen 1991,STD-Owen-1991 11.842 1.552 13 12,2.47166142303798,1.55160735371967,25,Gynaecology & Urology,efficacy,DICH,1,2,no,1991.0,Live birth rate per woman randomised,Growth hormone versus placebo: Poor responder as defined by the study,1.59296836091467,"positive 
",positive,positive,"the outcome ""live birth",0.0,positive,1.0,"positive, as it",1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,neutral,0.0
159,CD000099,Tapanainen 1992,STD-Tapanainen-1992 0.472 1.271 19 19,-0.750305594399894,1.27058218347627,38,Gynaecology & Urology,efficacy,DICH,1,1,no,1992.0,Live birth rate per woman randomised,Growth hormone versus placebo: Routine use,-0.590521104543655,"positive 
",positive,positive,neutral.,0.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,neutral,0.0
160,CD000100,Averhoff 1998,STD-Averhoff-1998 1.308 0.126 891 874,0.307150565345716,0.14430914627938,1765,Hepato-Biliary,efficacy,DICH,1,6,no,1998.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) at follow-up (7 months),Different brands of RV (10 µg Recombinvax-HB versus 20 µg Engerix-B by intramuscular route),2.12842063905691,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because having",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
161,CD000100,Chan 1992,STD-Chan-1992 1.474 0.261 100 100,0.505548566665147,0.338497315444139,200,Hepato-Biliary,efficacy,DICH,1,3,no,1992.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) at follow-up (12 months),Different doses of plasma-derived vaccine (PDV) by intramuscular route,1.49350834880868,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
162,CD000100,Coleman 1991,STD-Coleman-1991 2.208 0.239 209 216,0.939366972182687,0.279389727586139,425,Hepato-Biliary,efficacy,DICH,1,7,no,1991.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) at maximum follow-up,Intradermal route versus intramuscular route,3.36221012955127,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative. a higher,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
163,CD000100,Crosnier 1981,STD-Crosnier-1981 0.686 0.236 184 170,-0.454571778056469,0.284199733223705,354,Hepato-Biliary,efficacy,DICH,1,1,no,1981.0,Hepatitis B events at maximum follow-up - Risk of infection,Plasma-derived vaccine (PDV) versus placebo by intramuscular route,-1.59947996044971,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because a",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
164,CD000100,de Lalla 1988,STD-de-Lalla-1988 21.127 1.011 71 75,3.36797173403383,1.04073116444679,146,Hepato-Biliary,efficacy,DICH,1,2,no,1988.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) at one year follow-up,Gluteal intramuscular injection versus deltoid intramuscular injection (20 µg plasma-derived vaccine),3.23615920142462,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because a",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
165,CD000100,Halliday 1990,STD-Halliday-1990 1.451 0.256 600 200,0.415036689251665,0.282316603273711,800,Hepato-Biliary,efficacy,DICH,1,5,no,1990.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) at maximum follow-up,Recombinant vaccine (RV) versus plasma-derived vaccine (PDV),1.47011080623296,"negative 
",negative,negative,negative.,1.0,negative.,1.0,this would be considered a,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
166,CD000100,Pennie 1992,STD-Pennie-1992 1.27 0.184 349 344,0.280900826995294,0.215045365573771,693,Hepato-Biliary,efficacy,DICH,1,4,no,1992.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) at follow-up (7 months),Plasma-derived vaccines (PDV) produced in different countries: 20 µg by intramuscular route,1.30623985430149,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because a",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
167,CD000100,Ricciardi 1990,STD-Ricciardi-1990 5.2 0.768 50 65,1.79175946922805,0.815280650869711,115,Hepato-Biliary,efficacy,DICH,1,8,no,1990.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) by recombinant vaccine,"Rapid schedule (0, 1, and 2 months) versus standard schedule (0, 1, and 6 months)",2.19772107594688,"negative 
",negative,negative,negative.,1.0,negative.,1.0,this would be considered a,0.0,negative,1.0,"**negative** 
",1.0,1.0,1.0,negative,negative,negative,1.0
168,CD000100,Williams 2001,STD-Williams-2001 1.154 0.28 13 15,0.405465108108165,0.799305253885453,28,Hepato-Biliary,efficacy,DICH,1,9,no,2001.0,Number of health-care workers without protective anti-HBs level (< 10 IU/litre) after booster vaccination,Booster vaccination with recombinant vaccine in non-responders,0.507271916626574,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
169,CD000101,Harrison 1985,STD-Harrison-1985 0.054 0.914 10 10,-3.80666248977032,1.58564993434418,20,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1985.0,Miscarriage,HCG vs placebo for recurrent spontaneous miscarriage (RSM),-2.40069539141042,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
170,CD000102,"Connor AN, IP, PNb",STD-Connor-AN_x002c_-IP_x002c_-PNb 0.305 0.357 121 127,-1.39091330697619,0.403378747236983,248,Infectious Diseases,efficacy,DICH,1,1,no,1994.0,HIV infection status in the child,Any zidovudine vs placebo/no treatment,-3.44815713892589,"negative 
",negative,negative,negative.,1.0,negative.,1.0,this would be considered a,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
171,CD000102,"Guay IP, PNb",STD-Guay-IP_x002c_-PNb 0.578 0.185 246 250,-0.685447784137899,0.229350685223008,496,Infectious Diseases,efficacy,DICH,1,7,no,1999.0,HIV infection status in the child,Nevirapine versus zidovudine,-2.98864502397893,"negative 
",negative,neutral,negative.,1.0,negative.,1.0,"negative, because hiv",1.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,neutral,0.0
172,CD000102,MOD,STD-MOD 0.168 0.608 170 200,-1.87651815563131,0.626519749954658,370,Infectious Diseases,efficacy,DICH,1,5,no,1999.0,HIV infection status in the child,Caesarean section versus vaginal delivery,-2.99514605208713,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"neutral

",0.0,negative,1.0,"**negative** 
",1.0,1.0,1.0,negative,negative,neutral,0.0
173,CD000102,"Stiehm AN, IP, PNb",STD-Stiehm-AN_x002c_-IP_x002c_-PNb 0.674 0.423 230 224,-0.414029348167004,0.444182858071884,454,Infectious Diseases,efficacy,DICH,1,6,no,1999.0,HIV infection status in the child,HIVIG plus zidovudine versus IVIG plus zidovudine,-0.932114647477009,"negative 
",negative,negative,negative.,1.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
174,CD000103,ALIAS-Part 1 2011,STD-ALIAS_x002d_Part-1-2011 1.514 0.423 207 217,0.437404700763307,0.444967998306775,424,Neurology,efficacy,DICH,1,1,no,2011.0,Mortality at early follow-up (not later than 28 days),"Haemodilution, all types, versus control",0.983002603395642,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
175,CD000104,Clark 1992,STD-Clark-1992 1.059 0.529 37 28,0.0707690708882072,0.647818444519791,65,Neonatal,efficacy,DICH,1,1,yes,1992.0,Death by 28 to 30 days,HFOV versus CV (all trials),0.109242136414727,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
176,CD000104,Dani 2006,STD-Dani-2006 1.846 1.157 13 12,0.693147180559945,1.29684932888065,25,Neonatal,efficacy,DICH,1,6,yes,2006.0,Death by 36 to 37 weeks or discharge,HFOV versus CV subgrouped by age at randomisation,0.534485514333592,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because death",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
177,CD000105,Rush 1980,STD-Rush-1980 1.694 0.249 249 256,0.534773035057438,0.253817554364473,505,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1980.0,SGA,High protein supplementation in pregnancy,2.10691902849841,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

s",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
178,CD000106,Cameron 1993,STD-Cameron-1993 0.984 0.26 127 125,-0.0196084713883762,0.320847411235342,252,Emergency & Trauma,efficacy,DICH,1,1,no,1993.0,Dead by the end of scheduled follow-up,Organised inpatient rehabilitation vs Conventional care,-0.0611146317586877,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

this",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
179,CD000107,Brooks-Gunn 1994,STD-Brooks_x002d_Gunn-1994 1.047 0.321 345 551,0.0455014602422144,0.319747729101975,896,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1994.0,Child injury,Additional home based support vs usual support for socially disadvantaged mothers,0.142304248321035,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as child",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
180,CD000108,Duenhoelter 1976,STD-Duenhoelter-1976 0.557 0.622 315 307,-0.595626225458455,0.631985688345929,622,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1976.0,Fetal death,Oestriol levels reported versus not reported,-0.94246790147632,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
181,CD000110,Crowther 1989,STD-Crowther-1989 0.986 0.993 140 138,-0.0145987994211527,1.00727320920794,278,Pregnancy & Childbirth,efficacy,DICH,1,1,yes,1989.0,Perinatal death,Hospitalisation for bed rest for women with a multiple pregnancy,-0.0144933859926964,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative health outcome,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
182,CD000111,Cammu 1994,STD-Cammu-1994 0.935 0.071 54 56,-0.573187865480966,0.605266035369603,110,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1994.0,Mode of birth (spontaneous vaginal birth),Immersion in water versus no immersion during first stage of labour,-0.947001536491225,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,neutral,0.0
183,CD000111,Chaichian 2009,STD-Chaichian-2009 1.259 0.072 53 53,3.36567179390073,1.45917014850527,106,Pregnancy & Childbirth,efficacy,DICH,1,3,yes,2009.0,Mode of birth (spontaneous vaginal birth),Immersion in water versus no immersion during any stage of labour,2.30656568553601,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,neutral,0.0
184,CD000111,Eriksson 1997,STD-Eriksson-1997 2.211 0.238 100 100,1.12723678324295,0.325619657084124,200,Pregnancy & Childbirth,efficacy,DICH,1,4,no,1997.0,Use of pharmacological analgesia (epidural/spinal analgesia/paracervical block),Early versus late immersion in water,3.46182043595643,"negative 
",negative,neutral,negative.,1.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,neutral,0.0
185,CD000111,Nikodem 1999,STD-Nikodem-1999 1.017 0.029 60 60,0.710241613919242,1.23862445149961,120,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1999.0,Mode of birth (spontaneous vaginal birth),Immersion in water versus no immersion during second stage of labour,0.573411588201207,"positive 
",positive,positive,positive.,1.0,positive.,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,neutral,0.0
186,CD000112,Cauchi 1991,STD-Cauchi-1991 0.703 0.66 20 22,-0.361790044605503,0.670034988972133,42,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1991.0,Live birth rate,Paternal white cell immunization versus placebo,-0.539956943383668,"positive 
",positive,positive,positive,1.0,positive,1.0,"positive

the",1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
187,CD000112,Christiansen 1995,STD-Christiansen-1995 3.447 0.87 14 8,1.38629436111989,0.978945010372561,22,Pregnancy & Childbirth,efficacy,DICH,1,4,no,1995.0,Live birth rate,Intravenous immunoglobulin versus placebo,1.4161105541488,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
188,CD000112,Johnson 1991,STD-Johnson-1991 0.396 0.663 17 20,-0.965080896043587,0.688626422094265,37,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1991.0,Live birth rate,Trophoblast membrane immunization versus placebo,-1.40145783704982,"positive 
",positive,positive,positive,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
189,CD000114,Barkai 1989,STD-Barkai-1989 2.231 0.296 84 84,1.05769316433378,0.379041106963134,168,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1989.0,Failure to obtain sample greater than 5 mg,Portex cannula compared with silver cannula (transcervical),2.79044447924919,"negative 
",negative,negative,negative,1.0,negative.,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
190,CD000114,Battagliarin 2009,STD-Battagliarin-2009 1.02 0.324 99 101,0.0238106486937188,0.385762749178089,200,Pregnancy & Childbirth,efficacy,DICH,1,7,no,2009.0,Failure to obtain sample > 5 mg on first attempt,Standard syringe with hand-grip device compared with vacutainer needle techniques (transabdominal),0.0617235561091632,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
191,CD000114,Buyukkurt 2010,STD-Buyukkurt-2010 2.735 0.474 43 42,1.27324149983891,0.577008108328027,85,Pregnancy & Childbirth,efficacy,DICH,1,8,no,2010.0,Failure to obtain sample > 5 mg on first attempt,Standard syringe compared with fixed piston syringe needle techniques (transabdominal),2.20662670326822,"negative 
",negative,negative,negative,1.0,negative.,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
192,CD000114,Chalkiadakis 1993,STD-Chalkiadakis-1993 0.111 1.438 12 12,-2.5828870581482,1.55559290337985,24,Pregnancy & Childbirth,efficacy,DICH,1,6,no,1993.0,First insertion failed,Flexible catheter compared with catheter with a stiff guided probe (transcervical),-1.6603875297556,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
193,CD000114,MacKenzie 1986,STD-MacKenzie-1986 1.87 0.321 35 31,1.06566813294876,0.521245849396448,66,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1986.0,Difficult insertion,Portex cannula compared with malleable cannula (transcervical),2.04446353708657,"negative 
",negative,negative,negative.,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
194,CD000114,Pons 1989,STD-Pons-1989 5.333 0.406 60 60,2.33075596996074,0.502144870430308,120,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1989.0,Failure to obtain sample > 5 mg,Aspiration cannula compared with biopsy forceps (transcervical),4.64160067584365,"negative 
",negative,negative,negative,1.0,negative,1.0,"negative, as it",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
195,CD000115,Boyer 1986,STD-Boyer-1986 0.138 0.342 85 79,-2.28968168815814,0.434313295476939,164,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1983.0,Infant colonisation with Group B strep,Intrapartum antibiotics for Group B streptococcal colonisation,-5.27195854237835,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as infant",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
196,CD000116,Amer-Wahlin 2001,STD-Amer_x002d_Wahlin-2001 0.919 0.092 2519 2447,-0.0926274659089659,0.100741924666464,4966,Pregnancy & Childbirth,efficacy,DICH,1,1,no,2001.0,Caesarean section,Fetal ECG plus CTG versus CTG alone,-0.919453010408887,"negative 
",negative,negative,negative.,1.0,negative,1.0,"the outcome ""ca",0.0,negative,1.0,"neutral 
",1.0,1.0,0.0,negative,neutral,negative,1.0
197,CD000117,Burma 1976,STD-Burma-1976 0.055 0.616 30 25,-4.34267547823064,1.47942858030606,55,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1976.0,Low pre delivery haemoglobin,Routine iron versus no iron or placebo in pregnancy,-2.93537351923553,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative. low pre,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
198,CD000117,Finland 1991,STD-Finland-1991 1.357 0.138 1358 1336,0.307574780664184,0.139295564668137,2694,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1991.0,Caesarean section,Selective versus routine iron in pregnancy,2.20807303805374,"negative 
",negative,negative,negative,1.0,negative.,1.0,negative. a ca,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
199,CD000118,Mardones 1988,STD-Mardones-1988 1.61 0.147 391 391,0.479798026838023,0.148510276741171,782,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1988.0,SGA birth,Isocaloric balanced protein supplementation in pregnancy,3.2307395647389,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

an",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
200,CD000120,Crawford 1972,STD-Crawford-1972 0.528 0.509 61 86,-0.690403694614195,0.555408723299523,147,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1972.0,low Apgar score (as defined by authors),Lateral tilt vs supine position for Caesarean,-1.24305518738112,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
201,CD000121,Dahle 1995,STD-Dahle-1995 0.18 0.611 34 35,-2.06576143777575,0.815285460487115,69,Pregnancy & Childbirth,efficacy,DICH,1,5,no,1995.0,women with persisting leg cramps,Magnesium versus placebo,-2.53378913017964,"negative 
",negative,negative,negative.,1.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
202,CD000121,Hammar 1981,STD-Hammar-1981 0.051 0.611 21 21,-4.04305126783455,0.970319776071918,42,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1981.0,Women with persisting leg cramps,Calcium versus placebo or no treatment,-4.16672046425949,"negative 
",negative,negative,negative.,1.0,negative,1.0,neutral. the,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
203,CD000121,Thauvin 1992,STD-Thauvin-1992 0.226 0.764 11 18,-1.72722094809048,0.914391114956347,29,Pregnancy & Childbirth,efficacy,DICH,1,4,no,1992.0,women with persisting leg cramps,Multivitamin and mineral supplements versus placebo,-1.8889301523593,"negative 
",negative,negative,negative.,1.0,negative,1.0,neutral. the,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
204,CD000122,Braz 2006,STD-Braz-2006 1.002 0.157 95 93,0.0031868909285189,0.292559275734023,188,Neonatal,efficacy,DICH,1,1,yes,1997.0,"Acute ROP, all infants < 2001 g birth weight",Reduced light versus controls,0.0108931460830394,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

red",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
205,CD000123,Castano 1999,STD-Castano-1999 0.187 1.57 31 31,-1.67503519491991,1.57023703205305,62,Heart & Hypertension,efficacy,DICH,1,1,no,1999.0,All-cause mortality,Any lipid-lowering regimen vs control: all trials,-1.06674034602906,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
206,CD000126,Forssell 1989,STD-Forssell-1989 1.973 0.836 56 55,0.71219537553064,0.887749229095171,111,Neurology,efficacy,DICH,1,1,yes,1989.0,Any stroke within 30 days of operation,Local versus general anaesthetic: randomised trials,0.802248373965401,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as a",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
207,CD000127,Bangladesh 1998,STD-Bangladesh-1998 0.429 0.675 100 100,-0.889409345737331,0.70516128843906,200,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1998.0,Maternal death,Magnesium sulphate versus diazepam,-1.26128498588759,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as mater",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
208,CD000128,Brazil 2003,STD-Brazil-2003 0.254 1.616 41 31,-1.4065790322914,1.65031813219595,72,Pregnancy & Childbirth,efficacy,DICH,1,4,no,2003.0,Pulmonary oedema,Magnesium sulphate vs phenytoin (subgroup by IV or IM magnesium maintenance),-0.852307809537164,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
209,CD000128,Collab Trial 1995,STD-Collab-Trial-1995 0.499 0.381 388 387,-0.722679528124963,0.394170392452084,775,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1995.0,Maternal death,Magnesium sulphate versus phenytoin,-1.8334191049441,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, as mater",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
210,CD000129,CS Burkina Faso 1988,STD-CS-Burkina-Faso-1988 1.77 0.478 35 35,0.583251509736728,0.486576517461481,70,Infectious Diseases,efficacy,DICH,1,2,no,1988.0,New malaria infection,CS-NANP vaccine versus placebo,1.19868404825537,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because a",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
211,CD000129,MSP/RESA PNG 1998,STD-MSP_x002f_RESA-PNG-1998 2.506 0.512 30 30,0.952008814476234,0.531441020947149,60,Infectious Diseases,efficacy,DICH,1,4,no,1998.0,Clinical malaria episodes,MSP/RESA vaccine versus placebo,1.7913724702311,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
212,CD000129,"RTS,S Gambia 1998",STD-RTS_x002c_S-Gambia-1998 0.791 0.264 131 119,-0.236038839299943,0.265493323180398,250,Infectious Diseases,efficacy,DICH,1,3,no,1998.0,New malaria infection (P. falciparum),"RTS,S vaccine versus placebo",-0.889057534375577,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because new",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
213,CD000129,SPf66 Brazil 1991,STD-SPf66-Brazil-1991 0.862 0.188 269 271,-0.14886143139567,0.188362129568222,540,Infectious Diseases,efficacy,DICH,1,1,no,1991.0,New malaria infection (P. falciparum),SPf66 vaccine versus placebo,-0.79029384376202,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative, because new",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
214,CD000132,Chandra 1986,STD-Chandra-1986 0.399 0.564 35 36,-0.970778917158225,0.603524998854583,71,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1986.0,Incidence of atopic eczema in first 12-18 months,Maternal antigen avoidance during lactation in women at high risk for atopic offspring,-1.60851484031423,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because at",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
215,CD000133,Falth-Magnusson 1987,STD-Falth_x002d_Magnusson-1987 1.31 0.263 76 95,0.361601062274788,0.353702735507693,171,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1987.0,Atopic eczema in first 12-18 months,Maternal antigen avoidance in pregnancy in women at high risk for atopic offspring,1.02233040905312,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as at",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
216,CD000133,Lovegrove 1994,STD-Lovegrove-1994 0.729 0.413 12 14,-0.624154309072994,0.796570028009973,26,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1994.0,Incidence of atopic eczema in first 18 months,Maternal antigen avoidance during lactation in women at high risk for atopic offspring,-0.783552339563018,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, because at",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
217,CD000135,New Guinea 1971,STD-New-Guinea-1971 0.73 0.147 498 534,-0.373548629625477,0.173389555153407,1032,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1991.0,Death during infancy and early childhood,Iodine supplementation versus no supplementation,-2.15438945728294,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

i",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
218,CD000136,Thorp 1995,STD-Thorp-1995 1.073 1.397 41 44,0.0723206615796261,1.43117288052614,85,Pregnancy & Childbirth,efficacy,DICH,1,2,no,1995.0,Assisted vaginal delivery,Prophylactic maternal oxygen,0.0505324427004507,"negative 
",negative,neutral,positive,0.0,positive,0.0,neutral. the,0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,positive,0.0
219,CD000137,Battaglia 1992,STD-Battaglia-1992 0.43 0.407 17 19,-1.64865862558738,0.72589467343622,36,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1992.0,Perinatal mortality,Maternal oxygen therapy versus no treatment,-2.27120915184982,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

per",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
220,CD000138,Ohrt 1997,STD-Ohrt-1997 0.04 0.35 68 69,-6.09630219882355,1.44703012737714,137,Infectious Diseases,efficacy,DICH,1,1,no,1997.0,Smear positive malarial illness,Mefloquine versus placebo or no drug,-4.212975309556,"negative 
",negative,negative,negative.,1.0,negative,1.0,this would be considered a,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,positive,0.0
221,CD000139,Barrington 1993,STD-Barrington-1993 1.5 0.796 10 10,0.538996500732687,1.04937623195424,20,Neonatal,efficacy,DICH,1,1,yes,1993.0,Failed extubation,Methylxanthine vs control - all preterm infants,0.513635133253324,"negative 
",negative,negative,negative,1.0,negative,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
222,CD000140,Erenberg 2000,STD-Erenberg-2000 0.576 0.269 45 37,-0.957448804367663,0.460988248609946,82,Neonatal,efficacy,DICH,1,1,no,2000.0,Failed apnoea reduction after 2 - 7 days,Any methylxanthine vs control,-2.07694839782735,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative

the",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
223,CD000141,Corbet 1995,STD-Corbet-1995 0.816 0.182 416 410,-0.233693762209362,0.208885167110868,826,Neonatal,efficacy,DICH,1,1,no,1995.0,Pneumothorax,Multiple vs single dose surfactant for severe RDS,-1.1187666670718,"negative 
",negative,negative,negative,1.0,negative,1.0,"negative, as p",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
224,CD000143,Annibale 1994,STD-Annibale-1994 0.926 0.277 40 42,-0.125163142954006,0.45331026469564,82,Neonatal,efficacy,DICH,1,1,yes,1994.0,Failure,Nasal CPAP vs Headbox,-0.276109218568087,"negative 
",negative,negative,negative.,1.0,negative,1.0,"negative

in",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
225,CD000144,Ainsworth 2000,STD-Ainsworth-2000 0.456 0.289 99 100,-1.00347462676294,0.360477593548117,199,Neonatal,efficacy,DICH,1,1,no,2000.0,Mortality,Animal derived surfactant extract versus protein free synthetic surfactant,-2.78373647828127,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"negative, as a",1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
226,CD000145,Carlsson 2000,STD-Carlsson-2000 0.233 0.759 17 16,-1.45528723260684,0.75907211527659,33,Pregnancy & Childbirth,efficacy,DICH,1,14,no,2000.0,Effect on persistent vomiting,Acupuncture or acupressure for hyperemesis gravidarum,-1.91719232378411,"negative 
",negative,positive,negative.,1.0,negative.,1.0,this would be considered a,0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,neutral,0.0
227,CD000145,Cartwright 1951,STD-Cartwright-1951 0.626 0.46 39 38,-0.468266009347195,0.459928055705586,77,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1951.0,Effect on nausea,All antiemetic medication compared with placebo,-1.0181288215367,"negative 
",negative,neutral,"the outcome ""effect on",0.0,negative.,1.0,"neutral

",0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,negative,1.0
228,CD000145,De Aloysio 1992,STD-De-Aloysio-1992 0.178 0.596 26 28,-1.72722094809048,0.596284793999944,54,Pregnancy & Childbirth,efficacy,DICH,1,7,no,1988.0,Effect on morning sickness,"Acupuncture or acupressure, compared with sham or dummy acupuncture or acupressure",-2.89663758906897,"negative 
",negative,neutral,"the outcome ""effect on",0.0,negative.,1.0,"positive, as it",0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,positive,0.0
229,CD000145,Ditto 1999,STD-Ditto-1999 0.638 0.96 25 25,-0.449916870678998,0.960346885066768,50,Pregnancy & Childbirth,efficacy,DICH,1,11,no,1999.0,Effect on persistence of vomiting,Diazepam versus placebo for hyperemesis gravidarum,-0.468494121941904,"negative 
",negative,negative,negative.,1.0,negative.,1.0,"neutral

",0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
230,CD000145,Nelson-Piercy 2001,STD-Nelson_x002d_Piercy-2001 1.96 0.828 12 12,0.672944473242426,0.828078671210825,24,Pregnancy & Childbirth,efficacy,DICH,1,9,no,2001.0,Effect on persistent vomiting within 4 days of treatment,Adrenocorticotropic hormone or steroids versus placebo for hyperemesis gravidarum,0.812657657585166,"negative 
",negative,neutral,"neutral.

the outcome is",0.0,"the outcome ""effect on",0.0,this would be considered a,0.0,negative,1.0,"**negative** 
",0.0,1.0,1.0,negative,negative,neutral,0.0
231,CD000145,Safari 1998,STD-Safari-1998 1.588 0.974 20 20,0.462623521948113,0.973505222533836,40,Pregnancy & Childbirth,efficacy,DICH,1,12,no,1998.0,Effect on persistence of vomiting,Methylprednisolone versus promethazine for hyperemesis gravidarum,0.475214216872918,"negative 
",negative,negative,negative.,1.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,neutral,0.0
232,CD000145,Sahakian 1991,STD-Sahakian-1991 0.301 0.559 31 28,-1.19915351788999,0.558630472190077,59,Pregnancy & Childbirth,efficacy,DICH,1,5,no,1991.0,Effect on vomiting,Vitamin B6 compared with placebo,-2.14659524960888,"negative 
",negative,neutral,negative.,1.0,negative.,1.0,"neutral

",0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,negative,1.0
233,CD000145,Sullivan 1996,STD-Sullivan-1996 0.286 1.22 15 15,-1.25276296849537,1.21987509118567,30,Pregnancy & Childbirth,efficacy,DICH,1,13,no,1996.0,Effect on persistence of vomiting,Ondansetron versus promethazine for hyperemesis gravidarum,-1.02696003676715,"negative 
",negative,neutral,negative.,1.0,negative.,1.0,neutral. the,0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,neutral,0.0
234,CD000145,Vutyavanich 2001,STD-Vutyavanich-2001 0.313 0.51 32 35,-1.16141318990714,0.510044044702251,67,Pregnancy & Childbirth,efficacy,DICH,1,6,no,2001.0,Effect on vomiting,Ginger compared with placebo,-2.2770841106186,"negative 
",negative,neutral,negative.,1.0,negative.,1.0,"positive

the",0.0,negative,1.0,"negative 
",0.0,1.0,1.0,negative,negative,neutral,0.0
235,CD000146,Abelin 1989,STD-Abelin-1989 1.53 0.36 100 99,0.493814277939454,0.416106295861498,199,Psychiatry & Mental Health,efficacy,DICH,1,1,no,1989.0,Smoking cessation at 6+ months follow up,Any type of NRT versus placebo/no NRT control,1.18675031560643,"positive 
",positive,positive,positive,1.0,positive,1.0,this would be considered a,0.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
236,CD000146,Berlin 2014,STD-Berlin-2014 1.078 0.425 203 199,0.0795618228361859,0.448785505039356,402,Psychiatry & Mental Health,efficacy,DICH,1,5,no,2014.0,Smoking cessation,NRT in pregnancy,0.177282514570538,"positive 
",positive,positive,positive,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
237,CD000146,Bolliger 2000b,STD-Bolliger-2000b 0.497 1.229 200 200,-0.698184974589902,1.22885134604583,400,Psychiatry & Mental Health,efficacy,DICH,1,6,no,2000.0,Palpitations/chest pains,Palpitations in NRT vs placebo users,-0.568160645985787,"negative 
",negative,negative,negative.,1.0,negative,1.0,this would be considered a,0.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
238,CD000148,Herre 1976,STD-Herre-1976 0.536 0.514 16 15,-0.965080896043587,0.775364737520656,31,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1976.0,Low weight for gestational age (< 5th centile),Calf blood extract versus placebo,-1.24467988978913,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative. low weight,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
239,CD000148,Viehweg 1987,STD-Viehweg-1987 1.111 0.279 15 15,0.287682072451781,0.760116950066092,30,Pregnancy & Childbirth,efficacy,DICH,1,3,no,1987.0,Small-for-gestational age (birthweight < 10th centile),Glucose versus bed rest,0.37847080298205,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
240,CD000149,Kafatos 1989,STD-Kafatos-1989 1.007 0.37 265 250,0.0066711388170221,0.370726381678767,515,Pregnancy & Childbirth,efficacy,DICH,1,1,no,1989.0,Small for gestational age,Nutritional advice during pregnancy,0.0179947776762288,"negative 
",negative,negative,negative.,1.0,negative.,1.0,negative,1.0,negative,1.0,"negative 
",1.0,1.0,1.0,negative,negative,negative,1.0
241,CD000150,Aafjes 1983,STD-Aafjes-1983 2.513 0.857 27 32,0.958850346292951,0.909291809158588,59,Gynaecology & Urology,efficacy,DICH,1,1,no,1983.0,pregnancy rate (per patient),Androgens with stimulatory effect versus no treatment/placebo,1.05450234637022,"negative 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,0.0,1.0,negative,positive,positive,1.0
242,CD000151,Ainmelk 1987,STD-Ainmelk-1987 7.898 1.438 16 16,1.73864964391411,1.59046269300711,32,Gynaecology & Urology,efficacy,DICH,1,1,no,1987.0,pregnancy,Anti-oestrogens versus placebo/no treatment,1.09317222689884,"positive 
",positive,positive,negative.,0.0,positive,1.0,this would be considered a,0.0,negative,0.0,it depends on the context,1.0,1.0,0.0,positive,,neutral,0.0
243,CD000152,Hovatta 1979,STD-Hovatta-1979 0.441 1.189 20 18,-0.864997437486604,1.27087827070391,38,Gynaecology & Urology,efficacy,DICH,1,1,no,1979.0,pregnancy rate (per patient),Bromocriptine versus placebo/no treatment,-0.680629653859374,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
244,CD000153,Izzo 1984,STD-Izzo-1984 7.426 1.441 15 14,1.68089687641625,1.59469106453741,29,Gynaecology & Urology,efficacy,DICH,1,1,no,1984.0,Pregnancy rate (per patient),Kinin enhancing drugs versus placebo/no treatment,1.05405800144986,"positive 
",positive,positive,neutral.,0.0,positive,1.0,"neutral

",0.0,negative,0.0,it depends on the context,1.0,1.0,0.0,positive,,neutral,0.0
245,CD000154,Agarwal 2016,STD-Agarwal-2016 0.37 0.588 25 25,-0.994933859193268,0.588354647937302,50,Gynaecology & Urology,efficacy,DICH,1,4,yes,2016.0,Response to treatment,COCP versus CVR,-1.6910444451852,"neutral 
",positive,positive,"the outcome ""response to",0.0,positive,1.0,the term 'response to,0.0,negative,0.0,"neutral. 
",1.0,0.0,0.0,neutral,neutral,positive,1.0
246,CD000154,Endrikat 2009,STD-Endrikat-2009 0.146 0.734 19 20,-1.92529086185258,0.73395536389516,39,Gynaecology & Urology,efficacy,DICH,1,3,yes,2009.0,Treatment success (PBAC < 100 at end of treatment or no requirement for alternative treatment ),COCP versus LNG IUS,-2.6231715940257,"positive 
",positive,positive,positive.,1.0,positive,1.0,positive,1.0,negative,0.0,"**positive** 
",1.0,1.0,1.0,positive,positive,positive,1.0
247,CD000154,Fraser 2011,STD-Fraser-2011 59.211 1.021 136 76,4.08109933547208,1.0213510144592,212,Gynaecology & Urology,efficacy,DICH,1,1,yes,2011.0,Response to treatment,COCP vs placebo,3.99578526647177,"neutral 
",positive,positive,neutral.,0.0,positive,1.0,neutral. the,0.0,negative,0.0,"neutral. 
",1.0,0.0,0.0,neutral,neutral,neutral,0.0
248,CD000155,Bayer 1988,STD-Bayer-1988 0.611 0.473 37 36,-0.501878837776184,0.479629911440974,73,Gynaecology & Urology,efficacy,DICH,1,1,no,1988.0,Clinical pregnancy,Ovulation suppression versus placebo,-1.04638769560549,"negative 
",positive,positive,positive,1.0,positive,1.0,"neutral

",0.0,negative,0.0,"negative 
",1.0,0.0,0.0,negative,negative,positive,1.0
249,CD000155,Burry 1989,STD-Burry-1989 4.359 0.657 30 14,1.79175946922805,0.84656167328002,44,Gynaecology & Urology,efficacy,DICH,1,3,no,1989.0,Clinical Pregnancy,GnRHa versus danazol,2.11651380611864,"positive 
",positive,positive,positive.,1.0,positive,1.0,"positive, as clinical",1.0,negative,0.0,"positive 
",1.0,1.0,1.0,positive,positive,positive,1.0
